{"83cfd4e4f2ba744bccc85d7da2fe54157ee19136": [["IntroductionThe complement system is composed of more than 30 plasma and membrane-bound proteins, and is considered to be a nonspecific host immune response.", [["plasma", "ANATOMY", 62, 68], ["membrane", "ANATOMY", 73, 81], ["plasma", "ORGANISM_SUBSTANCE", 62, 68], ["membrane", "CELLULAR_COMPONENT", 73, 81], ["membrane-bound proteins", "PROTEIN", 73, 96], ["membrane-bound proteins", "TEST", 73, 96]]], ["It is activated immediately after injury and to a greater degree during resuscitation 1 .", [["injury", "PROBLEM", 34, 40], ["resuscitation", "TREATMENT", 72, 85], ["greater degree", "OBSERVATION_MODIFIER", 50, 64]]], ["However, the inappropriate activation of the complement system has been demonstrated to play a role in the pathogenesis of a wide range of auto-immune disorders, acute inflammatory diseases and tissue injuries 2,3 .", [["tissue", "ANATOMY", 194, 200], ["auto-immune disorders", "DISEASE", 139, 160], ["inflammatory diseases", "DISEASE", 168, 189], ["injuries", "DISEASE", 201, 209], ["tissue", "TISSUE", 194, 200], ["auto-immune disorders", "PROBLEM", 139, 160], ["acute inflammatory diseases", "PROBLEM", 162, 189], ["tissue injuries", "PROBLEM", 194, 209], ["auto-immune", "OBSERVATION", 139, 150], ["acute", "OBSERVATION_MODIFIER", 162, 167], ["inflammatory", "OBSERVATION", 168, 180], ["tissue", "ANATOMY", 194, 200], ["injuries", "OBSERVATION", 201, 209]]], ["C3a, C4a and C5a, the anaphylatoxins cleaved respectively from the complement components C3, C4 and C5 during complement activation, may trigger degranulation of endothelial cells, mast cells or phagocytes, and induce inflammatory responses as well as the fatal shock-like syndrome 4 .", [["endothelial cells", "ANATOMY", 162, 179], ["mast cells", "ANATOMY", 181, 191], ["phagocytes", "ANATOMY", 195, 205], ["shock", "DISEASE", 262, 267], ["C3a", "GENE_OR_GENE_PRODUCT", 0, 3], ["C4a", "GENE_OR_GENE_PRODUCT", 5, 8], ["C5a", "GENE_OR_GENE_PRODUCT", 13, 16], ["anaphylatoxins", "GENE_OR_GENE_PRODUCT", 22, 36], ["complement components C3", "GENE_OR_GENE_PRODUCT", 67, 91], ["C4", "GENE_OR_GENE_PRODUCT", 93, 95], ["C5", "GENE_OR_GENE_PRODUCT", 100, 102], ["endothelial cells", "CELL", 162, 179], ["mast cells", "CELL", 181, 191], ["phagocytes", "CELL", 195, 205], ["C3a", "PROTEIN", 0, 3], ["C4a", "PROTEIN", 5, 8], ["C5a", "PROTEIN", 13, 16], ["anaphylatoxins", "PROTEIN", 22, 36], ["C3", "PROTEIN", 89, 91], ["C4", "PROTEIN", 93, 95], ["C5", "PROTEIN", 100, 102], ["endothelial cells", "CELL_TYPE", 162, 179], ["mast cells", "CELL_TYPE", 181, 191], ["phagocytes", "CELL_TYPE", 195, 205], ["C3a", "TEST", 0, 3], ["the anaphylatoxins", "PROBLEM", 18, 36], ["degranulation of endothelial cells", "PROBLEM", 145, 179], ["mast cells", "PROBLEM", 181, 191], ["phagocytes", "PROBLEM", 195, 205], ["inflammatory responses", "PROBLEM", 218, 240], ["the fatal shock-like syndrome", "PROBLEM", 252, 281], ["C4a", "ANATOMY", 5, 8], ["C5a", "ANATOMY", 13, 16], ["C3", "ANATOMY_MODIFIER", 89, 91], ["C4", "ANATOMY_MODIFIER", 93, 95], ["C5", "ANATOMY_MODIFIER", 100, 102], ["endothelial cells", "OBSERVATION", 162, 179], ["mast cells", "OBSERVATION", 181, 191], ["inflammatory", "OBSERVATION", 218, 230], ["fatal", "OBSERVATION_MODIFIER", 256, 261], ["shock", "OBSERVATION", 262, 267]]], ["Modulation of the complement activity could be beneficial in treating various complementassociated diseases 5, 6 .IntroductionAcute lung injury (ALI) is characterized with respiratory dysfunction, hypoxemia with presence of diffuse pulmonary infiltrates, widespread lung inflammation 7 , increased pulmonary vascular permeability and accumulation of activated neutrophils in the lung 8 .", [["lung", "ANATOMY", 132, 136], ["respiratory", "ANATOMY", 172, 183], ["pulmonary", "ANATOMY", 232, 241], ["lung", "ANATOMY", 266, 270], ["pulmonary vascular", "ANATOMY", 298, 316], ["neutrophils", "ANATOMY", 360, 371], ["lung", "ANATOMY", 379, 383], ["IntroductionAcute lung injury", "DISEASE", 114, 143], ["ALI", "DISEASE", 145, 148], ["respiratory dysfunction", "DISEASE", 172, 195], ["hypoxemia", "DISEASE", 197, 206], ["lung inflammation", "DISEASE", 266, 283], ["lung", "ORGAN", 132, 136], ["pulmonary infiltrates", "PATHOLOGICAL_FORMATION", 232, 253], ["lung", "ORGAN", 266, 270], ["pulmonary vascular", "MULTI-TISSUE_STRUCTURE", 298, 316], ["neutrophils", "CELL", 360, 371], ["lung", "ORGAN", 379, 383], ["activated neutrophils", "CELL_TYPE", 350, 371], ["various complementassociated diseases", "PROBLEM", 70, 107], ["IntroductionAcute lung injury", "PROBLEM", 114, 143], ["respiratory dysfunction", "PROBLEM", 172, 195], ["hypoxemia", "PROBLEM", 197, 206], ["diffuse pulmonary infiltrates", "PROBLEM", 224, 253], ["widespread lung inflammation", "PROBLEM", 255, 283], ["increased pulmonary vascular permeability", "PROBLEM", 288, 329], ["activated neutrophils in the lung", "PROBLEM", 350, 383], ["lung", "ANATOMY", 132, 136], ["injury", "OBSERVATION", 137, 143], ["ALI", "OBSERVATION", 145, 148], ["respiratory dysfunction", "OBSERVATION", 172, 195], ["hypoxemia", "OBSERVATION", 197, 206], ["diffuse", "OBSERVATION_MODIFIER", 224, 231], ["pulmonary", "ANATOMY", 232, 241], ["infiltrates", "OBSERVATION", 242, 253], ["widespread", "OBSERVATION_MODIFIER", 255, 265], ["lung", "ANATOMY", 266, 270], ["inflammation", "OBSERVATION", 271, 283], ["increased", "OBSERVATION_MODIFIER", 288, 297], ["pulmonary", "ANATOMY_MODIFIER", 298, 307], ["vascular", "ANATOMY", 308, 316], ["permeability", "OBSERVATION_MODIFIER", 317, 329], ["accumulation", "OBSERVATION_MODIFIER", 334, 346], ["activated neutrophils", "OBSERVATION", 350, 371], ["lung", "ANATOMY", 379, 383]]], ["Acute respiratory distress syndrome (ARDS) is the most severe form of ALI 9 .", [["respiratory", "ANATOMY", 6, 17], ["Acute respiratory distress syndrome", "DISEASE", 0, 35], ["ARDS", "DISEASE", 37, 41], ["ALI", "DISEASE", 70, 73], ["Acute respiratory distress syndrome", "PROBLEM", 0, 35], ["ARDS", "PROBLEM", 37, 41], ["ALI", "PROBLEM", 70, 73], ["respiratory distress", "OBSERVATION", 6, 26], ["ARDS", "OBSERVATION", 37, 41], ["most severe", "OBSERVATION_MODIFIER", 50, 61], ["ALI", "OBSERVATION", 70, 73]]], ["Complement activation is an early step in ALI 3 through both the classical pathway and the alternative pathway 10 .", [["ALI", "DISEASE", 42, 45], ["Complement", "GENE_OR_GENE_PRODUCT", 0, 10], ["ALI 3", "GENE_OR_GENE_PRODUCT", 42, 47]]], ["The loss of endothelial integrity in the process of ALI/ARDS also causes injured pulmonary cells to release some tissue factors or enzymes, which would lead to the initiation of complement cascade 10, 11 .", [["endothelial", "ANATOMY", 12, 23], ["pulmonary cells", "ANATOMY", 81, 96], ["tissue", "ANATOMY", 113, 119], ["ALI", "DISEASE", 52, 55], ["ARDS", "DISEASE", 56, 60], ["endothelial", "TISSUE", 12, 23], ["pulmonary cells", "CELL", 81, 96], ["tissue", "TISSUE", 113, 119], ["injured pulmonary cells", "CELL_TYPE", 73, 96], ["tissue factors", "PROTEIN", 113, 127], ["enzymes", "PROTEIN", 131, 138], ["The loss of endothelial integrity", "PROBLEM", 0, 33], ["ALI", "PROBLEM", 52, 55], ["ARDS", "PROBLEM", 56, 60], ["injured pulmonary cells", "PROBLEM", 73, 96], ["some tissue factors", "PROBLEM", 108, 127], ["enzymes", "TEST", 131, 138], ["complement cascade", "TREATMENT", 178, 196], ["loss", "OBSERVATION_MODIFIER", 4, 8], ["endothelial integrity", "OBSERVATION", 12, 33], ["ALI", "OBSERVATION", 52, 55], ["ARDS", "OBSERVATION", 56, 60], ["injured", "OBSERVATION_MODIFIER", 73, 80], ["pulmonary cells", "OBSERVATION", 81, 96]]], ["A cycle of complement activation and lung injury is consequently formed.", [["lung", "ANATOMY", 37, 41], ["lung injury", "DISEASE", 37, 48], ["lung", "ORGAN", 37, 41], ["complement activation", "TREATMENT", 11, 32], ["lung injury", "PROBLEM", 37, 48], ["lung", "ANATOMY", 37, 41], ["injury", "OBSERVATION", 42, 48]]], ["Hence, the application of complement inhibitors should be a novel treatment strategy for infectious fever and ALI.IntroductionFever is another characteristic symptom of infectious diseases.", [["infectious fever", "DISEASE", 89, 105], ["ALI", "DISEASE", 110, 113], ["infectious diseases", "DISEASE", 169, 188], ["complement inhibitors", "TREATMENT", 26, 47], ["a novel treatment strategy", "TREATMENT", 58, 84], ["infectious fever", "PROBLEM", 89, 105], ["ALI", "PROBLEM", 110, 113], ["infectious diseases", "PROBLEM", 169, 188], ["infectious", "OBSERVATION", 169, 179]]], ["It is one of complex and nonspecific host defense responses to infections 12 .", [["infections", "DISEASE", 63, 73], ["infections", "PROBLEM", 63, 73], ["one of complex", "OBSERVATION_MODIFIER", 6, 20], ["nonspecific", "OBSERVATION_MODIFIER", 25, 36], ["host defense", "OBSERVATION_MODIFIER", 37, 49], ["infections", "OBSERVATION", 63, 73]]], ["It is reported that hyper-activated complement system also involves in fever 13 .IntroductionAs a traditional Chinese medicine with actions of clearing heat and eliminating toxins, the whole plant of Houttuynia cordata Thunb.", [["fever", "DISEASE", 71, 76], ["Houttuynia cordata", "ORGANISM", 200, 218], ["Thunb", "ORGANISM", 219, 224], ["Houttuynia cordata", "SPECIES", 200, 218], ["Houttuynia cordata", "SPECIES", 200, 218], ["hyper-activated complement system", "PROBLEM", 20, 53], ["fever", "PROBLEM", 71, 76], ["clearing heat", "TREATMENT", 143, 156], ["toxins", "PROBLEM", 173, 179]]], ["(Saururaceae) is commonly used for the treatment of pulmonary symptoms (including lung abscess, dyspnea, phlegm and cough), as well as infectious diseases, anaphylaxis, cancer and viral infection [14] [15] [16] [17] .", [["pulmonary", "ANATOMY", 52, 61], ["lung", "ANATOMY", 82, 86], ["cancer", "ANATOMY", 169, 175], ["Saururaceae", "CHEMICAL", 1, 12], ["pulmonary symptoms", "DISEASE", 52, 70], ["lung abscess", "DISEASE", 82, 94], ["dyspnea", "DISEASE", 96, 103], ["phlegm", "DISEASE", 105, 111], ["cough", "DISEASE", 116, 121], ["infectious diseases", "DISEASE", 135, 154], ["anaphylaxis", "DISEASE", 156, 167], ["cancer", "DISEASE", 169, 175], ["viral infection", "DISEASE", 180, 195], ["pulmonary", "ORGAN", 52, 61], ["lung", "ORGAN", 82, 86], ["cancer", "CANCER", 169, 175], ["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 196, 215], ["pulmonary symptoms", "PROBLEM", 52, 70], ["lung abscess", "PROBLEM", 82, 94], ["dyspnea", "PROBLEM", 96, 103], ["phlegm", "PROBLEM", 105, 111], ["cough", "PROBLEM", 116, 121], ["infectious diseases", "PROBLEM", 135, 154], ["anaphylaxis", "PROBLEM", 156, 167], ["cancer", "PROBLEM", 169, 175], ["viral infection", "PROBLEM", 180, 195], ["pulmonary", "ANATOMY", 52, 61], ["symptoms", "OBSERVATION", 62, 70], ["lung", "ANATOMY", 82, 86], ["abscess", "OBSERVATION", 87, 94], ["phlegm", "ANATOMY", 105, 111], ["cancer", "OBSERVATION", 169, 175]]], ["A Chinese multiherb remedy with H. cordata as the principal ingredient had been used for the treatment and prevention of severe acute respiratory syndrome (SARS) in 2003 18 and was found to have significant anti-complementary activity 19 .", [["acute respiratory syndrome", "DISEASE", 128, 154], ["SARS", "DISEASE", 156, 160], ["H. cordata", "ORGANISM", 32, 42], ["H. cordata", "SPECIES", 32, 42], ["H. cordata", "SPECIES", 32, 42], ["H. cordata", "TREATMENT", 32, 42], ["the treatment", "TREATMENT", 89, 102], ["severe acute respiratory syndrome", "PROBLEM", 121, 154], ["significant anti-complementary activity", "PROBLEM", 195, 234], ["severe", "OBSERVATION_MODIFIER", 121, 127], ["acute", "OBSERVATION_MODIFIER", 128, 133], ["respiratory syndrome", "OBSERVATION", 134, 154], ["significant", "OBSERVATION_MODIFIER", 195, 206], ["anti-complementary activity", "OBSERVATION", 207, 234]]], ["Our previous study indicated that the crude H. cordata polysaccharides (CHCP) 20 and flavonoids 21 were the major anti-complementary principles of this plant.", [["CHCP) 20 and flavonoids 21", "CHEMICAL", 72, 98], ["flavonoids", "CHEMICAL", 85, 95], ["H. cordata", "ORGANISM", 44, 54], ["polysaccharides", "SIMPLE_CHEMICAL", 55, 70], ["CHCP) 20", "SIMPLE_CHEMICAL", 72, 80], ["flavonoids 21", "SIMPLE_CHEMICAL", 85, 98], ["H. cordata", "SPECIES", 44, 54], ["H. cordata", "SPECIES", 44, 54], ["Our previous study", "TEST", 0, 18], ["the crude H. cordata polysaccharides", "TEST", 34, 70], ["flavonoids", "TREATMENT", 85, 95]]], ["Some anti-complementary polysaccharides showed potent effects on complement-associated diseases in vivo 22, 23 .", [["Some anti-complementary polysaccharides", "PROBLEM", 0, 39], ["associated diseases in vivo", "PROBLEM", 76, 103], ["potent effects", "OBSERVATION", 47, 61], ["diseases", "OBSERVATION", 87, 95]]], ["The presence of lipopolysaccharide (LPS), a prototypical endotoxin, in blood can cause the immediate activation of the complement cascade.", [["blood", "ANATOMY", 71, 76], ["lipopolysaccharide", "CHEMICAL", 16, 34], ["LPS", "CHEMICAL", 36, 39], ["lipopolysaccharide", "SIMPLE_CHEMICAL", 16, 34], ["LPS", "SIMPLE_CHEMICAL", 36, 39], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["lipopolysaccharide (LPS", "PROBLEM", 16, 39], ["a prototypical endotoxin", "PROBLEM", 42, 66], ["the complement cascade", "TREATMENT", 115, 137], ["lipopolysaccharide", "OBSERVATION_MODIFIER", 16, 34]]], ["We had reported that CHCP could ameliorate LPS-induced ALI in mice and reduce the complement activation products deposited in the lung tissue 20 .", [["lung tissue", "ANATOMY", 130, 141], ["CHCP", "CHEMICAL", 21, 25], ["LPS", "CHEMICAL", 43, 46], ["ALI", "DISEASE", 55, 58], ["CHCP", "CHEMICAL", 21, 25], ["CHCP", "SIMPLE_CHEMICAL", 21, 25], ["LPS", "SIMPLE_CHEMICAL", 43, 46], ["mice", "ORGANISM", 62, 66], ["lung tissue", "TISSUE", 130, 141], ["complement activation products", "PROTEIN", 82, 112], ["mice", "SPECIES", 62, 66], ["mice", "SPECIES", 62, 66], ["LPS", "TEST", 43, 46], ["the complement activation products", "TREATMENT", 78, 112], ["lung", "ANATOMY", 130, 134], ["tissue", "ANATOMY_MODIFIER", 135, 141]]], ["However, it is still unclear whether this effect was a direct result of CHCP's anti-complementary activity in vivo.", [["CHCP", "CHEMICAL", 72, 76], ["CHCP", "CHEMICAL", 72, 76], ["CHCP", "SIMPLE_CHEMICAL", 72, 76]]], ["Herein, the beneficial effect of CHCP on ALI was further evaluated using a \"two-hit\" ALI rat model induced by hemorrhagic shock plus LPS instillation, which is more susceptive to lung injury 24 .", [["lung", "ANATOMY", 179, 183], ["CHCP", "CHEMICAL", 33, 37], ["ALI", "DISEASE", 41, 44], ["ALI", "DISEASE", 85, 88], ["hemorrhagic shock", "DISEASE", 110, 127], ["LPS", "CHEMICAL", 133, 136], ["lung injury", "DISEASE", 179, 190], ["CHCP", "CHEMICAL", 33, 37], ["CHCP", "SIMPLE_CHEMICAL", 33, 37], ["rat", "ORGANISM", 89, 92], ["LPS", "SIMPLE_CHEMICAL", 133, 136], ["lung", "ORGAN", 179, 183], ["rat", "SPECIES", 89, 92], ["hit\" ALI rat model", "TREATMENT", 80, 98], ["hemorrhagic shock", "PROBLEM", 110, 127], ["LPS instillation", "TREATMENT", 133, 149], ["lung injury", "PROBLEM", 179, 190], ["hemorrhagic", "OBSERVATION_MODIFIER", 110, 121], ["shock", "OBSERVATION", 122, 127], ["lung", "ANATOMY", 179, 183], ["injury", "OBSERVATION", 184, 190]]], ["Specifically, the in vivo anti-complementary activity of CHCP was also assessed.", [["CHCP", "CHEMICAL", 57, 61], ["CHCP", "CHEMICAL", 57, 61], ["CHCP", "SIMPLE_CHEMICAL", 57, 61]]], ["Besides pulmonary infections, fever is another typical indication for heat-clearing traditional Chinese medicine (TCM).", [["pulmonary", "ANATOMY", 8, 17], ["pulmonary infections", "DISEASE", 8, 28], ["fever", "DISEASE", 30, 35], ["pulmonary", "ORGAN", 8, 17], ["pulmonary infections", "PROBLEM", 8, 28], ["fever", "PROBLEM", 30, 35], ["pulmonary", "ANATOMY", 8, 17], ["infections", "OBSERVATION", 18, 28], ["fever", "OBSERVATION", 30, 35]]], ["Therefore this paper investigated in vivo the anti-pyretic effects and anti-complementary activity of CHCP on a febrile rat model induced by LPS.Agents and animalsThe dried whole plant of H. cordata was purchased from Shanghai Hua-Yu Chinese Materia Medica Co., Ltd.", [["CHCP", "CHEMICAL", 102, 106], ["febrile", "DISEASE", 112, 119], ["LPS", "CHEMICAL", 141, 144], ["CHCP", "CHEMICAL", 102, 106], ["CHCP", "SIMPLE_CHEMICAL", 102, 106], ["rat", "ORGANISM", 120, 123], ["LPS", "SIMPLE_CHEMICAL", 141, 144], ["H. cordata", "ORGANISM", 188, 198], ["rat", "SPECIES", 120, 123], ["H. cordata", "SPECIES", 188, 198], ["H. cordata", "SPECIES", 188, 198], ["the anti-pyretic effects", "TREATMENT", 42, 66], ["a febrile rat model", "TREATMENT", 110, 129], ["Agents", "TREATMENT", 145, 151], ["Hua", "ANATOMY", 227, 230]]], ["A voucher specimen (DFC-YXC-2006072601) has been deposited at the Department of Pharmacognosy, School of Pharmacy, Fudan University, Shanghai, China.Agents and animalsCHCP was prepared through the process of water extraction, alcohol precipitation and deproteinization as previously reported 20 .", [["specimen", "ANATOMY", 10, 18], ["DFC-YXC-2006072601", "CHEMICAL", 20, 38], ["animalsCHCP", "CHEMICAL", 160, 171], ["alcohol", "CHEMICAL", 226, 233], ["animalsCHCP", "CHEMICAL", 160, 171], ["alcohol", "CHEMICAL", 226, 233], ["DFC-YXC-2006072601", "CELL", 20, 38], ["animalsCHCP", "SIMPLE_CHEMICAL", 160, 171], ["water", "SIMPLE_CHEMICAL", 208, 213], ["alcohol", "SIMPLE_CHEMICAL", 226, 233], ["A voucher specimen", "TEST", 0, 18], ["water extraction", "TREATMENT", 208, 224], ["alcohol precipitation", "TREATMENT", 226, 247], ["deproteinization", "TREATMENT", 252, 268]]], ["The dried whole plant of H. cordata was grounded and defatted with 95% ethanol.", [["ethanol", "CHEMICAL", 71, 78], ["ethanol", "CHEMICAL", 71, 78], ["H. cordata", "ORGANISM", 25, 35], ["ethanol", "SIMPLE_CHEMICAL", 71, 78], ["H. cordata", "SPECIES", 25, 35], ["H. cordata", "SPECIES", 25, 35], ["H. cordata", "TREATMENT", 25, 35]]], ["The residue was extracted with hot water.", [["The residue", "PROBLEM", 0, 11]]], ["The water extract was concentrated and precipitated with trichloroacetic acid to remove proteins.", [["trichloroacetic acid", "CHEMICAL", 57, 77], ["trichloroacetic acid", "CHEMICAL", 57, 77], ["trichloroacetic acid", "SIMPLE_CHEMICAL", 57, 77], ["The water extract", "TREATMENT", 0, 17], ["trichloroacetic acid", "TREATMENT", 57, 77]]], ["The supernatant was dialyzed in running water for 3 days, and then precipitated by adding 4 volumes of 95% ethanol.", [["supernatant", "ANATOMY", 4, 15], ["ethanol", "CHEMICAL", 107, 114], ["ethanol", "CHEMICAL", 107, 114], ["ethanol", "SIMPLE_CHEMICAL", 107, 114]]], ["The precipitate was lyophilized to yield the polysaccharides (CHCP).", [["CHCP", "SIMPLE_CHEMICAL", 62, 66]]], ["The total carbohydrate content was determined with the phenol-sulfuric acid using D-galactose as the standard.", [["phenol-sulfuric acid", "CHEMICAL", 55, 75], ["D-galactose", "CHEMICAL", 82, 93], ["carbohydrate", "CHEMICAL", 10, 22], ["phenol-sulfuric acid", "CHEMICAL", 55, 75], ["D-galactose", "CHEMICAL", 82, 93], ["phenol-sulfuric acid", "SIMPLE_CHEMICAL", 55, 75], ["D-galactose", "SIMPLE_CHEMICAL", 82, 93], ["The total carbohydrate content", "TEST", 0, 30], ["the phenol-sulfuric acid", "TREATMENT", 51, 75], ["D-galactose", "TREATMENT", 82, 93]]], ["The m-hydroxybiphenyl method was used to test the uronic acid content with D-galacturonic acid as the standard.", [["m-hydroxybiphenyl", "CHEMICAL", 4, 21], ["uronic acid", "CHEMICAL", 50, 61], ["D-galacturonic acid", "CHEMICAL", 75, 94], ["m-hydroxybiphenyl", "CHEMICAL", 4, 21], ["uronic acid", "CHEMICAL", 50, 61], ["D-galacturonic acid", "CHEMICAL", 75, 94], ["m-hydroxybiphenyl", "SIMPLE_CHEMICAL", 4, 21], ["uronic acid", "SIMPLE_CHEMICAL", 50, 61], ["D-galacturonic acid", "SIMPLE_CHEMICAL", 75, 94], ["The m-hydroxybiphenyl method", "TREATMENT", 0, 28], ["the uronic acid content", "TEST", 46, 69], ["D-galacturonic acid", "TREATMENT", 75, 94]]], ["The concentration of total protein was evaluated using the Coomassie brilliant blue method, with bovine serum albumin as the standard.", [["serum", "ANATOMY", 104, 109], ["Coomassie brilliant blue", "CHEMICAL", 59, 83], ["Coomassie", "SIMPLE_CHEMICAL", 59, 68], ["bovine", "ORGANISM", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["albumin", "GENE_OR_GENE_PRODUCT", 110, 117], ["bovine", "SPECIES", 97, 103], ["Coomassie brilliant blue", "SPECIES", 59, 83], ["bovine", "SPECIES", 97, 103], ["total protein", "TREATMENT", 21, 34], ["the Coomassie brilliant blue method", "TREATMENT", 55, 90], ["bovine serum albumin", "TEST", 97, 117]]], ["High performance gel permeation chromatography (HPGPC) was carried out to analyse the molecular weight of CHCP on a TSKgel GMPWxl column (300 mm \u00d7 7.6 mm, TOSOH, Japan).", [["CHCP", "CHEMICAL", 106, 110], ["CHCP", "SIMPLE_CHEMICAL", 106, 110], ["High performance gel permeation chromatography", "TEST", 0, 46], ["a TSKgel GMPWxl column", "TREATMENT", 114, 136]]], ["Gas chromatography (GC) was used to analyze the monosaccharide composition of the completely hydrolyzed CHCP on a HP6890 (Hewlett-Packard, Wilmington, USA) fitted with a capillary column DB-225 ( Buffers: barbitol buffer solution (BBS), containing 0.5 mmol/L Mg 2\u00fe and 0.15 mmol/L Ca 2\u00fe .", [["CHCP", "CHEMICAL", 104, 108], ["HP6890", "CHEMICAL", 114, 120], ["DB-225", "CHEMICAL", 187, 193], ["Mg", "CHEMICAL", 259, 261], ["Ca", "CHEMICAL", 281, 283], ["monosaccharide", "CHEMICAL", 48, 62], ["DB-225", "CHEMICAL", 187, 193], ["Mg", "CHEMICAL", 259, 261], ["Ca 2", "CHEMICAL", 281, 285], ["CHCP", "SIMPLE_CHEMICAL", 104, 108], ["capillary", "TISSUE", 170, 179], ["barbitol buffer solution", "SIMPLE_CHEMICAL", 205, 229], ["Gas chromatography", "TEST", 0, 18], ["a capillary column DB", "TREATMENT", 168, 189], ["barbitol buffer solution", "TREATMENT", 205, 229]]], ["GVB-Mg-EGTA, veronal buffer saline, containing 5 mmol/L Mg 2\u00fe and 8 mmol/L Ca 2\u00fe .Assays of anti-complementary activities of CHCPAnti-complementary activity through the classical pathway was studied based on Mayer's modified method 25 with BBS as the buffer.", [["GVB-Mg-EGTA", "CHEMICAL", 0, 11], ["Mg", "CHEMICAL", 56, 58], ["Ca", "CHEMICAL", 75, 77], ["CHCPAnti", "CHEMICAL", 125, 133], ["Mg", "CHEMICAL", 4, 6], ["EGTA", "CHEMICAL", 7, 11], ["Mg", "CHEMICAL", 56, 58], ["Ca 2\u00fe", "CHEMICAL", 75, 80], ["GVB-Mg-EGTA", "SIMPLE_CHEMICAL", 0, 11], ["veronal buffer saline", "SIMPLE_CHEMICAL", 13, 34], ["CHCPAnti", "SIMPLE_CHEMICAL", 125, 133], ["GVB", "TEST", 0, 3], ["Mg", "TREATMENT", 4, 6], ["EGTA", "TREATMENT", 7, 11], ["veronal buffer saline", "TREATMENT", 13, 34], ["Mg", "TREATMENT", 56, 58], ["CHCPAnti", "TREATMENT", 125, 133]]], ["As the complement source, the 1:80 diluted serum of guinea pig was chosen to give sub-maximal lysis in the absence of complement inhibitors.", [["serum", "ANATOMY", 43, 48], ["serum", "ORGANISM_SUBSTANCE", 43, 48], ["guinea pig", "ORGANISM", 52, 62], ["guinea pig", "SPECIES", 52, 62], ["guinea pig", "SPECIES", 52, 62], ["guinea pig", "TREATMENT", 52, 62], ["sub-maximal lysis", "TREATMENT", 82, 99], ["complement inhibitors", "TREATMENT", 118, 139], ["lysis", "OBSERVATION", 94, 99]]], ["CHCP and heparin, used as the positive control, were dissolved in BBS.", [["CHCP", "CHEMICAL", 0, 4], ["heparin", "CHEMICAL", 9, 16], ["CHCP", "SIMPLE_CHEMICAL", 0, 4], ["heparin", "SIMPLE_CHEMICAL", 9, 16], ["CHCP", "TREATMENT", 0, 4], ["heparin", "TREATMENT", 9, 16], ["the positive control", "TREATMENT", 26, 46]]], ["Different dilutions of samples (200 \u03bcL) were incubated with 200 \u03bcL guinea pig serum, 100 \u03bcL sheep erythrocytes (4.0 \u00d7 10 8 cells/mL) and 100 \u03bcL rabbit antisheep erythrocyte antibody at 37\u00b0C for 30 min.", [["samples", "ANATOMY", 23, 30], ["serum", "ANATOMY", 78, 83], ["erythrocytes", "ANATOMY", 98, 110], ["cells", "ANATOMY", 123, 128], ["guinea", "ORGANISM", 67, 73], ["pig", "ORGANISM", 74, 77], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["sheep", "ORGANISM", 92, 97], ["erythrocytes", "CELL", 98, 110], ["rabbit", "ORGANISM", 144, 150], ["erythrocyte", "CELL", 161, 172], ["sheep erythrocytes", "CELL_TYPE", 92, 110], ["antisheep erythrocyte antibody", "PROTEIN", 151, 181], ["guinea pig", "SPECIES", 67, 77], ["sheep", "SPECIES", 92, 97], ["rabbit", "SPECIES", 144, 150], ["guinea pig", "SPECIES", 67, 77], ["sheep", "SPECIES", 92, 97], ["rabbit", "SPECIES", 144, 150], ["samples", "TEST", 23, 30], ["guinea pig serum", "TEST", 67, 83], ["sheep erythrocytes", "TEST", 92, 110], ["erythrocyte antibody", "TEST", 161, 181]]], ["Then the reaction mixture was centrifuged at 1800 \u00d7 g for 5 min.", [["the reaction mixture", "TREATMENT", 5, 25]]], ["Optical density (OD) of the supernatant was measured at 405 nm.", [["supernatant", "ANATOMY", 28, 39], ["density", "OBSERVATION", 8, 15]]], ["The sample control of each dilution, the blank control and 100% lysis control were all prepared under the same conditions.", [["each dilution", "TREATMENT", 22, 35], ["the blank control", "TREATMENT", 37, 54], ["100% lysis control", "TREATMENT", 59, 77]]], ["The corrected absorbance of each dilution of CHCP sample was obtained by subtracting the absorbance of the sample control from each value.", [["CHCP sample", "ANATOMY", 45, 56], ["the sample control", "TREATMENT", 103, 121], ["absorbance", "OBSERVATION_MODIFIER", 14, 24]]], ["The activity was determined by means of triplicate measurements and expressed as the 50% inhibition (CH 50 ).Assays of anti-complementary activities of CHCPAccording to the method of Klerx et al. 26 , the samples were dissolved in GVB-Mg-EGTA for the anti-complementary assay through alternative pathway.", [["samples", "ANATOMY", 205, 212], ["GVB-Mg", "CHEMICAL", 231, 237], ["EGTA", "CHEMICAL", 238, 242], ["GVB-Mg-EGTA", "CHEMICAL", 231, 242], ["GVB-Mg-EGTA", "SIMPLE_CHEMICAL", 231, 242], ["the samples", "TEST", 201, 212], ["EGTA", "TREATMENT", 238, 242]]], ["150 \u03bcL sample was mixed with 150 \u03bcL 1:10 diluted NHS, and 200 \u03bcL rabbit erythrocytes were added.", [["\u03bcL sample", "ANATOMY", 4, 13], ["erythrocytes", "ANATOMY", 72, 84], ["NHS", "SIMPLE_CHEMICAL", 49, 52], ["rabbit", "ORGANISM", 65, 71], ["erythrocytes", "CELL", 72, 84], ["rabbit erythrocytes", "CELL_TYPE", 65, 84], ["rabbit", "SPECIES", 65, 71], ["rabbit", "SPECIES", 65, 71], ["200 \u03bcL rabbit erythrocytes", "TREATMENT", 58, 84]]], ["Following the incubation at 37\u00b0C for 30 min, the cell lysis was measured as described above.", [["cell", "ANATOMY", 49, 53], ["cell", "CELL", 49, 53], ["the incubation", "TREATMENT", 10, 24], ["the cell lysis", "TREATMENT", 45, 59], ["cell lysis", "OBSERVATION", 49, 59]]], ["The 50% inhibition was presented as AP 50 .Identification of the targets of CHCP in the complement activation cascadeThe identification of the targets of CHCP was conducted using complement-depleted (C-depleted) sera as described in the literatures 21, 27 .", [["sera", "ANATOMY", 212, 216], ["CHCP", "GENE_OR_GENE_PRODUCT", 76, 80], ["CHCP", "SIMPLE_CHEMICAL", 154, 158], ["sera", "ORGANISM_SUBSTANCE", 212, 216], ["CHCP", "DNA", 76, 80], ["CHCP", "DNA", 154, 158], ["The 50% inhibition", "TREATMENT", 0, 18], ["complement-depleted (C-depleted) sera", "TREATMENT", 179, 216]]], ["Six components of the complement system (C1q, C2, C3, C4, C5 and C9) were selected as possible targets.", [["C1q", "GENE_OR_GENE_PRODUCT", 41, 44], ["C2", "GENE_OR_GENE_PRODUCT", 46, 48], ["C3", "GENE_OR_GENE_PRODUCT", 50, 52], ["C4", "GENE_OR_GENE_PRODUCT", 54, 56], ["C5", "GENE_OR_GENE_PRODUCT", 58, 60], ["C9", "GENE_OR_GENE_PRODUCT", 65, 67], ["C1q", "PROTEIN", 41, 44], ["C2", "PROTEIN", 46, 48], ["C3", "PROTEIN", 50, 52], ["C4", "PROTEIN", 54, 56], ["C5", "PROTEIN", 58, 60], ["C9", "PROTEIN", 65, 67], ["the complement system (C1q, C2, C3, C4, C5 and C9)", "TEST", 18, 68], ["C2", "ANATOMY_MODIFIER", 46, 48], ["C3", "ANATOMY_MODIFIER", 50, 52], ["C4", "ANATOMY_MODIFIER", 54, 56], ["C5", "ANATOMY_MODIFIER", 58, 60]]], ["Different dilutions of each antiserum (anti-C1q, C2, C3, C4, C5 and C9) were incubated with the same volume of NHS (1:8) at 37\u00b0C for 15 min.", [["antiserum", "ORGANISM_SUBSTANCE", 28, 37], ["anti-C1q", "GENE_OR_GENE_PRODUCT", 39, 47], ["NHS", "SIMPLE_CHEMICAL", 111, 114], ["anti", "PROTEIN", 39, 43], ["C1q", "PROTEIN", 44, 47], ["C2", "PROTEIN", 49, 51], ["C3", "PROTEIN", 53, 55], ["C4", "PROTEIN", 57, 59], ["C5", "PROTEIN", 61, 63], ["C9", "PROTEIN", 68, 70], ["Different dilutions of each antiserum", "TEST", 0, 37], ["anti-C1q, C2, C3, C4, C5 and C9", "TREATMENT", 39, 70], ["C2", "ANATOMY_MODIFIER", 49, 51], ["C3", "ANATOMY_MODIFIER", 53, 55], ["C4", "ANATOMY_MODIFIER", 57, 59], ["C5", "ANATOMY_MODIFIER", 61, 63]]], ["After centrifugation, 200 \u03bcL supernatant was incubated with 200 \u03bcL erythrocyte (EA) and 200 \u03bcL BBS.", [["\u03bcL supernatant", "ANATOMY", 26, 40], ["erythrocyte", "ANATOMY", 67, 78], ["erythrocyte", "CELL", 67, 78], ["centrifugation", "TREATMENT", 6, 20]]], ["Then cell lysis was measured and the antiserum dilution against the NHS hemolytic capacity was thus determined.", [["cell", "ANATOMY", 5, 9], ["hemolytic", "DISEASE", 72, 81], ["cell", "CELL", 5, 9], ["antiserum", "ORGANISM_SUBSTANCE", 37, 46], ["NHS", "SIMPLE_CHEMICAL", 68, 71], ["cell lysis", "TREATMENT", 5, 15], ["the antiserum dilution", "TREATMENT", 33, 55], ["the NHS hemolytic capacity", "PROBLEM", 64, 90], ["cell lysis", "OBSERVATION", 5, 15]]], ["The optimal dilutions for antisera are 1:128 for C1q and C2, 1:1 for C3 and C4, 1:32 for C5, 1:64 for C9.", [["C1q", "GENE_OR_GENE_PRODUCT", 49, 52], ["C1q", "PROTEIN", 49, 52], ["C2", "PROTEIN", 57, 59], ["C3", "PROTEIN", 69, 71], ["C4", "PROTEIN", 76, 78], ["C9", "PROTEIN", 102, 104], ["The optimal dilutions", "TEST", 0, 21], ["antisera", "TEST", 26, 34], ["C1q and C2, 1:1 for C3 and C4", "TEST", 49, 78], ["C2", "ANATOMY", 57, 59], ["C4", "ANATOMY", 76, 78]]], ["The antisera at the above dilutions were incubated with the same volume of NHS (1:8) at 37\u00b0C for 15 min.", [["NHS", "SIMPLE_CHEMICAL", 75, 78], ["The antisera", "TREATMENT", 0, 12]]], ["After centrifugation, the supernatants were stored at \u221270\u00b0C in aliquots as the C-depleted sera.Identification of the targets of CHCP in the complement activation cascadeTarget identification is performed by evaluating the capacity of various C-depleted sera to restore the hemolytic capacity of the CHCP-treated serum.", [["supernatants", "ANATOMY", 26, 38], ["sera", "ANATOMY", 90, 94], ["sera", "ANATOMY", 253, 257], ["serum", "ANATOMY", 312, 317], ["hemolytic", "DISEASE", 273, 282], ["CHCP", "CHEMICAL", 299, 303], ["C", "SIMPLE_CHEMICAL", 79, 80], ["sera", "ORGANISM_SUBSTANCE", 90, 94], ["CHCP", "GENE_OR_GENE_PRODUCT", 128, 132], ["C", "SIMPLE_CHEMICAL", 242, 243], ["sera", "ORGANISM_SUBSTANCE", 253, 257], ["CHCP", "SIMPLE_CHEMICAL", 299, 303], ["serum", "ORGANISM_SUBSTANCE", 312, 317], ["CHCP", "DNA", 128, 132], ["centrifugation", "TREATMENT", 6, 20], ["the supernatants", "TREATMENT", 22, 38], ["the C-depleted sera", "TREATMENT", 75, 94], ["Target identification", "TEST", 169, 190], ["various C-depleted sera", "TREATMENT", 234, 257], ["the hemolytic capacity", "PROBLEM", 269, 291], ["the CHCP", "TEST", 295, 303], ["hemolytic", "OBSERVATION_MODIFIER", 273, 282]]], ["The optimal concentration of CHCP was 1.4 mg/mL, being just sufficient to completely inhibit the hemolytic activity of 1:8 diluted NHS through CP.", [["CHCP", "CHEMICAL", 29, 33], ["hemolytic", "DISEASE", 97, 106], ["CHCP", "CHEMICAL", 29, 33], ["CHCP", "SIMPLE_CHEMICAL", 29, 33], ["NHS", "SIMPLE_CHEMICAL", 131, 134], ["The optimal concentration of CHCP", "TREATMENT", 0, 33], ["the hemolytic activity", "PROBLEM", 93, 115], ["CP", "PROBLEM", 143, 145], ["hemolytic", "OBSERVATION", 97, 106]]], ["200 \u03bcL sensitized erythrocytes and 200 \u03bcL individual C-depleted serum were added to 200 \u03bcL sample-treated NHS, and the mixture was incubated at 37\u00b0C for 30 min.", [["erythrocytes", "ANATOMY", 18, 30], ["serum", "ANATOMY", 64, 69], ["erythrocytes", "CELL", 18, 30], ["C", "SIMPLE_CHEMICAL", 53, 54], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["NHS", "SIMPLE_CHEMICAL", 106, 109], ["\u03bcL sensitized erythrocytes", "CELL_LINE", 4, 30], ["erythrocytes", "TEST", 18, 30]]], ["After centrifugation, the percentage of hemolysis was calculated.", [["hemolysis", "DISEASE", 40, 49], ["centrifugation", "TREATMENT", 6, 20], ["hemolysis", "PROBLEM", 40, 49], ["percentage", "OBSERVATION_MODIFIER", 26, 36], ["hemolysis", "OBSERVATION", 40, 49]]], ["The capacity of C-depleted sera to lyse erythrocytes was also assessed by incubating C-depleted serum directly with erythrocytes under the same conditions.", [["sera", "ANATOMY", 27, 31], ["erythrocytes", "ANATOMY", 40, 52], ["serum", "ANATOMY", 96, 101], ["erythrocytes", "ANATOMY", 116, 128], ["C", "SIMPLE_CHEMICAL", 16, 17], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["erythrocytes", "CELL", 40, 52], ["C", "SIMPLE_CHEMICAL", 85, 86], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["erythrocytes", "CELL", 116, 128], ["lyse erythrocytes", "CELL_TYPE", 35, 52], ["erythrocytes", "CELL_TYPE", 116, 128], ["C-depleted sera to lyse erythrocytes", "PROBLEM", 16, 52], ["capacity", "OBSERVATION_MODIFIER", 4, 12]]], ["All controls (vehicle, 100% lysis, complement and sample control) were treated in the same way.Influence of CHCP on coagulationInfluence of CHCP on the coagulation system was examined by determining the recalcification time (RT) and thrombin time (TT) 21, 27 .", [["CHCP", "CHEMICAL", 108, 112], ["CHCP", "CHEMICAL", 140, 144], ["CHCP", "SIMPLE_CHEMICAL", 108, 112], ["CHCP", "SIMPLE_CHEMICAL", 140, 144], ["thrombin", "GENE_OR_GENE_PRODUCT", 233, 241], ["thrombin", "PROTEIN", 233, 241], ["All controls (vehicle", "TREATMENT", 0, 21], ["100% lysis", "TREATMENT", 23, 33], ["complement and sample control)", "TREATMENT", 35, 65], ["the coagulation system", "TEST", 148, 170]]], ["Platelet poor plasma (PPP) was prepared from the anticoagulant blood of guinea pigs.", [["Platelet", "ANATOMY", 0, 8], ["plasma", "ANATOMY", 14, 20], ["anticoagulant blood", "ANATOMY", 49, 68], ["Platelet", "CELL", 0, 8], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["PPP", "SIMPLE_CHEMICAL", 22, 25], ["blood", "ORGANISM_SUBSTANCE", 63, 68], ["guinea pigs", "ORGANISM", 72, 83], ["guinea pigs", "SPECIES", 72, 83], ["guinea pigs", "SPECIES", 72, 83], ["Platelet poor plasma", "PROBLEM", 0, 20], ["PPP", "TEST", 22, 25], ["the anticoagulant blood of guinea pigs", "TREATMENT", 45, 83]]], ["Guinea pigs were anesthetized with 1 g/kg urethane intraperitoneally (i.p.).", [["urethane", "CHEMICAL", 42, 50], ["urethane", "CHEMICAL", 42, 50], ["pigs", "ORGANISM", 7, 11], ["urethane", "SIMPLE_CHEMICAL", 42, 50], ["Guinea pigs", "SPECIES", 0, 11], ["Guinea pigs", "TREATMENT", 0, 11]]], ["The right common carotid artery was separated and cannulated with a 24-gauge angiocath (Shanghai Puyi Medical Instruments Co., Ltd., Shanghai, China) filled with 3.8% (w/w) trisodium citrate for blood sampling.", [["right common carotid artery", "ANATOMY", 4, 31], ["blood", "ANATOMY", 195, 200], ["trisodium citrate", "CHEMICAL", 173, 190], ["trisodium citrate", "CHEMICAL", 173, 190], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 17, 31], ["/w) trisodium citrate", "SIMPLE_CHEMICAL", 169, 190], ["blood", "ORGANISM_SUBSTANCE", 195, 200], ["a 24-gauge angiocath", "TREATMENT", 66, 86], ["w/w) trisodium citrate", "TREATMENT", 168, 190], ["blood sampling", "TEST", 195, 209], ["right", "ANATOMY_MODIFIER", 4, 9], ["common carotid artery", "ANATOMY", 10, 31]]], ["The whole blood of guinea pig was mixed with 3.8% trisodium citrate (9:1, v/v) and centrifuged for 10 min at 1000 \u00d7 g.", [["whole blood", "ANATOMY", 4, 15], ["trisodium citrate", "CHEMICAL", 50, 67], ["trisodium citrate", "CHEMICAL", 50, 67], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["guinea", "ORGANISM", 19, 25], ["pig", "ORGANISM", 26, 29], ["trisodium citrate", "SIMPLE_CHEMICAL", 50, 67], ["guinea pig", "SPECIES", 19, 29], ["pig", "SPECIES", 26, 29], ["guinea pig", "TREATMENT", 19, 29], ["3.8% trisodium citrate", "TREATMENT", 45, 67]]], ["The supernatant obtained was used as PPP.", [["supernatant", "ANATOMY", 4, 15], ["PPP", "SIMPLE_CHEMICAL", 37, 40], ["PPP", "TEST", 37, 40]]], ["Samples (15 \u03bcL) were incubated with 150 \u03bcL PPP at 37\u00b0C for 5 min.", [["Samples", "ANATOMY", 0, 7], ["PPP", "CHEMICAL", 43, 46], ["PPP", "SIMPLE_CHEMICAL", 43, 46], ["Samples", "TEST", 0, 7]]], ["A total of 150 \u03bcL CaCl 2 (0.025 mol/L) or 150 \u03bcL thrombin was added for the assay of RT or TT, respectively.", [["CaCl 2", "CHEMICAL", 18, 24], ["CaCl 2", "CHEMICAL", 18, 24], ["thrombin", "GENE_OR_GENE_PRODUCT", 49, 57], ["thrombin", "PROTEIN", 49, 57], ["A total of 150 \u03bcL CaCl", "TREATMENT", 0, 22], ["\u03bcL thrombin", "TREATMENT", 46, 57]]], ["Heparin (5.5 mg/L) was used as the positive control.Model and groupingBefore the experiment, all male SD rats were fasted overnight (8 h), with free access to water.", [["Heparin", "CHEMICAL", 0, 7], ["Heparin", "SIMPLE_CHEMICAL", 0, 7], ["rats", "ORGANISM", 105, 109], ["rats", "SPECIES", 105, 109], ["Heparin", "TREATMENT", 0, 7]]], ["The \"two-hit\" ALI animal model induced by hemorrhagic shock/resuscitation and LPS instillation 24 was used in this study.", [["ALI", "DISEASE", 14, 17], ["hemorrhagic shock", "DISEASE", 42, 59], ["LPS", "CHEMICAL", 78, 81], ["hemorrhagic shock/resuscitation", "TREATMENT", 42, 73], ["LPS instillation", "TREATMENT", 78, 94], ["this study", "TEST", 110, 120], ["hemorrhagic", "OBSERVATION_MODIFIER", 42, 53], ["shock", "OBSERVATION", 54, 59]]], ["The rats were randomly divided into six groups: Sham, ALI model and prednisone (70 mg/kg) groups, as well as CHCP groups of 25, 50 and 100 mg/kg.", [["ALI", "DISEASE", 54, 57], ["prednisone", "CHEMICAL", 68, 78], ["CHCP", "CHEMICAL", 109, 113], ["prednisone", "CHEMICAL", 68, 78], ["rats", "ORGANISM", 4, 8], ["prednisone", "SIMPLE_CHEMICAL", 68, 78], ["rats", "SPECIES", 4, 8], ["ALI model", "TREATMENT", 54, 63], ["prednisone", "TREATMENT", 68, 78]]], ["All animals were anesthetized with 1 g/kg urethane (i.p.).", [["urethane", "CHEMICAL", 42, 50], ["urethane", "CHEMICAL", 42, 50], ["urethane", "SIMPLE_CHEMICAL", 42, 50]]], ["The right common carotid artery was cannulated with a 24-gauge Angiocath indwelling needle filled with 0.4% heparin for the monitor of mean arterial pressure (MAP), blood sampling and resuscitation.", [["right common carotid artery", "ANATOMY", 4, 31], ["arterial", "ANATOMY", 140, 148], ["blood", "ANATOMY", 165, 170], ["heparin", "CHEMICAL", 108, 115], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 17, 31], ["heparin", "SIMPLE_CHEMICAL", 108, 115], ["arterial", "MULTI-TISSUE_STRUCTURE", 140, 148], ["blood", "ORGANISM_SUBSTANCE", 165, 170], ["a 24-gauge Angiocath indwelling needle", "TREATMENT", 52, 90], ["0.4% heparin", "TREATMENT", 103, 115], ["mean arterial pressure", "TEST", 135, 157], ["blood sampling", "TEST", 165, 179], ["resuscitation", "TREATMENT", 184, 197], ["right", "ANATOMY_MODIFIER", 4, 9], ["common carotid artery", "ANATOMY", 10, 31], ["cannulated", "OBSERVATION", 36, 46]]], ["The heparinization was performed by injecting 0.1 mL 0.4% heparin through the angiocath to prevent clotting.", [["heparin", "CHEMICAL", 58, 65], ["heparin", "SIMPLE_CHEMICAL", 58, 65], ["The heparinization", "TREATMENT", 0, 18], ["heparin", "TREATMENT", 58, 65], ["the angiocath", "TREATMENT", 74, 87], ["clotting", "PROBLEM", 99, 107], ["clotting", "OBSERVATION", 99, 107]]], ["Hemorrhagic shock was initiated by blood withdrawal, leading to a reduction of the MAP to 4075 mmHg in 20 min.", [["blood", "ANATOMY", 35, 40], ["Hemorrhagic shock", "DISEASE", 0, 17], ["blood", "ORGANISM_SUBSTANCE", 35, 40], ["Hemorrhagic shock", "PROBLEM", 0, 17], ["blood withdrawal", "PROBLEM", 35, 51], ["the MAP", "TEST", 79, 86], ["shock", "OBSERVATION", 12, 17]]], ["This blood pressure was maintained by further blood withdrawal if MAP was higher than 45 mmHg and by infusion of 0.5 mL normal saline (NS) if the MAP was less than 35 mmHg.", [["blood", "ANATOMY", 5, 10], ["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 5, 10], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["saline", "SIMPLE_CHEMICAL", 127, 133], ["This blood pressure", "TEST", 0, 19], ["further blood withdrawal", "PROBLEM", 38, 62], ["MAP", "TEST", 66, 69], ["normal saline (NS", "TREATMENT", 120, 137], ["the MAP", "TEST", 142, 149], ["pressure", "OBSERVATION_MODIFIER", 11, 19]]], ["After a hypotensive period of 60 min, rats were resuscitated by transfusion of the withdrawn blood in 1 h.", [["blood", "ANATOMY", 93, 98], ["hypotensive", "DISEASE", 8, 19], ["rats", "ORGANISM", 38, 42], ["blood", "ORGANISM_SUBSTANCE", 93, 98], ["rats", "SPECIES", 38, 42]]], ["Then, either LPS (1 mg/kg in 200 \u03bcL NS) or NS alone was administered intratracheally (i.t.).", [["LPS", "CHEMICAL", 13, 16], ["NS", "CHEMICAL", 43, 45], ["LPS", "SIMPLE_CHEMICAL", 13, 16], ["LPS", "TREATMENT", 13, 16], ["NS", "TREATMENT", 36, 38], ["NS", "TREATMENT", 43, 45]]], ["CHCP (100 mg/kg, 50 mg/kg and 25 mg/kg, dissolved in saline) was given intragastrically (i.g.) at 30 min before the LPS instillation.", [["CHCP", "CHEMICAL", 0, 4], ["LPS", "CHEMICAL", 116, 119], ["CHCP", "CHEMICAL", 0, 4], ["CHCP", "SIMPLE_CHEMICAL", 0, 4], ["saline", "SIMPLE_CHEMICAL", 53, 59], ["LPS", "SIMPLE_CHEMICAL", 116, 119], ["CHCP", "TREATMENT", 0, 4], ["dissolved in saline)", "TREATMENT", 40, 60], ["the LPS instillation", "TREATMENT", 112, 132]]], ["The rats of the positive control group received a single dose of prednisone 70 mg/kg i.p.", [["prednisone", "CHEMICAL", 65, 75], ["prednisone", "CHEMICAL", 65, 75], ["rats", "ORGANISM", 4, 8], ["prednisone", "SIMPLE_CHEMICAL", 65, 75], ["rats", "SPECIES", 4, 8], ["prednisone", "TREATMENT", 65, 75]]], ["Sham animals underwent the same surgical procedures but without the hypotensive process, and received intratracheal instillation of NS.", [["hypotensive", "DISEASE", 68, 79], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 102, 115], ["the same surgical procedures", "TREATMENT", 23, 51], ["the hypotensive process", "PROBLEM", 64, 87], ["intratracheal instillation of NS", "TREATMENT", 102, 134]]], ["Serum samples of all animals were obtained from the right carotid artery at 0, 2 and 4 h after the administration of LPS.", [["Serum samples", "ANATOMY", 0, 13], ["right carotid artery", "ANATOMY", 52, 72], ["LPS", "CHEMICAL", 117, 120], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["right carotid artery", "MULTI-TISSUE_STRUCTURE", 52, 72], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["Serum samples", "TEST", 0, 13], ["LPS", "TREATMENT", 117, 120], ["right carotid artery", "ANATOMY", 52, 72]]], ["All animals were breathing spontaneously during the experiment and sacrificed at 4 h after LPS administration.Lung wet/dry weight ratioThe lower lobe of the right lung was used for the determination of wet-dry weight (W/D) ratio.", [["Lung", "ANATOMY", 110, 114], ["lower lobe", "ANATOMY", 139, 149], ["right lung", "ANATOMY", 157, 167], ["LPS", "CHEMICAL", 91, 94], ["LPS", "SIMPLE_CHEMICAL", 91, 94], ["Lung", "ORGAN", 110, 114], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 139, 149], ["lung", "ORGAN", 163, 167], ["LPS administration", "TREATMENT", 91, 109], ["Lung wet", "TEST", 110, 118], ["dry weight ratio", "TEST", 119, 135], ["the determination", "TEST", 181, 198], ["wet-dry weight", "TEST", 202, 216], ["wet", "OBSERVATION", 115, 118], ["dry", "OBSERVATION", 119, 122], ["lower lobe", "ANATOMY", 139, 149], ["right", "ANATOMY_MODIFIER", 157, 162], ["lung", "ANATOMY", 163, 167]]], ["It was harvested, weighed immediately and dried at 80\u00b0C for 48 h, then reweighed.Histologic examination and immunohistochemistryThe upper lobe of right lung was fixed immediately in 4% formaldehyde.", [["upper lobe", "ANATOMY", 132, 142], ["right lung", "ANATOMY", 146, 156], ["formaldehyde", "CHEMICAL", 185, 197], ["formaldehyde", "CHEMICAL", 185, 197], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 132, 142], ["lung", "ORGAN", 152, 156], ["formaldehyde", "SIMPLE_CHEMICAL", 185, 197], ["Histologic examination", "TEST", 81, 103], ["immunohistochemistry", "TEST", 108, 128], ["harvested", "OBSERVATION", 7, 16], ["upper lobe", "ANATOMY", 132, 142], ["right", "ANATOMY_MODIFIER", 146, 151], ["lung", "ANATOMY", 152, 156], ["fixed", "OBSERVATION_MODIFIER", 161, 166]]], ["After the routine paraffin embedding, the sample was cut into 5-\u03bcm sections and stained with haematoxylin and eosin (H&E) for the detection of lung histopathological alteration.", [["sample", "ANATOMY", 42, 48], ["sections", "ANATOMY", 67, 75], ["lung", "ANATOMY", 143, 147], ["haematoxylin", "CHEMICAL", 93, 105], ["eosin", "CHEMICAL", 110, 115], ["haematoxylin", "SIMPLE_CHEMICAL", 93, 105], ["eosin", "SIMPLE_CHEMICAL", 110, 115], ["lung", "ORGAN", 143, 147], ["the routine paraffin embedding", "TREATMENT", 6, 36], ["the sample", "TEST", 38, 48], ["haematoxylin", "TEST", 93, 105], ["the detection", "TEST", 126, 139], ["lung histopathological alteration", "PROBLEM", 143, 176], ["lung", "ANATOMY", 143, 147], ["histopathological alteration", "OBSERVATION", 148, 176]]], ["The severity of the lung injury was blindly quantified by a pathologist based on microscopic changes, including extent of disease, alveolar wall thickness, exudation, pulmonary congestion and inflammation degree.", [["lung", "ANATOMY", 20, 24], ["alveolar wall", "ANATOMY", 131, 144], ["pulmonary", "ANATOMY", 167, 176], ["lung injury", "DISEASE", 20, 31], ["pulmonary congestion", "DISEASE", 167, 187], ["inflammation", "DISEASE", 192, 204], ["lung", "ORGAN", 20, 24], ["alveolar wall", "TISSUE", 131, 144], ["pulmonary", "ORGAN", 167, 176], ["the lung injury", "PROBLEM", 16, 31], ["microscopic changes", "PROBLEM", 81, 100], ["disease", "PROBLEM", 122, 129], ["alveolar wall thickness", "PROBLEM", 131, 154], ["exudation", "PROBLEM", 156, 165], ["pulmonary congestion", "PROBLEM", 167, 187], ["inflammation degree", "PROBLEM", 192, 211], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["lung", "ANATOMY", 20, 24], ["injury", "OBSERVATION", 25, 31], ["extent", "OBSERVATION_MODIFIER", 112, 118], ["disease", "OBSERVATION", 122, 129], ["alveolar", "ANATOMY_MODIFIER", 131, 139], ["wall", "ANATOMY_MODIFIER", 140, 144], ["thickness", "OBSERVATION_MODIFIER", 145, 154], ["exudation", "OBSERVATION_MODIFIER", 156, 165], ["pulmonary", "ANATOMY", 167, 176], ["congestion", "OBSERVATION", 177, 187], ["inflammation", "OBSERVATION_MODIFIER", 192, 204], ["degree", "OBSERVATION_MODIFIER", 205, 211]]], ["The injury was graded from 0 (normal) to 4 (severe) in the above categories.", [["The injury", "PROBLEM", 0, 10], ["injury", "OBSERVATION", 4, 10]]], ["The deposit of complement activation products was determined using immunohistochemical staining with rabbit anti-human C3c 20 .BALF collection and analysisBronchoalveolar lavage fluid (BALF) was collected immediately after sacrifice.", [["BALF", "ANATOMY", 127, 131], ["Bronchoalveolar lavage fluid", "ANATOMY", 155, 183], ["BALF", "ANATOMY", 185, 189], ["rabbit", "ORGANISM", 101, 107], ["anti-human C3c 20", "GENE_OR_GENE_PRODUCT", 108, 125], ["BALF", "ORGANISM_SUBSTANCE", 127, 131], ["Bronchoalveolar lavage fluid", "ORGANISM_SUBSTANCE", 155, 183], ["BALF", "ORGANISM_SUBSTANCE", 185, 189], ["complement activation products", "PROTEIN", 15, 45], ["rabbit anti-human C3c 20", "PROTEIN", 101, 125], ["rabbit", "SPECIES", 101, 107], ["rabbit", "SPECIES", 101, 107], ["complement activation products", "TREATMENT", 15, 45], ["immunohistochemical staining", "TEST", 67, 95], ["rabbit anti-human C3c", "TREATMENT", 101, 122], ["BALF collection", "TEST", 127, 142], ["analysis", "TEST", 147, 155], ["Bronchoalveolar lavage fluid (BALF)", "TEST", 155, 190], ["deposit", "OBSERVATION_MODIFIER", 4, 11], ["Bronchoalveolar lavage", "OBSERVATION", 155, 177]]], ["The lobes of left lung were lavaged with a total volume of 4 mL saline at 4\u00b0C. BALF was centrifuged at 111 \u00d7 g for 10 min.", [["lobes", "ANATOMY", 4, 9], ["left lung", "ANATOMY", 13, 22], ["BALF", "ANATOMY", 79, 83], ["lobes", "MULTI-TISSUE_STRUCTURE", 4, 9], ["lung", "ORGAN", 18, 22], ["BALF", "ORGANISM_SUBSTANCE", 79, 83], ["a total volume of 4 mL saline", "TREATMENT", 41, 70], ["lobes", "ANATOMY_MODIFIER", 4, 9], ["left", "ANATOMY_MODIFIER", 13, 17], ["lung", "ANATOMY", 18, 22], ["lavaged", "OBSERVATION", 28, 35]]], ["The cell-free supernatant was collected and stored at \u221220\u00b0C for further assays.", [["cell", "ANATOMY", 4, 8], ["supernatant", "ANATOMY", 14, 25], ["cell", "CELL", 4, 8], ["C", "GENE_OR_GENE_PRODUCT", 58, 59], ["further assays", "TEST", 64, 78], ["cell", "ANATOMY", 4, 8]]], ["Total cell counts were performed on the Neubauer's counting chamber.", [["cell", "ANATOMY", 6, 10], ["cell", "CELL", 6, 10], ["Total cell counts", "TEST", 0, 17], ["cell counts", "OBSERVATION", 6, 17]]], ["The leukocyte classifications were examined by counting at least 100 cells/smear prepared using cytospin and Wright-Giemsa staining.", [["leukocyte", "ANATOMY", 4, 13], ["cells", "ANATOMY", 69, 74], ["leukocyte", "CELL", 4, 13], ["cells", "CELL", 69, 74], ["The leukocyte classifications", "TEST", 0, 29], ["smear", "TEST", 75, 80], ["cytospin", "TEST", 96, 104], ["leukocyte", "ANATOMY", 4, 13]]], ["The obtained values represented the percentage of neutrophils or lymphocytes in total leukocytes 28 .", [["neutrophils", "ANATOMY", 50, 61], ["lymphocytes", "ANATOMY", 65, 76], ["leukocytes", "ANATOMY", 86, 96], ["neutrophils", "CELL", 50, 61], ["lymphocytes", "CELL", 65, 76], ["leukocytes", "CELL", 86, 96], ["neutrophils", "CELL_TYPE", 50, 61], ["lymphocytes", "CELL_TYPE", 65, 76], ["neutrophils", "TEST", 50, 61], ["lymphocytes", "TEST", 65, 76], ["total leukocytes", "TEST", 80, 96], ["neutrophils", "OBSERVATION", 50, 61], ["lymphocytes", "ANATOMY", 65, 76]]], ["The concentration of the total protein was determined by the Coomassie brilliant blue method 29 .", [["Coomassie brilliant blue", "CHEMICAL", 61, 85], ["Coomassie brilliant blue", "SPECIES", 61, 85], ["the total protein", "TEST", 21, 38], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["The assays of superoxide dismutase (SOD) activity and malondialdehyde (MDA) content were carried out using commercial kits.Complement activity assayThe sera collected at different times were tested for their hemolytic activity according to Mayer's method 25 .", [["sera", "ANATOMY", 152, 156], ["superoxide", "CHEMICAL", 14, 24], ["malondialdehyde", "CHEMICAL", 54, 69], ["MDA", "CHEMICAL", 71, 74], ["hemolytic", "DISEASE", 208, 217], ["superoxide", "CHEMICAL", 14, 24], ["malondialdehyde", "CHEMICAL", 54, 69], ["MDA", "CHEMICAL", 71, 74], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 14, 34], ["SOD", "SIMPLE_CHEMICAL", 36, 39], ["malondialdehyde", "SIMPLE_CHEMICAL", 54, 69], ["MDA", "SIMPLE_CHEMICAL", 71, 74], ["sera", "ORGANISM_SUBSTANCE", 152, 156], ["superoxide dismutase", "PROTEIN", 14, 34], ["SOD", "PROTEIN", 36, 39], ["The assays", "TEST", 0, 10], ["superoxide dismutase (SOD) activity and malondialdehyde (MDA) content", "PROBLEM", 14, 83], ["Complement activity assay", "TEST", 123, 148], ["The sera", "TEST", 148, 156]]], ["Serum complement activities at 2 and 4 h were quantified as relative changes normalized to their initial values at 0 h.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum complement activities", "TEST", 0, 27]]], ["The contents of complement components C3 and C4 in the sera collected at 4 h were measured through immunonephelometric method under the instructions of the commercial kits.Complement activity assay2.6.", [["sera", "ANATOMY", 55, 59], ["complement components C3", "GENE_OR_GENE_PRODUCT", 16, 40], ["C4", "GENE_OR_GENE_PRODUCT", 45, 47], ["sera", "ORGANISM_SUBSTANCE", 55, 59], ["Complement", "GENE_OR_GENE_PRODUCT", 172, 182], ["complement components", "PROTEIN", 16, 37], ["C3", "PROTEIN", 38, 40], ["C4", "PROTEIN", 45, 47], ["complement components C3 and C4 in the sera", "TEST", 16, 59], ["complement", "OBSERVATION_MODIFIER", 16, 26], ["components", "OBSERVATION_MODIFIER", 27, 37], ["C3", "OBSERVATION_MODIFIER", 38, 40], ["C4", "ANATOMY_MODIFIER", 45, 47]]], ["Fever experiment 2.6.1.", [["Fever", "DISEASE", 0, 5], ["Fever experiment", "PROBLEM", 0, 16]]], ["Model and grouping Adult male Wistar rats (200-230 g) were housed at least 3 days before experiments under room temperature at 1872\u00b0C, relative humidity at 55%-60% and a 12-h light-dark cycle.", [["Wistar rats", "ORGANISM", 30, 41], ["rats", "SPECIES", 37, 41]]], ["The rectal temperature was determined twice every day.", [["rectal", "ANATOMY", 4, 10], ["rectal", "ORGAN", 4, 10], ["The rectal temperature", "TEST", 0, 22], ["rectal", "ANATOMY", 4, 10]]], ["On the day before experiments, each two rats were housed in one cage, fasted for 10 h with free access to water.", [["rats", "ORGANISM", 40, 44], ["rats", "SPECIES", 40, 44]]], ["The rats with stable baseline temperatures were selected for experiment by determining their rectal temperature three times every 20 min, and divided into six groups (n \u00bc 6): sham group, LPS-induced model group, CHCP (at different doses of 50, 100, and 200 mg/kg) groups, and aspirin (150 mg/kg) group.", [["rectal", "ANATOMY", 93, 99], ["LPS", "CHEMICAL", 187, 190], ["CHCP", "CHEMICAL", 212, 216], ["aspirin", "CHEMICAL", 276, 283], ["aspirin", "CHEMICAL", 276, 283], ["rats", "ORGANISM", 4, 8], ["rectal", "ORGANISM_SUBDIVISION", 93, 99], ["LPS", "SIMPLE_CHEMICAL", 187, 190], ["CHCP", "SIMPLE_CHEMICAL", 212, 216], ["aspirin", "SIMPLE_CHEMICAL", 276, 283], ["rats", "SPECIES", 4, 8], ["aspirin", "TREATMENT", 276, 283], ["stable", "OBSERVATION_MODIFIER", 14, 20]]], ["The drugs were diluted in normal saline for oral administration.", [["oral", "ANATOMY", 44, 48], ["saline", "SIMPLE_CHEMICAL", 33, 39], ["oral", "ORGANISM_SUBDIVISION", 44, 48], ["The drugs", "TREATMENT", 0, 9], ["normal saline", "TREATMENT", 26, 39], ["oral administration", "TREATMENT", 44, 63]]], ["After drug administration for 30 min, LPS (60 \u03bcg/kg) was injected intraperitoneally (i.p.) to induce fever.", [["intraperitoneally", "ANATOMY", 66, 83], ["LPS", "CHEMICAL", 38, 41], ["fever", "DISEASE", 101, 106], ["LPS", "SIMPLE_CHEMICAL", 38, 41], ["LPS", "TEST", 38, 41], ["fever", "PROBLEM", 101, 106], ["fever", "OBSERVATION", 101, 106]]], ["The same volume saline (1 mL/kg) without LPS was injected in the sham group.", [["LPS", "CHEMICAL", 41, 44], ["saline", "SIMPLE_CHEMICAL", 16, 22], ["LPS", "SIMPLE_CHEMICAL", 41, 44], ["The same volume saline", "TREATMENT", 0, 22], ["LPS", "TREATMENT", 41, 44]]], ["The body temperature was recorded every 30 min from 0 to 6 h after LPS injection.", [["body", "ANATOMY", 4, 8], ["LPS", "CHEMICAL", 67, 70], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["LPS", "SIMPLE_CHEMICAL", 67, 70], ["The body temperature", "TEST", 0, 20], ["LPS injection", "TREATMENT", 67, 80]]], ["The change of body temperature was calculated as \u0394T.", [["body", "ANATOMY", 14, 18], ["body", "ORGANISM_SUBDIVISION", 14, 18], ["body temperature", "TEST", 14, 30], ["body temperature", "OBSERVATION_MODIFIER", 14, 30]]], ["The thermal response index (TRI,\u00b0C \u00d7 h) of each group was evaluated as the area under the temperature-time curve, which was calculated by summing the area of the trapezoids under every two data points.", [["The thermal response index", "TEST", 0, 26], ["TRI", "TEST", 28, 31]]], ["The area of each trapezoid from t i to t i\u00fe1 under the curve was calculated as (t i\u00fe1 -t i ) \u00d7 (\u0394T i \u00fe\u0394T i\u00fe1 )/2.", [["t i\u00fe1", "DNA", 39, 44], ["the curve", "TEST", 51, 60]]], ["After the rats were anesthetized with 1 g/kg urethane i.p., the serum and blood samples were collected for complement activity assay and leukocyte counts, respectively.Complement activity assayThe total number of leukocytes in peripheral blood was detected on the Neubauer's counting chamber.Statistical analysisAll quantitative data were expressed as mean7SD.", [["serum", "ANATOMY", 64, 69], ["blood samples", "ANATOMY", 74, 87], ["leukocyte", "ANATOMY", 137, 146], ["leukocytes", "ANATOMY", 213, 223], ["peripheral blood", "ANATOMY", 227, 243], ["urethane", "CHEMICAL", 45, 53], ["urethane", "CHEMICAL", 45, 53], ["rats", "ORGANISM", 10, 14], ["urethane", "SIMPLE_CHEMICAL", 45, 53], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["blood samples", "ORGANISM_SUBSTANCE", 74, 87], ["leukocyte", "CELL", 137, 146], ["leukocytes", "CELL", 213, 223], ["peripheral blood", "ORGANISM_SUBSTANCE", 227, 243], ["leukocytes", "CELL_TYPE", 213, 223], ["rats", "SPECIES", 10, 14], ["the serum and blood samples", "TEST", 60, 87], ["complement activity assay", "TEST", 107, 132], ["leukocyte counts", "TEST", 137, 153], ["Complement activity assay", "TEST", 168, 193], ["leukocytes in peripheral blood", "PROBLEM", 213, 243], ["Statistical analysis", "TEST", 292, 312], ["All quantitative data", "TEST", 312, 333], ["total", "OBSERVATION_MODIFIER", 197, 202], ["number", "OBSERVATION_MODIFIER", 203, 209], ["leukocytes", "OBSERVATION", 213, 223], ["peripheral", "ANATOMY_MODIFIER", 227, 237], ["blood", "ANATOMY", 238, 243]]], ["Statistical analysis was carried out by using SPSS 13.0 (IBM, Chicago, USA).", [["Statistical analysis", "TEST", 0, 20], ["SPSS", "TEST", 46, 50]]], ["Differences among groups were assessed by a one-way analysis of variance (ANOVA) followed by Dunnett's Test.", [["Dunnett's Test", "TEST", 93, 107]]], ["Nonparametric data were evaluated using the Mann-Whitney test.", [["Nonparametric data", "TEST", 0, 18]]], ["A P value less than 0.05 was considered statistically significant.Characterization of CHCP and its anti-complementary activities in vitroCHCP was a dark brown powder and soluble in water.", [["CHCP", "CHEMICAL", 86, 90], ["vitroCHCP", "CHEMICAL", 132, 141], ["CHCP", "CHEMICAL", 86, 90], ["CHCP", "SIMPLE_CHEMICAL", 86, 90], ["vitroCHCP", "SIMPLE_CHEMICAL", 132, 141], ["A P value", "TEST", 0, 9], ["CHCP", "TEST", 86, 90], ["a dark brown powder", "TREATMENT", 146, 165]]], ["The total carbohydrate, uronic acid and protein contents of CHCP were 77.2172.84%, 36.6974.94% and 6.1771.93%, respectively.", [["uronic acid", "CHEMICAL", 24, 35], ["CHCP", "CHEMICAL", 60, 64], ["carbohydrate", "CHEMICAL", 10, 22], ["uronic acid", "CHEMICAL", 24, 35], ["carbohydrate", "SIMPLE_CHEMICAL", 10, 22], ["uronic acid", "SIMPLE_CHEMICAL", 24, 35], ["The total carbohydrate", "TEST", 0, 22], ["uronic acid", "TEST", 24, 35], ["protein contents", "TEST", 40, 56], ["CHCP", "TEST", 60, 64]]], ["HPGPC analysis showed that CHCP contained one major polysaccharide and several minor ones, with molecular weight ranging from 1000 to 5000 kDa (Supporting information Fig. S1 ).", [["CHCP", "CHEMICAL", 27, 31], ["CHCP", "SIMPLE_CHEMICAL", 27, 31], ["S1", "GENE_OR_GENE_PRODUCT", 172, 174], ["S1", "PROTEIN", 172, 174], ["HPGPC analysis", "TEST", 0, 14], ["molecular weight", "TEST", 96, 112]]], ["GC analysis indicated that the complex macromolecules were linked by multiple monosacchrides, mainly including glucose, galactose, arabinose and rhamnose in the ratio of 3.40:2.14:1.17:1, together CHCP showed stronger inhibitory effect than heparin through classical pathway (Po0.001), while its inhibition on alternative pathway was a little weaker compared with heparin (Po0.01) (Fig. 1 ).", [["glucose", "CHEMICAL", 111, 118], ["galactose", "CHEMICAL", 120, 129], ["arabinose", "CHEMICAL", 131, 140], ["rhamnose", "CHEMICAL", 145, 153], ["CHCP", "CHEMICAL", 197, 201], ["heparin", "CHEMICAL", 241, 248], ["heparin", "CHEMICAL", 364, 371], ["monosacchrides", "CHEMICAL", 78, 92], ["glucose", "CHEMICAL", 111, 118], ["galactose", "CHEMICAL", 120, 129], ["arabinose", "CHEMICAL", 131, 140], ["rhamnose", "CHEMICAL", 145, 153], ["CHCP", "CHEMICAL", 197, 201], ["monosacchrides", "SIMPLE_CHEMICAL", 78, 92], ["glucose", "SIMPLE_CHEMICAL", 111, 118], ["galactose", "SIMPLE_CHEMICAL", 120, 129], ["arabinose", "SIMPLE_CHEMICAL", 131, 140], ["rhamnose", "SIMPLE_CHEMICAL", 145, 153], ["CHCP", "SIMPLE_CHEMICAL", 197, 201], ["heparin", "SIMPLE_CHEMICAL", 241, 248], ["Po0.001", "SIMPLE_CHEMICAL", 276, 283], ["heparin", "SIMPLE_CHEMICAL", 364, 371], ["Po0.01", "SIMPLE_CHEMICAL", 373, 379], ["GC analysis", "TEST", 0, 11], ["the complex macromolecules", "PROBLEM", 27, 53], ["glucose", "TEST", 111, 118], ["galactose", "TEST", 120, 129], ["arabinose", "TEST", 131, 140], ["rhamnose in the ratio", "TEST", 145, 166], ["heparin", "TREATMENT", 241, 248], ["a little weaker", "PROBLEM", 334, 349], ["heparin", "TREATMENT", 364, 371]]], ["Its CH 50 and AP 50 values were 0.09270.020 mg/mL and 0.20970.036 mg/mL (n \u00bc3), respectively.Characterization of CHCP and its anti-complementary activities in vitroThe targets of CHCP in the complement activation cascade are indicated in Fig. 2 .", [["CHCP", "CHEMICAL", 113, 117], ["CHCP", "CHEMICAL", 179, 183], ["CHCP", "SIMPLE_CHEMICAL", 113, 117], ["CHCP", "GENE_OR_GENE_PRODUCT", 179, 183], ["CHCP", "PROTEIN", 179, 183], ["Its CH", "TEST", 0, 6], ["AP 50 values", "TEST", 14, 26], ["CHCP", "TEST", 113, 117]]], ["The 1:8 NHS led to 96.7772.15% of hemolysis in the complement-control group.", [["hemolysis", "DISEASE", 34, 43], ["hemolysis", "PROBLEM", 34, 43], ["hemolysis", "OBSERVATION", 34, 43]]], ["CHCP at the concentration of 1.4 mg/mL exhibited a strong inhibitory effect on the hemolysis (3.2970.67%).", [["CHCP", "CHEMICAL", 0, 4], ["hemolysis", "DISEASE", 83, 92], ["CHCP", "SIMPLE_CHEMICAL", 0, 4], ["the hemolysis", "TEST", 79, 92], ["hemolysis", "OBSERVATION", 83, 92]]], ["The hemolytic percentages induced by all the C-depleted sera were less than 10%, indicating that the C-depleted sera would not lyse erythrocyte independently.", [["sera", "ANATOMY", 56, 60], ["sera", "ANATOMY", 112, 116], ["erythrocyte", "ANATOMY", 132, 143], ["hemolytic", "DISEASE", 4, 13], ["C", "SIMPLE_CHEMICAL", 45, 46], ["sera", "ORGANISM_SUBSTANCE", 56, 60], ["C", "SIMPLE_CHEMICAL", 101, 102], ["sera", "ORGANISM_SUBSTANCE", 112, 116], ["erythrocyte", "CELL", 132, 143], ["The hemolytic percentages", "TEST", 0, 25], ["the C-depleted sera", "TEST", 41, 60], ["the C-depleted sera", "PROBLEM", 97, 116], ["hemolytic", "OBSERVATION_MODIFIER", 4, 13], ["percentages", "OBSERVATION_MODIFIER", 14, 25]]], ["After treating with CHCP, the serum depleted of C1q still restored the hemolytic activity to 67.4074.79%, suggesting that CHCP did not block the complement cascade at C1q.", [["serum", "ANATOMY", 30, 35], ["CHCP", "CHEMICAL", 20, 24], ["hemolytic", "DISEASE", 71, 80], ["CHCP", "CHEMICAL", 122, 126], ["CHCP", "CHEMICAL", 20, 24], ["CHCP", "CHEMICAL", 122, 126], ["CHCP", "SIMPLE_CHEMICAL", 20, 24], ["serum", "ORGANISM_SUBSTANCE", 30, 35], ["C1q", "GENE_OR_GENE_PRODUCT", 48, 51], ["CHCP", "SIMPLE_CHEMICAL", 122, 126], ["C1q", "GENE_OR_GENE_PRODUCT", 167, 170], ["C1q", "PROTEIN", 48, 51], ["C1q", "PROTEIN", 167, 170], ["CHCP", "TREATMENT", 20, 24], ["the serum", "TEST", 26, 35], ["the hemolytic activity", "PROBLEM", 67, 89], ["hemolytic", "OBSERVATION_MODIFIER", 71, 80]]], ["C2-depleted and C9depleted sera also restored the hemolysis markedly (72.82710.61% for C2 and 63.2172.27% for C9).", [["sera", "ANATOMY", 27, 31], ["hemolysis", "DISEASE", 50, 59], ["C2", "GENE_OR_GENE_PRODUCT", 0, 2], ["C9depleted", "ORGANISM", 16, 26], ["sera", "ORGANISM_SUBSTANCE", 27, 31], ["C2", "PROTEIN", 0, 2], ["C9", "PROTEIN", 110, 112], ["the hemolysis", "PROBLEM", 46, 59], ["C2", "TEST", 87, 89], ["depleted", "OBSERVATION", 3, 11], ["hemolysis", "OBSERVATION", 50, 59]]], ["However, CHCP nearly abolished the hemolysis when C3-or C4-depleted serum was added (9.2971.69% for C3, 12.3471.39% for C4).", [["serum", "ANATOMY", 68, 73], ["CHCP", "CHEMICAL", 9, 13], ["hemolysis", "DISEASE", 35, 44], ["CHCP", "CHEMICAL", 9, 13], ["CHCP", "SIMPLE_CHEMICAL", 9, 13], ["C3", "SIMPLE_CHEMICAL", 50, 52], ["C4", "SIMPLE_CHEMICAL", 56, 58], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["C3", "PROTEIN", 50, 52], ["the hemolysis", "PROBLEM", 31, 44], ["C3", "TEST", 50, 52], ["C4-depleted serum", "TEST", 56, 73], ["C3", "TEST", 100, 102], ["hemolysis", "OBSERVATION", 35, 44]]], ["For C5, the hemolysis was only partly restored (44.5473.92%).", [["hemolysis", "DISEASE", 12, 21], ["the hemolysis", "TEST", 8, 21], ["hemolysis", "OBSERVATION", 12, 21]]], ["These results suggested that CHCP mainly block C3 and C4, and may interact with C5.Characterization of CHCP and its anti-complementary activities in vitroAs shown in Table 1Histopathological observation and complement activation products depositionHistopathological findings of lung tissues with H&E staining showed clear pulmonary structure and little cellular influx in the Sham group, whereas the ALI animals exhibited severe lung injury, including marked interstitial edema, septal thickening, hemorrhage and inflammatory cell infiltration (Fig. 3A) .", [["lung tissues", "ANATOMY", 278, 290], ["pulmonary", "ANATOMY", 322, 331], ["cellular", "ANATOMY", 353, 361], ["lung", "ANATOMY", 429, 433], ["interstitial", "ANATOMY", 459, 471], ["septal", "ANATOMY", 479, 485], ["inflammatory cell", "ANATOMY", 513, 530], ["CHCP", "CHEMICAL", 29, 33], ["CHCP", "CHEMICAL", 103, 107], ["ALI", "DISEASE", 400, 403], ["lung injury", "DISEASE", 429, 440], ["interstitial edema", "DISEASE", 459, 477], ["hemorrhage", "DISEASE", 498, 508], ["CHCP", "CHEMICAL", 29, 33], ["CHCP", "SIMPLE_CHEMICAL", 29, 33], ["C3", "GENE_OR_GENE_PRODUCT", 47, 49], ["C4", "GENE_OR_GENE_PRODUCT", 54, 56], ["CHCP", "SIMPLE_CHEMICAL", 103, 107], ["lung tissues", "TISSUE", 278, 290], ["pulmonary", "ORGAN", 322, 331], ["cellular", "CELL", 353, 361], ["lung", "ORGAN", 429, 433], ["interstitial edema", "PATHOLOGICAL_FORMATION", 459, 477], ["septal", "TISSUE", 479, 485], ["inflammatory cell", "CELL", 513, 530], ["CHCP", "PROTEIN", 29, 33], ["C3", "PROTEIN", 47, 49], ["C4", "PROTEIN", 54, 56], ["C5", "PROTEIN", 80, 82], ["CHCP mainly block C3 and C4", "PROBLEM", 29, 56], ["CHCP", "TEST", 103, 107], ["complement activation products", "TREATMENT", 207, 237], ["lung tissues", "PROBLEM", 278, 290], ["H&E staining", "TEST", 296, 308], ["clear pulmonary structure", "PROBLEM", 316, 341], ["severe lung injury", "PROBLEM", 422, 440], ["marked interstitial edema", "PROBLEM", 452, 477], ["septal thickening", "PROBLEM", 479, 496], ["hemorrhage", "PROBLEM", 498, 508], ["inflammatory cell infiltration", "PROBLEM", 513, 543], ["C4", "ANATOMY_MODIFIER", 54, 56], ["C5", "ANATOMY_MODIFIER", 80, 82], ["lung", "ANATOMY", 278, 282], ["clear", "OBSERVATION_MODIFIER", 316, 321], ["pulmonary", "ANATOMY", 322, 331], ["little", "OBSERVATION_MODIFIER", 346, 352], ["cellular", "OBSERVATION_MODIFIER", 353, 361], ["influx", "OBSERVATION_MODIFIER", 362, 368], ["ALI", "ANATOMY", 400, 403], ["severe", "OBSERVATION_MODIFIER", 422, 428], ["lung", "ANATOMY", 429, 433], ["injury", "OBSERVATION", 434, 440], ["marked", "OBSERVATION_MODIFIER", 452, 458], ["interstitial", "ANATOMY_MODIFIER", 459, 471], ["edema", "OBSERVATION", 472, 477], ["septal", "ANATOMY_MODIFIER", 479, 485], ["thickening", "OBSERVATION", 486, 496], ["hemorrhage", "OBSERVATION", 498, 508], ["inflammatory cell infiltration", "OBSERVATION", 513, 543]]], ["Prednisone was effective in suppressing lung damage.", [["lung", "ANATOMY", 40, 44], ["Prednisone", "CHEMICAL", 0, 10], ["lung damage", "DISEASE", 40, 51], ["Prednisone", "CHEMICAL", 0, 10], ["Prednisone", "SIMPLE_CHEMICAL", 0, 10], ["lung", "ORGAN", 40, 44], ["Prednisone", "TREATMENT", 0, 10], ["suppressing lung damage", "PROBLEM", 28, 51], ["lung", "ANATOMY", 40, 44], ["damage", "OBSERVATION", 45, 51]]], ["Administration of CHCP (50 mg/kg and 100 mg/kg) significantly attenuated the neutrophil accumulation, alveolar wall thickening, and intra-alveolar exudation.", [["neutrophil", "ANATOMY", 77, 87], ["alveolar wall", "ANATOMY", 102, 115], ["intra-alveolar", "ANATOMY", 132, 146], ["CHCP", "CHEMICAL", 18, 22], ["CHCP", "CHEMICAL", 18, 22], ["CHCP", "SIMPLE_CHEMICAL", 18, 22], ["neutrophil", "CELL", 77, 87], ["alveolar wall", "TISSUE", 102, 115], ["intra-alveolar", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 146], ["CHCP", "TREATMENT", 18, 22], ["the neutrophil accumulation", "PROBLEM", 73, 100], ["alveolar wall thickening", "PROBLEM", 102, 126], ["intra-alveolar exudation", "PROBLEM", 132, 156], ["neutrophil accumulation", "OBSERVATION", 77, 100], ["alveolar", "ANATOMY_MODIFIER", 102, 110], ["wall", "ANATOMY_MODIFIER", 111, 115], ["thickening", "OBSERVATION", 116, 126], ["intra-alveolar exudation", "OBSERVATION", 132, 156]]], ["However, serious pulmonary inflammation was still seen in the low-dose group of CHCP (25 mg/kg).", [["pulmonary", "ANATOMY", 17, 26], ["pulmonary inflammation", "DISEASE", 17, 39], ["CHCP", "CHEMICAL", 80, 84], ["CHCP", "CHEMICAL", 80, 84], ["pulmonary", "ORGAN", 17, 26], ["CHCP", "SIMPLE_CHEMICAL", 80, 84], ["serious pulmonary inflammation", "PROBLEM", 9, 39], ["CHCP", "TREATMENT", 80, 84], ["serious", "OBSERVATION_MODIFIER", 9, 16], ["pulmonary", "ANATOMY", 17, 26], ["inflammation", "OBSERVATION", 27, 39]]], ["The above results were confirmed by the total lung injury scores listed in Table 2 .Histopathological observation and complement activation products depositionThe result of immunohistochemistry showed very low level of yellow-stained deposit of C3c in the lungs of sham group, but very intense C3c deposit in the model group.", [["lung", "ANATOMY", 46, 50], ["lungs", "ANATOMY", 256, 261], ["lung injury", "DISEASE", 46, 57], ["lung", "ORGAN", 46, 50], ["C3c", "GENE_OR_GENE_PRODUCT", 245, 248], ["lungs", "ORGAN", 256, 261], ["C3c", "GENE_OR_GENE_PRODUCT", 294, 297], ["C3c", "PROTEIN", 245, 248], ["C3c", "PROTEIN", 294, 297], ["the total lung injury scores", "PROBLEM", 36, 64], ["Histopathological observation", "TEST", 84, 113], ["complement activation products deposition", "TREATMENT", 118, 159], ["immunohistochemistry", "TEST", 173, 193], ["very low level of yellow-stained deposit of C3c", "PROBLEM", 201, 248], ["very intense C3c deposit", "PROBLEM", 281, 305], ["lung", "ANATOMY", 46, 50], ["injury", "OBSERVATION", 51, 57], ["very", "OBSERVATION_MODIFIER", 201, 205], ["low level", "OBSERVATION_MODIFIER", 206, 215], ["yellow", "OBSERVATION_MODIFIER", 219, 225], ["stained deposit", "OBSERVATION", 226, 241], ["C3c", "OBSERVATION", 245, 248], ["lungs", "ANATOMY", 256, 261], ["sham", "ANATOMY", 265, 269], ["very", "OBSERVATION_MODIFIER", 281, 285], ["intense", "OBSERVATION_MODIFIER", 286, 293], ["C3c deposit", "OBSERVATION", 294, 305], ["model group", "OBSERVATION_MODIFIER", 313, 324]]], ["Treatment with CHCP (50 and 100 mg/kg) significantly reduced the complement activation products deposit in the lungs of ALI rats (Fig. 3B ).CHCP attenuated severity of inflammation in the lung and BALFAs shown in Table 2 , the lung W/D ratio in ALI model group was notably higher than that in the Sham group.", [["lungs", "ANATOMY", 111, 116], ["lung", "ANATOMY", 188, 192], ["lung", "ANATOMY", 227, 231], ["CHCP", "CHEMICAL", 15, 19], ["ALI", "DISEASE", 120, 123], ["CHCP", "CHEMICAL", 140, 144], ["inflammation", "DISEASE", 168, 180], ["ALI", "DISEASE", 245, 248], ["CHCP", "CHEMICAL", 15, 19], ["CHCP", "CHEMICAL", 140, 144], ["CHCP", "SIMPLE_CHEMICAL", 15, 19], ["lungs", "ORGAN", 111, 116], ["rats", "ORGANISM", 124, 128], ["CHCP", "SIMPLE_CHEMICAL", 140, 144], ["lung", "ORGAN", 188, 192], ["lung", "ORGAN", 227, 231], ["D", "SIMPLE_CHEMICAL", 234, 235], ["complement activation products", "PROTEIN", 65, 95], ["rats", "SPECIES", 124, 128], ["CHCP", "TREATMENT", 15, 19], ["the complement activation products", "TREATMENT", 61, 95], ["inflammation in the lung and BALFAs", "PROBLEM", 168, 203], ["the lung W/D ratio", "TEST", 223, 241], ["activation products", "OBSERVATION", 76, 95], ["deposit", "OBSERVATION_MODIFIER", 96, 103], ["lungs", "ANATOMY", 111, 116], ["ALI", "ANATOMY", 120, 123], ["attenuated", "OBSERVATION_MODIFIER", 145, 155], ["severity", "OBSERVATION_MODIFIER", 156, 164], ["inflammation", "OBSERVATION", 168, 180], ["lung", "ANATOMY", 188, 192], ["lung", "ANATOMY", 227, 231], ["ALI model", "OBSERVATION", 245, 254], ["higher", "OBSERVATION_MODIFIER", 273, 279]]], ["The lung W/D ratios were significantly reduced in 100 and 50 mg/kg CHCP groups (Po0.01 and Po0.05, respectively), as well as in prednisone group (Po0.05), compared with ALI rats.CHCP attenuated severity of inflammation in the lung and BALFElevated protein concentration in BALF is an important marker of injury to the pulmonary alveolar-capillary barrier.", [["lung", "ANATOMY", 4, 8], ["lung", "ANATOMY", 226, 230], ["BALF", "ANATOMY", 273, 277], ["pulmonary alveolar-capillary barrier", "ANATOMY", 318, 354], ["prednisone", "CHEMICAL", 128, 138], ["ALI", "DISEASE", 169, 172], ["CHCP", "CHEMICAL", 178, 182], ["inflammation", "DISEASE", 206, 218], ["CHCP", "CHEMICAL", 67, 71], ["prednisone", "CHEMICAL", 128, 138], ["lung", "ORGAN", 4, 8], ["D", "SIMPLE_CHEMICAL", 11, 12], ["prednisone", "SIMPLE_CHEMICAL", 128, 138], ["rats", "ORGANISM", 173, 177], ["CHCP", "SIMPLE_CHEMICAL", 178, 182], ["lung", "ORGAN", 226, 230], ["BALFElevated protein", "GENE_OR_GENE_PRODUCT", 235, 255], ["BALF", "ORGANISM_SUBSTANCE", 273, 277], ["pulmonary alveolar-capillary barrier", "TISSUE", 318, 354], ["BALF", "CELL_TYPE", 273, 277], ["rats", "SPECIES", 173, 177], ["The lung W/D ratios", "TEST", 0, 19], ["prednisone group", "TREATMENT", 128, 144], ["inflammation in the lung and BALFElevated protein concentration in BALF", "PROBLEM", 206, 277], ["injury", "PROBLEM", 304, 310], ["lung", "ANATOMY", 4, 8], ["attenuated", "OBSERVATION_MODIFIER", 183, 193], ["severity", "OBSERVATION_MODIFIER", 194, 202], ["inflammation", "OBSERVATION", 206, 218], ["lung", "ANATOMY", 226, 230], ["BALFElevated protein", "OBSERVATION", 235, 255], ["concentration", "OBSERVATION_MODIFIER", 256, 269], ["BALF", "ANATOMY", 273, 277], ["injury", "OBSERVATION", 304, 310], ["pulmonary", "ANATOMY", 318, 327], ["alveolar", "ANATOMY_MODIFIER", 328, 336], ["capillary barrier", "OBSERVATION", 337, 354]]], ["The pulmonary protein exudation was significantly reduced by CHCP at the dose of 50 and 100 mg/kg and by prednisone (Fig. 4) , indicating that the treatment ameliorated the alveolar-capillary barrier damage during ALI.CHCP attenuated severity of inflammation in the lung and BALFThe cells in BALF were classified and counted to estimate the inflammatory responses during ALI.", [["pulmonary", "ANATOMY", 4, 13], ["alveolar-capillary barrier", "ANATOMY", 173, 199], ["lung", "ANATOMY", 266, 270], ["BALF", "ANATOMY", 275, 279], ["cells", "ANATOMY", 283, 288], ["BALF", "ANATOMY", 292, 296], ["CHCP", "CHEMICAL", 61, 65], ["prednisone", "CHEMICAL", 105, 115], ["ALI.CHCP", "CHEMICAL", 214, 222], ["inflammation", "DISEASE", 246, 258], ["ALI", "DISEASE", 371, 374], ["CHCP", "CHEMICAL", 61, 65], ["prednisone", "CHEMICAL", 105, 115], ["pulmonary", "ORGAN", 4, 13], ["CHCP", "SIMPLE_CHEMICAL", 61, 65], ["prednisone", "SIMPLE_CHEMICAL", 105, 115], ["alveolar-capillary barrier", "TISSUE", 173, 199], ["lung", "ORGAN", 266, 270], ["cells", "CELL", 283, 288], ["BALF", "CELL", 292, 296], ["BALF", "CELL_TYPE", 275, 279], ["BALF", "CELL_TYPE", 292, 296], ["The pulmonary protein exudation", "PROBLEM", 0, 31], ["prednisone", "TREATMENT", 105, 115], ["the treatment", "TREATMENT", 143, 156], ["capillary barrier damage", "PROBLEM", 182, 206], ["inflammation in the lung", "PROBLEM", 246, 270], ["BALF", "TEST", 275, 279], ["The cells in BALF", "TEST", 279, 296], ["pulmonary", "ANATOMY", 4, 13], ["protein exudation", "OBSERVATION", 14, 31], ["alveolar", "ANATOMY", 173, 181], ["capillary barrier", "OBSERVATION", 182, 199], ["inflammation", "OBSERVATION", 246, 258], ["lung", "ANATOMY", 266, 270], ["BALF", "ANATOMY", 275, 279], ["BALF", "ANATOMY", 292, 296], ["inflammatory", "OBSERVATION", 341, 353]]], ["BALF from the Sham animals contained the minimal number of leukocytes, the lowest percentage of neutrophils and the highest proportion of lymphocytes.", [["BALF", "ANATOMY", 0, 4], ["leukocytes", "ANATOMY", 59, 69], ["neutrophils", "ANATOMY", 96, 107], ["lymphocytes", "ANATOMY", 138, 149], ["BALF", "ORGANISM_SUBSTANCE", 0, 4], ["Sham animals", "ORGANISM", 14, 26], ["leukocytes", "CELL", 59, 69], ["neutrophils", "CELL", 96, 107], ["lymphocytes", "CELL", 138, 149], ["BALF", "CELL_TYPE", 0, 4], ["leukocytes", "CELL_TYPE", 59, 69], ["neutrophils", "CELL_TYPE", 96, 107], ["lymphocytes", "CELL_TYPE", 138, 149], ["BALF from the Sham animals", "TEST", 0, 26], ["neutrophils", "TEST", 96, 107], ["minimal", "OBSERVATION_MODIFIER", 41, 48], ["number", "OBSERVATION_MODIFIER", 49, 55], ["leukocytes", "ANATOMY", 59, 69], ["lowest", "OBSERVATION_MODIFIER", 75, 81], ["percentage", "OBSERVATION_MODIFIER", 82, 92], ["neutrophils", "OBSERVATION", 96, 107], ["highest", "OBSERVATION_MODIFIER", 116, 123], ["lymphocytes", "ANATOMY", 138, 149]]], ["The development of ALI elicited a massive recruitment of total leukocytes and neutrophils into the lungs.", [["leukocytes", "ANATOMY", 63, 73], ["neutrophils", "ANATOMY", 78, 89], ["lungs", "ANATOMY", 99, 104], ["ALI", "DISEASE", 19, 22], ["leukocytes", "CELL", 63, 73], ["neutrophils", "CELL", 78, 89], ["lungs", "ORGAN", 99, 104], ["total leukocytes", "CELL_TYPE", 57, 73], ["neutrophils", "CELL_TYPE", 78, 89], ["ALI", "PROBLEM", 19, 22], ["total leukocytes and neutrophils into the lungs", "PROBLEM", 57, 104], ["ALI", "OBSERVATION", 19, 22], ["massive", "OBSERVATION_MODIFIER", 34, 41], ["recruitment", "OBSERVATION_MODIFIER", 42, 53], ["total leukocytes", "OBSERVATION", 57, 73], ["neutrophils", "OBSERVATION", 78, 89], ["lungs", "ANATOMY", 99, 104]]], ["As shown in Fig. 4 , the numbers of leukocytes and the percentages of neutrophils in BALF were apparently higher in ALI animals (Po0.001) than those in Sham animals, while the proportion of lymphocytes in BALF was much lower (Po0.001).", [["leukocytes", "ANATOMY", 36, 46], ["neutrophils", "ANATOMY", 70, 81], ["BALF", "ANATOMY", 85, 89], ["lymphocytes", "ANATOMY", 190, 201], ["BALF", "ANATOMY", 205, 209], ["ALI", "DISEASE", 116, 119], ["leukocytes", "CELL", 36, 46], ["neutrophils", "CELL", 70, 81], ["BALF", "CELL", 85, 89], ["Sham animals", "ORGANISM", 152, 164], ["lymphocytes", "CELL", 190, 201], ["BALF", "CELL", 205, 209], ["leukocytes", "CELL_TYPE", 36, 46], ["neutrophils", "CELL_TYPE", 70, 81], ["BALF", "CELL_TYPE", 85, 89], ["lymphocytes", "CELL_TYPE", 190, 201], ["BALF", "CELL_TYPE", 205, 209], ["leukocytes", "TEST", 36, 46], ["neutrophils in BALF", "TEST", 70, 89], ["lymphocytes in BALF", "TEST", 190, 209], ["Fig", "OBSERVATION", 12, 15], ["numbers", "OBSERVATION_MODIFIER", 25, 32], ["leukocytes", "OBSERVATION", 36, 46], ["percentages", "OBSERVATION_MODIFIER", 55, 66], ["neutrophils", "OBSERVATION", 70, 81], ["higher", "OBSERVATION_MODIFIER", 106, 112], ["lymphocytes", "OBSERVATION", 190, 201], ["BALF", "ANATOMY", 205, 209]]], ["Administration of CHCP (50 and 100 mg/kg) and prednisone apparently suppressed the accumulation of leukocytes and attenuated lung neutrophilia, as indicated by the reduction in total leukocyte counts and neutrophil percentages in BALF, while they all had good ability in inhibiting the decrease of lymphocytes (Po0.001).Effect on SOD activity and MDA contentAs shown in Fig. 4 , the pathogenesis of ALI resulted in significant decrease of SOD activity and marked increase of MDA content in comparison with the Sham group (Po0.001).", [["leukocytes", "ANATOMY", 99, 109], ["lung", "ANATOMY", 125, 129], ["leukocyte", "ANATOMY", 183, 192], ["neutrophil", "ANATOMY", 204, 214], ["BALF", "ANATOMY", 230, 234], ["lymphocytes", "ANATOMY", 298, 309], ["CHCP", "CHEMICAL", 18, 22], ["prednisone", "CHEMICAL", 46, 56], ["lung neutrophilia", "DISEASE", 125, 142], ["MDA", "CHEMICAL", 347, 350], ["ALI", "DISEASE", 399, 402], ["MDA", "CHEMICAL", 475, 478], ["CHCP", "CHEMICAL", 18, 22], ["prednisone", "CHEMICAL", 46, 56], ["MDA", "CHEMICAL", 347, 350], ["MDA", "CHEMICAL", 475, 478], ["CHCP", "SIMPLE_CHEMICAL", 18, 22], ["prednisone", "SIMPLE_CHEMICAL", 46, 56], ["leukocytes", "CELL", 99, 109], ["lung", "ORGAN", 125, 129], ["leukocyte", "CELL", 183, 192], ["neutrophil", "CELL", 204, 214], ["BALF", "ORGANISM_SUBSTANCE", 230, 234], ["lymphocytes", "CELL", 298, 309], ["SOD", "SIMPLE_CHEMICAL", 330, 333], ["MDA", "SIMPLE_CHEMICAL", 347, 350], ["SOD", "GENE_OR_GENE_PRODUCT", 439, 442], ["MDA", "SIMPLE_CHEMICAL", 475, 478], ["leukocytes", "CELL_TYPE", 99, 109], ["neutrophil", "CELL_TYPE", 204, 214], ["BALF", "CELL_TYPE", 230, 234], ["lymphocytes", "CELL_TYPE", 298, 309], ["SOD", "PROTEIN", 330, 333], ["SOD", "PROTEIN", 439, 442], ["CHCP", "TREATMENT", 18, 22], ["prednisone", "TREATMENT", 46, 56], ["the accumulation of leukocytes", "PROBLEM", 79, 109], ["attenuated lung neutrophilia", "PROBLEM", 114, 142], ["total leukocyte counts", "TEST", 177, 199], ["neutrophil percentages", "TEST", 204, 226], ["BALF", "TEST", 230, 234], ["the decrease of lymphocytes", "PROBLEM", 282, 309], ["SOD activity", "TEST", 330, 342], ["MDA content", "TEST", 347, 358], ["ALI", "PROBLEM", 399, 402], ["significant decrease of SOD activity", "PROBLEM", 415, 451], ["marked increase of MDA content", "PROBLEM", 456, 486], ["leukocytes", "OBSERVATION", 99, 109], ["attenuated", "OBSERVATION_MODIFIER", 114, 124], ["lung", "ANATOMY", 125, 129], ["neutrophilia", "OBSERVATION", 130, 142], ["reduction", "OBSERVATION_MODIFIER", 164, 173], ["total leukocyte counts", "OBSERVATION", 177, 199], ["neutrophil percentages", "OBSERVATION", 204, 226], ["decrease", "OBSERVATION_MODIFIER", 286, 294], ["MDA content", "OBSERVATION", 347, 358], ["ALI", "OBSERVATION", 399, 402], ["significant", "OBSERVATION_MODIFIER", 415, 426], ["decrease", "OBSERVATION_MODIFIER", 427, 435], ["SOD activity", "OBSERVATION", 439, 451], ["marked", "OBSERVATION_MODIFIER", 456, 462], ["increase", "OBSERVATION_MODIFIER", 463, 471], ["MDA content", "OBSERVATION", 475, 486]]], ["Treatment with prednisone or CHCP at the dose of 50 and 100 mg/kg significantly Figure 2 Hemolytic assays for individual components utilizing C-depleted serum.", [["serum", "ANATOMY", 153, 158], ["prednisone", "CHEMICAL", 15, 25], ["CHCP", "CHEMICAL", 29, 33], ["prednisone", "CHEMICAL", 15, 25], ["CHCP", "CHEMICAL", 29, 33], ["prednisone", "SIMPLE_CHEMICAL", 15, 25], ["CHCP", "SIMPLE_CHEMICAL", 29, 33], ["C", "SIMPLE_CHEMICAL", 142, 143], ["serum", "ORGANISM_SUBSTANCE", 153, 158], ["prednisone", "TREATMENT", 15, 25], ["CHCP", "TREATMENT", 29, 33], ["Hemolytic assays", "TEST", 89, 105], ["individual components", "PROBLEM", 110, 131], ["C-depleted serum", "TREATMENT", 142, 158]]], ["CHCP-treated serum was mixed with various depleted sera, and the capacity of these depleted sera to restore the classical pathway hemolysis was estimated by adding sheep antibodysensitized erythrocytes.", [["serum", "ANATOMY", 13, 18], ["sera", "ANATOMY", 51, 55], ["sera", "ANATOMY", 92, 96], ["erythrocytes", "ANATOMY", 189, 201], ["CHCP", "CHEMICAL", 0, 4], ["hemolysis", "DISEASE", 130, 139], ["CHCP", "CHEMICAL", 0, 4], ["CHCP", "SIMPLE_CHEMICAL", 0, 4], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["sera", "ORGANISM_SUBSTANCE", 51, 55], ["sera", "ORGANISM_SUBSTANCE", 92, 96], ["erythrocytes", "CELL", 189, 201], ["CHCP", "PROTEIN", 0, 4], ["sheep antibodysensitized erythrocytes", "CELL_TYPE", 164, 201], ["sheep", "SPECIES", 164, 169], ["sheep", "SPECIES", 164, 169], ["various depleted sera", "PROBLEM", 34, 55], ["these depleted sera", "PROBLEM", 77, 96], ["the classical pathway hemolysis", "PROBLEM", 108, 139], ["sheep antibodysensitized erythrocytes", "PROBLEM", 164, 201], ["depleted", "OBSERVATION_MODIFIER", 42, 50], ["sera", "OBSERVATION", 51, 55], ["hemolysis", "OBSERVATION", 130, 139]]], ["Results were expressed as hemolytic percentages.", [["hemolytic", "DISEASE", 26, 35], ["hemolytic percentages", "TEST", 26, 47], ["hemolytic", "OBSERVATION_MODIFIER", 26, 35]]], ["Data were listed as mean7SD, n \u00bc3. .001) , indicating that CHCP reduced the consumption of the complement components (Fig. 5 ).Effect of CHCP on LPS-induced fever3.3.1.", [["CHCP", "CHEMICAL", 59, 63], ["CHCP", "CHEMICAL", 137, 141], ["LPS", "CHEMICAL", 145, 148], ["CHCP", "CHEMICAL", 59, 63], ["CHCP", "SIMPLE_CHEMICAL", 59, 63], ["CHCP", "SIMPLE_CHEMICAL", 137, 141], ["LPS", "SIMPLE_CHEMICAL", 145, 148], ["LPS", "TEST", 145, 148]]], ["Body temperature and the TRI During the experiment, the body temperature of rats in sham group was maintained at a normal range with minor changes.", [["Body", "ANATOMY", 0, 4], ["body", "ANATOMY", 56, 60], ["TRI", "CHEMICAL", 25, 28], ["Body", "ORGANISM_SUBDIVISION", 0, 4], ["body", "ORGANISM_SUBDIVISION", 56, 60], ["rats", "ORGANISM", 76, 80], ["rats", "SPECIES", 76, 80], ["Body temperature", "TEST", 0, 16], ["the TRI", "TEST", 21, 28], ["the body temperature", "TEST", 52, 72]]], ["The body temperature and TRI of the model group were significantly higher than those of the sham group at 30 min and from 2 to 6 h (Po0.01 or 0.001), except for a normal period from 60 to 90 min (Fig. 6A ).Effect of CHCP on LPS-induced feverAs shown in Fig. 3A , the CHCP (50, 100 and 200 mg/kg) treatment significantly inhibited the fever induced by LPS from 30 min to 6 h (Po0.05, 0.01 or 0.001).", [["body", "ANATOMY", 4, 8], ["TRI", "CHEMICAL", 25, 28], ["CHCP", "CHEMICAL", 216, 220], ["LPS", "CHEMICAL", 224, 227], ["feverAs", "DISEASE", 236, 243], ["CHCP", "CHEMICAL", 267, 271], ["fever", "DISEASE", 334, 339], ["LPS", "CHEMICAL", 351, 354], ["CHCP", "CHEMICAL", 267, 271], ["body", "ORGANISM_SUBDIVISION", 4, 8], ["CHCP", "SIMPLE_CHEMICAL", 216, 220], ["LPS", "SIMPLE_CHEMICAL", 224, 227], ["CHCP", "SIMPLE_CHEMICAL", 267, 271], ["LPS", "SIMPLE_CHEMICAL", 351, 354], ["The body temperature", "TEST", 0, 20], ["LPS", "TEST", 224, 227], ["feverAs", "PROBLEM", 236, 243], ["treatment", "TREATMENT", 296, 305], ["the fever", "PROBLEM", 330, 339], ["body", "OBSERVATION_MODIFIER", 4, 8], ["fever", "OBSERVATION", 334, 339]]], ["Aspirin also inhibited the temperature increase.", [["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "CHEMICAL", 0, 7], ["Aspirin", "SIMPLE_CHEMICAL", 0, 7], ["Aspirin", "TREATMENT", 0, 7], ["the temperature increase", "PROBLEM", 23, 47]]], ["Similar results were found in TRI (Fig. 6B ).Complement activity in sera and number of leukocytes in peripheral bloodAs shown in Fig. 6C , complement levels of the model group were significantly decreased compared with those of the sham group (Po0.001).", [["sera", "ANATOMY", 68, 72], ["leukocytes", "ANATOMY", 87, 97], ["peripheral blood", "ANATOMY", 101, 117], ["TRI", "CHEMICAL", 30, 33], ["Complement", "GENE_OR_GENE_PRODUCT", 45, 55], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["leukocytes", "CELL", 87, 97], ["peripheral blood", "ORGANISM_SUBSTANCE", 101, 117], ["leukocytes", "CELL_TYPE", 87, 97], ["Complement activity in sera", "PROBLEM", 45, 72], ["leukocytes", "TEST", 87, 97], ["peripheral blood", "TEST", 101, 117], ["complement levels", "TEST", 139, 156], ["activity", "OBSERVATION_MODIFIER", 56, 64], ["peripheral", "ANATOMY_MODIFIER", 101, 111], ["blood", "ANATOMY", 112, 117], ["significantly", "OBSERVATION_MODIFIER", 181, 194], ["decreased", "OBSERVATION_MODIFIER", 195, 204]]], ["LPS injection increased the number of leukocytes in peripheral blood (Po0.001) in the model rats (Fig. 6D) .Complement activity in sera and number of leukocytes in peripheral bloodThe CHCP (100 and 200 mg/kg) treatment partly restored complement levels in serum (Po0.05), but no significant effect was observed in the low-dose group of CHCP (50 mg/kg) and aspirin group.", [["leukocytes", "ANATOMY", 38, 48], ["peripheral blood", "ANATOMY", 52, 68], ["sera", "ANATOMY", 131, 135], ["leukocytes", "ANATOMY", 150, 160], ["peripheral blood", "ANATOMY", 164, 180], ["serum", "ANATOMY", 256, 261], ["LPS", "CHEMICAL", 0, 3], ["CHCP", "CHEMICAL", 184, 188], ["CHCP", "CHEMICAL", 336, 340], ["aspirin", "CHEMICAL", 356, 363], ["CHCP", "CHEMICAL", 336, 340], ["aspirin", "CHEMICAL", 356, 363], ["LPS", "SIMPLE_CHEMICAL", 0, 3], ["leukocytes", "CELL", 38, 48], ["peripheral blood", "ORGANISM_SUBSTANCE", 52, 68], ["Po0.001", "SIMPLE_CHEMICAL", 70, 77], ["rats", "ORGANISM", 92, 96], ["Complement", "GENE_OR_GENE_PRODUCT", 108, 118], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["leukocytes", "CELL", 150, 160], ["peripheral blood", "ORGANISM_SUBSTANCE", 164, 180], ["CHCP", "SIMPLE_CHEMICAL", 184, 188], ["serum", "ORGANISM_SUBSTANCE", 256, 261], ["Po0.05", "SIMPLE_CHEMICAL", 263, 269], ["CHCP", "SIMPLE_CHEMICAL", 336, 340], ["aspirin", "SIMPLE_CHEMICAL", 356, 363], ["leukocytes", "CELL_TYPE", 38, 48], ["leukocytes", "CELL_TYPE", 150, 160], ["rats", "SPECIES", 92, 96], ["LPS injection", "TREATMENT", 0, 13], ["peripheral blood", "TEST", 52, 68], ["Complement activity in sera", "PROBLEM", 108, 135], ["leukocytes", "TEST", 150, 160], ["treatment", "TREATMENT", 209, 218], ["complement levels", "TEST", 235, 252], ["serum", "TEST", 256, 261], ["CHCP", "TREATMENT", 336, 340], ["aspirin group", "TREATMENT", 356, 369], ["leukocytes", "OBSERVATION", 38, 48], ["peripheral", "ANATOMY_MODIFIER", 52, 62], ["blood", "ANATOMY", 63, 68], ["activity", "OBSERVATION_MODIFIER", 119, 127], ["peripheral", "ANATOMY_MODIFIER", 164, 174], ["blood", "ANATOMY", 175, 180], ["no", "UNCERTAINTY", 276, 278], ["significant", "OBSERVATION_MODIFIER", 279, 290], ["effect", "OBSERVATION", 291, 297]]], ["All the CHCP groups (50 mg/kg, Po0.01; 100 and 200 mg/kg, Po0.001) and aspirin group (Po0.001) significantly inhibited the increase in leukocytes in peripheral blood induced by LPS.DiscussionThe heat-clearing Chinese medicines are well known for their effects on fever and inflammation of infectious diseases.", [["leukocytes", "ANATOMY", 135, 145], ["peripheral blood", "ANATOMY", 149, 165], ["CHCP", "CHEMICAL", 8, 12], ["Po0.01", "CHEMICAL", 31, 37], ["aspirin", "CHEMICAL", 71, 78], ["Po0.001", "CHEMICAL", 86, 93], ["LPS", "CHEMICAL", 177, 180], ["fever", "DISEASE", 263, 268], ["inflammation", "DISEASE", 273, 285], ["infectious diseases", "DISEASE", 289, 308], ["aspirin", "CHEMICAL", 71, 78], ["aspirin", "SIMPLE_CHEMICAL", 71, 78], ["Po0.001", "SIMPLE_CHEMICAL", 86, 93], ["leukocytes", "CELL", 135, 145], ["peripheral blood", "ORGANISM_SUBSTANCE", 149, 165], ["LPS", "SIMPLE_CHEMICAL", 177, 180], ["leukocytes", "CELL_TYPE", 135, 145], ["All the CHCP groups", "TREATMENT", 0, 19], ["aspirin group", "TREATMENT", 71, 84], ["leukocytes in peripheral blood", "PROBLEM", 135, 165], ["The heat", "TREATMENT", 191, 199], ["clearing Chinese medicines", "TREATMENT", 200, 226], ["fever", "PROBLEM", 263, 268], ["inflammation of infectious diseases", "PROBLEM", 273, 308], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["leukocytes", "OBSERVATION", 135, 145], ["peripheral", "ANATOMY_MODIFIER", 149, 159], ["blood", "ANATOMY", 160, 165], ["infectious", "OBSERVATION", 289, 299]]], ["Our previous studies led to the isolation of a series of complement inhibitors from these medicines, indicating the inhibition on the excessively activated complement system would be a key mechanism for TCM to clear heat [20] [21] [22] [23] .", [["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 221, 240], ["Our previous studies", "TEST", 0, 20], ["complement inhibitors", "TREATMENT", 57, 78], ["these medicines", "TREATMENT", 84, 99]]], ["In this study, the anti-complementary properties of CHCP were elucidated both in vitro and in vivo.DiscussionThe in vitro experiments clearly revealed that CHCP is a potent anti-complementary agent affecting both classical pathway and the alternative pathway by selectively blocking the key components C3 and C4 in the complement activation cascade.", [["CHCP", "CHEMICAL", 52, 56], ["CHCP", "CHEMICAL", 156, 160], ["CHCP", "CHEMICAL", 52, 56], ["CHCP", "CHEMICAL", 156, 160], ["CHCP", "SIMPLE_CHEMICAL", 52, 56], ["CHCP", "SIMPLE_CHEMICAL", 156, 160], ["C3", "GENE_OR_GENE_PRODUCT", 302, 304], ["C4", "GENE_OR_GENE_PRODUCT", 309, 311], ["C3", "PROTEIN", 302, 304], ["C4", "PROTEIN", 309, 311], ["this study", "TEST", 3, 13], ["C4", "ANATOMY_MODIFIER", 309, 311], ["activation cascade", "OBSERVATION", 330, 348]]], ["As demonstrated in the literature, C3 functions to activate both the classical and alternative pathways and makes up 70% of the total protein in the complement system 30 .", [["C3", "GENE_OR_GENE_PRODUCT", 35, 37], ["C3", "PROTEIN", 35, 37], ["the total protein", "TEST", 124, 141]]], ["C4, the second most abundant complement protein in serum, is a glycoprotein which functions as the limited activation step in the activation of the classical pathway 2 .", [["serum", "ANATOMY", 51, 56], ["C4", "GENE_OR_GENE_PRODUCT", 0, 2], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["C4", "PROTEIN", 0, 2], ["complement protein", "PROTEIN", 29, 47], ["glycoprotein", "PROTEIN", 63, 75], ["a glycoprotein", "TREATMENT", 61, 75], ["protein", "OBSERVATION", 40, 47]]], ["It suggested that CHCP could be effective in treating the complement-associated diseases.", [["CHCP", "CHEMICAL", 18, 22], ["CHCP", "CHEMICAL", 18, 22], ["CHCP", "SIMPLE_CHEMICAL", 18, 22], ["the complement-associated diseases", "PROBLEM", 54, 88], ["diseases", "OBSERVATION", 80, 88]]], ["ALI is a life-threatening complication of various systemic inflammations and of pulmonary disorders that can cause a mortality rate of 30-40% 9 .", [["pulmonary", "ANATOMY", 80, 89], ["ALI", "DISEASE", 0, 3], ["inflammations", "DISEASE", 59, 72], ["pulmonary disorders", "DISEASE", 80, 99], ["pulmonary", "ORGAN", 80, 89], ["ALI", "PROBLEM", 0, 3], ["various systemic inflammations", "PROBLEM", 42, 72], ["pulmonary disorders", "PROBLEM", 80, 99], ["a mortality rate", "TEST", 115, 131], ["various", "OBSERVATION_MODIFIER", 42, 49], ["systemic", "OBSERVATION_MODIFIER", 50, 58], ["inflammations", "OBSERVATION", 59, 72], ["pulmonary", "ANATOMY", 80, 89], ["disorders", "OBSERVATION", 90, 99]]], ["The current main treatment against ALI has been the application of glucocorticoids, which often lead to severe adverse reactions during the long treatment.DiscussionHence, other choice of agents with less adverse effects is crucial to the recovery of ALI.", [["ALI", "DISEASE", 35, 38], ["ALI", "DISEASE", 251, 254], ["glucocorticoids", "SIMPLE_CHEMICAL", 67, 82], ["ALI", "PROBLEM", 35, 38], ["glucocorticoids", "TREATMENT", 67, 82], ["severe adverse reactions", "PROBLEM", 104, 128], ["the long treatment", "TREATMENT", 136, 154], ["agents", "TREATMENT", 188, 194], ["ALI", "PROBLEM", 251, 254], ["main", "OBSERVATION_MODIFIER", 12, 16], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["ALI", "OBSERVATION", 251, 254]]], ["Based on the important role of complement activation in the induction of inflammatory response in ALI/ ARDS 3, 12 , the in vivo anti-complementary activity of CHCP and its preventive effect on ALI were examined in the \"two-hit\" ALI rat model of ischemia/reperfusion (I/R) injury followed by LPS instillation.", [["ALI", "DISEASE", 98, 101], ["ARDS", "DISEASE", 103, 107], ["CHCP", "CHEMICAL", 159, 163], ["ALI", "DISEASE", 193, 196], ["ALI", "DISEASE", 228, 231], ["ischemia", "DISEASE", 245, 253], ["LPS", "CHEMICAL", 291, 294], ["CHCP", "CHEMICAL", 159, 163], ["CHCP", "SIMPLE_CHEMICAL", 159, 163], ["rat", "ORGANISM", 232, 235], ["LPS", "SIMPLE_CHEMICAL", 291, 294], ["rat", "SPECIES", 232, 235], ["inflammatory response", "PROBLEM", 73, 94], ["ALI", "PROBLEM", 98, 101], ["ARDS", "PROBLEM", 103, 107], ["ALI", "PROBLEM", 193, 196], ["ischemia", "PROBLEM", 245, 253], ["reperfusion (I/R) injury", "PROBLEM", 254, 278], ["LPS instillation", "TREATMENT", 291, 307], ["inflammatory", "OBSERVATION_MODIFIER", 73, 85], ["ARDS", "OBSERVATION", 103, 107], ["ischemia", "OBSERVATION", 245, 253], ["reperfusion", "OBSERVATION", 254, 265]]], ["This \"two-hit\" ALI rat model had been shown to induce an exaggerated response for more susceptibility to lung injury 24 .", [["lung", "ANATOMY", 105, 109], ["ALI", "DISEASE", 15, 18], ["lung injury", "DISEASE", 105, 116], ["rat", "ORGANISM", 19, 22], ["lung", "ORGAN", 105, 109], ["rat", "SPECIES", 19, 22], ["hit\" ALI rat model", "PROBLEM", 10, 28], ["an exaggerated response", "PROBLEM", 54, 77], ["lung injury", "PROBLEM", 105, 116], ["lung", "ANATOMY", 105, 109], ["injury", "OBSERVATION", 110, 116]]], ["I/R is believed to augment neutrophil-mediated lung injury by priming circulating neutrophils for increased superoxide production 31 .", [["neutrophil", "ANATOMY", 27, 37], ["lung", "ANATOMY", 47, 51], ["neutrophils", "ANATOMY", 82, 93], ["lung injury", "DISEASE", 47, 58], ["superoxide", "CHEMICAL", 108, 118], ["superoxide", "CHEMICAL", 108, 118], ["I/R", "GENE_OR_GENE_PRODUCT", 0, 3], ["neutrophil", "CELL", 27, 37], ["lung", "ORGAN", 47, 51], ["neutrophils", "CELL", 82, 93], ["superoxide", "SIMPLE_CHEMICAL", 108, 118], ["I/R", "PROTEIN", 0, 3], ["neutrophil", "CELL_TYPE", 27, 37], ["circulating neutrophils", "CELL_TYPE", 70, 93], ["neutrophil", "TEST", 27, 37], ["lung injury", "PROBLEM", 47, 58], ["increased superoxide production", "PROBLEM", 98, 129], ["neutrophil", "OBSERVATION", 27, 37], ["lung", "ANATOMY", 47, 51], ["injury", "OBSERVATION", 52, 58], ["superoxide production", "OBSERVATION", 108, 129]]], ["The activation of complement system is known to be necessary for the full development of inflammatory responses and tissue injuries associated with I/R in pulmonary injury 3 .", [["tissue", "ANATOMY", 116, 122], ["pulmonary", "ANATOMY", 155, 164], ["tissue injuries", "DISEASE", 116, 131], ["pulmonary injury", "DISEASE", 155, 171], ["tissue", "TISSUE", 116, 122], ["I/R", "GENE_OR_GENE_PRODUCT", 148, 151], ["pulmonary", "ORGAN", 155, 164], ["inflammatory responses", "PROBLEM", 89, 111], ["tissue injuries", "PROBLEM", 116, 131], ["I/R in pulmonary injury", "PROBLEM", 148, 171], ["inflammatory", "OBSERVATION", 89, 101], ["pulmonary", "ANATOMY", 155, 164], ["injury", "OBSERVATION", 165, 171]]], ["Based on I/R, intratracheal instillation of LPS will induce an ideal experimental model of ALI by resulting in pulmonary injury with great BALF neutrophil infiltration 32 .DiscussionHistological examination revealed marked inflammation, extensive alveolar wall thickness, congestion as well as diffused interstitial infiltration in ALI.", [["pulmonary", "ANATOMY", 111, 120], ["BALF neutrophil", "ANATOMY", 139, 154], ["alveolar wall", "ANATOMY", 247, 260], ["interstitial", "ANATOMY", 303, 315], ["LPS", "CHEMICAL", 44, 47], ["ALI", "DISEASE", 91, 94], ["pulmonary injury", "DISEASE", 111, 127], ["inflammation", "DISEASE", 223, 235], ["interstitial infiltration", "DISEASE", 303, 328], ["ALI", "DISEASE", 332, 335], ["I/R", "GENE_OR_GENE_PRODUCT", 9, 12], ["intratracheal", "IMMATERIAL_ANATOMICAL_ENTITY", 14, 27], ["LPS", "SIMPLE_CHEMICAL", 44, 47], ["pulmonary", "ORGAN", 111, 120], ["neutrophil", "CELL", 144, 154], ["alveolar wall", "MULTI-TISSUE_STRUCTURE", 247, 260], ["interstitial", "IMMATERIAL_ANATOMICAL_ENTITY", 303, 315], ["intratracheal instillation of LPS", "TREATMENT", 14, 47], ["pulmonary injury", "PROBLEM", 111, 127], ["great BALF neutrophil infiltration", "PROBLEM", 133, 167], ["Histological examination", "TEST", 182, 206], ["marked inflammation", "PROBLEM", 216, 235], ["extensive alveolar wall thickness", "PROBLEM", 237, 270], ["congestion", "PROBLEM", 272, 282], ["diffused interstitial infiltration in ALI", "PROBLEM", 294, 335], ["intratracheal", "ANATOMY", 14, 27], ["ALI", "OBSERVATION", 91, 94], ["pulmonary", "ANATOMY", 111, 120], ["injury", "OBSERVATION", 121, 127], ["great", "OBSERVATION_MODIFIER", 133, 138], ["BALF neutrophil infiltration", "OBSERVATION", 139, 167], ["marked", "OBSERVATION_MODIFIER", 216, 222], ["inflammation", "OBSERVATION", 223, 235], ["extensive", "OBSERVATION_MODIFIER", 237, 246], ["alveolar", "ANATOMY_MODIFIER", 247, 255], ["wall", "ANATOMY_MODIFIER", 256, 260], ["thickness", "OBSERVATION_MODIFIER", 261, 270], ["congestion", "OBSERVATION", 272, 282], ["diffused", "OBSERVATION_MODIFIER", 294, 302], ["interstitial", "ANATOMY_MODIFIER", 303, 315], ["infiltration", "OBSERVATION", 316, 328], ["ALI", "ANATOMY", 332, 335]]], ["The immunohistochemistry showed over-activation of complement in ALI by the abundantly increased complement activation products deposition.", [["ALI", "DISEASE", 65, 68], ["The immunohistochemistry", "TEST", 0, 24], ["complement in ALI", "PROBLEM", 51, 68], ["abundantly", "OBSERVATION_MODIFIER", 76, 86], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["complement activation", "OBSERVATION", 97, 118], ["products deposition", "OBSERVATION", 119, 138]]], ["The administration of CHCP (especially 50 and 100 mg/kg) significantly improved the histologic changes combined with the inhibition of the overactivation of complement system, the regulation of the oxidantantioxidant imbalance, as well as reducing the numbers of leukocytes and neutrophils in BALF.", [["leukocytes", "ANATOMY", 263, 273], ["neutrophils", "ANATOMY", 278, 289], ["BALF", "ANATOMY", 293, 297], ["CHCP", "CHEMICAL", 22, 26], ["CHCP", "CHEMICAL", 22, 26], ["CHCP", "SIMPLE_CHEMICAL", 22, 26], ["oxidantantioxidant", "SIMPLE_CHEMICAL", 198, 216], ["leukocytes", "CELL", 263, 273], ["neutrophils", "CELL", 278, 289], ["BALF", "CELL", 293, 297], ["leukocytes", "CELL_TYPE", 263, 273], ["neutrophils", "CELL_TYPE", 278, 289], ["BALF", "CELL_TYPE", 293, 297], ["CHCP", "TREATMENT", 22, 26], ["the histologic changes", "PROBLEM", 80, 102], ["the overactivation of complement system", "PROBLEM", 135, 174], ["the oxidantantioxidant imbalance", "PROBLEM", 194, 226], ["leukocytes", "TEST", 263, 273], ["neutrophils in BALF", "TEST", 278, 297], ["leukocytes", "ANATOMY", 263, 273]]], ["The protective effect of CHCP against ALI was also accompanied with a decrease in pulmonary edema indicated by lung W/D weight ratio, and a reduction in protein concentrations in the BALF, which represented a preserved pulmonary epithelial-endothelial barrier function 11 .", [["pulmonary", "ANATOMY", 82, 91], ["lung", "ANATOMY", 111, 115], ["BALF", "ANATOMY", 183, 187], ["pulmonary epithelial", "ANATOMY", 219, 239], ["endothelial", "ANATOMY", 240, 251], ["CHCP", "CHEMICAL", 25, 29], ["ALI", "DISEASE", 38, 41], ["pulmonary edema", "DISEASE", 82, 97], ["CHCP", "CHEMICAL", 25, 29], ["CHCP", "SIMPLE_CHEMICAL", 25, 29], ["pulmonary", "ORGAN", 82, 91], ["lung", "ORGAN", 111, 115], ["D", "SIMPLE_CHEMICAL", 118, 119], ["BALF", "ORGANISM_SUBSTANCE", 183, 187], ["pulmonary epithelial", "TISSUE", 219, 239], ["endothelial barrier", "TISSUE", 240, 259], ["BALF", "CELL_TYPE", 183, 187], ["ALI", "PROBLEM", 38, 41], ["a decrease in pulmonary edema", "PROBLEM", 68, 97], ["lung W/D weight ratio", "TEST", 111, 132], ["a reduction in protein concentrations", "PROBLEM", 138, 175], ["the BALF", "TEST", 179, 187], ["decrease", "OBSERVATION_MODIFIER", 70, 78], ["pulmonary", "ANATOMY", 82, 91], ["edema", "OBSERVATION", 92, 97], ["lung", "ANATOMY", 111, 115], ["reduction", "OBSERVATION_MODIFIER", 140, 149], ["protein concentrations", "OBSERVATION", 153, 175], ["BALF", "ANATOMY", 183, 187], ["preserved", "OBSERVATION", 209, 218], ["pulmonary", "ANATOMY", 219, 228], ["epithelial", "ANATOMY_MODIFIER", 229, 239], ["endothelial barrier function", "OBSERVATION", 240, 268]]], ["Activation of the complement system decreases complement levels in serum, which can be accounted for by the reduction in C3 or C4 concentrations 33 .", [["serum", "ANATOMY", 67, 72], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["C3", "SIMPLE_CHEMICAL", 121, 123], ["C3", "PROTEIN", 121, 123], ["the complement system", "TEST", 14, 35], ["complement levels in serum", "TEST", 46, 72], ["the reduction in C3 or C4 concentrations", "TREATMENT", 104, 144]]], ["In the Sham group, minor surgical injuries caused a slight activation of the complement cascade, represented by the minimal decrease of hemolysis of serum.", [["serum", "ANATOMY", 149, 154], ["injuries", "DISEASE", 34, 42], ["hemolysis", "DISEASE", 136, 145], ["serum", "ORGANISM_SUBSTANCE", 149, 154], ["minor surgical injuries", "PROBLEM", 19, 42], ["a slight activation of the complement cascade", "PROBLEM", 50, 95], ["hemolysis of serum", "PROBLEM", 136, 154], ["minor", "OBSERVATION_MODIFIER", 19, 24], ["surgical injuries", "OBSERVATION", 25, 42], ["slight", "OBSERVATION_MODIFIER", 52, 58], ["activation", "OBSERVATION", 59, 69], ["minimal", "OBSERVATION_MODIFIER", 116, 123], ["decrease", "OBSERVATION_MODIFIER", 124, 132], ["hemolysis", "OBSERVATION", 136, 145]]], ["The \"two-hit\" ALI caused significantly more complement consumption.", [["ALI", "DISEASE", 14, 17]]], ["Oral administration of CHCP (100 and 50 mg/kg) apparently reduced the consumption of complement system.", [["Oral", "ANATOMY", 0, 4], ["CHCP", "CHEMICAL", 23, 27], ["CHCP", "CHEMICAL", 23, 27], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["CHCP", "SIMPLE_CHEMICAL", 23, 27], ["Oral administration of CHCP", "TREATMENT", 0, 27], ["complement system", "TREATMENT", 85, 102]]], ["The effects of CHCP on C3 and C4 were consistent with the results of the in vitro complement-target test.DiscussionThe systemic activation of the complement system generates C5-derived chemotactic activity.", [["CHCP", "CHEMICAL", 15, 19], ["CHCP", "CHEMICAL", 15, 19], ["CHCP", "SIMPLE_CHEMICAL", 15, 19], ["C3", "GENE_OR_GENE_PRODUCT", 23, 25], ["C3", "PROTEIN", 23, 25], ["C5", "PROTEIN", 174, 176], ["CHCP on C3 and C4", "PROBLEM", 15, 32], ["C4", "ANATOMY", 30, 32], ["consistent with", "UNCERTAINTY", 38, 53], ["chemotactic activity", "OBSERVATION", 185, 205]]], ["This causes blood neutrophils to sequester in pulmonary capillaries and dramatically result in the release of toxic oxygen species, which can destroy pulmonary endothelial cells as well as basement membranes 34 .", [["blood neutrophils", "ANATOMY", 12, 29], ["pulmonary capillaries", "ANATOMY", 46, 67], ["pulmonary endothelial cells", "ANATOMY", 150, 177], ["basement membranes", "ANATOMY", 189, 207], ["oxygen", "CHEMICAL", 116, 122], ["oxygen", "CHEMICAL", 116, 122], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["neutrophils", "CELL", 18, 29], ["pulmonary capillaries", "TISSUE", 46, 67], ["oxygen species", "SIMPLE_CHEMICAL", 116, 130], ["pulmonary endothelial cells", "CELL", 150, 177], ["basement membranes", "CELLULAR_COMPONENT", 189, 207], ["blood neutrophils", "CELL_TYPE", 12, 29], ["pulmonary endothelial cells", "CELL_TYPE", 150, 177], ["blood neutrophils", "PROBLEM", 12, 29], ["toxic oxygen species", "PROBLEM", 110, 130], ["blood neutrophils", "OBSERVATION", 12, 29], ["pulmonary capillaries", "ANATOMY", 46, 67], ["toxic", "OBSERVATION_MODIFIER", 110, 115], ["oxygen species", "OBSERVATION", 116, 130], ["pulmonary", "ANATOMY", 150, 159], ["endothelial cells", "OBSERVATION", 160, 177]]], ["And an oxidant-antioxidant imbalance is thought to underlie as one of the important pathogenesis of lung injury 10 .", [["lung", "ANATOMY", 100, 104], ["lung injury", "DISEASE", 100, 111], ["lung", "ORGAN", 100, 104], ["an oxidant-antioxidant imbalance", "PROBLEM", 4, 36], ["lung injury", "PROBLEM", 100, 111], ["lung", "ANATOMY", 100, 104], ["injury", "OBSERVATION", 105, 111]]], ["These findings provide strong evidence that ALI following the over-activation of complement system is closely linked to the production of oxygen metabolites by lung-sequestered neutrophils.", [["lung", "ANATOMY", 160, 164], ["neutrophils", "ANATOMY", 177, 188], ["ALI", "DISEASE", 44, 47], ["oxygen", "CHEMICAL", 138, 144], ["oxygen", "CHEMICAL", 138, 144], ["oxygen", "SIMPLE_CHEMICAL", 138, 144], ["lung", "ORGAN", 160, 164], ["neutrophils", "CELL", 177, 188], ["lung-sequestered neutrophils", "CELL_TYPE", 160, 188], ["ALI", "PROBLEM", 44, 47], ["complement system", "TREATMENT", 81, 98], ["oxygen metabolites", "TEST", 138, 156], ["ALI", "OBSERVATION", 44, 47], ["oxygen metabolites", "OBSERVATION", 138, 156], ["lung", "ANATOMY", 160, 164], ["sequestered neutrophils", "OBSERVATION", 165, 188]]], ["In the experiment, the proportions of neutrophils were actually suppressed with the administration of CHCP, suggesting that CHCP potently attenuated the neutrophil respiratory burst.", [["neutrophils", "ANATOMY", 38, 49], ["neutrophil", "ANATOMY", 153, 163], ["CHCP", "CHEMICAL", 102, 106], ["CHCP", "CHEMICAL", 124, 128], ["CHCP", "CHEMICAL", 102, 106], ["CHCP", "CHEMICAL", 124, 128], ["neutrophils", "CELL", 38, 49], ["CHCP", "SIMPLE_CHEMICAL", 102, 106], ["CHCP", "SIMPLE_CHEMICAL", 124, 128], ["neutrophil", "CELL", 153, 163], ["neutrophils", "CELL_TYPE", 38, 49], ["the neutrophil respiratory burst", "PROBLEM", 149, 181], ["neutrophils", "OBSERVATION", 38, 49], ["neutrophil respiratory burst", "OBSERVATION", 153, 181]]], ["SOD is an important antioxidant enzyme that scavenges the superoxide free radicals 35 .", [["superoxide", "CHEMICAL", 58, 68], ["superoxide", "CHEMICAL", 58, 68], ["SOD", "GENE_OR_GENE_PRODUCT", 0, 3], ["superoxide", "SIMPLE_CHEMICAL", 58, 68], ["SOD", "PROTEIN", 0, 3]]], ["MDA is recognized as a standard measurement for the degree of oxidation 36 .", [["MDA", "CHEMICAL", 0, 3], ["MDA", "CHEMICAL", 0, 3], ["MDA", "SIMPLE_CHEMICAL", 0, 3], ["a standard measurement", "TEST", 21, 43]]], ["The pathogenesis of ALI resulted in the decreased SOD level and the elevated MDA content.", [["ALI", "DISEASE", 20, 23], ["MDA", "CHEMICAL", 77, 80], ["MDA", "CHEMICAL", 77, 80], ["SOD", "SIMPLE_CHEMICAL", 50, 53], ["MDA", "SIMPLE_CHEMICAL", 77, 80], ["SOD", "PROTEIN", 50, 53], ["ALI", "PROBLEM", 20, 23], ["the decreased SOD level", "PROBLEM", 36, 59], ["the elevated MDA content", "PROBLEM", 64, 88], ["ALI", "OBSERVATION", 20, 23], ["decreased", "OBSERVATION_MODIFIER", 40, 49], ["elevated", "OBSERVATION_MODIFIER", 68, 76], ["MDA content", "OBSERVATION", 77, 88]]], ["Taking CHCP could reduce the pulmonary oxidative stress to modulate the oxidantantioxidant balance.DiscussionLPS-induced fever is a classic inflammatory heat model, characterized with high body temperature, increased leukocyte and hyper-activated complement system 37 .", [["pulmonary", "ANATOMY", 29, 38], ["body", "ANATOMY", 189, 193], ["leukocyte", "ANATOMY", 217, 226], ["CHCP", "CHEMICAL", 7, 11], ["DiscussionLPS", "CHEMICAL", 99, 112], ["fever", "DISEASE", 121, 126], ["CHCP", "SIMPLE_CHEMICAL", 7, 11], ["pulmonary", "ORGAN", 29, 38], ["oxidantantioxidant", "SIMPLE_CHEMICAL", 72, 90], ["DiscussionLPS", "SIMPLE_CHEMICAL", 99, 112], ["body", "ORGANISM_SUBDIVISION", 189, 193], ["leukocyte", "CELL", 217, 226], ["complement system 37", "GENE_OR_GENE_PRODUCT", 247, 267], ["the pulmonary oxidative stress", "PROBLEM", 25, 55], ["fever", "PROBLEM", 121, 126], ["a classic inflammatory heat model", "PROBLEM", 130, 163], ["high body temperature", "PROBLEM", 184, 205], ["increased leukocyte", "PROBLEM", 207, 226], ["hyper-activated complement system", "PROBLEM", 231, 264], ["pulmonary", "ANATOMY", 29, 38], ["oxidative stress", "OBSERVATION", 39, 55], ["fever", "OBSERVATION", 121, 126], ["inflammatory", "OBSERVATION_MODIFIER", 140, 152], ["high body", "OBSERVATION_MODIFIER", 184, 193], ["increased", "OBSERVATION_MODIFIER", 207, 216], ["leukocyte", "ANATOMY", 217, 226]]], ["In this study, both CHCP, the complement inhibitor, and aspirin, the cyclooxygenase inhibitor, significantly decreased the body temperature and leukocytes in peripheral blood of the LPS-induced fever rats.", [["body", "ANATOMY", 123, 127], ["leukocytes", "ANATOMY", 144, 154], ["peripheral blood", "ANATOMY", 158, 174], ["CHCP", "CHEMICAL", 20, 24], ["aspirin", "CHEMICAL", 56, 63], ["LPS", "CHEMICAL", 182, 185], ["fever", "DISEASE", 194, 199], ["CHCP", "CHEMICAL", 20, 24], ["aspirin", "CHEMICAL", 56, 63], ["CHCP", "SIMPLE_CHEMICAL", 20, 24], ["aspirin", "SIMPLE_CHEMICAL", 56, 63], ["cyclooxygenase", "GENE_OR_GENE_PRODUCT", 69, 83], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["leukocytes", "CELL", 144, 154], ["peripheral blood", "ORGANISM_SUBSTANCE", 158, 174], ["LPS", "SIMPLE_CHEMICAL", 182, 185], ["rats", "ORGANISM", 200, 204], ["leukocytes", "CELL_TYPE", 144, 154], ["rats", "SPECIES", 200, 204], ["this study", "TEST", 3, 13], ["the complement inhibitor", "TREATMENT", 26, 50], ["aspirin", "TREATMENT", 56, 63], ["the cyclooxygenase inhibitor", "TREATMENT", 65, 93], ["the body temperature", "TEST", 119, 139], ["leukocytes", "TEST", 144, 154], ["the LPS", "TEST", 178, 185], ["fever rats", "PROBLEM", 194, 204], ["leukocytes", "OBSERVATION", 144, 154], ["peripheral", "ANATOMY_MODIFIER", 158, 168], ["blood", "ANATOMY", 169, 174]]], ["Remarkably, only CHCP (100 and 200 mg/kg) but not aspirin could inhibit the decreased complement level of the fever rats, indicating the characteristic effect of CHCP on complement system in vivo.DiscussionOur recent bioactivity-guided fractionation on CHCP led to the isolation of three anti-complementary homogeneous polysaccharides with CH 50 and AP 50 values not more than 0.3 mg/mL, and similar monosaccharide composition to that of CHCP (data not published).", [["CHCP", "CHEMICAL", 17, 21], ["aspirin", "CHEMICAL", 50, 57], ["fever", "DISEASE", 110, 115], ["CHCP", "CHEMICAL", 162, 166], ["CHCP", "CHEMICAL", 253, 257], ["CHCP", "CHEMICAL", 17, 21], ["aspirin", "CHEMICAL", 50, 57], ["CHCP", "CHEMICAL", 162, 166], ["monosaccharide", "CHEMICAL", 400, 414], ["CHCP", "SIMPLE_CHEMICAL", 17, 21], ["aspirin", "SIMPLE_CHEMICAL", 50, 57], ["rats", "ORGANISM", 116, 120], ["CHCP", "SIMPLE_CHEMICAL", 162, 166], ["CHCP", "SIMPLE_CHEMICAL", 253, 257], ["monosaccharide", "SIMPLE_CHEMICAL", 400, 414], ["CHCP", "SIMPLE_CHEMICAL", 438, 442], ["rats", "SPECIES", 116, 120], ["aspirin", "TREATMENT", 50, 57], ["the fever rats", "PROBLEM", 106, 120], ["AP 50 values", "TEST", 350, 362], ["decreased", "OBSERVATION", 76, 85]]], ["These results further confirmed that the anti-complementary polysaccharides should be the key material basis of the beneficial effects of CHCP on ALI and fever.", [["CHCP", "CHEMICAL", 138, 142], ["ALI", "DISEASE", 146, 149], ["fever", "DISEASE", 154, 159], ["CHCP", "CHEMICAL", 138, 142], ["CHCP", "SIMPLE_CHEMICAL", 138, 142], ["the anti-complementary polysaccharides", "TREATMENT", 37, 75], ["CHCP", "PROBLEM", 138, 142], ["ALI", "PROBLEM", 146, 149], ["fever", "PROBLEM", 154, 159]]], ["Composed of large amount of monosaccharides through glucosidic bonds, polysaccharides are too complex to accurately control the quality by one specific analytical method.", [["monosaccharides", "CHEMICAL", 28, 43], ["monosaccharides", "SIMPLE_CHEMICAL", 28, 43], ["glucosidic bonds", "SIMPLE_CHEMICAL", 52, 68], ["polysaccharides", "SIMPLE_CHEMICAL", 70, 85], ["monosaccharides through glucosidic bonds", "PROBLEM", 28, 68], ["polysaccharides", "TREATMENT", 70, 85], ["large", "OBSERVATION_MODIFIER", 12, 17], ["amount", "OBSERVATION_MODIFIER", 18, 24]]], ["Multiple methods were used to comprehensively characterize the structure of CHCP, including contents of carbohydrate and uronic acid, molecular weight, and monosaccharide composition.DiscussionIn conclusion, this study demonstrated that CHCP can ameliorate not only the \"two-hit\" ALI, but also the LPS-induced fever in rats, both of which are associated with inhibition of the excessively activated complement system.", [["uronic acid", "CHEMICAL", 121, 132], ["CHCP", "CHEMICAL", 237, 241], ["ALI", "DISEASE", 280, 283], ["LPS", "CHEMICAL", 298, 301], ["fever", "DISEASE", 310, 315], ["carbohydrate", "CHEMICAL", 104, 116], ["uronic acid", "CHEMICAL", 121, 132], ["monosaccharide", "CHEMICAL", 156, 170], ["CHCP", "CHEMICAL", 237, 241], ["CHCP", "SIMPLE_CHEMICAL", 76, 80], ["carbohydrate", "SIMPLE_CHEMICAL", 104, 116], ["uronic acid", "SIMPLE_CHEMICAL", 121, 132], ["monosaccharide", "SIMPLE_CHEMICAL", 156, 170], ["CHCP", "SIMPLE_CHEMICAL", 237, 241], ["LPS", "SIMPLE_CHEMICAL", 298, 301], ["rats", "ORGANISM", 319, 323], ["rats", "SPECIES", 319, 323], ["Multiple methods", "TREATMENT", 0, 16], ["carbohydrate", "TEST", 104, 116], ["uronic acid", "TEST", 121, 132], ["monosaccharide composition", "TREATMENT", 156, 182], ["this study", "TEST", 208, 218], ["hit\" ALI", "PROBLEM", 275, 283], ["the LPS", "TEST", 294, 301], ["fever in rats", "PROBLEM", 310, 323], ["the excessively activated complement system", "PROBLEM", 373, 416], ["fever", "OBSERVATION", 310, 315]]], ["The anti-complementary polysaccharides were shown to play an important role in the heat-clearing effect of H. cordata.", [["H. cordata", "ORGANISM", 107, 117], ["H. cordata", "SPECIES", 107, 117], ["H. cordata", "SPECIES", 107, 117], ["The anti-complementary polysaccharides", "PROBLEM", 0, 38], ["H. cordata", "PROBLEM", 107, 117]]], ["Moreover, CHCP has no interference with the coagulation system.", [["CHCP", "CHEMICAL", 10, 14], ["CHCP", "CHEMICAL", 10, 14], ["CHCP", "SIMPLE_CHEMICAL", 10, 14], ["the coagulation system", "TEST", 40, 62], ["no", "UNCERTAINTY", 19, 21], ["interference", "OBSERVATION", 22, 34]]], ["CHCP could be a promising natural complement inhibitor to be applied in the treatment of complementassociated diseases.", [["CHCP", "CHEMICAL", 0, 4], ["CHCP", "SIMPLE_CHEMICAL", 0, 4], ["a promising natural complement inhibitor", "TREATMENT", 14, 54], ["complementassociated diseases", "PROBLEM", 89, 118]]]], "PMC7438267": [["On March 11, 2020, the World Health Organization declared the COVID-19 pandemic and part of the response strategy included isolation and quarantine.", [["the COVID", "TEST", 58, 67], ["isolation and quarantine", "TREATMENT", 123, 147]]]], "PMC7510721": [["Healthcare workers (HCWs) are at the front lines of the coronavirus disease (COVID-19) pandemic; their interactions with patients and in the community put them at risk for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (1,2).", [["coronavirus disease", "DISEASE", 56, 75], ["infection", "DISEASE", 172, 181], ["acute respiratory syndrome coronavirus", "DISEASE", 194, 232], ["coronavirus", "ORGANISM", 56, 67], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["severe acute respiratory syndrome coronavirus", "SPECIES", 187, 232], ["SARS-CoV-2", "SPECIES", 236, 246], ["the coronavirus disease", "PROBLEM", 52, 75], ["infection", "PROBLEM", 172, 181], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 187, 232], ["SARS-CoV", "TEST", 236, 244], ["coronavirus disease", "OBSERVATION", 56, 75], ["infection", "OBSERVATION", 172, 181], ["severe", "OBSERVATION_MODIFIER", 187, 193], ["acute", "OBSERVATION_MODIFIER", 194, 199], ["respiratory syndrome", "OBSERVATION", 200, 220]]], ["Concern about whether HCWs are adequately protected from exposure while caring for patients has been fueled by limited availability of recommended personal protective equipment (PPE), in particular N95 respirators.", [["HCWs", "ORGANISM", 22, 26], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["personal protective equipment", "TREATMENT", 147, 176]]], ["Determining an HCW\u2019s source of SARS-CoV-2 infection\u2014community versus healthcare system\u2014is crucial for evaluating the effectiveness of hospital infection control and PPE practices.", [["SARS", "DISEASE", 31, 35], ["infection", "DISEASE", 42, 51], ["infection", "DISEASE", 143, 152], ["SARS-CoV-2", "ORGANISM", 31, 41], ["SARS-CoV", "SPECIES", 31, 39], ["SARS", "PROBLEM", 31, 35], ["CoV", "PROBLEM", 36, 39], ["2 infection", "PROBLEM", 40, 51], ["hospital infection control", "TREATMENT", 134, 160], ["PPE practices", "TREATMENT", 165, 178]]], ["Although SARS-CoV-2 infections in HCWs are often presumed to be acquired during the course of patient care, few reports unambiguously identify the source of acquisition.", [["SARS-CoV-2 infections", "DISEASE", 9, 30], ["SARS-CoV-2", "ORGANISM", 9, 19], ["HCWs", "ORGANISM", 34, 38], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["SARS-CoV", "SPECIES", 9, 17], ["SARS", "PROBLEM", 9, 13], ["2 infections in HCWs", "PROBLEM", 18, 38], ["infections", "OBSERVATION", 20, 30]]], ["Forensic genomics, using viral sequencing, may be a promising approach.", [["viral sequencing", "TREATMENT", 25, 41]]]], "517e30bf5914010a7d8968bad04d54aaa0bf9999": [["IntroductionCerebral venous thrombosis (CVT) is a rare neurovascular emergency, and its incidence is estimated to be around 1.6 cases per 100,000 per year in a population-based study [1] .", [["IntroductionCerebral venous", "ANATOMY", 0, 27], ["neurovascular", "ANATOMY", 55, 68], ["IntroductionCerebral venous thrombosis", "DISEASE", 0, 38], ["CVT", "DISEASE", 40, 43], ["IntroductionCerebral venous", "MULTI-TISSUE_STRUCTURE", 0, 27], ["IntroductionCerebral venous thrombosis", "PROBLEM", 0, 38], ["CVT", "PROBLEM", 40, 43], ["based study", "TEST", 171, 182], ["venous", "ANATOMY", 21, 27], ["thrombosis", "OBSERVATION", 28, 38]]], ["While the occurrence of arterial acute ischemic stroke (AIS) as a devastating neurologic complication is increasingly being reported on, there have been sporadic case reports and case series examining the association between CVT and coronavirus disease 2019 (COVID-19) infection [2] .", [["arterial", "ANATOMY", 24, 32], ["neurologic", "ANATOMY", 78, 88], ["arterial acute ischemic stroke", "DISEASE", 24, 54], ["AIS", "DISEASE", 56, 59], ["CVT", "DISEASE", 225, 228], ["coronavirus disease", "DISEASE", 233, 252], ["infection", "DISEASE", 269, 278], ["arterial", "MULTI-TISSUE_STRUCTURE", 24, 32], ["arterial acute ischemic stroke", "PROBLEM", 24, 54], ["a devastating neurologic complication", "PROBLEM", 64, 101], ["case series", "TEST", 179, 190], ["CVT", "PROBLEM", 225, 228], ["coronavirus disease", "PROBLEM", 233, 252], ["COVID", "TEST", 259, 264], ["infection", "PROBLEM", 269, 278], ["arterial", "ANATOMY", 24, 32], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["ischemic", "OBSERVATION_MODIFIER", 39, 47], ["stroke", "OBSERVATION", 48, 54], ["devastating", "OBSERVATION_MODIFIER", 66, 77], ["coronavirus disease", "OBSERVATION", 233, 252]]], ["Several studies have illustrated a higher preponderance to venous thromboembolic manifestations, such as deep vein thrombosis and pulmonary embolism, especially in the critically ill cohorts [3, 4] .IntroductionHowever, the true incidence of cerebral venous thrombosis occurrence in COVID-19 patients remains unknown.", [["venous", "ANATOMY", 59, 65], ["deep vein", "ANATOMY", 105, 114], ["pulmonary", "ANATOMY", 130, 139], ["cerebral venous", "ANATOMY", 242, 257], ["venous thromboembolic", "DISEASE", 59, 80], ["deep vein thrombosis", "DISEASE", 105, 125], ["pulmonary embolism", "DISEASE", 130, 148], ["critically ill", "DISEASE", 168, 182], ["cerebral venous thrombosis", "DISEASE", 242, 268], ["venous", "MULTI-TISSUE_STRUCTURE", 59, 65], ["vein", "MULTI-TISSUE_STRUCTURE", 110, 114], ["pulmonary", "ORGAN", 130, 139], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 242, 257], ["patients", "ORGANISM", 292, 300], ["patients", "SPECIES", 292, 300], ["Several studies", "TEST", 0, 15], ["venous thromboembolic manifestations", "PROBLEM", 59, 95], ["deep vein thrombosis", "PROBLEM", 105, 125], ["pulmonary embolism", "PROBLEM", 130, 148], ["cerebral venous thrombosis", "PROBLEM", 242, 268], ["COVID", "TEST", 283, 288], ["venous", "ANATOMY", 59, 65], ["thromboembolic", "OBSERVATION", 66, 80], ["deep", "ANATOMY_MODIFIER", 105, 109], ["vein", "ANATOMY", 110, 114], ["thrombosis", "OBSERVATION", 115, 125], ["pulmonary", "ANATOMY", 130, 139], ["embolism", "OBSERVATION", 140, 148], ["cerebral venous", "ANATOMY", 242, 257], ["thrombosis", "OBSERVATION", 258, 268]]], ["Furthermore, the underlying mechanism of CVT in COVID-19 patients remains debatable.", [["CVT", "DISEASE", 41, 44], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["CVT", "PROBLEM", 41, 44], ["COVID", "TEST", 48, 53], ["CVT", "OBSERVATION", 41, 44]]], ["It has been proposed that COVID-19 may induce a prothrombotic state, as supported by the elevated levels of factor VIII, fibrinogen, D-dimer and circulating prothrombotic microparticles such as antiphospholipid antibodies [5] [6] [7] .IntroductionGiven the rapidly rising number of COVID-19 infections globally and the severity of CVT as a complication, it is critical to derive a more in-depth understanding of their association, clinical manifestations, severity and treatment outcomesIntroductionIn this report, we present a case series of patients with concomitant COVID-19 infection and CVT from Singapore.", [["COVID-19", "CHEMICAL", 26, 34], ["infections", "DISEASE", 291, 301], ["CVT", "DISEASE", 331, 334], ["COVID-19 infection", "DISEASE", 569, 587], ["CVT", "DISEASE", 592, 595], ["COVID-19", "CHEMICAL", 26, 34], ["COVID-19", "GENE_OR_GENE_PRODUCT", 26, 34], ["factor VIII", "GENE_OR_GENE_PRODUCT", 108, 119], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 121, 131], ["D-dimer", "GENE_OR_GENE_PRODUCT", 133, 140], ["5] [6] [7]", "SIMPLE_CHEMICAL", 223, 233], ["COVID-19", "CELL", 282, 290], ["patients", "ORGANISM", 543, 551], ["factor VIII", "PROTEIN", 108, 119], ["fibrinogen", "PROTEIN", 121, 131], ["D-dimer", "PROTEIN", 133, 140], ["antiphospholipid antibodies", "PROTEIN", 194, 221], ["patients", "SPECIES", 543, 551], ["COVID", "TEST", 26, 31], ["a prothrombotic state", "PROBLEM", 46, 67], ["the elevated levels", "PROBLEM", 85, 104], ["factor VIII", "TEST", 108, 119], ["fibrinogen", "TEST", 121, 131], ["D-dimer", "TEST", 133, 140], ["circulating prothrombotic microparticles", "TREATMENT", 145, 185], ["antiphospholipid antibodies", "TEST", 194, 221], ["COVID-19 infections", "PROBLEM", 282, 301], ["CVT", "PROBLEM", 331, 334], ["a complication", "PROBLEM", 338, 352], ["concomitant COVID-19 infection", "PROBLEM", 557, 587], ["CVT", "PROBLEM", 592, 595], ["prothrombotic", "OBSERVATION", 48, 61], ["rapidly", "OBSERVATION_MODIFIER", 257, 264], ["rising", "OBSERVATION_MODIFIER", 265, 271], ["number", "OBSERVATION_MODIFIER", 272, 278], ["CVT", "OBSERVATION", 331, 334], ["infection", "OBSERVATION", 578, 587]]], ["We subsequently perform a systematic review of the current literature to evaluate patient demographics, clinical characteristics, prothrombotic workup, neuroimaging findings, treatment and outcomes of COVID-19 patients who have suffered CVT.Local Case Series and IncidenceWe identified 3 patients with concomitant COVID-19 infection and CVT from a nationwide registry capturing cases of neurological manifestations in COVID-19 from all public healthcare institutions in Singapore.", [["neurological", "ANATOMY", 387, 399], ["CVT", "DISEASE", 237, 240], ["infection", "DISEASE", 323, 332], ["CVT", "DISEASE", 337, 340], ["patient", "ORGANISM", 82, 89], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 288, 296], ["patient", "SPECIES", 82, 89], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 288, 296], ["prothrombotic workup", "TEST", 130, 150], ["neuroimaging findings", "TEST", 152, 173], ["treatment", "TREATMENT", 175, 184], ["CVT", "PROBLEM", 237, 240], ["concomitant COVID-19 infection", "PROBLEM", 302, 332], ["CVT", "PROBLEM", 337, 340], ["neurological manifestations", "PROBLEM", 387, 414], ["COVID", "TEST", 418, 423], ["infection", "OBSERVATION", 323, 332]]], ["In 1 patient, CVT was found after significant trauma and was excluded from this case series and analyses.", [["CVT", "DISEASE", 14, 17], ["trauma", "DISEASE", 46, 52], ["patient", "ORGANISM", 5, 12], ["patient", "SPECIES", 5, 12], ["CVT", "PROBLEM", 14, 17], ["significant trauma", "PROBLEM", 34, 52], ["this case series", "TEST", 75, 91], ["analyses", "TEST", 96, 104], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["trauma", "OBSERVATION", 46, 52]]], ["The total number of COVID-19 infections at the time of reporting was obtained from the Ministry of Health, Singapore.", [["infections", "DISEASE", 29, 39], ["COVID", "TEST", 20, 25], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["Incidence was calculated as the proportion of patients with CVT amongst all COVID-19 cases.", [["CVT", "DISEASE", 60, 63], ["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54], ["CVT", "PROBLEM", 60, 63], ["all COVID", "TEST", 72, 81]]], ["We describe the remaining 2 cases and include details on their clinical presentation, prothrombotic workup, neuroimaging findings, treatment and outcomes.", [["prothrombotic workup", "TEST", 86, 106], ["neuroimaging findings", "TEST", 108, 129], ["treatment", "TREATMENT", 131, 140]]], ["The reference lists of these articles were also screened, and hand searched to identify further relevant studies.Study and Cohort SelectionAll studies (case reports, case series and observational cohort studies) that reported cerebral venous thrombosis in COVID-19 patients were included during the initial search.", [["cerebral venous", "ANATOMY", 226, 241], ["cerebral venous thrombosis", "DISEASE", 226, 252], ["cerebral venous", "MULTI-TISSUE_STRUCTURE", 226, 241], ["patients", "ORGANISM", 265, 273], ["patients", "SPECIES", 265, 273], ["further relevant studies", "TEST", 88, 112], ["Cohort SelectionAll studies", "TEST", 123, 150], ["observational cohort studies", "TEST", 182, 210], ["cerebral venous thrombosis", "PROBLEM", 226, 252], ["COVID", "TEST", 256, 261], ["cerebral venous", "ANATOMY", 226, 241], ["thrombosis", "OBSERVATION", 242, 252]]], ["We subsequently excluded all studies that reported only acute ischemic stroke, hemorrhagic stroke and those without an English translation.Data ExtractionRelevant quantitative data were extracted by two authors (YKT & CG) in the form of absolute frequencies of events or absolute numbers when appropriate.", [["ischemic stroke", "DISEASE", 62, 77], ["hemorrhagic stroke", "DISEASE", 79, 97], ["all studies", "TEST", 25, 36], ["acute ischemic stroke", "PROBLEM", 56, 77], ["hemorrhagic stroke", "PROBLEM", 79, 97], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["ischemic", "OBSERVATION_MODIFIER", 62, 70], ["stroke", "OBSERVATION", 71, 77], ["hemorrhagic", "OBSERVATION_MODIFIER", 79, 90], ["stroke", "OBSERVATION", 91, 97]]], ["Where available, the data included incidence rate, individual case data: patient demographics (age, gender), country of study origin,Risk of Bias AssessmentThe quality of the included case reports and case series was assessed using the guidelines recommended by the Johanna Briggs Institute.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["Bias Assessment", "TEST", 141, 156]]], ["For case series, each study was assessed if there were clear inclusion criteria, measured the condition in a reliable way, had a valid method to identify condition, had consecutive or complete inclusion and reported patient demographics, clinical information, and outcomes.", [["patient", "ORGANISM", 216, 223], ["patient", "SPECIES", 216, 223], ["case series", "TEST", 4, 15], ["each study", "TEST", 17, 27]]], ["For case reports, each study was assessed if the following was well described: patient demographics, medical history, clinical conditions, diagnostic tests, treatment, post-treatment clinical condition, adverse events and takeaway lessons.Statistical AnalysesAll data analysis was conducted using IBM SPSS Statistics 25.0 software.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["each study", "TEST", 18, 28], ["diagnostic tests", "TEST", 139, 155], ["treatment", "TREATMENT", 157, 166], ["post-treatment clinical condition", "PROBLEM", 168, 201], ["adverse events", "PROBLEM", 203, 217], ["Statistical Analyses", "TEST", 239, 259], ["All data analysis", "TEST", 259, 276]]], ["Individual case data were pooled with patient demographics, COVID-19 symptoms, stroke characteristics, treatment and clinical outcomes.Local Case Series and IncidenceAs of 3 July 2020, Singapore had reported 44,479 confirmed COVID-19 cases.", [["stroke", "DISEASE", 79, 85], ["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45], ["Individual case data", "TEST", 0, 20], ["COVID", "TEST", 60, 65], ["symptoms", "PROBLEM", 69, 77], ["stroke characteristics", "PROBLEM", 79, 101], ["treatment", "TREATMENT", 103, 112], ["COVID", "TEST", 225, 230]]], ["Of these COVID-19 cases, we describe 2 patients with concomitant CVT and COVID-19 infection, deriving an incidence of 2/44,479 (0.0045%) or 4.5 per 100,000 COVID-19 cases.Systematic Review ResultsThe electronic search strategy yielded 819 studies, with one additional study found after screening through reference lists.", [["CVT", "DISEASE", 65, 68], ["infection", "DISEASE", 82, 91], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["these COVID", "TEST", 3, 14], ["concomitant CVT", "PROBLEM", 53, 68], ["COVID-19 infection", "PROBLEM", 73, 91], ["one additional study", "TEST", 253, 273], ["screening", "TEST", 286, 295], ["infection", "OBSERVATION", 82, 91]]], ["After removing duplicates, 543 records were screened based on abstracts, of which a further 499 studies were excluded as they reported only acute ischemic stroke, hemorrhagic stroke or did not have an English translation.", [["ischemic stroke", "DISEASE", 146, 161], ["hemorrhagic stroke", "DISEASE", 163, 181], ["a further 499 studies", "TEST", 82, 103], ["acute ischemic stroke", "PROBLEM", 140, 161], ["hemorrhagic stroke", "PROBLEM", 163, 181], ["acute", "OBSERVATION_MODIFIER", 140, 145], ["ischemic", "OBSERVATION_MODIFIER", 146, 154], ["stroke", "OBSERVATION", 155, 161], ["hemorrhagic", "OBSERVATION_MODIFIER", 163, 174], ["stroke", "OBSERVATION", 175, 181]]], ["Lastly, 35 articles were excluded after full-text review (reported only on coagulopathy (n=13), venous thromboembolism events unrelated to CVT (n=11), were editorials/opinion letters to editors (n=5), were reviews Presence of CVT in the transverse sinus (75.0%) and sigmoid sinus (50.0%) was seen in the majority of the cases.", [["venous", "ANATOMY", 96, 102], ["transverse sinus", "ANATOMY", 237, 253], ["sigmoid sinus", "ANATOMY", 266, 279], ["coagulopathy", "DISEASE", 75, 87], ["venous thromboembolism", "DISEASE", 96, 118], ["CVT", "DISEASE", 139, 142], ["CVT", "DISEASE", 226, 229], ["transverse sinus", "MULTI-TISSUE_STRUCTURE", 237, 253], ["sigmoid sinus", "MULTI-TISSUE_STRUCTURE", 266, 279], ["coagulopathy", "TEST", 75, 87], ["venous thromboembolism events", "PROBLEM", 96, 125], ["CVT", "TEST", 139, 142], ["CVT in the transverse sinus", "PROBLEM", 226, 253], ["sigmoid sinus", "TEST", 266, 279], ["venous", "ANATOMY", 96, 102], ["thromboembolism", "OBSERVATION", 103, 118], ["CVT", "OBSERVATION", 226, 229], ["transverse sinus", "ANATOMY", 237, 253], ["sigmoid sinus", "ANATOMY", 266, 279]]], ["Involvement of the deep venous sinus system was also commonly observed, with 33.3% having internal cerebral vein or straight sinus thrombosis.", [["deep venous sinus system", "ANATOMY", 19, 43], ["internal cerebral vein", "ANATOMY", 90, 112], ["sinus", "ANATOMY", 125, 130], ["sinus thrombosis", "DISEASE", 125, 141], ["deep venous sinus", "MULTI-TISSUE_STRUCTURE", 19, 36], ["cerebral vein", "MULTI-TISSUE_STRUCTURE", 99, 112], ["sinus", "MULTI-TISSUE_STRUCTURE", 125, 130], ["Involvement of the deep venous sinus system", "PROBLEM", 0, 43], ["internal cerebral vein", "PROBLEM", 90, 112], ["straight sinus thrombosis", "PROBLEM", 116, 141], ["deep", "ANATOMY_MODIFIER", 19, 23], ["venous sinus", "ANATOMY", 24, 36], ["internal cerebral vein", "ANATOMY", 90, 112], ["straight sinus", "ANATOMY", 116, 130], ["thrombosis", "OBSERVATION", 131, 141]]], ["Intracranial bleeding was seen on initial neuroimaging in 61.5% of patients.Systematic Review ResultsIn terms of laboratory findings, a significant proportion of patients had raised D-dimer (75.0%) and CRP levels (50.0%).", [["Intracranial", "ANATOMY", 0, 12], ["Intracranial bleeding", "DISEASE", 0, 21], ["patients", "ORGANISM", 67, 75], ["patients", "ORGANISM", 162, 170], ["D-dimer", "GENE_OR_GENE_PRODUCT", 182, 189], ["CRP", "GENE_OR_GENE_PRODUCT", 202, 205], ["D-dimer", "PROTEIN", 182, 189], ["CRP", "PROTEIN", 202, 205], ["patients", "SPECIES", 67, 75], ["patients", "SPECIES", 162, 170], ["Intracranial bleeding", "PROBLEM", 0, 21], ["initial neuroimaging", "TEST", 34, 54], ["raised D-dimer", "PROBLEM", 175, 189], ["CRP levels", "TEST", 202, 212], ["bleeding", "OBSERVATION", 13, 21]]], ["Antibody testing was reported in four patients.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["Antibody testing", "TEST", 0, 16]]], ["In the 12 patients with information provided on CVT treatment, most received anticoagulation (91.7%).", [["CVT", "DISEASE", 48, 51], ["patients", "ORGANISM", 10, 18], ["patients", "SPECIES", 10, 18], ["CVT treatment", "TREATMENT", 48, 61], ["anticoagulation", "TREATMENT", 77, 92]]], ["Of note, Patient 1 underwent percutaneous venous mechanical thrombectomy with adjunct catheter-directed thrombolysis, while Patient 2 had an external ventricular drain inserted due to interval development of venous infarction with hemorrhagic transformation, intraventricular hemorrhage, and obstructive hydrocephalus.", [["venous", "ANATOMY", 42, 48], ["ventricular", "ANATOMY", 150, 161], ["venous", "ANATOMY", 208, 214], ["intraventricular", "ANATOMY", 259, 275], ["venous infarction", "DISEASE", 208, 225], ["hemorrhagic transformation", "DISEASE", 231, 257], ["intraventricular hemorrhage", "DISEASE", 259, 286], ["obstructive hydrocephalus", "DISEASE", 292, 317], ["ventricular drain", "MULTI-TISSUE_STRUCTURE", 150, 167], ["venous", "MULTI-TISSUE_STRUCTURE", 208, 214], ["Patient", "SPECIES", 9, 16], ["Patient", "SPECIES", 124, 131], ["percutaneous venous mechanical thrombectomy", "TREATMENT", 29, 72], ["adjunct catheter", "TREATMENT", 78, 94], ["directed thrombolysis", "TREATMENT", 95, 116], ["an external ventricular drain", "TREATMENT", 138, 167], ["venous infarction", "PROBLEM", 208, 225], ["hemorrhagic transformation", "PROBLEM", 231, 257], ["intraventricular hemorrhage", "PROBLEM", 259, 286], ["obstructive hydrocephalus", "PROBLEM", 292, 317], ["venous", "ANATOMY", 42, 48], ["thrombectomy", "OBSERVATION", 60, 72], ["catheter", "OBSERVATION", 86, 94], ["thrombolysis", "OBSERVATION", 104, 116], ["external ventricular", "ANATOMY", 141, 161], ["drain", "OBSERVATION", 162, 167], ["venous", "ANATOMY", 208, 214], ["infarction", "OBSERVATION", 215, 225], ["hemorrhagic", "OBSERVATION_MODIFIER", 231, 242], ["intraventricular", "ANATOMY_MODIFIER", 259, 275], ["hemorrhage", "OBSERVATION", 276, 286], ["obstructive", "OBSERVATION_MODIFIER", 292, 303], ["hydrocephalus", "OBSERVATION", 304, 317]]], ["Overall, mortality rate reported amongst COVID-19 patients with CVT in this study was 45.5%, while mortality rate amongst the subgroup of mild COVID-19 patients was 40.0%.DiscussionThis systematic review highlights the occurrence of CVT in patients across the spectrum of severity of COVID-19 infection.", [["CVT", "DISEASE", 64, 67], ["COVID", "DISEASE", 143, 148], ["CVT", "DISEASE", 233, 236], ["COVID", "DISEASE", 284, 289], ["infection", "DISEASE", 293, 302], ["patients", "ORGANISM", 50, 58], ["patients", "ORGANISM", 152, 160], ["patients", "ORGANISM", 240, 248], ["patients", "SPECIES", 50, 58], ["patients", "SPECIES", 152, 160], ["patients", "SPECIES", 240, 248], ["mortality rate", "TEST", 9, 23], ["COVID", "TEST", 41, 46], ["CVT", "PROBLEM", 64, 67], ["this study", "TEST", 71, 81], ["mortality rate", "TEST", 99, 113], ["mild COVID", "TEST", 138, 148], ["CVT", "PROBLEM", 233, 236], ["COVID-19 infection", "PROBLEM", 284, 302], ["CVT", "OBSERVATION", 233, 236], ["infection", "OBSERVATION", 293, 302]]], ["Of note, the majority of these patients were middle-aged and without significant comorbidities.", [["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["significant comorbidities", "PROBLEM", 69, 94], ["without", "UNCERTAINTY", 61, 68]]], ["The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first recognized in Wuhan after a cluster of atypical pneumonia was reported [17] .", [["acute respiratory syndrome coronavirus", "DISEASE", 46, 84], ["pneumonia", "DISEASE", 155, 164], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 39, 86], ["SARS-CoV-2", "ORGANISM", 88, 98], ["severe acute respiratory syndrome coronavirus", "SPECIES", 39, 84], ["SARS-CoV-2", "SPECIES", 88, 98], ["The COVID", "TEST", 0, 9], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 35, 84], ["CoV", "TEST", 93, 96], ["atypical pneumonia", "PROBLEM", 146, 164], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["acute", "OBSERVATION_MODIFIER", 46, 51], ["respiratory syndrome coronavirus", "OBSERVATION", 52, 84], ["atypical", "OBSERVATION_MODIFIER", 146, 154], ["pneumonia", "OBSERVATION", 155, 164]]], ["Since then, the pandemic has grown rapidly and reached global proportions, overwhelming healthcare systems around the world.", [["grown", "OBSERVATION_MODIFIER", 29, 34], ["rapidly", "OBSERVATION_MODIFIER", 35, 42]]], ["Being a novel coronavirus, much is to be learnt about its various clinical manifestations.", [["coronavirus", "DISEASE", 14, 25], ["coronavirus", "ORGANISM", 14, 25], ["a novel coronavirus", "PROBLEM", 6, 25]]], ["Interestingly, multiple studies have reported neurological manifestations of the COVID-19 infection, whereby 36.4% of patients were found to have neurological symptoms and that those with severe infection were further associated with strokes and coagulopathy [7, 18] .", [["neurological", "ANATOMY", 46, 58], ["neurological", "ANATOMY", 146, 158], ["infection", "DISEASE", 90, 99], ["neurological symptoms", "DISEASE", 146, 167], ["infection", "DISEASE", 195, 204], ["strokes", "DISEASE", 234, 241], ["coagulopathy", "DISEASE", 246, 258], ["patients", "ORGANISM", 118, 126], ["patients", "SPECIES", 118, 126], ["COVID-19", "SPECIES", 81, 89], ["multiple studies", "TEST", 15, 31], ["neurological manifestations", "PROBLEM", 46, 73], ["the COVID-19 infection", "PROBLEM", 77, 99], ["neurological symptoms", "PROBLEM", 146, 167], ["severe infection", "PROBLEM", 188, 204], ["strokes", "PROBLEM", 234, 241], ["coagulopathy", "PROBLEM", 246, 258], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["infection", "OBSERVATION", 195, 204], ["coagulopathy", "OBSERVATION", 246, 258]]], ["Indeed, new evidence seems to suggest a tendency for severe COVID-19 infection to trigger cytokine storms which leads to a proinflammatory and prothrombotic state [19] .", [["infection", "DISEASE", 69, 78], ["cytokine", "PROTEIN", 90, 98], ["a tendency", "PROBLEM", 38, 48], ["severe COVID-19 infection", "PROBLEM", 53, 78], ["cytokine storms", "PROBLEM", 90, 105], ["a proinflammatory and prothrombotic state", "PROBLEM", 121, 162], ["infection", "OBSERVATION", 69, 78]]], ["These patients may thus suffer from thromboembolic events, both arterial and venous [13, 20, 21] .", [["arterial", "ANATOMY", 64, 72], ["venous", "ANATOMY", 77, 83], ["thromboembolic", "DISEASE", 36, 50], ["patients", "ORGANISM", 6, 14], ["arterial", "MULTI-TISSUE_STRUCTURE", 64, 72], ["venous", "MULTI-TISSUE_STRUCTURE", 77, 83], ["patients", "SPECIES", 6, 14], ["thromboembolic events", "PROBLEM", 36, 57], ["thromboembolic", "OBSERVATION", 36, 50], ["arterial", "ANATOMY", 64, 72], ["venous", "ANATOMY", 77, 83]]], ["However, it is surprising that in this systematic review of patients with concomitant COVID-19 and CVT, a large majority were relatively young and healthy patients with relatively few co-morbidities.", [["CVT", "DISEASE", 99, 102], ["patients", "ORGANISM", 60, 68], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 60, 68], ["patients", "SPECIES", 155, 163], ["concomitant COVID", "TEST", 74, 91], ["CVT", "PROBLEM", 99, 102], ["relatively few co-morbidities", "PROBLEM", 169, 198], ["large", "OBSERVATION_MODIFIER", 106, 111], ["few", "OBSERVATION_MODIFIER", 180, 183], ["co-morbidities", "OBSERVATION", 184, 198]]], ["In addition, a significant proportion of CVT patients only displayed mild to moderate severity of COVID-19 infection, thus indicating that a hypercoagulable state may be present even in mild infection.DiscussionWe propose that the presence of COVID-19 should be screened in patients presenting with neurological complications CVT without prominent respiratory symptoms nor known prothrombotic risk factors.", [["neurological", "ANATOMY", 299, 311], ["respiratory", "ANATOMY", 348, 359], ["CVT", "DISEASE", 41, 44], ["COVID", "DISEASE", 98, 103], ["infection", "DISEASE", 107, 116], ["infection", "DISEASE", 191, 200], ["CVT", "DISEASE", 326, 329], ["patients", "ORGANISM", 45, 53], ["COVID-19", "GENE_OR_GENE_PRODUCT", 243, 251], ["patients", "ORGANISM", 274, 282], ["prothrombotic risk factors", "PROTEIN", 379, 405], ["patients", "SPECIES", 45, 53], ["patients", "SPECIES", 274, 282], ["CVT", "PROBLEM", 41, 44], ["mild to moderate severity of COVID-19 infection", "PROBLEM", 69, 116], ["a hypercoagulable state", "PROBLEM", 139, 162], ["mild infection", "PROBLEM", 186, 200], ["COVID", "TEST", 243, 248], ["neurological complications CVT", "PROBLEM", 299, 329], ["prominent respiratory symptoms", "PROBLEM", 338, 368], ["known prothrombotic risk factors", "PROBLEM", 373, 405], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["CVT", "OBSERVATION", 41, 44], ["mild", "OBSERVATION_MODIFIER", 69, 73], ["moderate", "OBSERVATION_MODIFIER", 77, 85], ["severity", "OBSERVATION_MODIFIER", 86, 94], ["infection", "OBSERVATION", 107, 116], ["hypercoagulable", "OBSERVATION", 141, 156], ["mild", "OBSERVATION_MODIFIER", 186, 190], ["infection", "OBSERVATION", 191, 200]]], ["From our systematic review, four (28.6%) patients (case 2, 11, 13 and 14) presented initially with neurological symptoms and all had no prothrombotic risk factors.DiscussionMoreover, COVID-19 could have been potentially missed as all 4 had mild respiratory symptoms.", [["neurological", "ANATOMY", 99, 111], ["respiratory", "ANATOMY", 245, 256], ["neurological symptoms", "DISEASE", 99, 120], ["respiratory symptoms", "DISEASE", 245, 265], ["patients", "ORGANISM", 41, 49], ["prothrombotic risk factors", "PROTEIN", 136, 162], ["COVID-19", "DNA", 183, 191], ["patients", "SPECIES", 41, 49], ["neurological symptoms", "PROBLEM", 99, 120], ["prothrombotic risk factors", "PROBLEM", 136, 162], ["COVID", "TEST", 183, 188], ["mild respiratory symptoms", "PROBLEM", 240, 265], ["mild", "OBSERVATION_MODIFIER", 240, 244], ["respiratory symptoms", "OBSERVATION", 245, 265]]], ["For our local 2 cases (13, 14) , COVID-19 was only diagnosed due to pro-active testing with RT-PCR, as they were living in workers dormitories where other cases of COVID-19 were known to occur.", [["COVID-19", "DNA", 33, 41], ["COVID", "TEST", 33, 38], ["pro-active testing", "TEST", 68, 86], ["RT-PCR", "TEST", 92, 98], ["COVID", "TEST", 164, 169]]], ["Additionally, the incidence of CVT in COVID-19 appears to be approximately 3 times higher than previously published population incidence (4.5 per 100,000 vs 1.6 per 100,000).DiscussionThe presence of concomitant COVID-19 infection and CVT seems to portend a much poorer prognosis than each condition individually.", [["CVT", "DISEASE", 31, 34], ["infection", "DISEASE", 221, 230], ["CVT", "DISEASE", 235, 238], ["CVT", "PROBLEM", 31, 34], ["COVID", "TEST", 38, 43], ["concomitant COVID-19 infection", "PROBLEM", 200, 230], ["CVT", "PROBLEM", 235, 238], ["CVT", "OBSERVATION", 31, 34], ["infection", "OBSERVATION", 221, 230]]], ["This study found an unusually high mortality rate of 45.5% in COVID-19 patients diagnosed with CVT, in contrast to the known mortality rates of CVT at 15% and current estimates of COVID-19 case fatality rate of 5.6% [22, 23] .", [["CVT", "DISEASE", 95, 98], ["CVT", "DISEASE", 144, 147], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["This study", "TEST", 0, 10], ["an unusually high mortality rate", "PROBLEM", 17, 49], ["COVID", "TEST", 62, 67], ["CVT", "PROBLEM", 95, 98], ["CVT", "TEST", 144, 147], ["COVID", "TEST", 180, 185], ["fatality rate", "TEST", 194, 207], ["unusually", "OBSERVATION_MODIFIER", 20, 29], ["high", "OBSERVATION_MODIFIER", 30, 34]]], ["One possibility for the poorer outcome in these patients may be due to the location of the occluded sinuses, which showed a higher predilection for the deep venous sinuses to be involved.DiscussionThrombus in the internal cerebral veins or straight sinus was seen in 33.3% of the patients and these sites of thrombosis are typically rare and have a higher morbidity and mortality rate [24] Consequently, this may be a contributing factor to the high mortality reported in our series, where 50% of the patients who died had involvement of the deep cerebral veins.DiscussionMany studies in the current COVID-19 literature have reported cases of arterial and venous thromboembolism, attributed to deranged coagulopathy, extensive systemic inflammation and endothelial dysfunction that are associated with severe COVID-19 [25] .", [["sinuses", "ANATOMY", 100, 107], ["deep venous sinuses", "ANATOMY", 152, 171], ["Thrombus", "ANATOMY", 197, 205], ["internal cerebral veins", "ANATOMY", 213, 236], ["straight sinus", "ANATOMY", 240, 254], ["sites", "ANATOMY", 299, 304], ["deep cerebral veins", "ANATOMY", 542, 561], ["arterial", "ANATOMY", 643, 651], ["venous", "ANATOMY", 656, 662], ["endothelial", "ANATOMY", 753, 764], ["thrombosis", "DISEASE", 308, 318], ["arterial and venous thromboembolism", "DISEASE", 643, 678], ["coagulopathy", "DISEASE", 703, 715], ["inflammation", "DISEASE", 736, 748], ["endothelial dysfunction", "DISEASE", 753, 776], ["COVID-19", "CHEMICAL", 809, 817], ["patients", "ORGANISM", 48, 56], ["sinuses", "MULTI-TISSUE_STRUCTURE", 100, 107], ["venous sinuses", "MULTI-TISSUE_STRUCTURE", 157, 171], ["Thrombus", "PATHOLOGICAL_FORMATION", 197, 205], ["cerebral veins", "MULTI-TISSUE_STRUCTURE", 222, 236], ["sinus", "MULTI-TISSUE_STRUCTURE", 249, 254], ["patients", "ORGANISM", 280, 288], ["patients", "ORGANISM", 501, 509], ["cerebral veins", "MULTI-TISSUE_STRUCTURE", 547, 561], ["arterial", "MULTI-TISSUE_STRUCTURE", 643, 651], ["venous", "MULTI-TISSUE_STRUCTURE", 656, 662], ["endothelial", "TISSUE", 753, 764], ["patients", "SPECIES", 48, 56], ["patients", "SPECIES", 280, 288], ["patients", "SPECIES", 501, 509], ["the occluded sinuses", "PROBLEM", 87, 107], ["a higher predilection", "PROBLEM", 122, 143], ["the deep venous sinuses", "PROBLEM", 148, 171], ["Thrombus in the internal cerebral veins", "PROBLEM", 197, 236], ["straight sinus", "PROBLEM", 240, 254], ["thrombosis", "PROBLEM", 308, 318], ["a higher morbidity", "PROBLEM", 347, 365], ["mortality rate", "TEST", 370, 384], ["the high mortality", "PROBLEM", 441, 459], ["involvement of the deep cerebral veins", "PROBLEM", 523, 561], ["DiscussionMany studies", "TEST", 562, 584], ["arterial and venous thromboembolism", "PROBLEM", 643, 678], ["deranged coagulopathy", "PROBLEM", 694, 715], ["extensive systemic inflammation", "PROBLEM", 717, 748], ["endothelial dysfunction", "PROBLEM", 753, 776], ["severe COVID", "PROBLEM", 802, 814], ["possibility for", "UNCERTAINTY", 4, 19], ["occluded", "OBSERVATION", 91, 99], ["sinuses", "ANATOMY", 100, 107], ["higher", "OBSERVATION_MODIFIER", 124, 130], ["predilection", "OBSERVATION", 131, 143], ["deep", "ANATOMY_MODIFIER", 152, 156], ["venous sinuses", "ANATOMY", 157, 171], ["Thrombus", "OBSERVATION", 197, 205], ["internal cerebral veins", "ANATOMY", 213, 236], ["straight sinus", "ANATOMY", 240, 254], ["thrombosis", "OBSERVATION", 308, 318], ["higher", "OBSERVATION_MODIFIER", 349, 355], ["morbidity", "OBSERVATION_MODIFIER", 356, 365], ["deep cerebral veins", "ANATOMY", 542, 561], ["arterial", "ANATOMY", 643, 651], ["venous", "ANATOMY", 656, 662], ["thromboembolism", "OBSERVATION", 663, 678], ["deranged", "OBSERVATION_MODIFIER", 694, 702], ["coagulopathy", "OBSERVATION", 703, 715], ["extensive", "OBSERVATION_MODIFIER", 717, 726], ["systemic", "OBSERVATION_MODIFIER", 727, 735], ["inflammation", "OBSERVATION", 736, 748], ["endothelial dysfunction", "OBSERVATION", 753, 776], ["severe", "OBSERVATION_MODIFIER", 802, 808]]], ["The incidence of venous thromboembolism reported thus far has ranged from 4.4% to 19.7%, with a remarkably high rate seen in the subgroup of severe COVID-19 patients in ICU reaching up to 69% [4, 26, 27] .", [["venous", "ANATOMY", 17, 23], ["venous thromboembolism", "DISEASE", 17, 39], ["COVID", "DISEASE", 148, 153], ["venous", "MULTI-TISSUE_STRUCTURE", 17, 23], ["patients", "ORGANISM", 157, 165], ["patients", "SPECIES", 157, 165], ["venous thromboembolism", "PROBLEM", 17, 39], ["a remarkably high rate", "PROBLEM", 94, 116], ["severe COVID", "PROBLEM", 141, 153], ["venous", "ANATOMY", 17, 23], ["thromboembolism", "OBSERVATION", 24, 39], ["high rate", "OBSERVATION", 107, 116], ["severe", "OBSERVATION_MODIFIER", 141, 147]]], ["This has led to several recommendations being made for the use of anticoagulation in hospitalised COVID-19 patients, where those treated with anticoagulation were observed to have improved outcomes [19, 28] .", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["anticoagulation", "TREATMENT", 66, 81], ["anticoagulation", "TREATMENT", 142, 157]]], ["At the same time, anticoagulation with low molecular weight or unfractionated heparin remains the mainstay of treatment in CVT.", [["heparin", "CHEMICAL", 78, 85], ["CVT", "DISEASE", 123, 126], ["heparin", "SIMPLE_CHEMICAL", 78, 85], ["anticoagulation", "TREATMENT", 18, 33], ["low molecular weight", "TREATMENT", 39, 59], ["unfractionated heparin", "TREATMENT", 63, 85], ["treatment", "TREATMENT", 110, 119], ["CVT", "PROBLEM", 123, 126]]], ["Given the higher mortality rates of CVT seen in COVID-19 infection, there may be a role for early initiation of anticoagulation in patients suspected to have CVT or predisposed to its formation.", [["CVT", "DISEASE", 36, 39], ["infection", "DISEASE", 57, 66], ["CVT", "DISEASE", 158, 161], ["COVID-19", "CELL", 48, 56], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 131, 139], ["COVID-19", "SPECIES", 48, 56], ["CVT", "PROBLEM", 36, 39], ["COVID-19 infection", "PROBLEM", 48, 66], ["anticoagulation", "TREATMENT", 112, 127], ["CVT", "PROBLEM", 158, 161], ["CVT", "OBSERVATION", 36, 39], ["infection", "OBSERVATION", 57, 66], ["CVT", "OBSERVATION", 158, 161]]], ["Amongst the patients treated with anticoagulation, 60.0% survived which is an encouraging sign.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["anticoagulation", "TREATMENT", 34, 49]]], ["Lastly, thrombectomy is a therapeutic option in patients with severe CVT, not unlike those with concomitant COVID-19 [24] .", [["CVT", "DISEASE", 69, 72], ["COVID-19", "CHEMICAL", 108, 116], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["thrombectomy", "TREATMENT", 8, 20], ["a therapeutic option", "TREATMENT", 24, 44], ["severe CVT", "PROBLEM", 62, 72], ["concomitant COVID", "TEST", 96, 113], ["thrombectomy", "OBSERVATION", 8, 20]]], ["In this study, while the only patient (case 1) who underwent endovascular treatment died, this may be related to the need for a salvage endovascular maneuver in a deteriorating patient despite anticoagulation rather than a reflection of the inability of endovascular treatment in COVID-19 patients with CVT.LimitationsThe following limitations of this study should be acknowledged.", [["CVT", "DISEASE", 303, 306], ["patient", "ORGANISM", 30, 37], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 61, 73], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 136, 148], ["patient", "ORGANISM", 177, 184], ["endovascular", "IMMATERIAL_ANATOMICAL_ENTITY", 254, 266], ["patients", "ORGANISM", 289, 297], ["patient", "SPECIES", 30, 37], ["patient", "SPECIES", 177, 184], ["patients", "SPECIES", 289, 297], ["this study", "TEST", 3, 13], ["endovascular treatment", "TREATMENT", 61, 83], ["a salvage endovascular maneuver", "TREATMENT", 126, 157], ["anticoagulation", "TREATMENT", 193, 208], ["endovascular treatment", "TREATMENT", 254, 276], ["CVT", "PROBLEM", 303, 306], ["this study", "TEST", 347, 357]]], ["Firstly, the patients included in this study were from case reports and case series which are retrospective in nature and may be limited by data availability or accuracy.", [["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["this study", "TEST", 34, 44], ["case series", "TEST", 72, 83], ["accuracy", "TEST", 161, 169]]], ["Secondly, the number of COVID-19 patients with CVT included in the analysis is small (n=14), which did not allow for further comparative analysis.LimitationsThe actual number of COVID-19 patients with CVT may be significantly higher but not detected as clinical suspicion may be low in a large number of COVID-19 patients who are intubated and without appropriate imaging done.", [["CVT", "DISEASE", 47, 50], ["CVT", "DISEASE", 201, 204], ["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 187, 195], ["patients", "ORGANISM", 313, 321], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 187, 195], ["patients", "SPECIES", 313, 321], ["COVID", "TEST", 24, 29], ["CVT", "PROBLEM", 47, 50], ["the analysis", "TEST", 63, 75], ["further comparative analysis", "TEST", 117, 145], ["COVID", "TEST", 178, 183], ["CVT", "PROBLEM", 201, 204], ["intubated", "TREATMENT", 330, 339], ["appropriate imaging", "TEST", 352, 371], ["small", "OBSERVATION_MODIFIER", 79, 84], ["may be", "UNCERTAINTY", 205, 211], ["significantly higher", "OBSERVATION_MODIFIER", 212, 232], ["low", "OBSERVATION_MODIFIER", 279, 282], ["large", "OBSERVATION_MODIFIER", 288, 293]]], ["Thirdly, there was insufficient data available from published studies to evaluate the overall incidence of CVT.", [["CVT", "DISEASE", 107, 110], ["published studies", "TEST", 52, 69], ["CVT", "PROBLEM", 107, 110], ["CVT", "OBSERVATION", 107, 110]]], ["However, we were able to calculate the local incidence of CVT in COVID-19 patients (4.5 per 100,000), which is higher than the previously published incidence of 1.6 per 100,000 in other population-based studies [1] .", [["CVT", "DISEASE", 58, 61], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["CVT", "PROBLEM", 58, 61], ["COVID", "TEST", 65, 70], ["CVT", "OBSERVATION", 58, 61], ["higher", "OBSERVATION_MODIFIER", 111, 117]]], ["Lastly, while the aforementioned factors limit the generalizability of the results, it is nevertheless useful in highlighting a likely association between COVID-19 infection and CVT, serving as a basis for future large cohort studies.ConclusionWhilst infrequently reported, CVT has been found to occur in patients with COVID-19 infection.ConclusionThe unusually high mortality rate warrants a high index of suspicion from physicians, and early treatment with anticoagulation should be initiated in these settings.", [["infection", "DISEASE", 164, 173], ["CVT", "DISEASE", 178, 181], ["CVT", "DISEASE", 274, 277], ["infection", "DISEASE", 328, 337], ["patients", "ORGANISM", 305, 313], ["COVID-19", "ORGANISM", 319, 327], ["patients", "SPECIES", 305, 313], ["COVID-19 infection", "PROBLEM", 155, 173], ["CVT", "PROBLEM", 178, 181], ["future large cohort studies", "TEST", 206, 233], ["CVT", "PROBLEM", 274, 277], ["COVID-19 infection", "PROBLEM", 319, 337], ["The unusually high mortality rate", "PROBLEM", 348, 381], ["anticoagulation", "TREATMENT", 459, 474], ["infection", "OBSERVATION", 164, 173], ["infection", "OBSERVATION", 328, 337]]]], "PMC7346794": [["Case reportWe present the case of a 54-year-old obese female with a past medical history of hypertension who was brought by Emergency Medical Service to the hospital because of progressive decline in mental status in the context of high-grade fever, dyspnea, orthopnea, nonproductive cough, and fatigue over the previous 5 days.", [["hypertension", "DISEASE", 92, 104], ["fever", "DISEASE", 243, 248], ["dyspnea", "DISEASE", 250, 257], ["orthopnea", "DISEASE", 259, 268], ["nonproductive cough", "DISEASE", 270, 289], ["fatigue", "DISEASE", 295, 302], ["female", "ORGANISM", 54, 60], ["hypertension", "PROBLEM", 92, 104], ["progressive decline in mental status", "PROBLEM", 177, 213], ["high-grade fever", "PROBLEM", 232, 248], ["dyspnea", "PROBLEM", 250, 257], ["orthopnea", "PROBLEM", 259, 268], ["nonproductive cough", "PROBLEM", 270, 289], ["fatigue", "PROBLEM", 295, 302], ["hypertension", "OBSERVATION", 92, 104], ["progressive", "OBSERVATION_MODIFIER", 177, 188], ["decline", "OBSERVATION", 189, 196], ["fever", "OBSERVATION", 243, 248], ["nonproductive", "OBSERVATION_MODIFIER", 270, 283], ["cough", "OBSERVATION", 284, 289]]], ["Upon arrival to the hospital, the patient was febrile up to 103.3\u00b0F, tachycardic, tachypneic, with oxygen saturation of 92% on a nonrebreather mask.", [["febrile", "DISEASE", 46, 53], ["tachypneic", "DISEASE", 82, 92], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["patient", "ORGANISM", 34, 41], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["patient", "SPECIES", 34, 41], ["febrile", "PROBLEM", 46, 53], ["tachycardic", "PROBLEM", 69, 80], ["tachypneic", "PROBLEM", 82, 92], ["oxygen saturation", "TEST", 99, 116], ["a nonrebreather mask", "TREATMENT", 127, 147], ["tachypneic", "OBSERVATION", 82, 92]]], ["Rapid COVID-19 testing using polymerase chain reaction returned positive.", [["Rapid COVID", "TEST", 0, 11], ["polymerase chain reaction", "TEST", 29, 54]]], ["Other laboratory workup was significant for C-reactive protein of 22.8 mg/L and N-terminal prohormone of brain natriuretic peptide (NT-Pro BNP) of 567 pg/mL.", [["N", "CHEMICAL", 80, 81], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 44, 62], ["brain natriuretic peptide", "GENE_OR_GENE_PRODUCT", 105, 130], ["NT-Pro BNP", "GENE_OR_GENE_PRODUCT", 132, 142], ["C-reactive protein", "PROTEIN", 44, 62], ["Other laboratory workup", "TEST", 0, 23], ["C", "TEST", 44, 45], ["reactive protein", "TEST", 46, 62], ["N", "TEST", 80, 81], ["brain natriuretic peptide", "TEST", 105, 130], ["NT-Pro BNP", "TEST", 132, 142]]], ["Chest X-ray showed multifocal airspace infiltrates suspicious for multifocal pneumonia with small pleural effusions (Fig. 1).", [["pleural", "ANATOMY", 98, 105], ["pneumonia", "DISEASE", 77, 86], ["pleural effusions", "DISEASE", 98, 115], ["airspace infiltrates", "PATHOLOGICAL_FORMATION", 30, 50], ["pleural effusions", "PATHOLOGICAL_FORMATION", 98, 115], ["Chest X-ray", "TEST", 0, 11], ["multifocal airspace infiltrates", "PROBLEM", 19, 50], ["multifocal pneumonia", "PROBLEM", 66, 86], ["small pleural effusions", "PROBLEM", 92, 115], ["multifocal", "OBSERVATION_MODIFIER", 19, 29], ["airspace", "ANATOMY_MODIFIER", 30, 38], ["infiltrates", "OBSERVATION", 39, 50], ["suspicious for", "UNCERTAINTY", 51, 65], ["multifocal", "OBSERVATION_MODIFIER", 66, 76], ["pneumonia", "OBSERVATION", 77, 86], ["small", "OBSERVATION_MODIFIER", 92, 97], ["pleural", "ANATOMY", 98, 105], ["effusions", "OBSERVATION", 106, 115]]], ["Arterial blood gas showed pH of 7.49, carbon dioxide level of 38 mm Hg, and arterial oxygen of 69 mm Hg.", [["Arterial blood", "ANATOMY", 0, 14], ["arterial", "ANATOMY", 76, 84], ["carbon dioxide", "CHEMICAL", 38, 52], ["oxygen", "CHEMICAL", 85, 91], ["carbon dioxide", "CHEMICAL", 38, 52], ["Hg", "CHEMICAL", 68, 70], ["oxygen", "CHEMICAL", 85, 91], ["Hg", "CHEMICAL", 101, 103], ["Arterial", "ORGANISM_SUBSTANCE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["carbon dioxide", "SIMPLE_CHEMICAL", 38, 52], ["arterial", "MULTI-TISSUE_STRUCTURE", 76, 84], ["oxygen", "SIMPLE_CHEMICAL", 85, 91], ["Arterial blood gas", "TEST", 0, 18], ["pH", "TEST", 26, 28], ["carbon dioxide level", "TEST", 38, 58], ["Hg", "TEST", 68, 70], ["arterial oxygen", "TEST", 76, 91], ["arterial", "ANATOMY", 76, 84]]], ["Owning to progressive respiratory insufficiency, the patient was intubated and was empirically treated with Levofloxacin 500 mg and Ceftriaxone 1 g for presumed superimposed pneumonia.", [["respiratory", "ANATOMY", 22, 33], ["respiratory insufficiency", "DISEASE", 22, 47], ["Levofloxacin", "CHEMICAL", 108, 120], ["Ceftriaxone", "CHEMICAL", 132, 143], ["pneumonia", "DISEASE", 174, 183], ["Levofloxacin", "CHEMICAL", 108, 120], ["Ceftriaxone", "CHEMICAL", 132, 143], ["patient", "ORGANISM", 53, 60], ["Levofloxacin", "SIMPLE_CHEMICAL", 108, 120], ["patient", "SPECIES", 53, 60], ["progressive respiratory insufficiency", "PROBLEM", 10, 47], ["intubated", "TREATMENT", 65, 74], ["Levofloxacin", "TREATMENT", 108, 120], ["Ceftriaxone", "TREATMENT", 132, 143], ["superimposed pneumonia", "PROBLEM", 161, 183], ["progressive", "OBSERVATION_MODIFIER", 10, 21], ["respiratory insufficiency", "OBSERVATION", 22, 47], ["superimposed", "OBSERVATION_MODIFIER", 161, 173], ["pneumonia", "OBSERVATION", 174, 183]]], ["Additionally, she also received Hydroxychloroquine 200 mg twice daily for 5 days.", [["Hydroxychloroquine", "CHEMICAL", 32, 50], ["Hydroxychloroquine", "CHEMICAL", 32, 50], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 32, 50], ["Hydroxychloroquine", "TREATMENT", 32, 50]]], ["Because of persistent hypoxemic respiratory failure, she was treated for 4 days with pronation, paralysis, and inhaled epoprostenol.", [["respiratory", "ANATOMY", 32, 43], ["hypoxemic respiratory failure", "DISEASE", 22, 51], ["paralysis", "DISEASE", 96, 105], ["epoprostenol", "CHEMICAL", 119, 131], ["epoprostenol", "CHEMICAL", 119, 131], ["epoprostenol", "SIMPLE_CHEMICAL", 119, 131], ["persistent hypoxemic respiratory failure", "PROBLEM", 11, 51], ["pronation", "TREATMENT", 85, 94], ["paralysis", "TREATMENT", 96, 105], ["inhaled epoprostenol", "TREATMENT", 111, 131], ["persistent", "OBSERVATION_MODIFIER", 11, 21], ["hypoxemic", "OBSERVATION_MODIFIER", 22, 31], ["respiratory failure", "OBSERVATION", 32, 51], ["paralysis", "OBSERVATION", 96, 105]]], ["However, the patient did not show signs of improvement.", [["patient", "ORGANISM", 13, 20], ["patient", "SPECIES", 13, 20], ["improvement", "OBSERVATION", 43, 54]]], ["She was subsequently started on veno-venous extracorporeal membrane oxygenation (ECMO) and received this treatment for 21 days.", [["veno-venous extracorporeal membrane", "ANATOMY", 32, 67], ["veno-venous extracorporeal membrane oxygenation", "TREATMENT", 32, 79], ["ECMO", "TREATMENT", 81, 85], ["this treatment", "TREATMENT", 100, 114]]], ["During this time, the antibiotic spectrum was broadened to cover for hospital-associated pneumonia and she additionally received empiric Tocilizumab 400 mg intravenously once (20).", [["pneumonia", "DISEASE", 89, 98], ["Tocilizumab", "CHEMICAL", 137, 148], ["Tocilizumab", "SIMPLE_CHEMICAL", 137, 148], ["the antibiotic spectrum", "TREATMENT", 18, 41], ["hospital-associated pneumonia", "PROBLEM", 69, 98], ["empiric Tocilizumab", "TREATMENT", 129, 148], ["pneumonia", "OBSERVATION", 89, 98]]], ["Owing to the persistent need for ventilatory support, the patient underwent tracheostomy, and was subsequently decannulated from veno-venous ECMO due to steady improvement of her respiratory status.", [["respiratory", "ANATOMY", 179, 190], ["patient", "ORGANISM", 58, 65], ["patient", "SPECIES", 58, 65], ["ventilatory support", "TREATMENT", 33, 52], ["tracheostomy", "TREATMENT", 76, 88], ["veno-venous ECMO", "TREATMENT", 129, 145], ["her respiratory status", "PROBLEM", 175, 197], ["persistent", "OBSERVATION_MODIFIER", 13, 23], ["tracheostomy", "OBSERVATION", 76, 88], ["respiratory status", "OBSERVATION", 179, 197]]], ["Before decannulation, the patient had episodes of epistaxis related to ECMO anticoagulation, which required nasal packing.", [["nasal", "ANATOMY", 108, 113], ["epistaxis", "DISEASE", 50, 59], ["patient", "ORGANISM", 26, 33], ["patient", "SPECIES", 26, 33], ["decannulation", "TREATMENT", 7, 20], ["epistaxis", "PROBLEM", 50, 59], ["ECMO anticoagulation", "TREATMENT", 71, 91], ["nasal packing", "TREATMENT", 108, 121], ["epistaxis", "OBSERVATION", 50, 59], ["ECMO anticoagulation", "OBSERVATION", 71, 91], ["nasal packing", "OBSERVATION", 108, 121]]], ["Because of concerns of localized swelling of the tongue and pharyngeal edema, she also received intravenous 2-mg Dexamethasone.", [["tongue", "ANATOMY", 49, 55], ["pharyngeal edema", "ANATOMY", 60, 76], ["intravenous", "ANATOMY", 96, 107], ["swelling of the tongue", "DISEASE", 33, 55], ["pharyngeal edema", "DISEASE", 60, 76], ["Dexamethasone", "CHEMICAL", 113, 126], ["Dexamethasone", "CHEMICAL", 113, 126], ["tongue", "ORGAN", 49, 55], ["pharyngeal edema", "PATHOLOGICAL_FORMATION", 60, 76], ["Dexamethasone", "SIMPLE_CHEMICAL", 113, 126], ["localized swelling of the tongue", "PROBLEM", 23, 55], ["pharyngeal edema", "PROBLEM", 60, 76], ["intravenous 2-mg Dexamethasone", "TREATMENT", 96, 126], ["localized", "OBSERVATION_MODIFIER", 23, 32], ["swelling", "OBSERVATION", 33, 41], ["tongue", "ANATOMY", 49, 55], ["pharyngeal", "ANATOMY", 60, 70], ["edema", "OBSERVATION", 71, 76]]], ["One day after decannulation, the patient had bright red bleeding per rectum and developed tachycardia and hypotension requiring vasopressor support.", [["rectum", "ANATOMY", 69, 75], ["bleeding", "DISEASE", 56, 64], ["tachycardia", "DISEASE", 90, 101], ["hypotension", "DISEASE", 106, 117], ["patient", "ORGANISM", 33, 40], ["rectum", "ORGAN", 69, 75], ["patient", "SPECIES", 33, 40], ["decannulation", "TREATMENT", 14, 27], ["bright red bleeding per rectum", "PROBLEM", 45, 75], ["tachycardia", "PROBLEM", 90, 101], ["hypotension", "PROBLEM", 106, 117], ["vasopressor support", "TREATMENT", 128, 147], ["decannulation", "OBSERVATION", 14, 27], ["bleeding", "OBSERVATION", 56, 64], ["rectum", "ANATOMY", 69, 75], ["tachycardia", "OBSERVATION", 90, 101], ["hypotension", "OBSERVATION", 106, 117], ["vasopressor support", "OBSERVATION", 128, 147]]], ["Chest X-ray showed free air under the right hemidiaphragm (Fig. 2), thereby raising concern for presumed bowel perforation.", [["right hemidiaphragm", "ANATOMY", 38, 57], ["bowel", "ANATOMY", 105, 110], ["bowel perforation", "DISEASE", 105, 122], ["hemidiaphragm", "ORGAN", 44, 57], ["bowel", "ORGAN", 105, 110], ["Chest X-ray", "TEST", 0, 11], ["free air under the right hemidiaphragm", "PROBLEM", 19, 57], ["bowel perforation", "PROBLEM", 105, 122], ["free air", "OBSERVATION", 19, 27], ["right", "ANATOMY_MODIFIER", 38, 43], ["hemidiaphragm", "ANATOMY", 44, 57], ["raising concern for", "UNCERTAINTY", 76, 95], ["bowel", "ANATOMY", 105, 110], ["perforation", "OBSERVATION", 111, 122]]], ["Despite being high risk, in view of her age and recent recovery from ECMO, the decision was made to take her to the operating room after discussion with a multidisciplinary team and the family members.", [["ECMO", "TREATMENT", 69, 73], ["high risk", "OBSERVATION_MODIFIER", 14, 23]]], ["Intraoperatively, 2 L of fecal material was found in the intraperitoneal cavity.", [["fecal material", "ANATOMY", 25, 39], ["intraperitoneal cavity", "ANATOMY", 57, 79], ["intraperitoneal cavity", "PATHOLOGICAL_FORMATION", 57, 79], ["fecal material", "PROBLEM", 25, 39], ["fecal material", "OBSERVATION", 25, 39], ["intraperitoneal cavity", "ANATOMY", 57, 79]]], ["The abdominal cavity was washed with 10 L of fluids, including all 4 quadrants.", [["abdominal cavity", "ANATOMY", 4, 20], ["abdominal cavity", "MULTI-TISSUE_STRUCTURE", 4, 20], ["fluids", "TREATMENT", 45, 51], ["abdominal cavity", "ANATOMY", 4, 20], ["all 4", "ANATOMY_MODIFIER", 63, 68], ["quadrants", "ANATOMY_MODIFIER", 69, 78]]], ["The cecum was found to be ischemic and perforated.", [["cecum", "ANATOMY", 4, 9], ["cecum", "ORGAN", 4, 9], ["ischemic", "PROBLEM", 26, 34], ["perforated", "PROBLEM", 39, 49], ["cecum", "ANATOMY", 4, 9], ["found to be", "UNCERTAINTY", 14, 25], ["ischemic", "OBSERVATION", 26, 34], ["perforated", "OBSERVATION", 39, 49]]], ["The stomach and duodenum appeared healthy.", [["stomach", "ANATOMY", 4, 11], ["duodenum", "ANATOMY", 16, 24], ["stomach", "ORGAN", 4, 11], ["duodenum", "ORGAN", 16, 24], ["stomach", "ANATOMY", 4, 11], ["duodenum", "ANATOMY", 16, 24], ["healthy", "OBSERVATION", 34, 41]]], ["The small bowel was run from the jejunum to terminal ileum with no signs of ischemia.", [["bowel", "ANATOMY", 10, 15], ["jejunum", "ANATOMY", 33, 40], ["ileum", "ANATOMY", 53, 58], ["ischemia", "DISEASE", 76, 84], ["bowel", "ORGAN", 10, 15], ["jejunum", "ORGAN", 33, 40], ["ileum", "MULTI-TISSUE_STRUCTURE", 53, 58], ["ischemia", "PROBLEM", 76, 84], ["small bowel", "ANATOMY", 4, 15], ["jejunum", "ANATOMY", 33, 40], ["terminal", "ANATOMY_MODIFIER", 44, 52], ["ileum", "ANATOMY", 53, 58], ["no signs of", "UNCERTAINTY", 64, 75], ["ischemia", "OBSERVATION", 76, 84]]], ["Because of her tenuous status and significant intraabdominal sepsis, she underwent right hemicolectomy with end ileostomy and Hartmann closure of the colon.", [["intraabdominal", "ANATOMY", 46, 60], ["right hemicolectomy", "ANATOMY", 83, 102], ["colon", "ANATOMY", 150, 155], ["intraabdominal sepsis", "DISEASE", 46, 67], ["intraabdominal", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 60], ["colon", "ORGAN", 150, 155], ["her tenuous status", "PROBLEM", 11, 29], ["significant intraabdominal sepsis", "PROBLEM", 34, 67], ["right hemicolectomy", "TREATMENT", 83, 102], ["end ileostomy", "TREATMENT", 108, 121], ["Hartmann closure of the colon", "TREATMENT", 126, 155], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["intraabdominal", "ANATOMY", 46, 60], ["sepsis", "OBSERVATION", 61, 67], ["right", "ANATOMY_MODIFIER", 83, 88], ["hemicolectomy", "OBSERVATION", 89, 102], ["end ileostomy", "OBSERVATION", 108, 121], ["Hartmann closure", "OBSERVATION", 126, 142], ["colon", "ANATOMY", 150, 155]]], ["Histopathologically, the tissue demonstrated transmural coagulative necrosis involving the cecum and extensive fibrinopurulent serositis (Fig. 3).", [["tissue", "ANATOMY", 25, 31], ["cecum", "ANATOMY", 91, 96], ["necrosis", "DISEASE", 68, 76], ["serositis", "DISEASE", 127, 136], ["tissue", "TISSUE", 25, 31], ["cecum", "ORGAN", 91, 96], ["transmural coagulative necrosis involving the cecum", "PROBLEM", 45, 96], ["extensive fibrinopurulent serositis", "PROBLEM", 101, 136], ["transmural", "OBSERVATION_MODIFIER", 45, 55], ["coagulative", "OBSERVATION_MODIFIER", 56, 67], ["necrosis", "OBSERVATION", 68, 76], ["cecum", "ANATOMY", 91, 96], ["extensive", "OBSERVATION_MODIFIER", 101, 110], ["fibrinopurulent", "OBSERVATION_MODIFIER", 111, 126], ["serositis", "OBSERVATION", 127, 136]]], ["There was no malignancy in the specimen.", [["specimen", "ANATOMY", 31, 39], ["malignancy", "DISEASE", 13, 23], ["malignancy in the specimen", "PROBLEM", 13, 39], ["no", "UNCERTAINTY", 10, 12], ["malignancy", "OBSERVATION", 13, 23]]], ["Postoperatively, the patient received antibiotics and vasopressors for septic shock.", [["septic shock", "DISEASE", 71, 83], ["patient", "ORGANISM", 21, 28], ["patient", "SPECIES", 21, 28], ["antibiotics", "TREATMENT", 38, 49], ["vasopressors", "TREATMENT", 54, 66], ["septic shock", "PROBLEM", 71, 83], ["septic shock", "OBSERVATION", 71, 83]]], ["The patient demonstrated progressive improvement in respiratory status and hemodynamics, was weaned off vasopressors, and discharged to a long-term acute care facility.DiscussionCOVID-19 has rapidly spread around the world.", [["respiratory", "ANATOMY", 52, 63], ["DiscussionCOVID-19", "CHEMICAL", 168, 186], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["vasopressors", "TREATMENT", 104, 116], ["progressive", "OBSERVATION_MODIFIER", 25, 36], ["improvement", "OBSERVATION_MODIFIER", 37, 48], ["respiratory status", "OBSERVATION", 52, 70]]], ["Over the last few months, there have been numerous publications in the literature that describe the devastating clinical effects of this virus [[8], [9], [10], [11]].", [["[9], [10], [11]]", "SIMPLE_CHEMICAL", 149, 165], ["this virus", "PROBLEM", 132, 142], ["numerous", "OBSERVATION_MODIFIER", 42, 50], ["publications", "OBSERVATION", 51, 63]]], ["However, to the best of our knowledge, this is the first report describing bowel perforation in a critically ill COVID-19\u2013positive patient receiving empiric Tocilizumab.", [["bowel", "ANATOMY", 75, 80], ["bowel perforation", "DISEASE", 75, 92], ["critically ill", "DISEASE", 98, 112], ["Tocilizumab", "CHEMICAL", 157, 168], ["bowel", "ORGAN", 75, 80], ["patient", "ORGANISM", 131, 138], ["Tocilizumab", "SIMPLE_CHEMICAL", 157, 168], ["patient", "SPECIES", 131, 138], ["bowel perforation", "PROBLEM", 75, 92], ["a critically ill COVID", "TREATMENT", 96, 118], ["empiric Tocilizumab", "TREATMENT", 149, 168], ["bowel", "ANATOMY", 75, 80], ["perforation", "OBSERVATION", 81, 92]]], ["New therapeutic approaches are being developed to treat critically ill COVID-19\u2013positive patients and rely on controlling the proinflammatory cytokines, mainly IL-6, IL-10, and tumor necrosis factor-\u03b1.", [["critically ill", "DISEASE", 56, 70], ["tumor necrosis", "DISEASE", 177, 191], ["patients", "ORGANISM", 89, 97], ["IL-6", "GENE_OR_GENE_PRODUCT", 160, 164], ["IL-10", "GENE_OR_GENE_PRODUCT", 166, 171], ["tumor necrosis factor-\u03b1.", "GENE_OR_GENE_PRODUCT", 177, 201], ["proinflammatory cytokines", "PROTEIN", 126, 151], ["IL-6", "PROTEIN", 160, 164], ["IL-10", "PROTEIN", 166, 171], ["patients", "SPECIES", 89, 97], ["New therapeutic approaches", "TREATMENT", 0, 26], ["critically ill COVID", "PROBLEM", 56, 76], ["the proinflammatory cytokines", "TEST", 122, 151], ["IL", "TEST", 160, 162], ["IL", "TEST", 166, 168], ["tumor necrosis factor", "PROBLEM", 177, 198], ["tumor", "OBSERVATION_MODIFIER", 177, 182], ["necrosis", "OBSERVATION", 183, 191]]], ["Tocilizumab, a monoclonal antiIL-6 receptor antibody primarily used for rheumatologic conditions, has been used in the management of cytokine release syndrome associated with severe COVID-19 infection [12].", [["Tocilizumab", "CHEMICAL", 0, 11], ["infection", "DISEASE", 191, 200], ["Tocilizumab", "CHEMICAL", 0, 11], ["Tocilizumab", "SIMPLE_CHEMICAL", 0, 11], ["antiIL-6 receptor", "GENE_OR_GENE_PRODUCT", 26, 43], ["monoclonal antiIL-6 receptor antibody", "PROTEIN", 15, 52], ["cytokine", "PROTEIN", 133, 141], ["Tocilizumab", "TREATMENT", 0, 11], ["a monoclonal antiIL-6 receptor antibody", "TREATMENT", 13, 52], ["rheumatologic conditions", "PROBLEM", 72, 96], ["cytokine release syndrome", "PROBLEM", 133, 158], ["severe COVID-19 infection", "PROBLEM", 175, 200], ["infection", "OBSERVATION", 191, 200]]], ["A randomized, double-blind, placebo-controlled phase III clinical trial is in the works to evaluate the safety and efficacy of tocilizumab plus standard of care in hospitalized patients with severe SARS-CoV-2 coronavirus pneumonia compared with placebo plus standard of care.", [["tocilizumab", "CHEMICAL", 127, 138], ["SARS-CoV-2 coronavirus pneumonia", "DISEASE", 198, 230], ["tocilizumab", "SIMPLE_CHEMICAL", 127, 138], ["patients", "ORGANISM", 177, 185], ["CoV-2 coronavirus", "ORGANISM", 203, 220], ["patients", "SPECIES", 177, 185], ["CoV-2 coronavirus", "SPECIES", 203, 220], ["SARS-CoV-2 coronavirus", "SPECIES", 198, 220], ["placebo", "TREATMENT", 28, 35], ["tocilizumab", "TREATMENT", 127, 138], ["severe SARS", "PROBLEM", 191, 202], ["CoV", "PROBLEM", 203, 206], ["2 coronavirus pneumonia", "PROBLEM", 207, 230], ["placebo", "TREATMENT", 245, 252], ["pneumonia", "OBSERVATION", 221, 230]]], ["The primary and secondary endpoints of the study include clinical status, mortality, mechanical ventilation, and intensive care unit variables [13].", [["the study", "TEST", 39, 48], ["mechanical ventilation", "TREATMENT", 85, 107], ["mechanical ventilation", "OBSERVATION", 85, 107]]], ["Although promising in controlling the disease in certain patients with hyperinflammatory phenotype, its safety and efficacy are still under debate.DiscussionOne of the most commonly reported complications of Tocilizumab in patients with rheumatologic conditions is the increased risk of lower gastrointestinal perforations.", [["lower gastrointestinal", "ANATOMY", 287, 309], ["Tocilizumab", "CHEMICAL", 208, 219], ["lower gastrointestinal perforations", "DISEASE", 287, 322], ["Tocilizumab", "CHEMICAL", 208, 219], ["patients", "ORGANISM", 57, 65], ["Tocilizumab", "SIMPLE_CHEMICAL", 208, 219], ["patients", "ORGANISM", 223, 231], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 287, 309], ["perforations", "PATHOLOGICAL_FORMATION", 310, 322], ["patients", "SPECIES", 57, 65], ["patients", "SPECIES", 223, 231], ["the disease", "PROBLEM", 34, 45], ["hyperinflammatory phenotype", "PROBLEM", 71, 98], ["Tocilizumab", "TREATMENT", 208, 219], ["rheumatologic conditions", "PROBLEM", 237, 261], ["lower gastrointestinal perforations", "PROBLEM", 287, 322], ["disease", "OBSERVATION", 38, 45], ["Tocilizumab", "OBSERVATION", 208, 219], ["increased", "OBSERVATION_MODIFIER", 269, 278], ["lower", "ANATOMY_MODIFIER", 287, 292], ["gastrointestinal", "ANATOMY", 293, 309], ["perforations", "OBSERVATION", 310, 322]]], ["Strangfeld et al. [14] reported a significant increased risk of bowel perforations in patients using Tocilizumab (2.7 events per 1000 person-years) when they compared them with patients taking other biological agents.", [["bowel", "ANATOMY", 64, 69], ["bowel perforations", "DISEASE", 64, 82], ["Tocilizumab", "CHEMICAL", 101, 112], ["Tocilizumab", "CHEMICAL", 101, 112], ["bowel", "ORGAN", 64, 69], ["patients", "ORGANISM", 86, 94], ["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 86, 94], ["patients", "SPECIES", 177, 185], ["bowel perforations", "PROBLEM", 64, 82], ["Tocilizumab", "TREATMENT", 101, 112], ["other biological agents", "TREATMENT", 193, 216], ["significant", "OBSERVATION_MODIFIER", 34, 45], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["bowel", "ANATOMY", 64, 69], ["perforations", "OBSERVATION", 70, 82]]], ["The 30-day mortality rate among patients with bowel perforation was 46%.", [["bowel", "ANATOMY", 46, 51], ["bowel perforation", "DISEASE", 46, 63], ["patients", "ORGANISM", 32, 40], ["bowel", "ORGAN", 46, 51], ["patients", "SPECIES", 32, 40], ["bowel perforation", "PROBLEM", 46, 63], ["bowel", "ANATOMY", 46, 51], ["perforation", "OBSERVATION", 52, 63]]], ["The pathophysiology is not completely understood; however, prior diverticulitis is a risk factor for the development of bowel perforation in patients taking Tocilizumab.", [["bowel", "ANATOMY", 120, 125], ["diverticulitis", "DISEASE", 65, 79], ["bowel perforation", "DISEASE", 120, 137], ["Tocilizumab", "CHEMICAL", 157, 168], ["Tocilizumab", "CHEMICAL", 157, 168], ["bowel", "ORGAN", 120, 125], ["patients", "ORGANISM", 141, 149], ["Tocilizumab", "SIMPLE_CHEMICAL", 157, 168], ["patients", "SPECIES", 141, 149], ["prior diverticulitis", "PROBLEM", 59, 79], ["a risk factor", "PROBLEM", 83, 96], ["bowel perforation", "PROBLEM", 120, 137], ["Tocilizumab", "TREATMENT", 157, 168], ["diverticulitis", "OBSERVATION", 65, 79], ["bowel", "ANATOMY", 120, 125], ["perforation", "OBSERVATION", 126, 137]]], ["Interestingly, our patient did not have diverticulosis seen on abdominal imaging.", [["abdominal", "ANATOMY", 63, 72], ["diverticulosis", "DISEASE", 40, 54], ["patient", "ORGANISM", 19, 26], ["diverticulosis", "PATHOLOGICAL_FORMATION", 40, 54], ["abdominal", "ORGANISM_SUBDIVISION", 63, 72], ["patient", "SPECIES", 19, 26], ["diverticulosis", "PROBLEM", 40, 54], ["abdominal imaging", "TEST", 63, 80], ["diverticulosis", "OBSERVATION", 40, 54], ["abdominal", "ANATOMY", 63, 72]]], ["In another retrospective study, it was shown that the concomitant use of Tocilizumab and Prednisone causes a higher incidence of lower gastrointestinal perforations in comparison to other tumor necrosis alpha inhibitors [15].", [["gastrointestinal", "ANATOMY", 135, 151], ["Tocilizumab", "CHEMICAL", 73, 84], ["Prednisone", "CHEMICAL", 89, 99], ["gastrointestinal perforations", "DISEASE", 135, 164], ["tumor", "DISEASE", 188, 193], ["necrosis", "DISEASE", 194, 202], ["Tocilizumab", "CHEMICAL", 73, 84], ["Prednisone", "CHEMICAL", 89, 99], ["Tocilizumab", "SIMPLE_CHEMICAL", 73, 84], ["Prednisone", "SIMPLE_CHEMICAL", 89, 99], ["lower gastrointestinal", "ORGANISM_SUBDIVISION", 129, 151], ["tumor necrosis alpha", "GENE_OR_GENE_PRODUCT", 188, 208], ["another retrospective study", "TEST", 3, 30], ["Tocilizumab", "TREATMENT", 73, 84], ["Prednisone", "TREATMENT", 89, 99], ["lower gastrointestinal perforations", "PROBLEM", 129, 164], ["other tumor necrosis alpha inhibitors", "TREATMENT", 182, 219], ["lower", "ANATOMY_MODIFIER", 129, 134], ["gastrointestinal", "ANATOMY", 135, 151], ["perforations", "OBSERVATION", 152, 164], ["tumor", "OBSERVATION_MODIFIER", 188, 193], ["necrosis", "OBSERVATION", 194, 202]]], ["Our patient received both medications before the acute large bowel perforation occurred, because she received empiric Tocilizumab for COVID-19 pneumonia and Dexamethasone for several days for pharyngeal edema.DiscussionIt has been established that COVID-19 infects the human organism by binding the angiotensin-converting enzyme receptors, similar to the mechanism previously described with the SARS pathogen [16].", [["bowel", "ANATOMY", 61, 66], ["pharyngeal edema", "ANATOMY", 192, 208], ["bowel perforation", "DISEASE", 61, 78], ["Tocilizumab", "CHEMICAL", 118, 129], ["COVID-19", "CHEMICAL", 134, 142], ["pneumonia", "DISEASE", 143, 152], ["Dexamethasone", "CHEMICAL", 157, 170], ["pharyngeal edema", "DISEASE", 192, 208], ["COVID-19", "CHEMICAL", 248, 256], ["angiotensin", "CHEMICAL", 299, 310], ["SARS", "DISEASE", 395, 399], ["Dexamethasone", "CHEMICAL", 157, 170], ["patient", "ORGANISM", 4, 11], ["bowel", "ORGAN", 61, 66], ["Tocilizumab", "SIMPLE_CHEMICAL", 118, 129], ["Dexamethasone", "SIMPLE_CHEMICAL", 157, 170], ["pharyngeal edema", "PATHOLOGICAL_FORMATION", 192, 208], ["COVID-19", "ORGANISM", 248, 256], ["human", "ORGANISM", 269, 274], ["angiotensin-converting enzyme receptors", "GENE_OR_GENE_PRODUCT", 299, 338], ["angiotensin-converting enzyme receptors", "PROTEIN", 299, 338], ["patient", "SPECIES", 4, 11], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 269, 274], ["both medications", "TREATMENT", 21, 37], ["the acute large bowel perforation", "PROBLEM", 45, 78], ["empiric Tocilizumab", "TREATMENT", 110, 129], ["COVID", "TREATMENT", 134, 139], ["pneumonia", "PROBLEM", 143, 152], ["Dexamethasone", "TREATMENT", 157, 170], ["pharyngeal edema", "PROBLEM", 192, 208], ["COVID", "TEST", 248, 253], ["the angiotensin-converting enzyme receptors", "TREATMENT", 295, 338], ["the SARS pathogen", "PROBLEM", 391, 408], ["acute", "OBSERVATION_MODIFIER", 49, 54], ["large", "OBSERVATION_MODIFIER", 55, 60], ["bowel", "ANATOMY", 61, 66], ["perforation", "OBSERVATION", 67, 78], ["pneumonia", "OBSERVATION", 143, 152], ["pharyngeal", "ANATOMY", 192, 202], ["edema", "OBSERVATION", 203, 208]]], ["Angiotensin-converting enzyme receptors are not only highly expressed in the airway and lung tissue but also present in the gastrointestinal tract.", [["airway", "ANATOMY", 77, 83], ["lung tissue", "ANATOMY", 88, 99], ["gastrointestinal tract", "ANATOMY", 124, 146], ["Angiotensin", "CHEMICAL", 0, 11], ["Angiotensin-converting enzyme receptors", "GENE_OR_GENE_PRODUCT", 0, 39], ["airway", "MULTI-TISSUE_STRUCTURE", 77, 83], ["lung tissue", "TISSUE", 88, 99], ["gastrointestinal tract", "ORGAN", 124, 146], ["Angiotensin-converting enzyme receptors", "PROTEIN", 0, 39], ["Angiotensin", "TREATMENT", 0, 11], ["converting enzyme receptors", "TEST", 12, 39], ["airway", "ANATOMY", 77, 83], ["lung", "ANATOMY", 88, 92], ["tissue", "OBSERVATION", 93, 99], ["gastrointestinal tract", "ANATOMY", 124, 146]]], ["Viral nucleic acids have been found in the stool and saliva of COVID-19\u2013positive patients [17].", [["stool", "ANATOMY", 43, 48], ["nucleic acids", "CHEMICAL", 6, 19], ["stool", "ORGANISM_SUBSTANCE", 43, 48], ["saliva", "ORGANISM_SUBSTANCE", 53, 59], ["patients", "ORGANISM", 81, 89], ["patients", "SPECIES", 81, 89], ["Viral nucleic acids", "TEST", 0, 19], ["COVID", "TEST", 63, 68], ["nucleic acids", "OBSERVATION", 6, 19], ["stool", "OBSERVATION", 43, 48]]], ["These findings support the possibility that this virus could spread through fecal oral transmission.", [["fecal oral", "ANATOMY", 76, 86], ["fecal oral transmission", "DISEASE", 76, 99], ["fecal", "ORGANISM", 76, 81], ["oral", "ORGANISM_SUBDIVISION", 82, 86], ["this virus", "PROBLEM", 44, 54], ["support the possibility", "UNCERTAINTY", 15, 38]]], ["A recent study showed that in patients who manifested with gastrointestinal complaints, the virus was isolated from fecal material in early stages of the infection [18].", [["gastrointestinal", "ANATOMY", 59, 75], ["fecal material", "ANATOMY", 116, 130], ["gastrointestinal complaints", "DISEASE", 59, 86], ["infection", "DISEASE", 154, 163], ["patients", "ORGANISM", 30, 38], ["gastrointestinal", "ORGANISM_SUBDIVISION", 59, 75], ["fecal material", "MULTI-TISSUE_STRUCTURE", 116, 130], ["patients", "SPECIES", 30, 38], ["A recent study", "TEST", 0, 14], ["gastrointestinal complaints", "PROBLEM", 59, 86], ["the virus", "PROBLEM", 88, 97], ["fecal material", "PROBLEM", 116, 130], ["the infection", "PROBLEM", 150, 163], ["gastrointestinal", "ANATOMY", 59, 75], ["fecal material", "OBSERVATION_MODIFIER", 116, 130], ["early stages", "OBSERVATION_MODIFIER", 134, 146], ["infection", "OBSERVATION", 154, 163]]], ["More research is needed to determine if the immune response to the virus could be a cause of gastrointestinal perforations.DiscussionAnother emerging theory for many of the complications noted in critically ill COVID-19 patients is the hypercoagulable state caused by the virus.", [["gastrointestinal", "ANATOMY", 93, 109], ["gastrointestinal perforations", "DISEASE", 93, 122], ["critically ill", "DISEASE", 196, 210], ["gastrointestinal perforations", "PATHOLOGICAL_FORMATION", 93, 122], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 220, 228], ["the virus", "PROBLEM", 63, 72], ["gastrointestinal perforations", "PROBLEM", 93, 122], ["the complications", "PROBLEM", 169, 186], ["the hypercoagulable state", "PROBLEM", 232, 257], ["the virus", "PROBLEM", 268, 277], ["gastrointestinal", "ANATOMY", 93, 109], ["perforations", "OBSERVATION", 110, 122], ["hypercoagulable", "OBSERVATION", 236, 251], ["virus", "OBSERVATION", 272, 277]]], ["The measurement of D-dimer levels has proven to be useful in predicting the risk of thrombosis and mortality in this patient population, as recently suggested by a study conducted in Wuhan [19].", [["thrombosis", "DISEASE", 84, 94], ["D-dimer", "GENE_OR_GENE_PRODUCT", 19, 26], ["patient", "ORGANISM", 117, 124], ["patient", "SPECIES", 117, 124], ["The measurement of D-dimer levels", "TEST", 0, 33], ["thrombosis", "PROBLEM", 84, 94], ["a study", "TEST", 162, 169], ["thrombosis", "OBSERVATION", 84, 94]]], ["An observational study that included 184 COVID-19\u2013positive cases showed a 31% incidence of thrombotic events.", [["thrombotic", "DISEASE", 91, 101], ["An observational study", "TEST", 0, 22], ["COVID", "TEST", 41, 46], ["thrombotic events", "PROBLEM", 91, 108], ["thrombotic", "OBSERVATION", 91, 101]]], ["Anticoagulation in these patients helped prevent the thrombotic effects of this virus.", [["thrombotic", "DISEASE", 53, 63], ["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["Anticoagulation", "TREATMENT", 0, 15], ["the thrombotic effects", "PROBLEM", 49, 71], ["this virus", "PROBLEM", 75, 85], ["thrombotic", "OBSERVATION", 53, 63]]], ["None of the patients observed in this study were diagnosed with disseminated intravascular coagulation.", [["intravascular", "ANATOMY", 77, 90], ["intravascular coagulation", "DISEASE", 77, 102], ["patients", "ORGANISM", 12, 20], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 77, 90], ["patients", "SPECIES", 12, 20], ["this study", "TEST", 33, 43], ["disseminated intravascular coagulation", "PROBLEM", 64, 102], ["disseminated", "OBSERVATION_MODIFIER", 64, 76], ["intravascular coagulation", "OBSERVATION", 77, 102]]], ["Pulmonary embolism was the most frequent thrombotic complication (n = 25, 81%) [20].", [["Pulmonary", "ANATOMY", 0, 9], ["Pulmonary embolism", "DISEASE", 0, 18], ["thrombotic", "DISEASE", 41, 51], ["Pulmonary", "ORGAN", 0, 9], ["Pulmonary embolism", "PROBLEM", 0, 18], ["frequent thrombotic complication", "PROBLEM", 32, 64], ["embolism", "OBSERVATION", 10, 18], ["most frequent", "OBSERVATION_MODIFIER", 27, 40], ["thrombotic", "OBSERVATION_MODIFIER", 41, 51], ["complication", "OBSERVATION", 52, 64]]], ["There is growing evidence that many of the complications and deaths are related to thrombotic events in critically ill COVID-19\u2013positive patients.", [["deaths", "DISEASE", 61, 67], ["thrombotic", "DISEASE", 83, 93], ["critically ill", "DISEASE", 104, 118], ["patients", "ORGANISM", 137, 145], ["patients", "SPECIES", 137, 145], ["the complications", "PROBLEM", 39, 56], ["deaths", "PROBLEM", 61, 67], ["thrombotic events", "PROBLEM", 83, 100], ["complications", "OBSERVATION", 43, 56], ["thrombotic", "OBSERVATION", 83, 93]]], ["Most physicians are now using prophylactic anticoagulation medications to treat patients infected with COVID-19 [21,22].", [["COVID-19", "CHEMICAL", 103, 111], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["prophylactic anticoagulation medications", "TREATMENT", 30, 70], ["COVID", "TEST", 103, 108]]], ["Currently, there are no reports of bowel ischemia or perforation caused by thrombotic events; however, this may be a contributing factor for acute large bowel perforation in COVID-19\u2013positive patients treated empirically with Tocilizumab.DiscussionAdditionally, hemodynamically unstable critically ill COVID-19\u2013positive patients may require vasoactive medication, potentially leading to intestinal hypoperfusion and intestinal ischemia.", [["bowel", "ANATOMY", 35, 40], ["bowel", "ANATOMY", 153, 158], ["intestinal", "ANATOMY", 387, 397], ["intestinal", "ANATOMY", 416, 426], ["bowel ischemia", "DISEASE", 35, 49], ["perforation", "DISEASE", 53, 64], ["thrombotic events", "DISEASE", 75, 92], ["bowel perforation", "DISEASE", 153, 170], ["Tocilizumab", "CHEMICAL", 226, 237], ["intestinal hypoperfusion", "DISEASE", 387, 411], ["intestinal ischemia", "DISEASE", 416, 435], ["Tocilizumab", "CHEMICAL", 226, 237], ["bowel", "ORGAN", 35, 40], ["bowel", "ORGAN", 153, 158], ["patients", "ORGANISM", 192, 200], ["Tocilizumab", "SIMPLE_CHEMICAL", 226, 237], ["patients", "ORGANISM", 320, 328], ["intestinal", "ORGAN", 387, 397], ["intestinal", "ORGAN", 416, 426], ["patients", "SPECIES", 192, 200], ["patients", "SPECIES", 320, 328], ["bowel ischemia", "PROBLEM", 35, 49], ["perforation", "PROBLEM", 53, 64], ["thrombotic events", "PROBLEM", 75, 92], ["a contributing factor", "PROBLEM", 115, 136], ["acute large bowel perforation", "PROBLEM", 141, 170], ["COVID", "TEST", 174, 179], ["Tocilizumab", "TREATMENT", 226, 237], ["hemodynamically unstable critically ill COVID", "PROBLEM", 262, 307], ["vasoactive medication", "TREATMENT", 341, 362], ["intestinal hypoperfusion", "PROBLEM", 387, 411], ["intestinal ischemia", "PROBLEM", 416, 435], ["no reports of", "UNCERTAINTY", 21, 34], ["bowel", "ANATOMY", 35, 40], ["ischemia", "OBSERVATION", 41, 49], ["perforation", "OBSERVATION", 53, 64], ["thrombotic", "OBSERVATION", 75, 85], ["acute", "OBSERVATION_MODIFIER", 141, 146], ["large", "OBSERVATION_MODIFIER", 147, 152], ["bowel", "ANATOMY", 153, 158], ["perforation", "OBSERVATION", 159, 170], ["intestinal", "ANATOMY", 387, 397], ["hypoperfusion", "OBSERVATION", 398, 411], ["intestinal", "ANATOMY", 416, 426], ["ischemia", "OBSERVATION", 427, 435]]], ["The pathogenesis is believed to be an interrelationship of several factors, such as inflammatory cells, activation of proinflammatory cytokine cascade, interruption of microcirculatory blood flow, as well as the functional integrity of the intestinal mucosa [23].", [["inflammatory cells", "ANATOMY", 84, 102], ["blood", "ANATOMY", 185, 190], ["intestinal mucosa", "ANATOMY", 240, 257], ["inflammatory cells", "CELL", 84, 102], ["blood", "ORGANISM_SUBSTANCE", 185, 190], ["intestinal mucosa", "MULTI-TISSUE_STRUCTURE", 240, 257], ["inflammatory cells", "CELL_TYPE", 84, 102], ["proinflammatory cytokine", "PROTEIN", 118, 142], ["inflammatory cells", "PROBLEM", 84, 102], ["proinflammatory cytokine cascade", "TREATMENT", 118, 150], ["microcirculatory blood flow", "TEST", 168, 195], ["believed to be", "UNCERTAINTY", 20, 34], ["several", "OBSERVATION_MODIFIER", 59, 66], ["factors", "OBSERVATION", 67, 74], ["inflammatory cells", "OBSERVATION", 84, 102], ["proinflammatory cytokine cascade", "OBSERVATION", 118, 150], ["microcirculatory blood flow", "OBSERVATION", 168, 195], ["intestinal mucosa", "ANATOMY", 240, 257]]], ["Intestinal hypoperfusion may have been a contributing factor; however, it is unlikely to be the main etiology of large bowel perforation in the case described herein, because there was no evidence of ischemia in other areas of the small or large intestine supplied by the superior mesenteric artery.ConclusionThis case report describes a rare case of colonic perforation in a critically ill, morbidly obese patient with COVID-19 pneumonia on empiric Tocilizumab therapy.", [["Intestinal", "ANATOMY", 0, 10], ["bowel", "ANATOMY", 119, 124], ["small", "ANATOMY", 231, 236], ["intestine", "ANATOMY", 246, 255], ["superior mesenteric artery", "ANATOMY", 272, 298], ["colonic", "ANATOMY", 351, 358], ["Intestinal hypoperfusion", "DISEASE", 0, 24], ["bowel perforation", "DISEASE", 119, 136], ["ischemia", "DISEASE", 200, 208], ["colonic perforation", "DISEASE", 351, 370], ["critically ill", "DISEASE", 376, 390], ["pneumonia", "DISEASE", 429, 438], ["Tocilizumab", "CHEMICAL", 450, 461], ["Intestinal", "ORGAN", 0, 10], ["bowel", "ORGAN", 119, 124], ["intestine", "ORGAN", 246, 255], ["superior mesenteric artery", "MULTI-TISSUE_STRUCTURE", 272, 298], ["colonic", "ORGAN", 351, 358], ["patient", "ORGANISM", 407, 414], ["Tocilizumab", "SIMPLE_CHEMICAL", 450, 461], ["patient", "SPECIES", 407, 414], ["Intestinal hypoperfusion", "PROBLEM", 0, 24], ["large bowel perforation", "PROBLEM", 113, 136], ["ischemia in other areas of the small or large intestine", "PROBLEM", 200, 255], ["colonic perforation", "PROBLEM", 351, 370], ["morbidly obese", "PROBLEM", 392, 406], ["COVID", "TEST", 420, 425], ["pneumonia", "PROBLEM", 429, 438], ["empiric Tocilizumab therapy", "TREATMENT", 442, 469], ["hypoperfusion", "OBSERVATION", 11, 24], ["unlikely to be", "UNCERTAINTY", 77, 91], ["large", "OBSERVATION_MODIFIER", 113, 118], ["bowel", "ANATOMY", 119, 124], ["perforation", "OBSERVATION", 125, 136], ["no evidence of", "UNCERTAINTY", 185, 199], ["ischemia", "OBSERVATION", 200, 208], ["small", "OBSERVATION", 231, 236], ["large intestine", "ANATOMY", 240, 255], ["superior mesenteric artery", "ANATOMY", 272, 298], ["colonic", "ANATOMY", 351, 358], ["perforation", "OBSERVATION", 359, 370], ["pneumonia", "OBSERVATION", 429, 438]]], ["It emphasizes the importance of close monitoring for gastrointestinal events in patients infected with COVID-19 receiving Tocilizumab empirically.", [["gastrointestinal", "ANATOMY", 53, 69], ["Tocilizumab", "CHEMICAL", 122, 133], ["Tocilizumab", "CHEMICAL", 122, 133], ["gastrointestinal", "ORGANISM_SUBDIVISION", 53, 69], ["patients", "ORGANISM", 80, 88], ["Tocilizumab", "SIMPLE_CHEMICAL", 122, 133], ["patients", "SPECIES", 80, 88], ["close monitoring", "TEST", 32, 48], ["gastrointestinal events", "PROBLEM", 53, 76], ["COVID", "TREATMENT", 103, 108], ["Tocilizumab", "TREATMENT", 122, 133]]], ["Further studies are needed to better understand the safety and efficacy of tocilizumab plus standard of care in hospitalized patients with severe COVID-19 infection.Disclosures", [["tocilizumab", "CHEMICAL", 75, 86], ["infection", "DISEASE", 155, 164], ["tocilizumab", "SIMPLE_CHEMICAL", 75, 86], ["patients", "ORGANISM", 125, 133], ["patients", "SPECIES", 125, 133], ["Further studies", "TEST", 0, 15], ["tocilizumab", "TREATMENT", 75, 86], ["severe COVID-19 infection", "PROBLEM", 139, 164], ["infection", "OBSERVATION", 155, 164]]]], "25ac1ac2e7fddb8b1dd850210fd77cbc9d20925b": [["INTRODUCTIONThe outbreak of novel coronavirus disease, previously treated as pneumonia of unknown aetiology in China, was declared a pandemic in March 2020 [1] .", [["coronavirus disease", "DISEASE", 34, 53], ["pneumonia", "DISEASE", 77, 86], ["coronavirus", "ORGANISM", 34, 45], ["novel coronavirus disease", "PROBLEM", 28, 53], ["pneumonia", "PROBLEM", 77, 86], ["coronavirus disease", "OBSERVATION", 34, 53], ["pneumonia", "OBSERVATION", 77, 86]]], ["It was named coronavirus disease 2019 (COVID-19) by World Health Organization (WHO) [2] .", [["coronavirus disease", "DISEASE", 13, 32], ["coronavirus disease", "PROBLEM", 13, 32], ["COVID", "TEST", 39, 44], ["coronavirus disease", "OBSERVATION", 13, 32]]], ["With a variety of presentations including conjunctivitis, transverse myelitis, stroke and enteric symptoms, coronavirus also affects human lung parenchyma causing acute respiratory distress and pneumonia [3] .", [["lung parenchyma", "ANATOMY", 139, 154], ["respiratory", "ANATOMY", 169, 180], ["conjunctivitis", "DISEASE", 42, 56], ["transverse myelitis", "DISEASE", 58, 77], ["stroke", "DISEASE", 79, 85], ["enteric symptoms", "DISEASE", 90, 106], ["coronavirus", "DISEASE", 108, 119], ["acute respiratory distress", "DISEASE", 163, 189], ["pneumonia", "DISEASE", 194, 203], ["coronavirus", "ORGANISM", 108, 119], ["human", "ORGANISM", 133, 138], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 139, 154], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 133, 138], ["conjunctivitis", "PROBLEM", 42, 56], ["transverse myelitis", "PROBLEM", 58, 77], ["stroke", "PROBLEM", 79, 85], ["enteric symptoms", "PROBLEM", 90, 106], ["coronavirus", "PROBLEM", 108, 119], ["human lung parenchyma", "PROBLEM", 133, 154], ["acute respiratory distress", "PROBLEM", 163, 189], ["pneumonia", "PROBLEM", 194, 203], ["conjunctivitis", "OBSERVATION", 42, 56], ["transverse myelitis", "OBSERVATION", 58, 77], ["enteric", "ANATOMY", 90, 97], ["lung", "ANATOMY", 139, 143], ["parenchyma", "ANATOMY_MODIFIER", 144, 154], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory distress", "OBSERVATION", 169, 189], ["pneumonia", "OBSERVATION", 194, 203]]], ["However, pleural effusion is rarely reported in COVID-19 patients [4] .", [["pleural effusion", "ANATOMY", 9, 25], ["pleural effusion", "DISEASE", 9, 25], ["pleural", "ORGAN", 9, 16], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["pleural effusion", "PROBLEM", 9, 25], ["pleural", "ANATOMY", 9, 16], ["effusion", "OBSERVATION", 17, 25]]], ["Here we present the case of a 38-year-old COVID-19-positive man with rheumatic mitral valve disease and bilateral pleural effusion with pneumonia.CASE PRESENTATIONA 38-year-old man, who was known to have rheumatic mitral valve disease for the past 4 years, attended the emergency department with a 2-day history of shortness of breath (New York Heart Association (NYHA) class II).", [["rheumatic mitral valve", "ANATOMY", 69, 91], ["pleural", "ANATOMY", 114, 121], ["mitral valve", "ANATOMY", 214, 226], ["rheumatic mitral valve disease", "DISEASE", 69, 99], ["pleural effusion", "DISEASE", 114, 130], ["pneumonia", "DISEASE", 136, 145], ["rheumatic mitral valve disease", "DISEASE", 204, 234], ["shortness of breath", "DISEASE", 315, 334], ["man", "ORGANISM", 60, 63], ["mitral valve", "PATHOLOGICAL_FORMATION", 79, 91], ["pleural", "ORGAN", 114, 121], ["man", "ORGANISM", 177, 180], ["mitral valve", "PATHOLOGICAL_FORMATION", 214, 226], ["man", "SPECIES", 60, 63], ["man", "SPECIES", 177, 180], ["rheumatic mitral valve disease", "PROBLEM", 69, 99], ["bilateral pleural effusion", "PROBLEM", 104, 130], ["pneumonia", "PROBLEM", 136, 145], ["rheumatic mitral valve disease", "PROBLEM", 204, 234], ["shortness of breath", "PROBLEM", 315, 334], ["rheumatic", "OBSERVATION", 69, 78], ["mitral valve", "ANATOMY", 79, 91], ["disease", "OBSERVATION", 92, 99], ["bilateral", "ANATOMY_MODIFIER", 104, 113], ["pleural", "ANATOMY", 114, 121], ["effusion", "OBSERVATION", 122, 130], ["pneumonia", "OBSERVATION", 136, 145], ["rheumatic", "OBSERVATION", 204, 213], ["mitral valve", "ANATOMY", 214, 226], ["disease", "OBSERVATION", 227, 234], ["Heart", "ANATOMY", 345, 350]]], ["He had severe mitral regurgitation and moderate mitral stenosis.", [["mitral", "ANATOMY", 14, 20], ["mitral", "ANATOMY", 48, 54], ["mitral regurgitation", "DISEASE", 14, 34], ["mitral stenosis", "DISEASE", 48, 63], ["mitral regurgitation", "PATHOLOGICAL_FORMATION", 14, 34], ["mitral stenosis", "PATHOLOGICAL_FORMATION", 48, 63], ["severe mitral regurgitation", "PROBLEM", 7, 34], ["moderate mitral stenosis", "PROBLEM", 39, 63], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["mitral", "ANATOMY", 14, 20], ["regurgitation", "OBSERVATION", 21, 34], ["moderate", "OBSERVATION_MODIFIER", 39, 47], ["mitral", "OBSERVATION", 48, 54], ["stenosis", "OBSERVATION", 55, 63]]], ["The patient had previously refused mitral valve replacement.", [["mitral valve", "ANATOMY", 35, 47], ["patient", "ORGANISM", 4, 11], ["mitral valve", "MULTI-TISSUE_STRUCTURE", 35, 47], ["patient", "SPECIES", 4, 11], ["mitral valve replacement", "TREATMENT", 35, 59], ["mitral valve", "ANATOMY", 35, 47], ["replacement", "OBSERVATION", 48, 59]]], ["He was stable on medical treatment with no history of hospitalization in the past 6 months.CASE PRESENTATIONHis shortness of breath was associated with fever (101\u00b0C) and dry cough.", [["shortness of breath", "DISEASE", 112, 131], ["fever", "DISEASE", 152, 157], ["dry cough", "DISEASE", 170, 179], ["medical treatment", "TREATMENT", 17, 34], ["shortness of breath", "PROBLEM", 112, 131], ["fever", "PROBLEM", 152, 157], ["dry cough", "PROBLEM", 170, 179], ["stable", "OBSERVATION_MODIFIER", 7, 13], ["dry", "OBSERVATION_MODIFIER", 170, 173], ["cough", "OBSERVATION", 174, 179]]], ["His heart rate was 96 beats/min and respiratory rate was 25 breaths/min.", [["heart", "ANATOMY", 4, 9], ["respiratory", "ANATOMY", 36, 47], ["heart", "ORGAN", 4, 9], ["His heart rate", "TEST", 0, 14], ["respiratory rate", "TEST", 36, 52], ["heart", "ANATOMY", 4, 9]]], ["Oxygen saturation was 86% on room air.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["Oxygen saturation", "TEST", 0, 17]]], ["On auscultation of the lungs, bilateral coarse crepitation at the base and decreased air entry on the left side were noted.", [["lungs", "ANATOMY", 23, 28], ["lungs", "ORGAN", 23, 28], ["auscultation", "TEST", 3, 15], ["bilateral coarse crepitation at the base", "PROBLEM", 30, 70], ["decreased air entry on the left side", "PROBLEM", 75, 111], ["auscultation", "OBSERVATION", 3, 15], ["lungs", "ANATOMY", 23, 28], ["bilateral", "ANATOMY_MODIFIER", 30, 39], ["coarse", "OBSERVATION_MODIFIER", 40, 46], ["crepitation", "OBSERVATION", 47, 58], ["base", "ANATOMY_MODIFIER", 66, 70], ["decreased", "OBSERVATION_MODIFIER", 75, 84], ["air entry", "OBSERVATION", 85, 94], ["left", "ANATOMY_MODIFIER", 102, 106]]], ["There was a displaced apex beat and a pansystolic murmur radiating to the axilla which was accentuated by expiration.", [["axilla", "ANATOMY", 74, 80], ["axilla", "ORGAN", 74, 80], ["a displaced apex beat", "PROBLEM", 10, 31], ["a pansystolic murmur", "PROBLEM", 36, 56], ["displaced", "OBSERVATION_MODIFIER", 12, 21], ["apex beat", "OBSERVATION", 22, 31], ["pansystolic", "OBSERVATION_MODIFIER", 38, 49], ["murmur", "OBSERVATION", 50, 56], ["axilla", "ANATOMY", 74, 80], ["expiration", "OBSERVATION_MODIFIER", 106, 116]]], ["His jugular vein was not distended and there was no pedal oedema.", [["jugular vein", "ANATOMY", 4, 16], ["oedema", "DISEASE", 58, 64], ["jugular vein", "MULTI-TISSUE_STRUCTURE", 4, 16], ["pedal", "ORGANISM_SUBDIVISION", 52, 57], ["oedema", "PATHOLOGICAL_FORMATION", 58, 64], ["distended", "PROBLEM", 25, 34], ["pedal oedema", "PROBLEM", 52, 64], ["jugular vein", "ANATOMY", 4, 16], ["not", "UNCERTAINTY", 21, 24], ["distended", "OBSERVATION", 25, 34], ["no", "UNCERTAINTY", 49, 51], ["pedal", "ANATOMY", 52, 57], ["oedema", "OBSERVATION", 58, 64]]], ["ECG showed atrial fibrillation with a rapid ventricular rate.", [["atrial", "ANATOMY", 11, 17], ["ventricular", "ANATOMY", 44, 55], ["atrial fibrillation", "DISEASE", 11, 30], ["atrial", "MULTI-TISSUE_STRUCTURE", 11, 17], ["ventricular", "MULTI-TISSUE_STRUCTURE", 44, 55], ["ECG", "TEST", 0, 3], ["atrial fibrillation", "PROBLEM", 11, 30], ["a rapid ventricular rate", "PROBLEM", 36, 60], ["atrial", "ANATOMY", 11, 17], ["fibrillation", "OBSERVATION", 18, 30], ["rapid ventricular rate", "OBSERVATION", 38, 60]]], ["The chest x-ray revealed bilateral patchy infiltrates and pleural effusion with fluid in the right lung fissure and cardiomegaly.", [["chest", "ANATOMY", 4, 9], ["pleural", "ANATOMY", 58, 65], ["fluid", "ANATOMY", 80, 85], ["right lung", "ANATOMY", 93, 103], ["pleural effusion", "DISEASE", 58, 74], ["fluid in the right lung fissure", "DISEASE", 80, 111], ["cardiomegaly", "DISEASE", 116, 128], ["pleural effusion", "PATHOLOGICAL_FORMATION", 58, 74], ["fluid", "ORGANISM_SUBSTANCE", 80, 85], ["lung", "ORGAN", 99, 103], ["The chest x-ray", "TEST", 0, 15], ["bilateral patchy infiltrates", "PROBLEM", 25, 53], ["pleural effusion", "PROBLEM", 58, 74], ["fluid in the right lung fissure", "PROBLEM", 80, 111], ["cardiomegaly", "PROBLEM", 116, 128], ["chest", "ANATOMY", 4, 9], ["bilateral", "ANATOMY_MODIFIER", 25, 34], ["patchy", "OBSERVATION_MODIFIER", 35, 41], ["infiltrates", "OBSERVATION", 42, 53], ["pleural", "ANATOMY", 58, 65], ["effusion", "OBSERVATION", 66, 74], ["fluid", "OBSERVATION", 80, 85], ["right", "ANATOMY_MODIFIER", 93, 98], ["lung", "ANATOMY", 99, 103], ["fissure", "ANATOMY_MODIFIER", 104, 111], ["cardiomegaly", "OBSERVATION", 116, 128]]], ["A complete blood count showed a total leukocyte count (TLC) of 26\u00d710 9 /l, lymphocytes 0.5\u00d710 9 /l and platelet count 520\u00d710 9 /l.", [["blood", "ANATOMY", 11, 16], ["leukocyte", "ANATOMY", 38, 47], ["lymphocytes", "ANATOMY", 75, 86], ["platelet", "ANATOMY", 103, 111], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["leukocyte", "CELL", 38, 47], ["lymphocytes", "CELL", 75, 86], ["platelet", "CELL", 103, 111], ["lymphocytes", "CELL_TYPE", 75, 86], ["A complete blood count", "TEST", 0, 22], ["a total leukocyte count", "TEST", 30, 53], ["TLC", "TEST", 55, 58], ["lymphocytes", "TEST", 75, 86], ["platelet count", "TEST", 103, 117]]], ["C-reactive protein (CRP) was 47 mg/l, D-dimers were 1205 \u00b5g/l and INR was 1.4.", [["C-reactive protein", "GENE_OR_GENE_PRODUCT", 0, 18], ["CRP", "GENE_OR_GENE_PRODUCT", 20, 23], ["D-dimers", "SIMPLE_CHEMICAL", 38, 46], ["C-reactive protein", "PROTEIN", 0, 18], ["CRP", "PROTEIN", 20, 23], ["C-reactive protein", "TEST", 0, 18], ["CRP", "TEST", 20, 23], ["D-dimers", "TEST", 38, 46], ["INR", "TEST", 66, 69], ["reactive protein", "OBSERVATION", 2, 18]]], ["A peripheral smear did not show any schistocytes or fragmented red blood cells.", [["peripheral smear", "ANATOMY", 2, 18], ["schistocytes", "ANATOMY", 36, 48], ["red blood cells", "ANATOMY", 63, 78], ["schistocytes", "DISEASE", 36, 48], ["red blood cells", "CELL", 63, 78], ["fragmented red blood cells", "CELL_TYPE", 52, 78], ["A peripheral smear", "TEST", 0, 18], ["any schistocytes", "PROBLEM", 32, 48], ["fragmented red blood cells", "PROBLEM", 52, 78], ["peripheral", "ANATOMY", 2, 12], ["smear", "OBSERVATION", 13, 18], ["schistocytes", "OBSERVATION", 36, 48], ["fragmented", "OBSERVATION_MODIFIER", 52, 62], ["red blood cells", "OBSERVATION", 63, 78]]], ["A swab was sent for PCR testing for coronavirus.", [["swab", "ANATOMY", 2, 6], ["coronavirus", "DISEASE", 36, 47], ["coronavirus", "ORGANISM", 36, 47], ["A swab", "TEST", 0, 6], ["PCR testing", "TEST", 20, 31], ["coronavirus", "PROBLEM", 36, 47]]], ["A CT scan of the chest revealed bilateral pleural effusion with consolidation (Figs 1 and 2) .", [["chest", "ANATOMY", 17, 22], ["pleural", "ANATOMY", 42, 49], ["pleural effusion", "DISEASE", 42, 58], ["chest", "ORGAN", 17, 22], ["A CT scan of the chest", "TEST", 0, 22], ["bilateral pleural effusion", "PROBLEM", 32, 58], ["consolidation", "PROBLEM", 64, 77], ["Figs", "TEST", 79, 83], ["chest", "ANATOMY", 17, 22], ["bilateral", "ANATOMY_MODIFIER", 32, 41], ["pleural", "ANATOMY", 42, 49], ["effusion", "OBSERVATION", 50, 58], ["consolidation", "OBSERVATION", 64, 77]]], ["On echocardiography, left ventricular function was fair with an ejection fraction of 45%.", [["left ventricular", "ANATOMY", 21, 37], ["left ventricular", "MULTI-TISSUE_STRUCTURE", 21, 37], ["echocardiography", "TEST", 3, 19], ["left ventricular function", "TEST", 21, 46], ["an ejection fraction", "TEST", 61, 81], ["left ventricular", "ANATOMY", 21, 37], ["ejection fraction", "OBSERVATION", 64, 81]]], ["There was severe mitral regurgitation and moderate mitral stenosis with a mitral valve area of 1.6 cm 2 on planimetry.Figures 1 and 2.", [["mitral", "ANATOMY", 17, 23], ["mitral", "ANATOMY", 51, 57], ["mitral valve area", "ANATOMY", 74, 91], ["mitral regurgitation", "DISEASE", 17, 37], ["mitral stenosis", "DISEASE", 51, 66], ["mitral regurgitation", "PATHOLOGICAL_FORMATION", 17, 37], ["mitral", "PATHOLOGICAL_FORMATION", 51, 57], ["severe mitral regurgitation", "PROBLEM", 10, 37], ["moderate mitral stenosis", "PROBLEM", 42, 66], ["a mitral valve area", "TEST", 72, 91], ["planimetry", "TEST", 107, 117], ["Figures", "TEST", 118, 125], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["mitral", "ANATOMY", 17, 23], ["regurgitation", "OBSERVATION", 24, 37], ["moderate", "OBSERVATION_MODIFIER", 42, 50], ["mitral", "OBSERVATION", 51, 57], ["stenosis", "OBSERVATION", 58, 66], ["mitral valve", "ANATOMY", 74, 86], ["area", "OBSERVATION_MODIFIER", 87, 91], ["1.6 cm", "OBSERVATION", 95, 101]]], ["Consolidation and pleural effusion bilaterallyThe patient was started on a furosemide infusion at 10 mg/min and azithromycin 500 mg once daily.", [["pleural effusion", "ANATOMY", 18, 34], ["pleural effusion", "DISEASE", 18, 34], ["furosemide", "CHEMICAL", 75, 85], ["azithromycin", "CHEMICAL", 112, 124], ["furosemide", "CHEMICAL", 75, 85], ["azithromycin", "CHEMICAL", 112, 124], ["pleural effusion", "PATHOLOGICAL_FORMATION", 18, 34], ["patient", "ORGANISM", 50, 57], ["furosemide", "SIMPLE_CHEMICAL", 75, 85], ["azithromycin", "SIMPLE_CHEMICAL", 112, 124], ["patient", "SPECIES", 50, 57], ["Consolidation", "PROBLEM", 0, 13], ["pleural effusion bilaterally", "PROBLEM", 18, 46], ["a furosemide infusion", "TREATMENT", 73, 94], ["azithromycin", "TREATMENT", 112, 124], ["pleural", "ANATOMY", 18, 25], ["effusion", "OBSERVATION", 26, 34], ["bilaterally", "ANATOMY_MODIFIER", 35, 46]]], ["On the second day, he was still symptomatic, maintaining oxygen saturation on a nasal cannula at 5 l/min of oxygen.", [["nasal", "ANATOMY", 80, 85], ["oxygen", "CHEMICAL", 57, 63], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "CHEMICAL", 57, 63], ["oxygen", "CHEMICAL", 108, 114], ["oxygen", "SIMPLE_CHEMICAL", 57, 63], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 80, 93], ["oxygen", "SIMPLE_CHEMICAL", 108, 114], ["still symptomatic", "PROBLEM", 26, 43], ["oxygen saturation", "TEST", 57, 74], ["a nasal cannula", "TREATMENT", 78, 93], ["oxygen", "TREATMENT", 108, 114], ["symptomatic", "OBSERVATION", 32, 43], ["oxygen saturation", "OBSERVATION", 57, 74]]], ["His COVID-19 PCR result was positive and he was moved to an isolation ward.", [["COVID-19 PCR", "DNA", 4, 16], ["His COVID", "TEST", 0, 9], ["PCR", "TEST", 13, 16]]], ["After discussion with the medical specialist team, the patient was started on enoxaparin 40 mg twice daily.", [["enoxaparin", "CHEMICAL", 78, 88], ["enoxaparin", "CHEMICAL", 78, 88], ["patient", "ORGANISM", 55, 62], ["enoxaparin", "SIMPLE_CHEMICAL", 78, 88], ["patient", "SPECIES", 55, 62], ["enoxaparin", "TREATMENT", 78, 88]]], ["Actemra (tocilizumab) was given in a single dose of 400 mg.", [["Actemra", "CHEMICAL", 0, 7], ["tocilizumab", "CHEMICAL", 9, 20], ["Actemra", "SIMPLE_CHEMICAL", 0, 7], ["tocilizumab", "SIMPLE_CHEMICAL", 9, 20], ["Actemra (tocilizumab)", "TREATMENT", 0, 21]]], ["As new evidence of the efficacy of the corticosteroid dexamethasone in COVID-19 patients was emerging, he was started on 100 mg twice daily.", [["dexamethasone", "CHEMICAL", 54, 67], ["dexamethasone", "CHEMICAL", 54, 67], ["dexamethasone", "SIMPLE_CHEMICAL", 54, 67], ["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["the corticosteroid dexamethasone", "TREATMENT", 35, 67]]], ["On the fourth day, the patient became afebrile.", [["patient", "ORGANISM", 23, 30], ["patient", "SPECIES", 23, 30], ["afebrile", "PROBLEM", 38, 46], ["afebrile", "OBSERVATION", 38, 46]]], ["His chest x-ray improved and pleural effusion subsided to only the left side.", [["chest", "ANATOMY", 4, 9], ["pleural", "ANATOMY", 29, 36], ["pleural effusion", "DISEASE", 29, 45], ["pleural effusion", "PATHOLOGICAL_FORMATION", 29, 45], ["His chest x-ray", "TEST", 0, 15], ["pleural effusion", "PROBLEM", 29, 45], ["chest", "ANATOMY", 4, 9], ["improved", "OBSERVATION_MODIFIER", 16, 24], ["pleural", "ANATOMY", 29, 36], ["effusion", "OBSERVATION", 37, 45], ["left", "ANATOMY_MODIFIER", 67, 71]]], ["His oxygen saturation started to improve and his furosemide infusion was stopped.", [["oxygen", "CHEMICAL", 4, 10], ["furosemide", "CHEMICAL", 49, 59], ["oxygen", "CHEMICAL", 4, 10], ["furosemide", "CHEMICAL", 49, 59], ["oxygen", "SIMPLE_CHEMICAL", 4, 10], ["furosemide", "SIMPLE_CHEMICAL", 49, 59], ["His oxygen saturation", "TEST", 0, 21], ["his furosemide infusion", "TREATMENT", 45, 68]]], ["His CRP dropped to 9 mg/l, D-dimer to 560 \u00b5g/l, and TLC to 15\u00d710 9 /l.", [["CRP", "GENE_OR_GENE_PRODUCT", 4, 7], ["D-dimer", "SIMPLE_CHEMICAL", 27, 34], ["CRP", "PROTEIN", 4, 7], ["His CRP", "TEST", 0, 7], ["D-dimer", "TEST", 27, 34], ["TLC", "TEST", 52, 55], ["TLC", "ANATOMY", 52, 55]]], ["On the sixth day, he was discharged on furosemide 40 mg twice daily, Aldactone 25 mg once daily, warfarin 2.5 mg once daily, and prednisolone 30 mg daily in divided doses.", [["furosemide", "CHEMICAL", 39, 49], ["Aldactone", "CHEMICAL", 69, 78], ["warfarin", "CHEMICAL", 97, 105], ["prednisolone", "CHEMICAL", 129, 141], ["furosemide", "CHEMICAL", 39, 49], ["warfarin", "CHEMICAL", 97, 105], ["prednisolone", "CHEMICAL", 129, 141], ["furosemide", "SIMPLE_CHEMICAL", 39, 49], ["Aldactone", "SIMPLE_CHEMICAL", 69, 78], ["warfarin", "SIMPLE_CHEMICAL", 97, 105], ["prednisolone", "SIMPLE_CHEMICAL", 129, 141], ["furosemide", "TREATMENT", 39, 49], ["Aldactone", "TREATMENT", 69, 78], ["warfarin", "TREATMENT", 97, 105], ["prednisolone", "TREATMENT", 129, 141]]], ["After cardiac stabilization and the agreement of the medical specialist at our institute, he was referred to a COVID-19-designated hospital for further management.DISCUSSIONWith the worldwide spread of COVID-19, uncommon presentations are still being reported.", [["cardiac", "ANATOMY", 6, 13], ["cardiac", "ORGAN", 6, 13], ["further management", "TREATMENT", 144, 162], ["COVID", "TEST", 202, 207], ["stabilization", "OBSERVATION", 14, 27]]], ["In our case, all clinical characteristics including signs and symptoms, laboratory investigations, and the results of CT of the chest suggested COVID-19.", [["chest", "ANATOMY", 128, 133], ["chest", "ORGANISM_SUBDIVISION", 128, 133], ["signs and symptoms", "PROBLEM", 52, 70], ["laboratory investigations", "TEST", 72, 97], ["CT of the chest", "TEST", 118, 133], ["COVID", "TEST", 144, 149], ["chest", "ANATOMY", 128, 133]]], ["The diagnosis was confirmed on COVID-19 PCR.", [["COVID-19 PCR", "DNA", 31, 43], ["COVID", "TEST", 31, 36], ["PCR", "TEST", 40, 43]]], ["However, pleural effusion, which was diagnosed on CT of the chest, is rare in the early phase of the disease [5] .", [["pleural effusion", "ANATOMY", 9, 25], ["chest", "ANATOMY", 60, 65], ["pleural effusion", "DISEASE", 9, 25], ["pleural effusion", "CANCER", 9, 25], ["chest", "ORGAN", 60, 65], ["pleural effusion", "PROBLEM", 9, 25], ["CT of the chest", "TEST", 50, 65], ["pleural", "ANATOMY", 9, 16], ["effusion", "OBSERVATION", 17, 25], ["chest", "ANATOMY", 60, 65], ["rare", "OBSERVATION_MODIFIER", 70, 74], ["early phase", "OBSERVATION_MODIFIER", 82, 93]]], ["It usually occurs with recurrent pneumonia or after the third week of COVID-19 pneumonia [6] .", [["pneumonia", "DISEASE", 33, 42], ["pneumonia", "DISEASE", 79, 88], ["recurrent pneumonia", "PROBLEM", 23, 42], ["COVID", "TEST", 70, 75], ["pneumonia", "PROBLEM", 79, 88], ["recurrent", "OBSERVATION_MODIFIER", 23, 32], ["pneumonia", "OBSERVATION", 33, 42], ["pneumonia", "OBSERVATION", 79, 88]]], ["At this stage, patients are severely sick compared with other patients.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 62, 70], ["severely sick", "PROBLEM", 28, 41], ["severely", "OBSERVATION_MODIFIER", 28, 36], ["sick", "OBSERVATION", 37, 41]]], ["A study of chest CT scans has shown that viral pneumonia has a higher incidence of pleural effusion than COVID-19 pneumonia (39% vs. 4%) [7] .", [["pleural effusion", "ANATOMY", 83, 99], ["viral pneumonia", "DISEASE", 41, 56], ["pleural effusion", "DISEASE", 83, 99], ["pneumonia", "DISEASE", 114, 123], ["pleural effusion", "PATHOLOGICAL_FORMATION", 83, 99], ["A study of chest CT scans", "TEST", 0, 25], ["viral pneumonia", "PROBLEM", 41, 56], ["pleural effusion", "PROBLEM", 83, 99], ["COVID", "TEST", 105, 110], ["pneumonia", "PROBLEM", 114, 123], ["chest", "ANATOMY", 11, 16], ["viral", "OBSERVATION_MODIFIER", 41, 46], ["pneumonia", "OBSERVATION", 47, 56], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["incidence", "OBSERVATION_MODIFIER", 70, 79], ["pleural", "ANATOMY", 83, 90], ["effusion", "OBSERVATION", 91, 99], ["pneumonia", "OBSERVATION", 114, 123]]], ["A similar study reported that the percentage of pleural effusion is 8% in patients with mild symptoms compared with 28% in patients critically ill with COVID-19 [8] .", [["pleural effusion", "ANATOMY", 48, 64], ["pleural effusion", "DISEASE", 48, 64], ["critically ill", "DISEASE", 132, 146], ["COVID-19", "CHEMICAL", 152, 160], ["pleural", "ORGAN", 48, 55], ["patients", "ORGANISM", 74, 82], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 123, 131], ["A similar study", "TEST", 0, 15], ["pleural effusion", "PROBLEM", 48, 64], ["mild symptoms", "PROBLEM", 88, 101], ["COVID", "TEST", 152, 157], ["percentage", "OBSERVATION_MODIFIER", 34, 44], ["pleural", "ANATOMY", 48, 55], ["effusion", "OBSERVATION", 56, 64], ["mild", "OBSERVATION_MODIFIER", 88, 92]]], ["Our patient presented with mild symptoms at an early stage and his medical examination and CT revealed pleural effusion.", [["pleural", "ANATOMY", 103, 110], ["pleural effusion", "DISEASE", 103, 119], ["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["mild symptoms", "PROBLEM", 27, 40], ["his medical examination", "TEST", 63, 86], ["CT", "TEST", 91, 93], ["pleural effusion", "PROBLEM", 103, 119], ["mild", "OBSERVATION_MODIFIER", 27, 31], ["pleural", "ANATOMY", 103, 110], ["effusion", "OBSERVATION", 111, 119]]], ["Although most patients have mild symptoms and a good prognosis, COVID-19 can develop into severe illness including pneumonia, pulmonary oedema, acute respiratory distress syndrome, multiple organ failure, and even death.", [["pulmonary", "ANATOMY", 126, 135], ["respiratory", "ANATOMY", 150, 161], ["organ", "ANATOMY", 190, 195], ["COVID-19", "CHEMICAL", 64, 72], ["illness", "DISEASE", 97, 104], ["pneumonia", "DISEASE", 115, 124], ["pulmonary oedema", "DISEASE", 126, 142], ["acute respiratory distress syndrome", "DISEASE", 144, 179], ["multiple organ failure", "DISEASE", 181, 203], ["death", "DISEASE", 214, 219], ["patients", "ORGANISM", 14, 22], ["pulmonary", "ORGAN", 126, 135], ["organ", "ORGAN", 190, 195], ["patients", "SPECIES", 14, 22], ["mild symptoms", "PROBLEM", 28, 41], ["COVID", "TEST", 64, 69], ["severe illness", "PROBLEM", 90, 104], ["pneumonia", "PROBLEM", 115, 124], ["pulmonary oedema", "PROBLEM", 126, 142], ["acute respiratory distress syndrome", "PROBLEM", 144, 179], ["multiple organ failure", "PROBLEM", 181, 203], ["even death", "PROBLEM", 209, 219], ["mild", "OBSERVATION_MODIFIER", 28, 32], ["symptoms", "OBSERVATION", 33, 41], ["severe", "OBSERVATION_MODIFIER", 90, 96], ["illness", "OBSERVATION", 97, 104], ["pneumonia", "OBSERVATION", 115, 124], ["pulmonary", "ANATOMY", 126, 135], ["oedema", "OBSERVATION", 136, 142], ["acute", "OBSERVATION_MODIFIER", 144, 149], ["respiratory distress syndrome", "OBSERVATION", 150, 179], ["multiple", "OBSERVATION_MODIFIER", 181, 189], ["organ", "ANATOMY", 190, 195], ["failure", "OBSERVATION", 196, 203]]]], "PMC7357761": [["IntroductionEndometriosis is characterized by the implantation and growth of endometrial tissue (glands and stroma) outside the uterine cavity.", [["endometrial tissue", "ANATOMY", 77, 95], ["glands", "ANATOMY", 97, 103], ["stroma", "ANATOMY", 108, 114], ["uterine cavity", "ANATOMY", 128, 142], ["Endometriosis", "DISEASE", 12, 25], ["endometrial tissue", "TISSUE", 77, 95], ["glands", "ORGAN", 97, 103], ["stroma", "TISSUE", 108, 114], ["uterine cavity", "MULTI-TISSUE_STRUCTURE", 128, 142], ["Endometriosis", "PROBLEM", 12, 25], ["the implantation", "TREATMENT", 46, 62], ["endometrial tissue (glands and stroma) outside the uterine cavity", "PROBLEM", 77, 142], ["Endometriosis", "OBSERVATION", 12, 25], ["implantation", "OBSERVATION", 50, 62], ["growth", "OBSERVATION_MODIFIER", 67, 73], ["endometrial tissue", "OBSERVATION", 77, 95], ["glands", "ANATOMY", 97, 103], ["uterine cavity", "ANATOMY", 128, 142]]], ["Women with endometriosis generally experience cyclical chronic pelvic pain, dyspareunia, and infertility, which significantly affect their quality of life.", [["endometriosis", "ANATOMY", 11, 24], ["pelvic", "ANATOMY", 63, 69], ["endometriosis", "DISEASE", 11, 24], ["chronic pelvic pain", "DISEASE", 55, 74], ["dyspareunia", "DISEASE", 76, 87], ["infertility", "DISEASE", 93, 104], ["Women", "ORGANISM", 0, 5], ["pelvic", "ORGAN", 63, 69], ["Women", "SPECIES", 0, 5], ["endometriosis", "PROBLEM", 11, 24], ["cyclical chronic pelvic pain", "PROBLEM", 46, 74], ["dyspareunia", "PROBLEM", 76, 87], ["infertility", "PROBLEM", 93, 104], ["endometriosis", "OBSERVATION", 11, 24], ["cyclical", "OBSERVATION_MODIFIER", 46, 54], ["chronic", "OBSERVATION_MODIFIER", 55, 62], ["pelvic", "ANATOMY", 63, 69], ["pain", "OBSERVATION", 70, 74], ["dyspareunia", "OBSERVATION", 76, 87], ["infertility", "OBSERVATION", 93, 104]]], ["An estimated 30\u201350% of women with the disease are infertile, and 25\u201350% of infertile women are diagnosed as having endometriosis [1].", [["endometriosis", "ANATOMY", 115, 128], ["endometriosis", "DISEASE", 115, 128], ["women", "ORGANISM", 23, 28], ["women", "ORGANISM", 85, 90], ["women", "SPECIES", 23, 28], ["women", "SPECIES", 85, 90], ["the disease", "PROBLEM", 34, 45], ["infertile", "PROBLEM", 50, 59], ["infertile women", "PROBLEM", 75, 90], ["endometriosis", "PROBLEM", 115, 128], ["disease", "OBSERVATION", 38, 45], ["endometriosis", "OBSERVATION", 115, 128]]], ["It has been suggested that endometriosis-associated infertility may be due to impaired pelvic anatomy, folliculogenesis, fertilization, and implantation [2\u20134]; however, the association between infertility and early-stage disease (minimal [stage I] and mild [stage II] endometriosis), in which no substantial pelvic anatomical changes are identified, remains controversial [4\u20136].", [["endometriosis", "ANATOMY", 27, 40], ["pelvic", "ANATOMY", 87, 93], ["pelvic", "ANATOMY", 308, 314], ["endometriosis", "DISEASE", 27, 40], ["infertility", "DISEASE", 52, 63], ["impaired pelvic anatomy", "DISEASE", 78, 101], ["infertility", "DISEASE", 193, 204], ["early-stage disease", "DISEASE", 209, 228], ["endometriosis", "DISEASE", 268, 281], ["pelvic", "ORGAN", 87, 93], ["pelvic", "ORGAN", 308, 314], ["endometriosis", "PROBLEM", 27, 40], ["infertility", "PROBLEM", 52, 63], ["impaired pelvic anatomy", "PROBLEM", 78, 101], ["folliculogenesis", "PROBLEM", 103, 119], ["implantation", "TREATMENT", 140, 152], ["infertility", "PROBLEM", 193, 204], ["early-stage disease", "PROBLEM", 209, 228], ["minimal [stage I]", "PROBLEM", 230, 247], ["mild [stage II] endometriosis", "PROBLEM", 252, 281], ["substantial pelvic anatomical changes", "PROBLEM", 296, 333], ["endometriosis", "OBSERVATION", 27, 40], ["may be due to", "UNCERTAINTY", 64, 77], ["impaired", "OBSERVATION_MODIFIER", 78, 86], ["pelvic", "ANATOMY", 87, 93], ["anatomy", "OBSERVATION", 94, 101], ["early", "OBSERVATION_MODIFIER", 209, 214], ["-stage", "OBSERVATION_MODIFIER", 214, 220], ["disease", "OBSERVATION", 221, 228], ["minimal", "OBSERVATION_MODIFIER", 230, 237], ["mild", "OBSERVATION_MODIFIER", 252, 256], ["stage II", "OBSERVATION_MODIFIER", 258, 266], ["endometriosis", "OBSERVATION", 268, 281], ["no", "UNCERTAINTY", 293, 295], ["substantial", "OBSERVATION_MODIFIER", 296, 307], ["pelvic", "ANATOMY", 308, 314], ["anatomical", "OBSERVATION", 315, 325]]], ["Endometrial receptivity is defined as a restricted period in the menstrual cycle during which the uterus is receptive to blastocyst attachment and implantation [7].", [["Endometrial", "ANATOMY", 0, 11], ["uterus", "ANATOMY", 98, 104], ["blastocyst", "ANATOMY", 121, 131], ["Endometrial", "MULTI-TISSUE_STRUCTURE", 0, 11], ["uterus", "ORGAN", 98, 104], ["blastocyst", "DEVELOPING_ANATOMICAL_STRUCTURE", 121, 131], ["Endometrial receptivity", "PROBLEM", 0, 23], ["blastocyst attachment and implantation", "TREATMENT", 121, 159], ["receptivity", "OBSERVATION", 12, 23], ["restricted", "OBSERVATION_MODIFIER", 40, 50], ["uterus", "ANATOMY", 98, 104], ["blastocyst attachment", "OBSERVATION", 121, 142]]], ["Innate pathology in the eutopic endometrium is suggested to contribute to implantation impairment in women with endometriosis with subfertility [8\u201310].IntroductionProgesterone resistance results in inadequate antagonism of estrogen action, increased inflammation, inadequate differentiation of the stroma, and remodeling of the endometrium, all of which can lead to a non-receptive endometrium for embryo implantation [11]. mRNA and protein levels of estrogen receptor 2 (ESR2) are significantly elevated in endometriotic cells as compared to normal stromal cells, whereas estrogen receptor 1 (ESR1), total progesterone receptor (PGR), and progesterone receptor B (PGR B) are repressed [12].", [["eutopic endometrium", "ANATOMY", 24, 43], ["endometriosis", "ANATOMY", 112, 125], ["stroma", "ANATOMY", 298, 304], ["endometrium", "ANATOMY", 328, 339], ["endometrium", "ANATOMY", 382, 393], ["embryo", "ANATOMY", 398, 404], ["endometriotic cells", "ANATOMY", 508, 527], ["stromal cells", "ANATOMY", 550, 563], ["implantation impairment", "DISEASE", 74, 97], ["endometriosis", "DISEASE", 112, 125], ["subfertility", "DISEASE", 131, 143], ["Progesterone", "CHEMICAL", 163, 175], ["estrogen", "CHEMICAL", 223, 231], ["inflammation", "DISEASE", 250, 262], ["estrogen", "CHEMICAL", 451, 459], ["estrogen", "CHEMICAL", 573, 581], ["progesterone", "CHEMICAL", 607, 619], ["progesterone", "CHEMICAL", 640, 652], ["Progesterone", "CHEMICAL", 163, 175], ["estrogen", "CHEMICAL", 223, 231], ["estrogen", "CHEMICAL", 451, 459], ["estrogen", "CHEMICAL", 573, 581], ["progesterone", "CHEMICAL", 607, 619], ["progesterone", "CHEMICAL", 640, 652], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 24, 43], ["women", "ORGANISM", 101, 106], ["Progesterone", "SIMPLE_CHEMICAL", 163, 175], ["estrogen", "SIMPLE_CHEMICAL", 223, 231], ["stroma", "TISSUE", 298, 304], ["endometrium", "MULTI-TISSUE_STRUCTURE", 328, 339], ["endometrium", "MULTI-TISSUE_STRUCTURE", 382, 393], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 398, 404], ["estrogen receptor 2", "GENE_OR_GENE_PRODUCT", 451, 470], ["ESR2", "GENE_OR_GENE_PRODUCT", 472, 476], ["endometriotic cells", "CELL", 508, 527], ["normal stromal cells", "CELL", 543, 563], ["estrogen receptor 1", "GENE_OR_GENE_PRODUCT", 573, 592], ["ESR1", "GENE_OR_GENE_PRODUCT", 594, 598], ["progesterone receptor", "GENE_OR_GENE_PRODUCT", 607, 628], ["PGR", "GENE_OR_GENE_PRODUCT", 630, 633], ["progesterone receptor B", "GENE_OR_GENE_PRODUCT", 640, 663], ["PGR B", "GENE_OR_GENE_PRODUCT", 665, 670], ["mRNA", "RNA", 424, 428], ["estrogen receptor 2", "PROTEIN", 451, 470], ["ESR2", "PROTEIN", 472, 476], ["endometriotic cells", "CELL_TYPE", 508, 527], ["normal stromal cells", "CELL_TYPE", 543, 563], ["estrogen receptor 1", "PROTEIN", 573, 592], ["ESR1", "PROTEIN", 594, 598], ["total progesterone receptor", "PROTEIN", 601, 628], ["PGR", "PROTEIN", 630, 633], ["progesterone receptor B", "PROTEIN", 640, 663], ["PGR B", "PROTEIN", 665, 670], ["women", "SPECIES", 101, 106], ["Innate pathology", "TEST", 0, 16], ["implantation impairment", "PROBLEM", 74, 97], ["endometriosis", "PROBLEM", 112, 125], ["subfertility", "PROBLEM", 131, 143], ["IntroductionProgesterone resistance", "TEST", 151, 186], ["inadequate antagonism of estrogen action", "PROBLEM", 198, 238], ["increased inflammation", "PROBLEM", 240, 262], ["the stroma", "PROBLEM", 294, 304], ["remodeling of the endometrium", "PROBLEM", 310, 339], ["a non-receptive endometrium", "TREATMENT", 366, 393], ["embryo implantation", "TREATMENT", 398, 417], ["mRNA and protein levels", "TEST", 424, 447], ["estrogen receptor", "TEST", 451, 468], ["ESR2", "TEST", 472, 476], ["significantly elevated in endometriotic cells", "PROBLEM", 482, 527], ["estrogen receptor", "TEST", 573, 590], ["ESR1", "TEST", 594, 598], ["total progesterone receptor (PGR)", "TREATMENT", 601, 634], ["progesterone receptor B (PGR B)", "TREATMENT", 640, 671], ["eutopic endometrium", "ANATOMY", 24, 43], ["implantation", "OBSERVATION", 74, 86], ["endometriosis", "OBSERVATION", 112, 125], ["inadequate antagonism", "OBSERVATION_MODIFIER", 198, 219], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["inflammation", "OBSERVATION", 250, 262], ["inadequate differentiation", "OBSERVATION_MODIFIER", 264, 290], ["stroma", "OBSERVATION", 298, 304], ["endometrium", "ANATOMY", 328, 339], ["elevated", "OBSERVATION_MODIFIER", 496, 504], ["endometriotic cells", "OBSERVATION", 508, 527], ["stromal cells", "OBSERVATION", 550, 563]]], ["Increased ESR2 levels are directly related to ESR2 promoter hypomethylation in endometriotic cells [12, 13].", [["endometriotic cells", "ANATOMY", 79, 98], ["ESR2", "GENE_OR_GENE_PRODUCT", 10, 14], ["ESR2", "GENE_OR_GENE_PRODUCT", 46, 50], ["endometriotic cells", "CELL", 79, 98], ["ESR2", "PROTEIN", 10, 14], ["ESR2 promoter", "DNA", 46, 59], ["endometriotic cells", "CELL_TYPE", 79, 98], ["Increased ESR2 levels", "PROBLEM", 0, 21], ["ESR2 promoter hypomethylation in endometriotic cells", "PROBLEM", 46, 98], ["endometriotic cells", "OBSERVATION", 79, 98]]], ["ESR2 represses ESR1 expression by directly binding to its promoter, which can result in progesterone resistance [12, 13].", [["progesterone", "CHEMICAL", 88, 100], ["progesterone", "CHEMICAL", 88, 100], ["ESR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ESR1", "GENE_OR_GENE_PRODUCT", 15, 19], ["progesterone", "SIMPLE_CHEMICAL", 88, 100], ["ESR2", "DNA", 0, 4], ["ESR1", "DNA", 15, 19], ["progesterone resistance", "PROBLEM", 88, 111]]], ["However, the complete repertoire of ESR2 functions is believed to be more complicated.IntroductionMicroRNAs (miRNAs) are approximately 22-nucleotide non-coding RNAs that negatively regulate protein expression via translational inhibition or mRNA degradation.", [["ESR2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ESR2", "PROTEIN", 36, 40], ["miRNAs", "DNA", 109, 115], ["22-nucleotide non-coding RNAs", "RNA", 135, 164], ["IntroductionMicroRNAs (miRNAs)", "TEST", 86, 116], ["nucleotide non-coding RNAs", "TREATMENT", 138, 164], ["translational inhibition", "TREATMENT", 213, 237], ["mRNA degradation", "PROBLEM", 241, 257], ["believed to be", "UNCERTAINTY", 54, 68], ["protein expression", "OBSERVATION", 190, 208]]], ["Emerging data suggest that dysregulation of miRNA expression may be implicated in the development and pathogenesis of endometriosis [14].", [["endometriosis", "ANATOMY", 118, 131], ["endometriosis", "DISEASE", 118, 131], ["Emerging data", "TEST", 0, 13], ["dysregulation of miRNA expression", "PROBLEM", 27, 60], ["endometriosis", "PROBLEM", 118, 131], ["miRNA expression", "OBSERVATION", 44, 60], ["endometriosis", "OBSERVATION", 118, 131]]], ["Using microarray-based miRNA profiling, we previously found that 66 mature miRNAs were differentially expressed (54 up- and 12 downregulated) in mid-luteal eutopic endometrium from women with minimal/mild endometriosis as compared with normal endometrial tissues [15].", [["eutopic endometrium", "ANATOMY", 156, 175], ["endometriosis", "ANATOMY", 205, 218], ["endometrial tissues", "ANATOMY", 243, 262], ["endometriosis", "DISEASE", 205, 218], ["eutopic endometrium", "TISSUE", 156, 175], ["women", "ORGANISM", 181, 186], ["endometrial tissues", "TISSUE", 243, 262], ["66 mature miRNAs", "RNA", 65, 81], ["women", "SPECIES", 181, 186], ["microarray-based miRNA profiling", "TEST", 6, 38], ["mid-luteal eutopic endometrium", "PROBLEM", 145, 175], ["minimal/mild endometriosis", "PROBLEM", 192, 218], ["mid-luteal", "ANATOMY_MODIFIER", 145, 155], ["eutopic endometrium", "ANATOMY", 156, 175], ["minimal", "OBSERVATION_MODIFIER", 192, 199], ["mild", "OBSERVATION_MODIFIER", 200, 204], ["endometriosis", "OBSERVATION", 205, 218], ["endometrial tissues", "ANATOMY", 243, 262]]], ["Specifically, miR-196a upregulated MEK/ERK signaling and mediated repressed PGR expression and decidualization of endometrial stromal cells (ESCs) from eutopic endometrium with endometriosis [15].", [["endometrial stromal cells", "ANATOMY", 114, 139], ["ESCs", "ANATOMY", 141, 145], ["eutopic endometrium", "ANATOMY", 152, 171], ["endometriosis", "ANATOMY", 177, 190], ["endometriosis", "DISEASE", 177, 190], ["miR-196a", "GENE_OR_GENE_PRODUCT", 14, 22], ["MEK", "GENE_OR_GENE_PRODUCT", 35, 38], ["ERK", "GENE_OR_GENE_PRODUCT", 39, 42], ["PGR", "GENE_OR_GENE_PRODUCT", 76, 79], ["endometrial stromal cells", "CELL", 114, 139], ["ESCs", "CELL", 141, 145], ["eutopic endometrium", "TISSUE", 152, 171], ["MEK", "PROTEIN", 35, 38], ["ERK", "PROTEIN", 39, 42], ["PGR", "PROTEIN", 76, 79], ["endometrial stromal cells", "CELL_TYPE", 114, 139], ["ESCs", "CELL_TYPE", 141, 145], ["miR", "TEST", 14, 17], ["ERK signaling", "TEST", 39, 52], ["repressed PGR expression", "PROBLEM", 66, 90], ["endometrial stromal cells", "PROBLEM", 114, 139], ["eutopic endometrium", "PROBLEM", 152, 171], ["endometriosis", "PROBLEM", 177, 190], ["endometrial", "ANATOMY", 114, 125], ["stromal cells", "OBSERVATION", 126, 139], ["endometriosis", "OBSERVATION", 177, 190]]], ["Likewise, upregulation of miR-194-3p in eutopic endometrium inhibited PGR expression and ESC decidualization in endometriosis, which hinders fertility by repressing the levels of PGR and decidualization in the eutopic endometrium [16].", [["eutopic endometrium", "ANATOMY", 40, 59], ["ESC", "ANATOMY", 89, 92], ["endometriosis", "ANATOMY", 112, 125], ["eutopic endometrium", "ANATOMY", 210, 229], ["endometriosis", "DISEASE", 112, 125], ["miR-194-3p", "GENE_OR_GENE_PRODUCT", 26, 36], ["eutopic endometrium", "CANCER", 40, 59], ["PGR", "GENE_OR_GENE_PRODUCT", 70, 73], ["ESC", "CELL", 89, 92], ["endometriosis", "PATHOLOGICAL_FORMATION", 112, 125], ["PGR", "GENE_OR_GENE_PRODUCT", 179, 182], ["miR-194-3p", "DNA", 26, 36], ["PGR", "PROTEIN", 70, 73], ["PGR", "PROTEIN", 179, 182], ["miR", "TEST", 26, 29], ["eutopic endometrium", "PROBLEM", 40, 59], ["PGR expression", "PROBLEM", 70, 84], ["ESC decidualization", "PROBLEM", 89, 108], ["endometriosis", "PROBLEM", 112, 125], ["decidualization in the eutopic endometrium", "PROBLEM", 187, 229], ["endometrium", "ANATOMY", 48, 59], ["ESC decidualization", "OBSERVATION", 89, 108], ["endometriosis", "OBSERVATION", 112, 125], ["eutopic endometrium", "ANATOMY", 210, 229]]], ["We have also shown that miR23a and miRNA23b are downregulated in endometriosis and they upregulate several unidentified genes required for Steroidogenic factor 1 (SF-1) expression in ESCs [17].IntroductionBioinformatics analysis of a downregulated miRNA, miR22-5p, revealed a binding site in the 3\u2032-untranslated region (3\u2032-UTR) of ten-eleven translocation 2 (TET2) [18].", [["endometriosis", "ANATOMY", 65, 78], ["ESCs", "ANATOMY", 183, 187], ["endometriosis", "DISEASE", 65, 78], ["miR23a", "GENE_OR_GENE_PRODUCT", 24, 30], ["miRNA23b", "GENE_OR_GENE_PRODUCT", 35, 43], ["endometriosis", "CANCER", 65, 78], ["Steroidogenic factor 1", "GENE_OR_GENE_PRODUCT", 139, 161], ["SF-1", "GENE_OR_GENE_PRODUCT", 163, 167], ["ESCs", "CELL", 183, 187], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 255, 263], ["ten-eleven translocation 2", "GENE_OR_GENE_PRODUCT", 331, 357], ["TET2", "GENE_OR_GENE_PRODUCT", 359, 363], ["miR23a", "PROTEIN", 24, 30], ["miRNA23b", "PROTEIN", 35, 43], ["Steroidogenic factor 1", "PROTEIN", 139, 161], ["SF", "PROTEIN", 163, 165], ["ESCs", "CELL_TYPE", 183, 187], ["miR22", "DNA", 255, 260], ["5p", "DNA", 261, 263], ["binding site", "DNA", 276, 288], ["3\u2032-untranslated region", "DNA", 296, 318], ["3\u2032-UTR", "DNA", 320, 326], ["ten-eleven translocation 2", "DNA", 331, 357], ["TET2", "DNA", 359, 363], ["miRNA23b", "TREATMENT", 35, 43], ["endometriosis", "PROBLEM", 65, 78], ["Steroidogenic factor", "TEST", 139, 159], ["Bioinformatics analysis", "TEST", 205, 228], ["a downregulated miRNA", "TEST", 232, 253], ["a binding site", "PROBLEM", 274, 288], ["ten-eleven translocation", "PROBLEM", 331, 355], ["endometriosis", "OBSERVATION", 65, 78], ["binding site", "OBSERVATION", 276, 288]]], ["The TET family encodes enzymes responsible for the oxidation of 5-methylcytosine (5mC) to 5-hmC in DNA demethylation.", [["TET", "CHEMICAL", 4, 7], ["5-methylcytosine", "CHEMICAL", 64, 80], ["5mC", "CHEMICAL", 82, 85], ["5-hmC", "CHEMICAL", 90, 95], ["5-methylcytosine", "CHEMICAL", 64, 80], ["5mC", "CHEMICAL", 82, 85], ["5-hmC", "CHEMICAL", 90, 95], ["TET", "CANCER", 4, 7], ["5-methylcytosine", "SIMPLE_CHEMICAL", 64, 80], ["5mC", "SIMPLE_CHEMICAL", 82, 85], ["5-hmC", "SIMPLE_CHEMICAL", 90, 95], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["TET family", "PROTEIN", 4, 14], ["enzymes", "TEST", 23, 30], ["the oxidation", "TEST", 47, 60], ["methylcytosine", "TREATMENT", 66, 80], ["DNA demethylation", "TREATMENT", 99, 116]]], ["Genome-wide analysis of endometriomas revealed significantly low TET gene expression associated with high 5-hmC levels upon in-vitro decidualization, suggesting a unique epigenetic regulation in these ectopic tissues [19].", [["endometriomas", "ANATOMY", 24, 37], ["ectopic tissues", "ANATOMY", 201, 216], ["endometriomas", "DISEASE", 24, 37], ["TET", "CHEMICAL", 65, 68], ["5-hmC", "CHEMICAL", 106, 111], ["endometriomas", "CANCER", 24, 37], ["TET", "GENE_OR_GENE_PRODUCT", 65, 68], ["hmC", "GENE_OR_GENE_PRODUCT", 108, 111], ["ectopic tissues", "TISSUE", 201, 216], ["TET gene", "DNA", 65, 73], ["hmC", "PROTEIN", 108, 111], ["endometriomas", "PROBLEM", 24, 37], ["significantly low TET gene expression", "PROBLEM", 47, 84], ["high 5-hmC levels", "PROBLEM", 101, 118], ["a unique epigenetic regulation in these ectopic tissues", "PROBLEM", 161, 216], ["endometriomas", "OBSERVATION", 24, 37], ["significantly", "OBSERVATION_MODIFIER", 47, 60], ["low TET", "OBSERVATION_MODIFIER", 61, 68], ["ectopic tissues", "OBSERVATION", 201, 216]]], ["However, how TET2 affects minimal/mild endometriosis-related infertility and the specific mechanism are unknown.IntroductionThe aim of the present study was to evaluate miR22-5p expression and the relationship between miR22-5p and TET2 expression in mid-luteal eutopic endometrium of infertile women with and without minimal/mild endometriosis using tissues and primary ESCs.Study population ::: Material and methodsThis study was approved by the Medical Research Review Board of West China Second University Hospital of Sichuan University, and written informed consent for participation was obtained from all participants.", [["mid-luteal eutopic endometrium", "ANATOMY", 250, 280], ["endometriosis", "ANATOMY", 330, 343], ["tissues", "ANATOMY", 350, 357], ["ESCs", "ANATOMY", 370, 374], ["endometriosis", "DISEASE", 39, 52], ["infertility", "DISEASE", 61, 72], ["endometriosis", "DISEASE", 330, 343], ["TET2", "GENE_OR_GENE_PRODUCT", 13, 17], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 169, 177], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 218, 226], ["TET2", "GENE_OR_GENE_PRODUCT", 231, 235], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 261, 280], ["women", "ORGANISM", 294, 299], ["tissues", "TISSUE", 350, 357], ["ESCs", "CELL", 370, 374], ["TET2", "PROTEIN", 13, 17], ["miR22", "PROTEIN", 169, 174], ["5p", "DNA", 175, 177], ["miR22-5p", "DNA", 218, 226], ["TET2", "DNA", 231, 235], ["primary ESCs", "CELL_TYPE", 362, 374], ["women", "SPECIES", 294, 299], ["participants", "SPECIES", 610, 622], ["minimal/mild endometriosis", "PROBLEM", 26, 52], ["infertility", "PROBLEM", 61, 72], ["the present study", "TEST", 135, 152], ["TET2 expression in mid-luteal eutopic endometrium", "PROBLEM", 231, 280], ["infertile women", "PROBLEM", 284, 299], ["minimal/mild endometriosis using tissues", "PROBLEM", 317, 357], ["This study", "TEST", 416, 426], ["minimal", "OBSERVATION_MODIFIER", 26, 33], ["mild", "OBSERVATION_MODIFIER", 34, 38], ["endometriosis", "OBSERVATION", 39, 52], ["TET2 expression", "OBSERVATION", 231, 246], ["mid-luteal", "ANATOMY_MODIFIER", 250, 260], ["eutopic endometrium", "ANATOMY", 261, 280], ["without", "UNCERTAINTY", 309, 316], ["minimal", "OBSERVATION_MODIFIER", 317, 324], ["mild", "OBSERVATION_MODIFIER", 325, 329], ["endometriosis", "OBSERVATION", 330, 343], ["primary ESCs", "OBSERVATION", 362, 374]]], ["In total, 50 infertile women aged 22\u201334 years old with regular menstrual cycles were enrolled in this study between January 2015 and May 2018.", [["women", "ORGANISM", 23, 28], ["women", "SPECIES", 23, 28], ["this study", "TEST", 97, 107]]], ["Normal endometrium was obtained from 24 infertile women without endometrial pathology, and eutopic endometrium was obtained from 26 infertile women with a laparoscopic and histological diagnosis of stage I\u2013II endometriosis according to the revised American Fertility Society classification system (Table 1).", [["endometrium", "ANATOMY", 7, 18], ["endometrial", "ANATOMY", 64, 75], ["eutopic endometrium", "ANATOMY", 91, 110], ["endometriosis", "DISEASE", 209, 222], ["endometrium", "MULTI-TISSUE_STRUCTURE", 7, 18], ["women", "ORGANISM", 50, 55], ["endometrial pathology", "CANCER", 64, 85], ["eutopic endometrium", "CANCER", 91, 110], ["women", "ORGANISM", 142, 147], ["women", "SPECIES", 50, 55], ["women", "SPECIES", 142, 147], ["endometrial pathology", "PROBLEM", 64, 85], ["a laparoscopic", "TREATMENT", 153, 167], ["stage I\u2013II endometriosis", "PROBLEM", 198, 222], ["endometrium", "ANATOMY", 7, 18], ["without", "UNCERTAINTY", 56, 63], ["endometrial", "ANATOMY", 64, 75], ["pathology", "OBSERVATION", 76, 85], ["eutopic endometrium", "ANATOMY", 91, 110], ["stage I\u2013II", "OBSERVATION_MODIFIER", 198, 208], ["endometriosis", "OBSERVATION", 209, 222]]], ["Participants with adenomyosis, leiomyomas, endometrial hyperplasia, genital tumors, acute pelvic inflammatory disease, or receiving hormonal treatment within the previous three months were excluded.", [["adenomyosis", "ANATOMY", 18, 29], ["leiomyomas", "ANATOMY", 31, 41], ["endometrial hyperplasia", "ANATOMY", 43, 66], ["genital tumors", "ANATOMY", 68, 82], ["pelvic", "ANATOMY", 90, 96], ["adenomyosis", "DISEASE", 18, 29], ["leiomyomas", "DISEASE", 31, 41], ["endometrial hyperplasia", "DISEASE", 43, 66], ["genital tumors", "DISEASE", 68, 82], ["acute pelvic inflammatory disease", "DISEASE", 84, 117], ["leiomyomas", "CANCER", 31, 41], ["endometrial hyperplasia", "CANCER", 43, 66], ["genital tumors", "CANCER", 68, 82], ["Participants", "SPECIES", 0, 12], ["adenomyosis", "PROBLEM", 18, 29], ["leiomyomas", "PROBLEM", 31, 41], ["endometrial hyperplasia", "PROBLEM", 43, 66], ["genital tumors", "PROBLEM", 68, 82], ["acute pelvic inflammatory disease", "PROBLEM", 84, 117], ["hormonal treatment", "TREATMENT", 132, 150], ["adenomyosis", "OBSERVATION", 18, 29], ["leiomyomas", "OBSERVATION", 31, 41], ["endometrial", "ANATOMY", 43, 54], ["hyperplasia", "OBSERVATION", 55, 66], ["genital", "ANATOMY", 68, 75], ["tumors", "OBSERVATION", 76, 82], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["pelvic", "ANATOMY", 90, 96], ["inflammatory", "OBSERVATION", 97, 109]]], ["Secretory-phase endometrial tissues, assessed based on the timing of the last menstrual period and histological analysis, were used in the study.Primary cell culture and transfection ::: Material and methodsESCs were isolated from eutopic endometrium (n = 3) and normal endometrium (n = 3) as described previously.", [["Secretory-phase endometrial tissues", "ANATOMY", 0, 35], ["cell", "ANATOMY", 153, 157], ["methodsESCs", "ANATOMY", 200, 211], ["eutopic endometrium", "ANATOMY", 231, 250], ["endometrium", "ANATOMY", 270, 281], ["endometrial tissues", "TISSUE", 16, 35], ["cell", "CELL", 153, 157], ["methodsESCs", "CELL", 200, 211], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 231, 250], ["endometrium", "MULTI-TISSUE_STRUCTURE", 270, 281], ["methodsESCs", "CELL_TYPE", 200, 211], ["histological analysis", "TEST", 99, 120], ["the study", "TEST", 135, 144], ["Primary cell culture", "TEST", 145, 165], ["methodsESCs", "TEST", 200, 211], ["phase endometrial tissues", "OBSERVATION", 10, 35], ["cell culture", "OBSERVATION", 153, 165], ["eutopic endometrium", "OBSERVATION", 231, 250], ["normal", "OBSERVATION", 263, 269], ["endometrium", "ANATOMY", 270, 281]]], ["Isolated ESCs were cultured in DMEM/F12 (1:1) supplemented with 10% fetal bovine serum (FBS) at 37\u00b0C. 293T human embryonic kidney cells were obtained from Sichuan University, Chinese University of Hong Kong Joint Laboratory for Reproductive Medicine, and were maintained in DMEM supplemented with 10% FBS.", [["ESCs", "ANATOMY", 9, 13], ["fetal bovine serum", "ANATOMY", 68, 86], ["FBS", "ANATOMY", 88, 91], ["293T", "ANATOMY", 102, 106], ["embryonic kidney cells", "ANATOMY", 113, 135], ["FBS", "ANATOMY", 301, 304], ["ESCs", "CELL", 9, 13], ["bovine", "ORGANISM", 74, 80], ["serum", "ORGANISM_SUBSTANCE", 81, 86], ["FBS", "ORGANISM_SUBSTANCE", 88, 91], ["human", "ORGANISM", 107, 112], ["embryonic kidney cells", "CELL", 113, 135], ["FBS", "ORGANISM_SUBSTANCE", 301, 304], ["ESCs", "CELL_TYPE", 9, 13], ["293T human embryonic kidney cells", "CELL_LINE", 102, 135], ["bovine", "SPECIES", 74, 80], ["human", "SPECIES", 107, 112], ["bovine", "SPECIES", 74, 80], ["human", "SPECIES", 107, 112], ["Isolated ESCs", "PROBLEM", 0, 13], ["10% fetal bovine serum (FBS", "TREATMENT", 64, 91], ["Reproductive Medicine", "TREATMENT", 228, 249], ["ESCs", "OBSERVATION", 9, 13], ["kidney", "ANATOMY", 123, 129]]], ["When cells reached 80% confluency, they were trypsinized and seeded into 6-well plates at 1.0 \u00d7 105 cells/mL.", [["cells", "ANATOMY", 5, 10], ["cells", "ANATOMY", 100, 105], ["cells", "CELL", 5, 10], ["cells", "CELL", 100, 105]]], ["When the cells reached 30\u201340% confluency, they were transfected with Hsa-miR22-5p mimics or inhibitor (100 nM, Guangzhou RiboBio, Guangzhou, China), using Lipofectamine 3000 transfection reagent (Invitrogen, Carlsbad, CA), according to the manufacturer\u2019s protocol.", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["Hsa-miR22-5p", "GENE_OR_GENE_PRODUCT", 69, 81], ["Hsa-miR22", "PROTEIN", 69, 78], ["Hsa-miR22", "TEST", 69, 78], ["inhibitor", "TREATMENT", 92, 101], ["Lipofectamine", "TREATMENT", 155, 168], ["transfection reagent", "TREATMENT", 174, 194]]], ["After 48\u201372 h of culture, the cells were harvested and collected for mRNA isolation or protein extraction.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["culture", "TEST", 17, 24], ["the cells", "PROBLEM", 26, 35], ["mRNA isolation", "TREATMENT", 69, 83], ["protein extraction", "TREATMENT", 87, 105]]], ["All experiments were performed in triplicate.RNA extraction and quantitative reverse-transcription (RT-q)PCR ::: Material and methodsTotal RNA was extracted from endometrial tissues and primary cultured ESCs using TRIzol reagent (Life Technologies, Carlsbad, CA), according to the manufacturer\u2019s protocol.", [["endometrial tissues", "ANATOMY", 162, 181], ["ESCs", "ANATOMY", 203, 207], ["endometrial tissues", "TISSUE", 162, 181], ["ESCs", "CELL", 203, 207], ["reverse-transcription (RT-q)PCR", "DNA", 77, 108], ["primary cultured ESCs", "CELL_TYPE", 186, 207], ["RNA extraction", "TEST", 45, 59], ["quantitative reverse-transcription", "TREATMENT", 64, 98], ["RT-q)PCR", "TEST", 100, 108], ["Material", "PROBLEM", 113, 121], ["Total RNA", "PROBLEM", 133, 142], ["endometrial tissues", "PROBLEM", 162, 181], ["primary cultured ESCs", "TREATMENT", 186, 207], ["TRIzol reagent", "TREATMENT", 214, 228], ["endometrial tissues", "ANATOMY", 162, 181]]], ["RNA quality and purification were analyzed using a NanoVue Plus spectrophotometer (Healthcare Bio-Sciences AB, Uppsala, Sweden). cDNA was synthesized from purified total RNA using a PrimeScript RT reagent kit (TaKaRa Biotechnology, Dalian, China).", [["cDNA", "DNA", 129, 133], ["RNA quality", "TEST", 0, 11], ["a NanoVue Plus spectrophotometer", "TREATMENT", 49, 81], ["a PrimeScript RT reagent kit", "TREATMENT", 180, 208]]], ["Primer sequences for TET2, ESR1, ESR2, and GAPDH (Sango Biotech, Shanghai, China) are listed in Table 2. qPCRs were run using SYBR Green real-time PCR Master Mix (Toyobo, Osaka, Japan) on an Applied Biosystems 7900 Real-time PCR Detection System (ABI, Foster City, CA).", [["TET2", "GENE_OR_GENE_PRODUCT", 21, 25], ["ESR1", "GENE_OR_GENE_PRODUCT", 27, 31], ["ESR2", "GENE_OR_GENE_PRODUCT", 33, 37], ["GAPDH", "GENE_OR_GENE_PRODUCT", 43, 48], ["Primer sequences", "DNA", 0, 16], ["TET2", "DNA", 21, 25], ["ESR1", "DNA", 27, 31], ["ESR2", "DNA", 33, 37], ["GAPDH", "DNA", 43, 48], ["Primer sequences", "TEST", 0, 16], ["TET2", "TEST", 21, 25], ["ESR1", "TEST", 27, 31], ["ESR2", "TEST", 33, 37], ["GAPDH", "TEST", 43, 48], ["qPCRs", "TEST", 105, 110], ["ABI", "TEST", 247, 250]]], ["The thermal cycles were 95\u00b0C for 20 s followed by 40 cycles of 95\u00b0C for 10 s and 60\u00b0C for 20 s.", [["The thermal cycles", "TREATMENT", 0, 18]]], ["The specificity of PCR products was confirmed by dissociation curve analysis.", [["PCR products", "TEST", 19, 31], ["dissociation curve analysis", "TEST", 49, 76]]], ["GAPDH was used as an endogenous control to normalize target gene expression, and relative expression was calculated using the 2\u2013\u0394\u0394Ct method.", [["GAPDH", "GENE_OR_GENE_PRODUCT", 0, 5], ["GAPDH", "PROTEIN", 0, 5], ["GAPDH", "PROBLEM", 0, 5], ["an endogenous control", "TREATMENT", 18, 39], ["the 2\u2013\u0394\u0394Ct method", "TREATMENT", 122, 139]]], ["For the quantitation of mature miRNAs, miRNA RT-qPCR was conducted using specific primers for miR22-5p and U6 small nuclear RNA (as an internal control) from the Bulge-Loop qRT-PCR Primer Set (Guangzhou RiboBio, Guangzhou, China), according to the manufacturers\u2019 protocol.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 94, 102], ["mature miRNAs", "RNA", 24, 37], ["miR22-5p", "DNA", 94, 102], ["U6 small nuclear RNA", "RNA", 107, 127], ["miRNA RT", "TREATMENT", 39, 47], ["specific primers", "TEST", 73, 89], ["miR22", "TEST", 94, 99], ["U6 small nuclear RNA", "PROBLEM", 107, 127], ["an internal control", "TREATMENT", 132, 151], ["the Bulge", "PROBLEM", 158, 167], ["Loop qRT", "TEST", 168, 176], ["small", "OBSERVATION_MODIFIER", 110, 115], ["nuclear RNA", "OBSERVATION", 116, 127], ["Bulge", "OBSERVATION", 162, 167]]], ["All experiments were repeated three times.Western blot analysis ::: Material and methodsTotal protein was extracted using radio immunoprecipitation lysis buffer (P0013B, Beyotime Biotechnology, Shanghai, China) according to the manufacturer\u2019s instructions.", [["Total protein", "TEST", 88, 101], ["radio immunoprecipitation lysis buffer", "TREATMENT", 122, 160]]], ["Protein concentrations were determined using a bicinchoninic acid assay kit (Beyotime Biotechnology).", [["bicinchoninic acid", "CHEMICAL", 47, 65], ["bicinchoninic acid", "CHEMICAL", 47, 65], ["Protein concentrations", "TEST", 0, 22], ["a bicinchoninic acid assay", "TREATMENT", 45, 71]]], ["Proteins (30 \u03bcg) from each sample were separated by 10% sodium dodecyl sulfate\u2013polyacrylamide gel electrophoresis and were transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA).", [["sample", "ANATOMY", 27, 33], ["sodium dodecyl sulfate\u2013polyacrylamide", "CHEMICAL", 56, 93], ["polyvinylidene fluoride", "CHEMICAL", 138, 161], ["sodium dodecyl sulfate\u2013polyacrylamide", "CHEMICAL", 56, 93], ["polyvinylidene fluoride", "CHEMICAL", 138, 161], ["sodium dodecyl sulfate\u2013polyacrylamide", "SIMPLE_CHEMICAL", 56, 93], ["polyvinylidene fluoride membranes", "SIMPLE_CHEMICAL", 138, 171], ["Proteins", "TEST", 0, 8], ["10% sodium dodecyl sulfate\u2013polyacrylamide gel electrophoresis", "TREATMENT", 52, 113], ["polyvinylidene fluoride membranes", "TREATMENT", 138, 171]]], ["The membranes were blocked in 5% defatted milk at room temperature for 1 h.", [["membranes", "ANATOMY", 4, 13], ["milk", "ANATOMY", 42, 46], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["milk", "ORGANISM_SUBSTANCE", 42, 46]]], ["Then, the membranes were incubated with mouse anti-human TET2 (1:400; ab94580, Abcam, Cambridge, UK), polyclonal rabbit anti-human ESR2 (1:400; ab3577, Abcam), polyclonal mouse anti-\u03b2-actin (1:30000; bs-2188R, Bioss, Beijing, China) antibodies at 4\u00b0C overnight and then with horseradish peroxidase\u2013conjugated secondary anti-mouse/rabbit antibody at room temperature for 1 h.", [["membranes", "ANATOMY", 10, 19], ["membranes", "CELLULAR_COMPONENT", 10, 19], ["mouse", "ORGANISM", 40, 45], ["TET2", "GENE_OR_GENE_PRODUCT", 57, 61], ["Abcam", "GENE_OR_GENE_PRODUCT", 79, 84], ["UK", "GENE_OR_GENE_PRODUCT", 97, 99], ["rabbit", "ORGANISM", 113, 119], ["ESR2", "GENE_OR_GENE_PRODUCT", 131, 135], ["ab3577", "GENE_OR_GENE_PRODUCT", 144, 150], ["Abcam", "GENE_OR_GENE_PRODUCT", 152, 157], ["mouse", "ORGANISM", 171, 176], ["horseradish peroxidase\u2013conjugated", "SIMPLE_CHEMICAL", 275, 308], ["rabbit", "ORGANISM", 330, 336], ["mouse anti-human TET2", "PROTEIN", 40, 61], ["polyclonal rabbit anti-human ESR2", "PROTEIN", 102, 135], ["1:400; ab3577, Abcam", "PROTEIN", 137, 157], ["polyclonal mouse anti-\u03b2-actin", "PROTEIN", 160, 189], ["Beijing, China) antibodies", "PROTEIN", 217, 243], ["horseradish peroxidase\u2013conjugated secondary anti-mouse/rabbit antibody", "PROTEIN", 275, 345], ["mouse", "SPECIES", 40, 45], ["rabbit", "SPECIES", 113, 119], ["mouse", "SPECIES", 171, 176], ["horseradish", "SPECIES", 275, 286], ["anti-mouse", "SPECIES", 319, 329], ["rabbit", "SPECIES", 330, 336], ["mouse", "SPECIES", 40, 45], ["rabbit", "SPECIES", 113, 119], ["mouse", "SPECIES", 171, 176], ["rabbit", "SPECIES", 330, 336], ["ab", "TEST", 70, 72], ["polyclonal rabbit anti-human ESR2", "TREATMENT", 102, 135], ["Abcam", "TEST", 152, 157], ["polyclonal mouse anti-\u03b2-actin", "TREATMENT", 160, 189], ["bs", "TEST", 200, 202], ["Bioss", "TEST", 210, 215], ["horseradish peroxidase\u2013conjugated", "TREATMENT", 275, 308], ["anti-mouse/rabbit antibody", "TREATMENT", 319, 345]]], ["Proteins bands were visualized using an enhanced chemiluminescence system (Millipore) and were analyzed with ImageJ 2X (National Institutes of Health, Bethesda, MD).", [["Proteins bands", "TEST", 0, 14], ["an enhanced chemiluminescence system", "TEST", 37, 73]]], ["Protein levels were normalized to that of \u03b2-actin.Luciferase reporter assay ::: Material and methodsThe base sequences of TET2 3\u2032-UTR fragments were identical to the sequences in the NCBI public bioinformation resource (www.ncbi.nlm.nih.gov/gene/54790).", [["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 42, 49], ["TET2", "GENE_OR_GENE_PRODUCT", 122, 126], ["\u03b2-actin", "PROTEIN", 42, 49], ["TET2 3\u2032-UTR fragments", "DNA", 122, 143], ["Protein levels", "TEST", 0, 14], ["\u03b2-actin", "TREATMENT", 42, 49], ["The base sequences", "TEST", 100, 118], ["TET2", "TEST", 122, 126], ["UTR fragments", "PROBLEM", 130, 143], ["base", "ANATOMY_MODIFIER", 104, 108]]], ["MiR22-5p targets were predicted using TargetScan (http://www.targetscan.org) and microRNA.org (http://microrna.org).", [["MiR22-5p", "GENE_OR_GENE_PRODUCT", 0, 8], ["MiR22-5p targets", "DNA", 0, 16], ["TargetScan", "DNA", 38, 48], ["microRNA.org", "DNA", 81, 93], ["TargetScan", "TEST", 38, 48]]], ["Three potential miR22-5p target sites were identified in the 3\u2032-UTR of the TET2 mRNA sequence.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 16, 24], ["TET2", "GENE_OR_GENE_PRODUCT", 75, 79], ["miR22-5p target sites", "DNA", 16, 37], ["3\u2032-UTR", "DNA", 61, 67], ["TET2 mRNA sequence", "RNA", 75, 93], ["TET2 mRNA", "OBSERVATION", 75, 84]]], ["Reporter genes were constructed by PCR amplification, gel purification, and restriction digest of the TET2 3\u2032-UTR.", [["TET2", "GENE_OR_GENE_PRODUCT", 102, 106], ["TET2 3\u2032-UTR", "DNA", 102, 113], ["PCR amplification", "TREATMENT", 35, 52], ["gel purification", "TREATMENT", 54, 70]]], ["Three wild-type (WT) TET2 3\u2032-UTR fragments each containing one of the predicted miR22-5p-binding sites were cloned into the pmiR-RB-REPORT vector (Promega, Fitchburg, WI).", [["TET2", "GENE_OR_GENE_PRODUCT", 21, 25], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 80, 88], ["pmiR", "GENE_OR_GENE_PRODUCT", 124, 128], ["wild-type (WT) TET2 3\u2032-UTR fragments", "DNA", 6, 42], ["miR22-5p-binding sites", "DNA", 80, 102], ["pmiR", "DNA", 124, 128], ["RB", "PROTEIN", 129, 131], ["TET2 3\u2032-UTR fragments", "TREATMENT", 21, 42], ["5p-binding sites", "TREATMENT", 86, 102]]], ["The constructed reporter plasmids were designated TET2 3\u2032-UTR WT1, TET2 3\u2032-UTR WT2, and TET2 3\u2032-UTR WT3.", [["plasmids", "ANATOMY", 25, 33], ["TET2", "GENE_OR_GENE_PRODUCT", 50, 54], ["WT1", "GENE_OR_GENE_PRODUCT", 62, 65], ["reporter plasmids", "DNA", 16, 33], ["TET2 3\u2032-UTR WT1", "DNA", 50, 65], ["TET2", "DNA", 67, 71], ["WT2", "DNA", 79, 82], ["TET2 3\u2032-UTR WT3", "DNA", 88, 103], ["The constructed reporter plasmids", "TREATMENT", 0, 33], ["TET2", "TEST", 50, 54], ["UTR WT1", "TEST", 58, 65], ["TET2", "TEST", 67, 71], ["UTR WT2", "TEST", 75, 82], ["TET2", "TEST", 88, 92], ["UTR WT3", "TEST", 96, 103]]], ["The differential expressed TET2 3\u2019-UTR WT1, mutation of TET2 3\u2019-UTR WT1 (TET2 3\u2019-UTR M1) was also designated.", [["TET2", "GENE_OR_GENE_PRODUCT", 27, 31], ["WT1", "GENE_OR_GENE_PRODUCT", 39, 42], ["TET2", "GENE_OR_GENE_PRODUCT", 56, 60], ["TET2 3\u2019-UTR M1", "GENE_OR_GENE_PRODUCT", 73, 87], ["TET2 3\u2019-UTR", "DNA", 27, 38], ["WT1", "DNA", 39, 42], ["TET2 3\u2019-UTR WT1", "DNA", 56, 71], ["TET2 3\u2019-UTR M1", "DNA", 73, 87], ["The differential", "TEST", 0, 16], ["TET2", "TEST", 27, 31], ["UTR WT1", "TEST", 35, 42], ["mutation", "TEST", 44, 52], ["TET2", "TEST", 56, 60], ["UTR WT1", "TEST", 64, 71], ["TET2", "TEST", 73, 77]]], ["293T cells were transfected with the reporter plasmids and 50 nM of miR22-5p mimic or miRNA negative control (Guangzhou RiboBio, Guangzhou, China).", [["293T cells", "ANATOMY", 0, 10], ["plasmids", "ANATOMY", 46, 54], ["293T cells", "CELL", 0, 10], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 68, 76], ["293T cells", "CELL_LINE", 0, 10], ["reporter plasmids", "DNA", 37, 54], ["miR22-5p mimic", "DNA", 68, 82], ["the reporter plasmids", "TREATMENT", 33, 54], ["miR22", "TEST", 68, 73]]], ["After 48 h, the cells were harvested and luciferase activity was measured using a dual-luciferase reporter assay system (Promega) according to the manufacturer\u2019s protocol.", [["cells", "ANATOMY", 16, 21], ["cells", "CELL", 16, 21], ["luciferase", "GENE_OR_GENE_PRODUCT", 41, 51], ["luciferase", "GENE_OR_GENE_PRODUCT", 87, 97], ["luciferase", "PROTEIN", 41, 51], ["the cells", "TREATMENT", 12, 21], ["luciferase activity", "TEST", 41, 60]]], ["All transfections and assays were performed three times, with six technical replicates.Immunofluorescence ::: Material and methodsEndometrial cells (25 \u00d7 103) were seeded on glass coverslips in 24-well plates.", [["Endometrial cells", "ANATOMY", 130, 147], ["Endometrial cells", "CELL", 130, 147], ["Endometrial cells", "CELL_TYPE", 130, 147], ["All transfections", "TEST", 0, 17], ["assays", "TEST", 22, 28], ["Immunofluorescence", "TEST", 87, 105], ["Material and methodsEndometrial cells", "PROBLEM", 110, 147], ["glass coverslips", "TEST", 174, 190]]], ["After treatment, the cells were fixed in 4% paraformaldehyde in 1\u00d7 PBS for 15 min, washed in PBS, and treated with 0.2% Triton X-100 in PBS for 15 min.", [["cells", "ANATOMY", 21, 26], ["Triton X-100", "CHEMICAL", 120, 132], ["paraformaldehyde", "CHEMICAL", 44, 60], ["cells", "CELL", 21, 26], ["paraformaldehyde", "SIMPLE_CHEMICAL", 44, 60], ["Triton X-100", "SIMPLE_CHEMICAL", 120, 132], ["treatment", "TREATMENT", 6, 15], ["the cells", "TREATMENT", 17, 26], ["PBS", "TEST", 67, 70], ["PBS", "TREATMENT", 93, 96], ["0.2% Triton", "TREATMENT", 115, 126]]], ["Permeabilized cells were denatured with 2 N HCl for 15 min and neutralized with 100 mM Tris-HCl (pH 8.5) for 10 min.", [["cells", "ANATOMY", 14, 19], ["2 N HCl", "CHEMICAL", 40, 47], ["Tris-HCl", "CHEMICAL", 87, 95], ["HCl", "CHEMICAL", 44, 47], ["Tris-HCl", "CHEMICAL", 87, 95], ["cells", "CELL", 14, 19], ["Tris-HCl", "SIMPLE_CHEMICAL", 87, 95], ["Permeabilized cells", "CELL_TYPE", 0, 19], ["Permeabilized cells", "PROBLEM", 0, 19], ["2 N HCl", "TREATMENT", 40, 47], ["pH", "TEST", 97, 99]]], ["Proteins were blocked in 1% BSA in PBS for 30 min and then, the cells were incubated with rabbit anti-human 5-hmc antibody (1:100) and mouse anti-human TET2 antibody (1:200) at room temperature for 2 h, followed by Alexa Fluor 488-labeled anti-mouse antibody (Life Technologies).", [["cells", "ANATOMY", 64, 69], ["BSA", "CHEMICAL", 28, 31], ["Alexa Fluor 488", "CHEMICAL", 215, 230], ["BSA", "SIMPLE_CHEMICAL", 28, 31], ["PBS", "SIMPLE_CHEMICAL", 35, 38], ["cells", "CELL", 64, 69], ["rabbit", "ORGANISM", 90, 96], ["5-hmc antibody", "GENE_OR_GENE_PRODUCT", 108, 122], ["mouse", "ORGANISM", 135, 140], ["TET2", "GENE_OR_GENE_PRODUCT", 152, 156], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 215, 230], ["rabbit anti-human 5-hmc antibody", "PROTEIN", 90, 122], ["1:100", "PROTEIN", 124, 129], ["mouse anti-human TET2 antibody", "PROTEIN", 135, 165], ["1:200", "PROTEIN", 167, 172], ["Alexa Fluor 488-labeled anti-mouse antibody", "PROTEIN", 215, 258], ["rabbit", "SPECIES", 90, 96], ["mouse", "SPECIES", 135, 140], ["rabbit", "SPECIES", 90, 96], ["mouse", "SPECIES", 135, 140], ["Proteins", "TEST", 0, 8], ["the cells", "TEST", 60, 69], ["rabbit anti-human", "TEST", 90, 107], ["hmc antibody", "TEST", 110, 122], ["mouse anti-human TET2 antibody", "TEST", 135, 165], ["Alexa Fluor", "TEST", 215, 226], ["anti-mouse antibody", "TEST", 239, 258]]], ["After washing, the cells were counterstained with 4\u2032,6-diamidino-2-phenylindole.Dot blot assay ::: Material and methodsGenomic DNA was extracted from primary cells using a DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer\u2019s protocol.", [["cells", "ANATOMY", 19, 24], ["primary cells", "ANATOMY", 150, 163], ["Blood", "ANATOMY", 179, 184], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 50, 79], ["4\u2032,6-diamidino-2-phenylindole", "CHEMICAL", 50, 79], ["cells", "CELL", 19, 24], ["4\u2032,6-diamidino-2-phenylindole", "SIMPLE_CHEMICAL", 50, 79], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["cells", "CELL", 158, 163], ["Tissue Kit", "ORGANISM_SUBSTANCE", 187, 197], ["Qiagen", "ORGANISM_SUBSTANCE", 199, 205], ["primary cells", "CELL_TYPE", 150, 163], ["diamidino", "TREATMENT", 55, 64], ["phenylindole", "TREATMENT", 67, 79], ["Material and methodsGenomic DNA", "PROBLEM", 99, 130], ["primary cells", "PROBLEM", 150, 163], ["a DNeasy Blood & Tissue Kit (Qiagen)", "TREATMENT", 170, 206], ["the manufacturer\u2019s protocol", "TREATMENT", 220, 247], ["Genomic DNA", "OBSERVATION", 119, 130], ["primary cells", "OBSERVATION", 150, 163]]], ["DNA samples were diluted with 2 N NaOH and 10 mM Tris Cl (pH 8.5) and blotted onto a nitrocellulose membrane.", [["samples", "ANATOMY", 4, 11], ["membrane", "ANATOMY", 100, 108], ["N NaOH", "CHEMICAL", 32, 38], ["Tris Cl", "CHEMICAL", 49, 56], ["NaOH", "CHEMICAL", 34, 38], ["Tris Cl", "CHEMICAL", 49, 56], ["nitrocellulose", "CHEMICAL", 85, 99], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["Tris Cl", "SIMPLE_CHEMICAL", 49, 56], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["DNA samples", "TEST", 0, 11], ["2 N NaOH", "TREATMENT", 30, 38], ["mM Tris Cl", "TEST", 46, 56], ["pH", "TEST", 58, 60], ["a nitrocellulose membrane", "TREATMENT", 83, 108]]], ["After baking at 80\u00b0C for 30 min and blocking in 5% nonfat milk at room temperature for 1 h, the membrane was incubated with a polyclonal rabbit anti-human 5-hmC antibody (Active Motif 39769, 1:10,000) at 4\u00b0C overnight.", [["milk", "ANATOMY", 58, 62], ["membrane", "ANATOMY", 96, 104], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["membrane", "CELLULAR_COMPONENT", 96, 104], ["rabbit", "ORGANISM", 137, 143], ["polyclonal rabbit anti-human 5-hmC antibody", "PROTEIN", 126, 169], ["rabbit", "SPECIES", 137, 143], ["rabbit", "SPECIES", 137, 143], ["a polyclonal rabbit anti-human", "TREATMENT", 124, 154]]], ["5-hmC was visualized using chemiluminescence.", [["5-hmC", "CHEMICAL", 0, 5], ["5-hmC", "SIMPLE_CHEMICAL", 0, 5], ["chemiluminescence", "TEST", 27, 44]]], ["The membranes were stained with methylene blue to assess equal DNA loading.Immunohistochemistry ::: Material and methodsTissue was embedded in paraffin, cut into 5-\u03bcm sections, and mounted onto gelatin-coated slides.", [["membranes", "ANATOMY", 4, 13], ["Tissue", "ANATOMY", 120, 126], ["sections", "ANATOMY", 167, 175], ["methylene blue", "CHEMICAL", 32, 46], ["methylene blue", "CHEMICAL", 32, 46], ["paraffin", "CHEMICAL", 143, 151], ["membranes", "CELLULAR_COMPONENT", 4, 13], ["methylene blue", "SIMPLE_CHEMICAL", 32, 46], ["DNA", "CELLULAR_COMPONENT", 63, 66], ["Tissue", "TISSUE", 120, 126], ["methylene blue", "TREATMENT", 32, 46]]], ["Sections were dried at 37\u00b0C overnight, deparaffinized in xylene, and rehydrated through a graded ethanol series.", [["ethanol", "CHEMICAL", 97, 104], ["xylene", "CHEMICAL", 57, 63], ["ethanol", "CHEMICAL", 97, 104], ["xylene", "SIMPLE_CHEMICAL", 57, 63], ["ethanol", "SIMPLE_CHEMICAL", 97, 104], ["xylene", "TREATMENT", 57, 63], ["a graded ethanol series", "TREATMENT", 88, 111]]], ["The slides were immersed in citrate antigen retrieval buffer (pH 6) at 120\u00b0C for 10 min to retrieve the epitopes, incubated with 3% H2O2 for 10 min to block endogenous peroxidase activity after cooling, blocked with 10% normal goat serum for 30 min, and incubated with the primary antibody (TET2 1:200, 5-hmc 1:200) at 4\u00b0C overnight.", [["serum", "ANATOMY", 232, 237], ["citrate", "CHEMICAL", 28, 35], ["H2O2", "CHEMICAL", 132, 136], ["citrate", "CHEMICAL", 28, 35], ["H2O2", "CHEMICAL", 132, 136], ["citrate", "SIMPLE_CHEMICAL", 28, 35], ["H2O2", "SIMPLE_CHEMICAL", 132, 136], ["peroxidase", "GENE_OR_GENE_PRODUCT", 168, 178], ["goat", "ORGANISM", 227, 231], ["serum", "ORGANISM_SUBSTANCE", 232, 237], ["epitopes", "PROTEIN", 104, 112], ["endogenous peroxidase", "PROTEIN", 157, 178], ["primary antibody", "PROTEIN", 273, 289], ["TET2 1:200", "PROTEIN", 291, 301], ["hmc 1:200", "PROTEIN", 305, 314], ["goat", "SPECIES", 227, 231], ["goat", "SPECIES", 227, 231], ["The slides", "TREATMENT", 0, 10], ["citrate antigen retrieval buffer", "TREATMENT", 28, 60], ["pH", "TEST", 62, 64], ["3% H2O2", "TREATMENT", 129, 136], ["block endogenous peroxidase activity", "PROBLEM", 151, 187], ["peroxidase activity", "OBSERVATION", 168, 187]]], ["Biotinylated secondary antibody and streptavidin-peroxidase conjugate were applied according to the manufacturer\u2019s instructions (Beijing Zhongshan Biotech, Beijing, China).", [["streptavidin-peroxidase conjugate", "SIMPLE_CHEMICAL", 36, 69], ["streptavidin-peroxidase conjugate", "PROTEIN", 36, 69], ["Biotinylated secondary antibody", "TREATMENT", 0, 31], ["streptavidin-peroxidase conjugate", "TREATMENT", 36, 69]]], ["Immunoreactivity was visualized with diaminobenzidine, and the sections were counterstained with hematoxylin and mounted.", [["sections", "ANATOMY", 63, 71], ["diaminobenzidine", "CHEMICAL", 37, 53], ["hematoxylin", "CHEMICAL", 97, 108], ["diaminobenzidine", "SIMPLE_CHEMICAL", 37, 53], ["hematoxylin", "SIMPLE_CHEMICAL", 97, 108], ["diaminobenzidine", "TREATMENT", 37, 53], ["hematoxylin", "TREATMENT", 97, 108]]], ["Isotype controls were performed with matched concentrations of mouse IgG for TET2 and rabbit IgG for 5-hmC.Bisulfite modification and sequencing ::: Material and methodsGenomic DNA was extracted from miR22-5p inhibitor- and control-transfected primary ESCs (n = 3) from infertile women without endometriosis using the DNeasy Tissue Kit (Qiagen) and was used for bisulfite modification and sequencing analysis (Sangon Biotech, Shanghai, China).", [["ESCs", "ANATOMY", 252, 256], ["endometriosis", "ANATOMY", 294, 307], ["Bisulfite", "CHEMICAL", 107, 116], ["endometriosis", "DISEASE", 294, 307], ["bisulfite", "CHEMICAL", 362, 371], ["Bisulfite", "CHEMICAL", 107, 116], ["bisulfite", "CHEMICAL", 362, 371], ["mouse", "ORGANISM", 63, 68], ["IgG", "GENE_OR_GENE_PRODUCT", 69, 72], ["TET2", "GENE_OR_GENE_PRODUCT", 77, 81], ["rabbit", "ORGANISM", 86, 92], ["IgG", "GENE_OR_GENE_PRODUCT", 93, 96], ["5-hmC", "SIMPLE_CHEMICAL", 101, 106], ["Bisulfite", "SIMPLE_CHEMICAL", 107, 116], ["DNA", "CELLULAR_COMPONENT", 177, 180], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 200, 208], ["ESCs", "CELL", 252, 256], ["women", "ORGANISM", 280, 285], ["mouse IgG", "PROTEIN", 63, 72], ["TET2", "PROTEIN", 77, 81], ["rabbit IgG", "PROTEIN", 86, 96], ["miR22-5p inhibitor", "DNA", 200, 218], ["primary ESCs", "CELL_TYPE", 244, 256], ["mouse", "SPECIES", 63, 68], ["rabbit", "SPECIES", 86, 92], ["women", "SPECIES", 280, 285], ["mouse", "SPECIES", 63, 68], ["rabbit", "SPECIES", 86, 92], ["Isotype controls", "TREATMENT", 0, 16], ["mouse IgG", "TREATMENT", 63, 72], ["TET2 and rabbit IgG", "TREATMENT", 77, 96], ["Material and methodsGenomic DNA", "PROBLEM", 149, 180], ["miR22-5p inhibitor", "TREATMENT", 200, 218], ["transfected primary ESCs", "PROBLEM", 232, 256], ["infertile women", "PROBLEM", 270, 285], ["endometriosis", "PROBLEM", 294, 307], ["the DNeasy Tissue Kit (Qiagen)", "TREATMENT", 314, 344], ["bisulfite modification", "TREATMENT", 362, 384], ["sequencing analysis", "TEST", 389, 408], ["endometriosis", "OBSERVATION", 294, 307]]], ["Three microliters of bisulfite-modified DNA was PCR-amplified a reaction volume of 50 \u03bcl, using the following primers for ESR2: forward: 5\u2032-ATTATTTTTGTGGGTGGATTAGGAG-3\u2032, and reverse: 5\u2032-AACCCCTTCTTCCTTTTAAAAACC-3\u2032.", [["bisulfite", "CHEMICAL", 21, 30], ["bisulfite", "CHEMICAL", 21, 30], ["bisulfite", "SIMPLE_CHEMICAL", 21, 30], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["ESR2", "GENE_OR_GENE_PRODUCT", 122, 126], ["ESR2", "DNA", 122, 126], ["reverse: 5\u2032-AACCCCTTCTTCCTTTTAAAAACC-3\u2032", "DNA", 174, 213], ["Three microliters of bisulfite", "TREATMENT", 0, 30], ["PCR", "TEST", 48, 51], ["a reaction volume", "TEST", 62, 79], ["ATTATTTTTGTGGGTGGATTAGGAG", "TEST", 140, 165]]], ["Thermal cycles were as follows: 98\u00b0C for 4 min, 20 cycles of denaturation at 94\u00b0C for 45 s, annealing at 66\u00b0C for 45 s, and elongation at 72\u00b0C for 1 min, and 20 cycles of denaturation at 94\u00b0C for 45 s, annealing at 56\u00b0C for 45 s, and elongation at 72\u00b0C for 1 min, and finally, 72\u00b0C for 8 min.", [["Thermal cycles", "TREATMENT", 0, 14], ["denaturation", "TEST", 61, 73], ["elongation", "TEST", 124, 134], ["denaturation", "TEST", 171, 183], ["elongation", "TEST", 234, 244]]], ["PCR products (166 bp) were gel-purified and cloned into the pUC18-T vector (Sangon Biotech).", [["pUC18", "GENE_OR_GENE_PRODUCT", 60, 65], ["PCR products", "DNA", 0, 12], ["pUC18-T vector", "DNA", 60, 74], ["PCR products", "TEST", 0, 12], ["bp", "TEST", 18, 20]]], ["Following transformation, ten clones with the correct insert were randomly picked for each PCR product and were sequenced using an Applied Biosystems 3730XL instrument.Statistical analysis ::: Material and methodsStatistical analysis was performed using SPSS version 18.0 (IBM Corp., USA).", [["the correct insert", "TREATMENT", 42, 60], ["each PCR product", "TREATMENT", 86, 102], ["an Applied Biosystems 3730XL instrument", "TREATMENT", 128, 167], ["Statistical analysis", "TEST", 213, 233], ["SPSS version", "TEST", 254, 266]]], ["Means of two groups were compared using Student\u2019s t-test.", [["Student\u2019s t-test", "TEST", 40, 56]]], ["P < 0.05 was considered statistically significant (two-tailed).MiR22-5p and TET2 expression signature discriminates eutopic endometrium of mild/minimal endometriosis from normal endometrium ::: ResultsIn our previous microarray-based miRNA profiling analysis of mid-luteal endometrium from women with minimal and mild endometriosis, we observed a marked downregulation of miR22-5p [15].", [["eutopic endometrium", "ANATOMY", 116, 135], ["endometriosis", "ANATOMY", 152, 165], ["endometrium", "ANATOMY", 178, 189], ["mid-luteal endometrium", "ANATOMY", 262, 284], ["endometriosis", "ANATOMY", 318, 331], ["endometriosis", "DISEASE", 152, 165], ["endometriosis", "DISEASE", 318, 331], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 63, 71], ["TET2", "GENE_OR_GENE_PRODUCT", 76, 80], ["eutopic endometrium", "CANCER", 116, 135], ["endometriosis", "CANCER", 152, 165], ["endometrium", "MULTI-TISSUE_STRUCTURE", 178, 189], ["mid-luteal endometrium", "MULTI-TISSUE_STRUCTURE", 262, 284], ["women", "ORGANISM", 290, 295], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 372, 380], ["MiR22", "DNA", 63, 68], ["TET2", "DNA", 76, 80], ["miR22", "PROTEIN", 372, 377], ["women", "SPECIES", 290, 295], ["MiR22", "TEST", 63, 68], ["TET2 expression signature", "TEST", 76, 101], ["eutopic endometrium", "PROBLEM", 116, 135], ["mild/minimal endometriosis", "PROBLEM", 139, 165], ["our previous microarray", "TEST", 204, 227], ["miRNA profiling analysis", "TEST", 234, 258], ["mid-luteal endometrium", "PROBLEM", 262, 284], ["minimal and mild endometriosis", "PROBLEM", 301, 331], ["eutopic endometrium", "OBSERVATION", 116, 135], ["mild", "OBSERVATION_MODIFIER", 139, 143], ["minimal", "OBSERVATION_MODIFIER", 144, 151], ["endometriosis", "OBSERVATION", 152, 165], ["normal endometrium", "OBSERVATION", 171, 189], ["mid-luteal endometrium", "ANATOMY", 262, 284], ["minimal", "OBSERVATION_MODIFIER", 301, 308], ["mild", "OBSERVATION_MODIFIER", 313, 317], ["endometriosis", "OBSERVATION", 318, 331], ["marked", "OBSERVATION_MODIFIER", 347, 353]]], ["To confirm these findings in this study, we subjected 13 endometrial tissues of mild/minimal endometriosis and 11 normal control tissues to RT-qPCR.", [["endometrial tissues", "ANATOMY", 57, 76], ["endometriosis", "ANATOMY", 93, 106], ["tissues", "ANATOMY", 129, 136], ["endometriosis", "DISEASE", 93, 106], ["endometrial tissues", "TISSUE", 57, 76], ["endometriosis", "CANCER", 93, 106], ["tissues", "TISSUE", 129, 136], ["this study", "TEST", 29, 39], ["mild/minimal endometriosis", "PROBLEM", 80, 106], ["mild", "OBSERVATION_MODIFIER", 80, 84], ["minimal", "OBSERVATION_MODIFIER", 85, 92], ["endometriosis", "OBSERVATION", 93, 106]]], ["MiR22-5p expression was significantly lower in eutopic endometrium of minimal/mild endometriosis than in normal tissues (Fig 1A).", [["eutopic endometrium", "ANATOMY", 47, 66], ["endometriosis", "ANATOMY", 83, 96], ["tissues", "ANATOMY", 112, 119], ["endometriosis", "DISEASE", 83, 96], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 0, 8], ["eutopic endometrium", "CANCER", 47, 66], ["normal tissues", "TISSUE", 105, 119], ["MiR22", "PROTEIN", 0, 5], ["5p", "DNA", 6, 8], ["MiR22", "TEST", 0, 5], ["minimal/mild endometriosis", "PROBLEM", 70, 96], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["lower", "OBSERVATION_MODIFIER", 38, 43], ["eutopic endometrium", "ANATOMY", 47, 66], ["minimal", "OBSERVATION_MODIFIER", 70, 77], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["endometriosis", "OBSERVATION", 83, 96], ["normal tissues", "OBSERVATION_MODIFIER", 105, 119]]], ["Next, we investigated the biological significance of miR22-5p downregulation in the regulation of target TET2 mRNAs.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 53, 61], ["TET2", "GENE_OR_GENE_PRODUCT", 105, 109], ["miR22", "PROTEIN", 53, 58], ["TET2 mRNAs", "RNA", 105, 115], ["target TET2 mRNAs", "PROBLEM", 98, 115], ["5p downregulation", "OBSERVATION", 59, 76], ["target TET2 mRNAs", "OBSERVATION", 98, 115]]], ["Compared to endometrium from women without endometriosis, TET2 expression was significantly higher in endometrium from women with minimal/mild endometriosis during the secretory phase (Fig 1B).", [["endometrium", "ANATOMY", 12, 23], ["endometriosis", "ANATOMY", 43, 56], ["endometrium", "ANATOMY", 102, 113], ["endometriosis", "ANATOMY", 143, 156], ["endometriosis", "DISEASE", 43, 56], ["endometriosis", "DISEASE", 143, 156], ["endometrium", "MULTI-TISSUE_STRUCTURE", 12, 23], ["women", "ORGANISM", 29, 34], ["TET2", "GENE_OR_GENE_PRODUCT", 58, 62], ["endometrium", "CANCER", 102, 113], ["women", "ORGANISM", 119, 124], ["TET2", "PROTEIN", 58, 62], ["women", "SPECIES", 29, 34], ["women", "SPECIES", 119, 124], ["endometriosis", "PROBLEM", 43, 56], ["TET2 expression", "PROBLEM", 58, 73], ["minimal/mild endometriosis", "PROBLEM", 130, 156], ["endometrium", "ANATOMY", 12, 23], ["without", "UNCERTAINTY", 35, 42], ["endometriosis", "OBSERVATION", 43, 56], ["TET2 expression", "OBSERVATION", 58, 73], ["significantly", "OBSERVATION_MODIFIER", 78, 91], ["higher", "OBSERVATION_MODIFIER", 92, 98], ["endometrium", "ANATOMY", 102, 113], ["minimal", "OBSERVATION_MODIFIER", 130, 137], ["mild", "OBSERVATION_MODIFIER", 138, 142], ["endometriosis", "OBSERVATION", 143, 156]]], ["TET2 protein levels were significantly higher in endometrium from women with minimal/mild endometriosis than in normal endometrium as indicated by western blot results (Fig 1C).", [["endometrium", "ANATOMY", 49, 60], ["endometriosis", "ANATOMY", 90, 103], ["endometrium", "ANATOMY", 119, 130], ["endometriosis", "DISEASE", 90, 103], ["TET2", "GENE_OR_GENE_PRODUCT", 0, 4], ["endometrium", "CANCER", 49, 60], ["women", "ORGANISM", 66, 71], ["endometrium", "MULTI-TISSUE_STRUCTURE", 119, 130], ["TET2", "PROTEIN", 0, 4], ["women", "SPECIES", 66, 71], ["TET2 protein levels", "TEST", 0, 19], ["minimal/mild endometriosis", "PROBLEM", 77, 103], ["significantly", "OBSERVATION_MODIFIER", 25, 38], ["higher", "OBSERVATION_MODIFIER", 39, 45], ["endometrium", "ANATOMY", 49, 60], ["minimal", "OBSERVATION_MODIFIER", 77, 84], ["mild", "OBSERVATION_MODIFIER", 85, 89], ["endometriosis", "OBSERVATION", 90, 103], ["normal endometrium", "OBSERVATION", 112, 130]]], ["Immunohistochemistry revealed that TET2 was strongly expressed in both the nucleus and the cytoplasm of epithelial and stromal cells of eutopic endometrium of endometriosis, whereas normal endometrium exhibited weak to moderate expression (Fig 1D).", [["nucleus", "ANATOMY", 75, 82], ["cytoplasm", "ANATOMY", 91, 100], ["epithelial", "ANATOMY", 104, 114], ["stromal cells", "ANATOMY", 119, 132], ["eutopic endometrium", "ANATOMY", 136, 155], ["endometriosis", "ANATOMY", 159, 172], ["endometrium", "ANATOMY", 189, 200], ["endometriosis", "DISEASE", 159, 172], ["TET2", "GENE_OR_GENE_PRODUCT", 35, 39], ["nucleus", "CELLULAR_COMPONENT", 75, 82], ["cytoplasm", "ORGANISM_SUBSTANCE", 91, 100], ["epithelial", "CELL", 104, 114], ["stromal cells", "CELL", 119, 132], ["eutopic endometrium", "TISSUE", 136, 155], ["endometrium", "MULTI-TISSUE_STRUCTURE", 189, 200], ["TET2", "PROTEIN", 35, 39], ["epithelial and stromal cells", "CELL_TYPE", 104, 132], ["Immunohistochemistry", "TEST", 0, 20], ["TET2", "TEST", 35, 39], ["eutopic endometrium of endometriosis", "PROBLEM", 136, 172], ["TET2", "OBSERVATION", 35, 39], ["nucleus", "ANATOMY", 75, 82], ["epithelial", "ANATOMY", 104, 114], ["stromal cells", "OBSERVATION", 119, 132], ["eutopic endometrium", "OBSERVATION", 136, 155], ["endometriosis", "OBSERVATION", 159, 172], ["endometrium", "ANATOMY", 189, 200], ["weak", "OBSERVATION_MODIFIER", 211, 215], ["moderate", "OBSERVATION_MODIFIER", 219, 227], ["expression", "OBSERVATION", 228, 238]]], ["The above results suggested a correlation between miR22-5p and TET2 in minimal/mild endometriosis.", [["endometriosis", "ANATOMY", 84, 97], ["endometriosis", "DISEASE", 84, 97], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 50, 58], ["TET2", "GENE_OR_GENE_PRODUCT", 63, 67], ["endometriosis", "PATHOLOGICAL_FORMATION", 84, 97], ["miR22-5p", "DNA", 50, 58], ["TET2", "DNA", 63, 67], ["miR22", "TEST", 50, 55], ["TET2", "PROBLEM", 63, 67], ["minimal/mild endometriosis", "PROBLEM", 71, 97], ["minimal", "OBSERVATION_MODIFIER", 71, 78], ["mild", "OBSERVATION_MODIFIER", 79, 83], ["endometriosis", "OBSERVATION", 84, 97]]], ["The DNA pyrimidine nitrogen base 5-hmC was strongly expressed in both the nucleus and the cytoplasm of epithelial and stromal cells of eutopic and normal endometrium (Fig 1D).MiR22-5p regulates TET2 expression in primary ESCs ::: ResultsWe examined the impact of miR22-5p on TET2 expression by transfecting primary ESCs with miR22-5p mimics and inhibitor.", [["nucleus", "ANATOMY", 74, 81], ["cytoplasm", "ANATOMY", 90, 99], ["epithelial", "ANATOMY", 103, 113], ["stromal cells", "ANATOMY", 118, 131], ["eutopic", "ANATOMY", 135, 142], ["endometrium", "ANATOMY", 154, 165], ["ESCs", "ANATOMY", 221, 225], ["ESCs", "ANATOMY", 315, 319], ["pyrimidine nitrogen", "CHEMICAL", 8, 27], ["pyrimidine", "CHEMICAL", 8, 18], ["nitrogen", "CHEMICAL", 19, 27], ["DNA", "CELLULAR_COMPONENT", 4, 7], ["5-hmC", "SIMPLE_CHEMICAL", 33, 38], ["nucleus", "CELLULAR_COMPONENT", 74, 81], ["cytoplasm", "ORGANISM_SUBSTANCE", 90, 99], ["epithelial", "CELL", 103, 113], ["stromal cells", "CELL", 118, 131], ["eutopic", "TISSUE", 135, 142], ["endometrium", "MULTI-TISSUE_STRUCTURE", 154, 165], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 175, 183], ["TET2", "GENE_OR_GENE_PRODUCT", 194, 198], ["ESCs", "CELL", 221, 225], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 263, 271], ["TET2", "GENE_OR_GENE_PRODUCT", 275, 279], ["ESCs", "CELL", 315, 319], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 325, 333], ["DNA pyrimidine nitrogen base 5-hmC", "DNA", 4, 38], ["epithelial and stromal cells", "CELL_TYPE", 103, 131], ["MiR22-5p", "DNA", 175, 183], ["TET2", "DNA", 194, 198], ["primary ESCs", "CELL_TYPE", 213, 225], ["miR22-5p", "DNA", 263, 271], ["TET2", "DNA", 275, 279], ["primary ESCs", "CELL_TYPE", 307, 319], ["miR22", "PROTEIN", 325, 330], ["The DNA pyrimidine nitrogen base", "TEST", 0, 32], ["TET2 expression", "TREATMENT", 275, 290], ["miR22-5p mimics", "TREATMENT", 325, 340], ["inhibitor", "TREATMENT", 345, 354], ["nucleus", "ANATOMY", 74, 81], ["cytoplasm", "OBSERVATION_MODIFIER", 90, 99], ["epithelial", "ANATOMY", 103, 113], ["stromal cells", "OBSERVATION", 118, 131], ["eutopic", "OBSERVATION", 135, 142], ["normal endometrium", "OBSERVATION", 147, 165]]], ["Successful miR22-5p mimic and inhibitor transfection was validated by a significant increase (0.85 \u00b1 0.15 vs. 5189.65 \u00b1 3062.38; P < 0.001; Fig 2A) and decrease (0.98 \u00b1 0.22 vs. 0.17 \u00b1 0.09; P < 0.001; Fig 2A), respectively, in miR22-5p in ESCs.", [["miR22-5p", "ANATOMY", 228, 236], ["ESCs", "ANATOMY", 240, 244], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 11, 19], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 228, 236], ["ESCs", "CELL", 240, 244], ["miR22", "DNA", 11, 16], ["miR22", "PROTEIN", 228, 233], ["ESCs", "CELL_TYPE", 240, 244], ["Successful miR22-5p mimic and inhibitor transfection", "TREATMENT", 0, 52], ["P", "TEST", 129, 130], ["Fig", "TEST", 140, 143], ["decrease", "TEST", 152, 160], ["P", "TEST", 191, 192], ["Fig", "TEST", 202, 205], ["significant", "OBSERVATION_MODIFIER", 72, 83], ["increase", "OBSERVATION_MODIFIER", 84, 92]]], ["Upon miR22-5p mimic transfection, we observed significant decreases in the TET2 mRNA (1.03 \u00b1 0.12 vs. 0.51 \u00b1 0.24, P < 0.001, Fig 2B) and protein (1.05 \u00b1 0.20 vs. 0.12 \u00b1 0.04, P = 0.001, Fig 2C and 2E) levels.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 5, 13], ["TET2", "GENE_OR_GENE_PRODUCT", 75, 79], ["miR22", "PROTEIN", 5, 10], ["TET2 mRNA", "RNA", 75, 84], ["significant decreases in the TET2 mRNA", "PROBLEM", 46, 84], ["P", "TEST", 115, 116], ["Fig", "TEST", 126, 129], ["protein", "TEST", 138, 145], ["P", "TEST", 176, 177], ["Fig", "TEST", 187, 190], ["levels", "TEST", 202, 208], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["decreases", "OBSERVATION_MODIFIER", 58, 67]]], ["Accordingly, following transfection with miR22-5p inhibitor, we observed significant increases in the TET2 mRNA (1.07 \u00b1 0.17 vs. 1.52 \u00b1 0.28, P < 0.001, Fig 2B) and protein (1.53 \u00b1 0.14. vs. 1.02 \u00b1 0.19, P = 0.02, Fig 2D and 2E) levels.MiR22-5p regulates TET2 expression in primary ESCs ::: ResultsNext, we investigated 5-hmC expression in genomic DNA of ESCs following transfection with miR22-5p mimics and inhibitor by dot blot assays (Fig 2F).", [["ESCs", "ANATOMY", 282, 286], ["ESCs", "ANATOMY", 355, 359], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 41, 49], ["TET2", "GENE_OR_GENE_PRODUCT", 102, 106], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 236, 244], ["TET2", "GENE_OR_GENE_PRODUCT", 255, 259], ["ESCs", "CELL", 282, 286], ["hmC", "GENE_OR_GENE_PRODUCT", 322, 325], ["DNA", "CELLULAR_COMPONENT", 348, 351], ["ESCs", "CELL", 355, 359], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 388, 396], ["miR22", "PROTEIN", 41, 46], ["TET2 mRNA", "RNA", 102, 111], ["MiR22-5p", "DNA", 236, 244], ["TET2", "DNA", 255, 259], ["primary ESCs", "CELL_TYPE", 274, 286], ["hmC", "DNA", 322, 325], ["genomic DNA", "DNA", 340, 351], ["ESCs", "CELL_TYPE", 355, 359], ["miR22", "PROTEIN", 388, 393], ["miR22-5p inhibitor", "TREATMENT", 41, 59], ["significant increases in the TET2 mRNA", "PROBLEM", 73, 111], ["P", "TEST", 142, 143], ["Fig", "TEST", 153, 156], ["protein", "TEST", 165, 172], ["P", "TEST", 204, 205], ["Fig 2D and 2E) levels", "TEST", 214, 235], ["MiR22", "TEST", 236, 241], ["miR22-5p mimics", "TREATMENT", 388, 403], ["inhibitor", "TREATMENT", 408, 417], ["significant", "OBSERVATION_MODIFIER", 73, 84], ["increases", "OBSERVATION_MODIFIER", 85, 94]]], ["Treatment with the miR22-5p mimics and inhibitor decreased and increased global 5-hmC, respectively.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 19, 27], ["miR22-5p mimics", "DNA", 19, 34], ["the miR22-5p mimics", "TREATMENT", 15, 34], ["inhibitor", "TREATMENT", 39, 48]]], ["Consistent with the western blotting and DNA methylation dot blot assay results, immunofluorescence revealed that the expression of TET2 and 5-hmC was decreased in miR22-5p mimics-treated cells, whereas they were overexpressed in miR22-5p inhibitor-treated cells (Fig 3).MiR22-5p directly targets the TET2 3\u2032-UTR ::: ResultsWe used a luciferase reporter assay to determine whether TET2 regulation was mediated by direct binding of miR22-5p to its 3\u2032-UTR (Fig 4A).", [["miR22-5p", "ANATOMY", 164, 172], ["cells", "ANATOMY", 188, 193], ["cells", "ANATOMY", 257, 262], ["DNA", "CELLULAR_COMPONENT", 41, 44], ["TET2", "GENE_OR_GENE_PRODUCT", 132, 136], ["5-hmC", "GENE_OR_GENE_PRODUCT", 141, 146], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 164, 172], ["cells", "CELL", 188, 193], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 230, 238], ["cells", "CELL", 257, 262], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 271, 279], ["TET2 3", "GENE_OR_GENE_PRODUCT", 301, 307], ["luciferase", "GENE_OR_GENE_PRODUCT", 334, 344], ["TET2", "GENE_OR_GENE_PRODUCT", 381, 385], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 431, 439], ["TET2", "PROTEIN", 132, 136], ["5-hmC", "DNA", 141, 146], ["miR22", "PROTEIN", 164, 169], ["miR22", "PROTEIN", 230, 235], ["treated cells", "CELL_LINE", 249, 262], ["MiR22-5p", "DNA", 271, 279], ["TET2 3\u2032-UTR", "DNA", 301, 312], ["TET2", "PROTEIN", 381, 385], ["miR22", "PROTEIN", 431, 436], ["3\u2032-UTR", "DNA", 447, 453], ["the western blotting", "TEST", 16, 36], ["DNA methylation dot blot assay", "TEST", 41, 71], ["immunofluorescence", "TEST", 81, 99], ["TET2", "TEST", 132, 136], ["miR22-5p inhibitor", "TREATMENT", 230, 248], ["a luciferase reporter assay", "TEST", 332, 359], ["TET2 regulation", "PROBLEM", 381, 396], ["decreased", "OBSERVATION_MODIFIER", 151, 160]]], ["293T cells cotransfected with a reporter plasmid and miR22-5p mimics showed significantly decreased luciferase activity as compared to cells transfected with the reporter plasmid alone only for the TET2 3\u2032-UTR WT1 construct, among the three wild-type constructs evaluated (Fig 4B).", [["293T cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 135, 140], ["plasmid", "ANATOMY", 171, 178], ["293T cells", "CELL", 0, 10], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 53, 61], ["luciferase", "GENE_OR_GENE_PRODUCT", 100, 110], ["cells", "CELL", 135, 140], ["WT1", "GENE_OR_GENE_PRODUCT", 210, 213], ["293T cells", "CELL_LINE", 0, 10], ["reporter plasmid", "DNA", 32, 48], ["miR22", "DNA", 53, 58], ["luciferase", "PROTEIN", 100, 110], ["reporter plasmid", "DNA", 162, 178], ["TET2 3\u2032-UTR WT1 construct", "DNA", 198, 223], ["wild-type constructs", "DNA", 241, 261], ["a reporter plasmid", "TEST", 30, 48], ["miR22-5p mimics", "TEST", 53, 68], ["significantly decreased luciferase activity", "PROBLEM", 76, 119], ["the reporter plasmid", "TREATMENT", 158, 178], ["the TET2", "TEST", 194, 202], ["UTR WT1 construct", "TEST", 206, 223], ["decreased", "OBSERVATION_MODIFIER", 90, 99], ["luciferase activity", "OBSERVATION", 100, 119]]], ["Direct interaction of miR22-5p with TET2 was confirmed by using a luciferase reporter harboring a point mutation (Fig 4C).MiR22-5p affects ESR2 mRNA and protein expression ::: ResultsTo investigate the impact of miR22-5p on ESR2 expression, we assessed primary ESCs following transfection with miR22-5p mimics or its inhibitor.", [["ESCs", "ANATOMY", 261, 265], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 22, 30], ["TET2", "GENE_OR_GENE_PRODUCT", 36, 40], ["luciferase", "GENE_OR_GENE_PRODUCT", 66, 76], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 122, 130], ["ESR2", "GENE_OR_GENE_PRODUCT", 139, 143], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 212, 220], ["ESR2", "GENE_OR_GENE_PRODUCT", 224, 228], ["ESCs", "CELL", 261, 265], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 294, 302], ["miR22-5p", "DNA", 22, 30], ["TET2", "DNA", 36, 40], ["luciferase reporter", "DNA", 66, 85], ["MiR22", "PROTEIN", 122, 127], ["ESR2 mRNA", "RNA", 139, 148], ["miR22-5p", "DNA", 212, 220], ["ESR2", "DNA", 224, 228], ["primary ESCs", "CELL_TYPE", 253, 265], ["miR22", "PROTEIN", 294, 299], ["TET2", "TREATMENT", 36, 40], ["a luciferase reporter", "TREATMENT", 64, 85], ["ESR2 expression", "TREATMENT", 224, 239], ["miR22-5p mimics", "TREATMENT", 294, 309], ["its inhibitor", "TREATMENT", 313, 326]]], ["ESR2 mRNA expression was significantly downregulated after transfection with miR22-5p mimics (1.11 \u00b1 0.30 vs. 0.42 \u00b1 0.35, P < 0.001, Fig 5A), and significantly upregulated after treatment with the inhibitor (0.84 \u00b1 0.20 vs. 1.83 \u00b1 0.41, P < 0.001, Fig 5A).", [["ESR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 77, 85], ["ESR2 mRNA", "RNA", 0, 9], ["miR22", "PROTEIN", 77, 82], ["ESR2 mRNA expression", "PROBLEM", 0, 20], ["transfection", "TEST", 59, 71], ["miR22", "TEST", 77, 82], ["P", "TEST", 123, 124], ["the inhibitor", "TREATMENT", 194, 207], ["P", "TEST", 238, 239]]], ["There was no difference in ESR1 expression following either treatment.", [["ESR1", "GENE_OR_GENE_PRODUCT", 27, 31], ["ESR1", "PROTEIN", 27, 31], ["difference in ESR1 expression", "PROBLEM", 13, 42], ["treatment", "TREATMENT", 60, 69], ["no", "UNCERTAINTY", 10, 12], ["difference", "OBSERVATION_MODIFIER", 13, 23], ["ESR1 expression", "OBSERVATION", 27, 42]]], ["Accordingly, the ESR1/ESR2 mRNA ratio was significantly increased after transfection of miRNA22-5p mimics (1.07 \u00b1 0.33 vs. 6.18 \u00b1 0.33, P = 0.019, Fig 5A) or inhibitor (1.142 \u00b1 0.48 vs. 0.68 \u00b1 0.29, P < 0.001, Fig 5A).", [["ESR1", "GENE_OR_GENE_PRODUCT", 17, 21], ["ESR2", "GENE_OR_GENE_PRODUCT", 22, 26], ["miRNA22-5p", "GENE_OR_GENE_PRODUCT", 88, 98], ["ESR1/ESR2 mRNA", "RNA", 17, 31], ["miRNA22", "PROTEIN", 88, 95], ["the ESR1/ESR2 mRNA ratio", "TEST", 13, 37], ["miRNA22", "TEST", 88, 95], ["mimics", "TEST", 99, 105], ["P", "TEST", 136, 137], ["Fig 5A", "TEST", 147, 153], ["inhibitor", "TEST", 158, 167], ["P", "TEST", 199, 200]]], ["ESR2 protein expression was significantly decreased in cells treated with miRNA22-5p mimics (0.87 \u00b1 0.11 vs. 0.43 \u00b1 0.15, P < 0.001, Fig 5B) and increased in cells treated with inhibitor (0.82 \u00b1 0.31 vs. 1.47 \u00b1 0.21, P < 0.001, Fig 5B), as demonstrated by western blot analysis.MiR22-5p affects the DNA methylation status of the ESR2 promoter region expression in primary endometrial cells ::: ResultsTo investigate the role of miR22-5p in DNA methylation further, we assessed the transfected ESCs by bisulfite sequencing.", [["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 158, 163], ["primary endometrial cells", "ANATOMY", 364, 389], ["ESCs", "ANATOMY", 493, 497], ["bisulfite", "CHEMICAL", 501, 510], ["bisulfite", "CHEMICAL", 501, 510], ["ESR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 55, 60], ["miRNA22-5p", "GENE_OR_GENE_PRODUCT", 74, 84], ["cells", "CELL", 158, 163], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 278, 286], ["DNA", "CELLULAR_COMPONENT", 299, 302], ["ESR2", "GENE_OR_GENE_PRODUCT", 329, 333], ["endometrial cells", "CELL", 372, 389], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 428, 436], ["DNA", "CELLULAR_COMPONENT", 440, 443], ["ESCs", "CELL", 493, 497], ["bisulfite", "SIMPLE_CHEMICAL", 501, 510], ["ESR2", "PROTEIN", 0, 4], ["miRNA22", "PROTEIN", 74, 81], ["MiR22-5p", "DNA", 278, 286], ["ESR2 promoter region", "DNA", 329, 349], ["primary endometrial cells", "CELL_TYPE", 364, 389], ["miR22-5p", "DNA", 428, 436], ["ESCs", "CELL_TYPE", 493, 497], ["ESR2 protein expression", "TEST", 0, 23], ["miRNA22", "TEST", 74, 81], ["mimics", "TEST", 85, 91], ["P", "TEST", 122, 123], ["Fig 5B", "TEST", 133, 139], ["increased in cells", "PROBLEM", 145, 163], ["inhibitor", "TREATMENT", 177, 186], ["P", "TEST", 217, 218], ["Fig 5B", "TEST", 228, 234], ["blot analysis", "TEST", 264, 277], ["the DNA methylation status of the ESR2 promoter", "TREATMENT", 295, 342], ["significantly", "OBSERVATION_MODIFIER", 28, 41], ["decreased", "OBSERVATION_MODIFIER", 42, 51], ["increased", "OBSERVATION_MODIFIER", 145, 154], ["primary endometrial cells", "OBSERVATION", 364, 389]]], ["We identified and approximately 550-bp classic CpG island (\u2013197/+359) within the ESR2 promoter and the downstream untranslated exon 0N region.", [["CpG", "CHEMICAL", 47, 50], ["ESR2", "GENE_OR_GENE_PRODUCT", 81, 85], ["550-bp classic CpG island", "DNA", 32, 57], ["ESR2 promoter", "DNA", 81, 94], ["downstream untranslated exon 0N region", "DNA", 103, 141], ["bp classic CpG island", "PROBLEM", 36, 57], ["the ESR2 promoter", "TREATMENT", 77, 94]]], ["The CpG methylation status after treatments is shown in Fig 6A.", [["CpG", "CHEMICAL", 4, 7], ["The CpG methylation status after treatments", "TREATMENT", 0, 43]]], ["The methylation status within this region after transfected with miRNA 22-5p inhibitor or controls was very low and it was not statistically significant (Fig 6B).DiscussionEndometriosis is an estrogen-dependent chronic inflammatory disease that contributes to cyclical chronic pain and infertility in reproductive women.", [["Endometriosis", "DISEASE", 172, 185], ["estrogen", "CHEMICAL", 192, 200], ["chronic pain", "DISEASE", 269, 281], ["infertility", "DISEASE", 286, 297], ["estrogen", "CHEMICAL", 192, 200], ["miRNA 22-5p", "GENE_OR_GENE_PRODUCT", 65, 76], ["estrogen", "SIMPLE_CHEMICAL", 192, 200], ["women", "ORGANISM", 314, 319], ["miRNA 22-5p inhibitor", "DNA", 65, 86], ["women", "SPECIES", 314, 319], ["miRNA 22-5p inhibitor", "TREATMENT", 65, 86], ["Endometriosis", "PROBLEM", 172, 185], ["an estrogen-dependent chronic inflammatory disease", "PROBLEM", 189, 239], ["cyclical chronic pain", "PROBLEM", 260, 281], ["infertility in reproductive women", "PROBLEM", 286, 319], ["estrogen", "OBSERVATION_MODIFIER", 192, 200], ["dependent", "OBSERVATION_MODIFIER", 201, 210], ["chronic", "OBSERVATION_MODIFIER", 211, 218], ["inflammatory disease", "OBSERVATION", 219, 239], ["cyclical", "OBSERVATION_MODIFIER", 260, 268], ["chronic", "OBSERVATION_MODIFIER", 269, 276], ["pain", "OBSERVATION", 277, 281], ["infertility", "OBSERVATION", 286, 297]]], ["Recent research has focused on microRNAs because of their roles in regulating epigenetic changes involved in the pathophysiology of infertility due to endometriosis.", [["endometriosis", "ANATOMY", 151, 164], ["infertility", "DISEASE", 132, 143], ["endometriosis", "DISEASE", 151, 164], ["endometriosis", "PATHOLOGICAL_FORMATION", 151, 164], ["infertility", "PROBLEM", 132, 143], ["endometriosis", "PROBLEM", 151, 164], ["endometriosis", "OBSERVATION", 151, 164]]], ["Previously, utilizing microRNA array analysis, we identified miR22-5p as one of 12 downregulated miRNAs in eutopic mid-luteal endometrium of minimal/mild endometriosis [15].", [["eutopic mid-luteal endometrium", "ANATOMY", 107, 137], ["endometriosis", "ANATOMY", 154, 167], ["endometriosis", "DISEASE", 154, 167], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 61, 69], ["mid-luteal endometrium", "TISSUE", 115, 137], ["miR22-5p", "DNA", 61, 69], ["microRNA array analysis", "TEST", 22, 45], ["minimal/mild endometriosis", "PROBLEM", 141, 167], ["mid-luteal endometrium", "ANATOMY", 115, 137], ["minimal", "OBSERVATION_MODIFIER", 141, 148], ["mild", "OBSERVATION_MODIFIER", 149, 153], ["endometriosis", "OBSERVATION", 154, 167]]], ["In the present study, we validated that miR22-5p expression was decreased in eutopic endometrium of minimal/mild endometrium during the mid-luteal phase.", [["eutopic endometrium", "ANATOMY", 77, 96], ["endometrium", "ANATOMY", 113, 124], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 40, 48], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 77, 96], ["endometrium", "MULTI-TISSUE_STRUCTURE", 113, 124], ["miR22", "PROTEIN", 40, 45], ["5p", "DNA", 46, 48], ["the present study", "TEST", 3, 20], ["minimal/mild endometrium during the mid-luteal phase", "PROBLEM", 100, 152], ["decreased", "OBSERVATION_MODIFIER", 64, 73], ["eutopic endometrium", "OBSERVATION", 77, 96], ["minimal", "OBSERVATION_MODIFIER", 100, 107], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["endometrium", "OBSERVATION", 113, 124]]], ["Utilizing a primary ESC model, we found that miR22-5p expression was inversely related to TET2 and 5-hmC expression.", [["ESC", "ANATOMY", 20, 23], ["ESC", "CELL", 20, 23], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 45, 53], ["TET2", "GENE_OR_GENE_PRODUCT", 90, 94], ["5-hmC", "GENE_OR_GENE_PRODUCT", 99, 104], ["primary ESC model", "CELL_LINE", 12, 29], ["miR22", "PROTEIN", 45, 50], ["TET2", "PROTEIN", 90, 94], ["hmC", "DNA", 101, 104], ["TET2", "TEST", 90, 94]]], ["MiR22-5p regulated ESR2 expression, but did not directly affect ESR2 promoter methylation.", [["MiR22-5p", "GENE_OR_GENE_PRODUCT", 0, 8], ["ESR2", "GENE_OR_GENE_PRODUCT", 19, 23], ["ESR2", "GENE_OR_GENE_PRODUCT", 64, 68], ["MiR22", "PROTEIN", 0, 5], ["ESR2", "DNA", 19, 23], ["ESR2 promoter", "DNA", 64, 77]]], ["These results support the hypothesis that miRNAs, and in casu, miR22-5p, contributes to the pathophysiology of endometriosis and may be a useful therapeutic target.DiscussionWomen with minimal/mild endometriosis are significantly less likely to achieve pregnancy than those with tubal factor infertility [20].", [["endometriosis", "ANATOMY", 111, 124], ["endometriosis", "ANATOMY", 198, 211], ["endometriosis", "DISEASE", 111, 124], ["endometriosis", "DISEASE", 198, 211], ["tubal factor infertility", "DISEASE", 279, 303], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 63, 71], ["endometriosis", "CANCER", 111, 124], ["casu, miR22-5p", "DNA", 57, 71], ["endometriosis", "PROBLEM", 111, 124], ["minimal/mild endometriosis", "PROBLEM", 185, 211], ["tubal factor infertility", "PROBLEM", 279, 303], ["endometriosis", "OBSERVATION", 111, 124], ["minimal", "OBSERVATION_MODIFIER", 185, 192], ["mild", "OBSERVATION_MODIFIER", 193, 197], ["endometriosis", "OBSERVATION", 198, 211]]], ["Endometriosis likely is the most common cause of endometrial receptivity defects, especially in cases of minimal/mild endometriosis, in which the loss of fertility cannot be explained by mechanical reasons [21].", [["endometrial", "ANATOMY", 49, 60], ["endometriosis", "ANATOMY", 118, 131], ["Endometriosis", "DISEASE", 0, 13], ["endometrial receptivity defects", "DISEASE", 49, 80], ["endometriosis", "DISEASE", 118, 131], ["loss of fertility", "DISEASE", 146, 163], ["endometrial", "ORGAN", 49, 60], ["endometriosis", "PATHOLOGICAL_FORMATION", 118, 131], ["Endometriosis", "PROBLEM", 0, 13], ["endometrial receptivity defects", "PROBLEM", 49, 80], ["minimal/mild endometriosis", "PROBLEM", 105, 131], ["most common", "OBSERVATION_MODIFIER", 28, 39], ["endometrial receptivity defects", "OBSERVATION", 49, 80], ["minimal", "OBSERVATION_MODIFIER", 105, 112], ["mild", "OBSERVATION_MODIFIER", 113, 117], ["endometriosis", "OBSERVATION", 118, 131]]], ["How the endometrium in women with minimal/mild endometriosis is resistant to embryo implantation remains unknown.", [["endometrium", "ANATOMY", 8, 19], ["endometriosis", "ANATOMY", 47, 60], ["embryo", "ANATOMY", 77, 83], ["endometriosis", "DISEASE", 47, 60], ["endometrium", "MULTI-TISSUE_STRUCTURE", 8, 19], ["women", "ORGANISM", 23, 28], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 77, 83], ["women", "SPECIES", 23, 28], ["minimal/mild endometriosis", "PROBLEM", 34, 60], ["embryo implantation", "TREATMENT", 77, 96], ["endometrium", "ANATOMY", 8, 19], ["minimal", "OBSERVATION_MODIFIER", 34, 41], ["mild", "OBSERVATION_MODIFIER", 42, 46], ["endometriosis", "OBSERVATION", 47, 60], ["resistant", "OBSERVATION_MODIFIER", 64, 73], ["embryo implantation", "OBSERVATION", 77, 96]]], ["Maciejak et al. reported upregulation of miR22-5p in the plasma and serum following acute myocardial infarction as a novel diagnostic biomarker [22].", [["plasma", "ANATOMY", 57, 63], ["serum", "ANATOMY", 68, 73], ["myocardial", "ANATOMY", 90, 100], ["acute myocardial infarction", "DISEASE", 84, 111], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 41, 49], ["plasma", "ORGANISM_SUBSTANCE", 57, 63], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["myocardial", "MULTI-TISSUE_STRUCTURE", 90, 100], ["miR22-5p", "DNA", 41, 49], ["the plasma", "TEST", 53, 63], ["acute myocardial infarction", "PROBLEM", 84, 111], ["acute", "OBSERVATION_MODIFIER", 84, 89], ["myocardial", "ANATOMY", 90, 100], ["infarction", "OBSERVATION", 101, 111]]], ["A direct relationship between miR22-5p and TET2 expression has been demonstrated in K562 cells, and in AML cells, low TET2 expression is related to proliferation [23].", [["K562 cells", "ANATOMY", 84, 94], ["AML cells", "ANATOMY", 103, 112], ["AML", "DISEASE", 103, 106], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 30, 38], ["TET2", "GENE_OR_GENE_PRODUCT", 43, 47], ["K562 cells", "CELL", 84, 94], ["AML cells", "CELL", 103, 112], ["TET2", "GENE_OR_GENE_PRODUCT", 118, 122], ["miR22-5p", "DNA", 30, 38], ["TET2", "DNA", 43, 47], ["K562 cells", "CELL_LINE", 84, 94], ["AML cells", "CELL_TYPE", 103, 112], ["TET2", "PROTEIN", 118, 122], ["K562 cells", "TEST", 84, 94], ["AML cells", "PROBLEM", 103, 112], ["low TET2 expression", "PROBLEM", 114, 133], ["K562 cells", "OBSERVATION", 84, 94], ["AML cells", "OBSERVATION", 103, 112], ["low TET2", "OBSERVATION", 114, 122]]], ["However, it has been widely reported that miR-22 negatively regulates TET2 expression and that its overexpression closely phenocopies many of the characteristics observed upon TET2 inactivation both in vitro and in vivo [24].", [["miR-22", "GENE_OR_GENE_PRODUCT", 42, 48], ["TET2", "GENE_OR_GENE_PRODUCT", 70, 74], ["TET2", "GENE_OR_GENE_PRODUCT", 176, 180], ["miR-22", "DNA", 42, 48], ["TET2", "DNA", 70, 74], ["TET2", "PROTEIN", 176, 180], ["TET2 expression", "PROBLEM", 70, 85], ["its overexpression closely phenocopies", "PROBLEM", 95, 133], ["TET2 inactivation", "PROBLEM", 176, 193]]], ["MiR-22 contributes to the inactivation of TET2 and other TET family members in tumorigenesis, and represents a tumorigenic pathway in addition to the more familiar TET family mutations and deletions [24, 25].", [["MiR-22", "CHEMICAL", 0, 6], ["TET", "CHEMICAL", 164, 167], ["MiR-22", "GENE_OR_GENE_PRODUCT", 0, 6], ["TET2", "GENE_OR_GENE_PRODUCT", 42, 46], ["TET", "GENE_OR_GENE_PRODUCT", 57, 60], ["TET", "CANCER", 164, 167], ["MiR-22", "PROTEIN", 0, 6], ["TET2", "PROTEIN", 42, 46], ["TET family members", "PROTEIN", 57, 75], ["the inactivation of TET2", "PROBLEM", 22, 46]]], ["These studies indicated that the regulatory relationships between TET2 and miR-22 or miR22-5p are worth investigating in other tissues.", [["tissues", "ANATOMY", 127, 134], ["TET2", "GENE_OR_GENE_PRODUCT", 66, 70], ["miR-22", "GENE_OR_GENE_PRODUCT", 75, 81], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 85, 93], ["tissues", "TISSUE", 127, 134], ["TET2", "DNA", 66, 70], ["miR-22", "DNA", 75, 81], ["miR22", "DNA", 85, 90], ["5p", "DNA", 91, 93], ["These studies", "TEST", 0, 13], ["TET2", "TEST", 66, 70]]], ["Based on a comprehensive analysis of minimal/mild endometriosis patients, we found that TET2 is upregulated in the endometrium during implantation window, and is directly affected by the miR22-5p level.DiscussionA subset of DNA hypomethylated canyons is maintained by the cooperative action of TET proteins, in particular, TET1 and TET2 [26].", [["endometrium", "ANATOMY", 115, 126], ["endometriosis", "DISEASE", 50, 63], ["TET", "CHEMICAL", 294, 297], ["patients", "ORGANISM", 64, 72], ["TET2", "GENE_OR_GENE_PRODUCT", 88, 92], ["endometrium", "MULTI-TISSUE_STRUCTURE", 115, 126], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 187, 195], ["DNA", "CELLULAR_COMPONENT", 224, 227], ["TET proteins", "GENE_OR_GENE_PRODUCT", 294, 306], ["TET1", "GENE_OR_GENE_PRODUCT", 323, 327], ["TET2", "GENE_OR_GENE_PRODUCT", 332, 336], ["TET2", "PROTEIN", 88, 92], ["miR22", "PROTEIN", 187, 192], ["TET proteins", "PROTEIN", 294, 306], ["TET1", "PROTEIN", 323, 327], ["TET2", "PROTEIN", 332, 336], ["patients", "SPECIES", 64, 72], ["a comprehensive analysis", "TEST", 9, 33], ["minimal/mild endometriosis", "PROBLEM", 37, 63], ["TET2", "PROBLEM", 88, 92], ["DNA hypomethylated canyons", "TREATMENT", 224, 250], ["TET proteins", "TREATMENT", 294, 306], ["minimal", "OBSERVATION_MODIFIER", 37, 44], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["endometriosis", "OBSERVATION", 50, 63], ["TET2", "OBSERVATION", 88, 92], ["upregulated", "OBSERVATION_MODIFIER", 96, 107], ["endometrium", "ANATOMY", 115, 126], ["implantation", "OBSERVATION", 134, 146]]], ["Aberrant expression of epigenetic alterations in endometriosis include genomic DNA methylation of the gene encoding progesterone receptor-\u03b2 [27], HOXA10 [28], ESR2 [13], which are candidate genes responsible for the development of progesterone resistance and implantation failure.", [["endometriosis", "ANATOMY", 49, 62], ["endometriosis", "DISEASE", 49, 62], ["progesterone", "CHEMICAL", 116, 128], ["progesterone", "CHEMICAL", 231, 243], ["implantation failure", "DISEASE", 259, 279], ["progesterone", "CHEMICAL", 116, 128], ["progesterone", "CHEMICAL", 231, 243], ["endometriosis", "CANCER", 49, 62], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["progesterone receptor-\u03b2 [27]", "GENE_OR_GENE_PRODUCT", 116, 144], ["HOXA10", "GENE_OR_GENE_PRODUCT", 146, 152], ["28", "GENE_OR_GENE_PRODUCT", 154, 156], ["ESR2 [13", "GENE_OR_GENE_PRODUCT", 159, 167], ["progesterone", "SIMPLE_CHEMICAL", 231, 243], ["progesterone receptor", "PROTEIN", 116, 137], ["HOXA10", "PROTEIN", 146, 152], ["epigenetic alterations", "PROBLEM", 23, 45], ["endometriosis", "PROBLEM", 49, 62], ["genomic DNA methylation of the gene encoding progesterone receptor", "TREATMENT", 71, 137], ["HOXA10", "TEST", 146, 152], ["ESR2", "TEST", 159, 163], ["progesterone resistance", "PROBLEM", 231, 254], ["implantation failure", "PROBLEM", 259, 279], ["epigenetic alterations", "OBSERVATION", 23, 45], ["endometriosis", "OBSERVATION", 49, 62], ["progesterone resistance", "OBSERVATION", 231, 254], ["implantation failure", "OBSERVATION", 259, 279]]], ["The ESR2 mRNA level was significantly increased in endometriotic ESCs when compared to normal ESCs.", [["endometriotic ESCs", "ANATOMY", 51, 69], ["ESCs", "ANATOMY", 94, 98], ["ESR2", "GENE_OR_GENE_PRODUCT", 4, 8], ["endometriotic ESCs", "CELL", 51, 69], ["ESCs", "CELL", 94, 98], ["ESR2 mRNA", "RNA", 4, 13], ["endometriotic ESCs", "CELL_TYPE", 51, 69], ["normal ESCs", "CELL_TYPE", 87, 98], ["The ESR2 mRNA level", "TEST", 0, 19], ["endometriotic ESCs", "PROBLEM", 51, 69], ["significantly", "OBSERVATION_MODIFIER", 24, 37], ["increased", "OBSERVATION_MODIFIER", 38, 47], ["endometriotic ESCs", "OBSERVATION", 51, 69]]], ["A hypomethylated (\u2013197/+359) promoter region of ESR2 in endometriotic cells was previously considered the primary mechanism responsible for the differential ESR2 expression in endometriotic and normal endometrium [13].", [["endometriotic cells", "ANATOMY", 56, 75], ["endometriotic", "ANATOMY", 176, 189], ["endometrium", "ANATOMY", 201, 212], ["ESR2", "GENE_OR_GENE_PRODUCT", 48, 52], ["endometriotic cells", "CELL", 56, 75], ["ESR2", "GENE_OR_GENE_PRODUCT", 157, 161], ["endometriotic", "CANCER", 176, 189], ["endometrium", "MULTI-TISSUE_STRUCTURE", 201, 212], ["hypomethylated (\u2013197/+359) promoter region", "DNA", 2, 44], ["ESR2", "DNA", 48, 52], ["endometriotic cells", "CELL_TYPE", 56, 75], ["ESR2", "DNA", 157, 161], ["A hypomethylated (\u2013197/+359) promoter region", "TREATMENT", 0, 44], ["ESR2 in endometriotic cells", "PROBLEM", 48, 75], ["hypomethylated", "OBSERVATION", 2, 16], ["endometriotic cells", "OBSERVATION", 56, 75], ["endometriotic", "OBSERVATION", 176, 189], ["normal endometrium", "OBSERVATION", 194, 212]]], ["We investigated whether increased TET2 expression due to decreased miR22-5p expression affected ESR2 expression, and we found that ESCs transfected with miR22-5p mimics demonstrated significantly attenuated ESR2 expression.", [["ESCs", "ANATOMY", 131, 135], ["TET2", "GENE_OR_GENE_PRODUCT", 34, 38], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 67, 75], ["ESR2", "GENE_OR_GENE_PRODUCT", 96, 100], ["ESCs", "CELL", 131, 135], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 153, 161], ["ESR2", "GENE_OR_GENE_PRODUCT", 207, 211], ["TET2", "PROTEIN", 34, 38], ["miR22", "PROTEIN", 67, 72], ["5p", "DNA", 73, 75], ["ESR2", "DNA", 96, 100], ["ESCs", "CELL_TYPE", 131, 135], ["miR22", "PROTEIN", 153, 158], ["ESR2", "DNA", 207, 211], ["increased TET2 expression", "PROBLEM", 24, 49], ["decreased miR22", "PROBLEM", 57, 72], ["miR22", "TEST", 153, 158], ["significantly attenuated ESR2 expression", "PROBLEM", 182, 222], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["TET2 expression", "OBSERVATION", 34, 49]]], ["Bioinformatics and genetic analyses revealed no potential miR22-5p target sites in the 3\u2032-UTR of the ESR2 mRNA sequence.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 58, 66], ["ESR2", "GENE_OR_GENE_PRODUCT", 101, 105], ["miR22-5p target sites", "DNA", 58, 79], ["3\u2032-UTR", "DNA", 87, 93], ["ESR2 mRNA sequence", "RNA", 101, 119], ["genetic analyses", "TEST", 19, 35], ["no", "UNCERTAINTY", 45, 47]]], ["Indeed, it is speculated that miR22-5p may regulate ESR2 promoter methylation by directly targeting TET2.", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 30, 38], ["ESR2", "GENE_OR_GENE_PRODUCT", 52, 56], ["TET2", "GENE_OR_GENE_PRODUCT", 100, 104], ["miR22-5p", "DNA", 30, 38], ["ESR2 promoter", "DNA", 52, 65], ["TET2", "PROTEIN", 100, 104], ["ESR2 promoter methylation", "TREATMENT", 52, 77]]], ["Bisulfite sequencing of this promoter region (\u2013197/+359) showed that there was no significant difference in the methylation status after transfection with miR22-5p inhibitor.", [["Bisulfite", "CHEMICAL", 0, 9], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 155, 163], ["promoter region", "DNA", 29, 44], ["\u2013197/+359", "DNA", 46, 55], ["miR22", "PROTEIN", 155, 160], ["Bisulfite sequencing", "TEST", 0, 20], ["miR22-5p inhibitor", "TREATMENT", 155, 173], ["no", "UNCERTAINTY", 79, 81], ["significant", "OBSERVATION_MODIFIER", 82, 93], ["difference", "OBSERVATION", 94, 104]]], ["Methylation tended to be lower in miR22-5p inhibitor-transfected cells than in control cells, but the promoter was extremely hypomethylated in both cases, which was inconsistent with a previous study [13].", [["cells", "ANATOMY", 65, 70], ["cells", "ANATOMY", 87, 92], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 34, 42], ["cells", "CELL", 65, 70], ["cells", "CELL", 87, 92], ["miR22", "PROTEIN", 34, 39], ["transfected cells", "CELL_LINE", 53, 70], ["control cells", "CELL_TYPE", 79, 92], ["Methylation", "TEST", 0, 11], ["transfected cells", "PROBLEM", 53, 70], ["a previous study", "TEST", 183, 199]]], ["In Xue\u2019s study, eutopic endometrium was not compared between subjects with endometriosis and disease-free subjects, and the menstrual cycles of the study subjects were unknown [13], whereas we utilized mid-luteal endometrium of infertile women with minimal/mild endometriosis in the embryo implantation phase.DiscussionDNA methylation profiles of human endometrium differ in different phases of the cycle [29, 30], which could explain the opposing findings in our and other studies.", [["eutopic endometrium", "ANATOMY", 16, 35], ["endometriosis", "ANATOMY", 75, 88], ["mid-luteal endometrium", "ANATOMY", 202, 224], ["endometriosis", "ANATOMY", 262, 275], ["embryo", "ANATOMY", 283, 289], ["endometrium", "ANATOMY", 353, 364], ["endometriosis", "DISEASE", 75, 88], ["endometriosis", "DISEASE", 262, 275], ["eutopic endometrium", "CANCER", 16, 35], ["mid-luteal endometrium", "MULTI-TISSUE_STRUCTURE", 202, 224], ["women", "ORGANISM", 238, 243], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 283, 289], ["human", "ORGANISM", 347, 352], ["endometrium", "MULTI-TISSUE_STRUCTURE", 353, 364], ["women", "SPECIES", 238, 243], ["human", "SPECIES", 347, 352], ["human", "SPECIES", 347, 352], ["endometriosis", "PROBLEM", 75, 88], ["disease", "PROBLEM", 93, 100], ["the study", "TEST", 144, 153], ["infertile women", "PROBLEM", 228, 243], ["minimal/mild endometriosis", "PROBLEM", 249, 275], ["the embryo implantation phase", "TREATMENT", 279, 308], ["methylation profiles of human endometrium", "PROBLEM", 323, 364], ["other studies", "TEST", 468, 481], ["eutopic endometrium", "OBSERVATION", 16, 35], ["endometriosis", "OBSERVATION", 75, 88], ["free", "OBSERVATION_MODIFIER", 101, 105], ["mid-luteal endometrium", "ANATOMY", 202, 224], ["minimal", "OBSERVATION_MODIFIER", 249, 256], ["mild", "OBSERVATION_MODIFIER", 257, 261], ["endometriosis", "OBSERVATION", 262, 275], ["embryo implantation", "OBSERVATION", 283, 302], ["human endometrium", "ANATOMY", 347, 364]]], ["Overall, our findings suggested that miR22-5p directly dysregulates TET2, which modified the 5-hmC level and altered ESR2, but not ESR1 expression in ESCs.", [["ESCs", "ANATOMY", 150, 154], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 37, 45], ["TET2", "GENE_OR_GENE_PRODUCT", 68, 72], ["5-hmC", "GENE_OR_GENE_PRODUCT", 93, 98], ["ESR2", "GENE_OR_GENE_PRODUCT", 117, 121], ["ESR1", "GENE_OR_GENE_PRODUCT", 131, 135], ["ESCs", "CELL", 150, 154], ["miR22-5p", "DNA", 37, 45], ["TET2", "PROTEIN", 68, 72], ["ESR2", "PROTEIN", 117, 121], ["ESR1", "PROTEIN", 131, 135], ["ESCs", "CELL_TYPE", 150, 154], ["altered ESR2", "PROBLEM", 109, 121], ["ESR1 expression in ESCs", "PROBLEM", 131, 154]]], ["This also contributed to an increase in the ESR1/ESR2 mRNA ratio.", [["ESR1", "GENE_OR_GENE_PRODUCT", 44, 48], ["ESR2", "GENE_OR_GENE_PRODUCT", 49, 53], ["ESR2 mRNA", "RNA", 49, 58], ["an increase in the ESR1/ESR2 mRNA ratio", "PROBLEM", 25, 64], ["increase", "OBSERVATION_MODIFIER", 28, 36]]], ["ESR2 is suggested to modulate ESR1 activity; thus, a change in the relative expression levels of ESR2 to ESR1 suggests a differential regulatory response in estrogen signaling [13].", [["estrogen", "CHEMICAL", 157, 165], ["estrogen", "CHEMICAL", 157, 165], ["ESR2", "GENE_OR_GENE_PRODUCT", 0, 4], ["ESR1", "GENE_OR_GENE_PRODUCT", 30, 34], ["ESR2", "GENE_OR_GENE_PRODUCT", 97, 101], ["ESR1", "GENE_OR_GENE_PRODUCT", 105, 109], ["estrogen", "SIMPLE_CHEMICAL", 157, 165], ["ESR2", "DNA", 0, 4], ["ESR1", "PROTEIN", 30, 34], ["ESR2", "PROTEIN", 97, 101], ["ESR1", "PROTEIN", 105, 109], ["ESR2", "TEST", 0, 4], ["ESR1 activity", "PROBLEM", 30, 43], ["a differential regulatory response in estrogen signaling", "PROBLEM", 119, 175]]], ["PR expression in the secretory phase of the menstrual cycle is regulated through ESR1 [31].", [["PR", "GENE_OR_GENE_PRODUCT", 0, 2], ["ESR1", "GENE_OR_GENE_PRODUCT", 81, 85], ["PR", "PROTEIN", 0, 2], ["ESR1", "PROTEIN", 81, 85]]], ["Therefore, altered miR22-5p expression in the endometrium may lead to dysregulation of the progesterone response and consequently, implantation-related infertility in women with endometriosis.DiscussionTo our knowledge, this is the first study to demonstrate downregulation of miR22-5p in eutopic endometrium of women with endometriosis during the secretory phase.", [["endometrium", "ANATOMY", 46, 57], ["endometriosis", "ANATOMY", 178, 191], ["eutopic endometrium", "ANATOMY", 289, 308], ["endometriosis", "ANATOMY", 323, 336], ["progesterone", "CHEMICAL", 91, 103], ["infertility", "DISEASE", 152, 163], ["endometriosis", "DISEASE", 178, 191], ["endometriosis", "DISEASE", 323, 336], ["progesterone", "CHEMICAL", 91, 103], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 19, 27], ["endometrium", "MULTI-TISSUE_STRUCTURE", 46, 57], ["progesterone", "SIMPLE_CHEMICAL", 91, 103], ["women", "ORGANISM", 167, 172], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 277, 285], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 289, 308], ["women", "ORGANISM", 312, 317], ["miR22", "PROTEIN", 19, 24], ["5p", "DNA", 25, 27], ["miR22-5p", "DNA", 277, 285], ["women", "SPECIES", 167, 172], ["women", "SPECIES", 312, 317], ["altered miR22", "PROBLEM", 11, 24], ["dysregulation of the progesterone response", "PROBLEM", 70, 112], ["implantation", "TREATMENT", 131, 143], ["infertility", "PROBLEM", 152, 163], ["endometriosis", "PROBLEM", 178, 191], ["downregulation of miR22", "PROBLEM", 259, 282], ["endometriosis", "PROBLEM", 323, 336], ["5p expression", "OBSERVATION", 25, 38], ["endometrium", "ANATOMY", 46, 57], ["may lead to", "UNCERTAINTY", 58, 69], ["endometriosis", "OBSERVATION", 178, 191], ["eutopic endometrium", "ANATOMY", 289, 308], ["endometriosis", "OBSERVATION", 323, 336]]], ["Further, we showed that TET2 upregulation during implantation window in human endometrium was directly regulated by miR22-5p.", [["endometrium", "ANATOMY", 78, 89], ["TET2", "GENE_OR_GENE_PRODUCT", 24, 28], ["human", "ORGANISM", 72, 77], ["endometrium", "MULTI-TISSUE_STRUCTURE", 78, 89], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 116, 124], ["TET2", "PROTEIN", 24, 28], ["miR22-5p", "DNA", 116, 124], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["TET2 upregulation during implantation window in human endometrium", "TREATMENT", 24, 89], ["TET2 upregulation", "OBSERVATION", 24, 41], ["endometrium", "ANATOMY", 78, 89]]], ["MiR22-5p, which has not been thoroughly studied in endometriosis to date, directly dysregulated the expression of TET2, which is a key marker for DNA hydroxymethylation.DiscussionThere are some limitations of our study.", [["endometriosis", "ANATOMY", 51, 64], ["endometriosis", "DISEASE", 51, 64], ["MiR22-5p", "GENE_OR_GENE_PRODUCT", 0, 8], ["endometriosis", "CANCER", 51, 64], ["TET2", "GENE_OR_GENE_PRODUCT", 114, 118], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["MiR22-5p", "DNA", 0, 8], ["TET2", "PROTEIN", 114, 118], ["endometriosis", "PROBLEM", 51, 64], ["DNA hydroxymethylation", "TREATMENT", 146, 168], ["our study", "TEST", 209, 218], ["endometriosis", "OBSERVATION", 51, 64]]], ["The first is that we found that ESR2 was also upregulated by miR22-5p, but it was not through the regulation of promoter region methylation of ESR2; hence, the regulatory mechanisms are needed to be further studied.", [["ESR2", "GENE_OR_GENE_PRODUCT", 32, 36], ["miR22-5", "GENE_OR_GENE_PRODUCT", 61, 68], ["ESR2", "GENE_OR_GENE_PRODUCT", 143, 147], ["ESR2", "PROTEIN", 32, 36], ["miR22", "PROTEIN", 61, 66], ["promoter region", "DNA", 112, 127], ["ESR2", "DNA", 143, 147]]], ["In addition, some studies have revealed the functions of miR22-5p in other diseases [32, 33].", [["miR22-5p", "GENE_OR_GENE_PRODUCT", 57, 65], ["miR22-5p", "DNA", 57, 65], ["some studies", "TEST", 13, 25], ["other diseases", "PROBLEM", 69, 83]]], ["However, this study only focused on that miR22-5p dysregulates directly the expression of TET2 in the eutopic endometrium of endometriosis without the exploration of specific functions of miR22-5p.", [["eutopic endometrium", "ANATOMY", 102, 121], ["endometriosis", "ANATOMY", 125, 138], ["endometriosis", "DISEASE", 125, 138], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 41, 49], ["TET2", "GENE_OR_GENE_PRODUCT", 90, 94], ["eutopic endometrium", "MULTI-TISSUE_STRUCTURE", 102, 121], ["endometriosis", "CANCER", 125, 138], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 188, 196], ["miR22-5p", "DNA", 41, 49], ["TET2", "PROTEIN", 90, 94], ["miR22-5p", "DNA", 188, 196], ["this study", "TEST", 9, 19], ["endometriosis", "PROBLEM", 125, 138], ["the exploration", "TEST", 147, 162], ["TET2", "OBSERVATION", 90, 94], ["eutopic endometrium", "OBSERVATION", 102, 121], ["endometriosis", "OBSERVATION", 125, 138]]], ["The role of miR22-5p in modulating the function of the eutopic ESCs and endometrial receptivity in endometriosis also requires exploration in the following study.", [["eutopic ESCs", "ANATOMY", 55, 67], ["endometrial", "ANATOMY", 72, 83], ["endometriosis", "ANATOMY", 99, 112], ["endometriosis", "DISEASE", 99, 112], ["miR22-5p", "GENE_OR_GENE_PRODUCT", 12, 20], ["eutopic ESCs", "CELL", 55, 67], ["endometrial", "MULTI-TISSUE_STRUCTURE", 72, 83], ["miR22-5p", "DNA", 12, 20], ["eutopic ESCs", "CELL_TYPE", 55, 67], ["the eutopic ESCs", "PROBLEM", 51, 67], ["endometrial receptivity in endometriosis", "PROBLEM", 72, 112], ["exploration", "TEST", 127, 138], ["the following study", "TEST", 142, 161], ["eutopic ESCs", "OBSERVATION", 55, 67], ["endometriosis", "OBSERVATION", 99, 112]]]], "21ba984053964b86407a47c42317df5a3001a855": [["to examine how best to accelerate vaccine development in the setting of a pandemic, without compromising ethical and scientific norms.", [["a pandemic", "PROBLEM", 72, 82]]]], "84c6fb023cfde66935e2dba83991efefd45b0cc4": [["IntroductionMedical anthropology operates as a focal area within anthropology that draws on all five of the discipline's major subfields: biological, cultural, and linguistic anthropology, archeology, and applied or engaged anthropology.", [["focal area", "ANATOMY", 47, 57], ["focal", "OBSERVATION_MODIFIER", 47, 52]]], ["Medical anthropologists study health and illness as biosocial states of being in the lifeworlds of different populations, are attentive to links and flows between macro-and microenvironments, and pay close attention to the distribution (and maldistribution) of diseases and resources promoting health.", [["diseases", "PROBLEM", 261, 269], ["diseases", "OBSERVATION", 261, 269]]], ["They are invested in several lines of research, of which five are highlighted.", [["several lines", "OBSERVATION_MODIFIER", 21, 34]]], ["The first is the biocultural examination of health and illness across the life course given changing social, cultural, material, and environmental conditions that affect biological processes.", [["illness", "DISEASE", 55, 62], ["the biocultural examination", "TEST", 13, 40]]], ["The second is the study of how cultural values and social institutions, socioeconomic processes, and power relations inform regarding the way illness and risk of illness is experienced, represented, and responded to by different groups and (ethno)medical systems.", [["illness", "DISEASE", 142, 149], ["illness", "DISEASE", 162, 169], ["the study", "TEST", 14, 23], ["illness", "PROBLEM", 162, 169]]], ["The third is an examination of health care provision and exclusion, disease surveillance, and control as a means of understanding the politics of responsibility locally, nationally, and globally.", [["an examination", "TEST", 13, 27], ["health care provision", "TREATMENT", 31, 52], ["disease surveillance", "TEST", 68, 88]]], ["The fourth involves the critical assessment of interventions developed in the name of health and development, and the ways they have been implemented, monitored, and evaluated.", [["interventions", "TREATMENT", 47, 60]]], ["And the fifth line of research is attentive to the production of knowledge about health, the way health problems are framed (and by whom), and the ways in which framing problems and groups in particular ways serve as charters for thinking about and solving problems in particular ways.Relevance to Environmental HealthEnvironmental health is a central concern for medical anthropologists, who view this field broadly using several different theoretical lenses.", [["fifth", "OBSERVATION_MODIFIER", 8, 13], ["line", "OBSERVATION_MODIFIER", 14, 18], ["theoretical lenses", "OBSERVATION", 441, 459]]], ["One lens is political ecology, which focuses on political and economic factors and the way they change ecological conditions that affect relationships between humans and other species that cohabit common landscapes, environmental practices and policy, and representations of environments.", [["humans", "ORGANISM", 159, 165], ["humans", "SPECIES", 159, 165], ["humans", "SPECIES", 159, 165], ["lens", "ANATOMY", 4, 8], ["political ecology", "OBSERVATION", 12, 29]]], ["In terms of scale, medical anthropologists frequently analyze biosocial phenomena on a continuum extending from the local to the global to document how social and economic relations play out in space and time.", [["biosocial phenomena", "PROBLEM", 62, 81]]], ["Medical anthropology's approach to environmental health begins with how human beings populate and move within and between environments, considers how their presence affects and is affected by ecosocial conditions within these environments, and considers how these conditions are shaped by local, regional, and global factors that span religion and cosmology, science and technology, economics and politics.", [["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77]]], ["This perspective expands the framing of environment beyond that of a discrete physical space in which humans reside, to nested and overlapping environments that synergistically affect each other in the context of rapid globalization.", [["humans", "ORGANISM", 102, 108], ["humans", "SPECIES", 102, 108], ["humans", "SPECIES", 102, 108], ["a discrete physical space", "PROBLEM", 67, 92], ["discrete", "OBSERVATION_MODIFIER", 69, 77]]], ["Local environments are modified, manipulated, and affected by regional and global processes such as changing agricultural patterns and practices, industrial development and resource extraction, demographic trends associated with transitions from rural to urban economies, and the movement of goods, humans, and microorganisms.", [["humans", "ORGANISM", 299, 305], ["humans", "SPECIES", 299, 305], ["humans", "SPECIES", 299, 305], ["resource extraction", "TREATMENT", 173, 192]]], ["Environment is not simply where people live, but where they are positioned given local ties, individual and community identity, and emergent global ecological flows and social networks.Methods and FramingMedical anthropologists engage in ethnographic research, the hallmarks of which include the study of behavior, thought, and speech in context; participant observation; in-depth interviews with multiple stakeholders occupying different positions of power in social formations; life histories and case studies; and historical and archival analysis.", [["people", "ORGANISM", 32, 38], ["social networks", "MULTI-TISSUE_STRUCTURE", 169, 184], ["people", "SPECIES", 32, 38], ["the study", "TEST", 292, 301], ["case studies", "TEST", 499, 511], ["historical and archival analysis", "TEST", 517, 549]]], ["They employ many qualitative assessment tools including surveys, sorting exercises, and focus groups, as well as standardized instruments, which generate biological, biometric, psychometric, and epidemiological data as relevant to research questions at hand.", [["hand", "ORGANISM_SUBDIVISION", 253, 257]]], ["They are also invested in involving populations in participatory research through the use of such visual and spatial technologies as participatory mapping and photo-voice.Methods and FramingMedical anthropologists also deem it essential to 'study up' and conduct systems level analysis of health care systems, health and development bureaucracies and philanthropies, non governmental organizations (NGOs), private-public partnerships, and environmental legislation that affects health outcomes.", [["philanthropies", "DISEASE", 351, 365], ["participatory mapping", "TEST", 133, 154], ["photo-voice", "TREATMENT", 159, 170], ["'study", "TEST", 240, 246], ["development bureaucracies", "PROBLEM", 321, 346], ["philanthropies", "TREATMENT", 351, 365]]], ["For example, medical anthropologists study the policies, politics, and bureaucracies responsible for the regulation of water and sanitation, forestry, food safety, etc., as they relate to health outcomes.", [["medical anthropologists study", "TEST", 13, 42]]], ["Global policies related to the control of environmental pollutants ranging from pesticides to tobacco smoke, and the accessibility and regulation of pharmaceutical products, also fall under the purview of medical anthropology.", [["smoke", "CHEMICAL", 102, 107], ["tobacco", "ORGANISM", 94, 101], ["tobacco", "SPECIES", 94, 101], ["Global policies", "PROBLEM", 0, 15], ["environmental pollutants", "PROBLEM", 42, 66], ["pharmaceutical products", "TREATMENT", 149, 172], ["pharmaceutical products", "OBSERVATION", 149, 172]]], ["In keeping with an important shift in analytical focus from 'international health' to 'global health,' medical anthropologists have become increasingly interested in health diplomacy and what it takes to introduce and enforce global policies across national boundaries for global good.", [["good", "OBSERVATION_MODIFIER", 280, 284]]], ["Much of the driving force behind global health is the recognition that emerging diseases such as severe acute respiratory syndrome (SARS) or influenza (both swine and avian) move quickly and require well-coordinated global disease control policies that demand the surveillance of local environments and the interface between animal and human ecosystems.", [["acute respiratory syndrome", "DISEASE", 104, 130], ["SARS", "DISEASE", 132, 136], ["influenza", "DISEASE", 141, 150], ["human", "ORGANISM", 336, 341], ["swine", "SPECIES", 157, 162], ["human", "SPECIES", 336, 341], ["swine", "SPECIES", 157, 162], ["human", "SPECIES", 336, 341], ["emerging diseases", "PROBLEM", 71, 88], ["severe acute respiratory syndrome", "PROBLEM", 97, 130], ["SARS", "PROBLEM", 132, 136], ["influenza", "PROBLEM", 141, 150], ["severe", "OBSERVATION_MODIFIER", 97, 103], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["respiratory syndrome", "OBSERVATION", 110, 130]]], ["Medical anthropologists are involved with both documenting examples of local-global disease linkages and representations of such linkages by the popular press and political parties, as well as the response of citizens and activists.Key ConceptsThere are a number of conceptual frameworks that assist medical anthropologists in their study of environmental health, a term that is defined quite broadly to encompass health/health care-related outcomes best understood in relation to the physical, social, political, economic, and communication environments in which they occur.", [["local-global disease linkages", "PROBLEM", 71, 100], ["global disease", "OBSERVATION", 77, 91]]], ["Then these concepts are expanded to consider how environmental health is linked to issues of risk and risk perception, the accumulation and persistence of meaning and memory in cultural landscapes, and the consequences of disproportionate exposure to risks and hazards.", [["the accumulation", "PROBLEM", 119, 135], ["meaning and memory in cultural landscapes", "PROBLEM", 155, 196]]], ["Also, implications are examined for effective governance in light of these disparities and the mobilization and response of emergent social movements as they address disparities and inequality.Political Ecology: Natural versus Cultural LandscapesPolitical ecology applies a system's perspective to understanding the ecological ramifications and sequelae of political economic inspired practices and policy on both macro-and microenvironments.", [["the mobilization", "TREATMENT", 91, 107], ["emergent social movements", "TREATMENT", 124, 149]]], ["Political ecology is attentive to the impact of ecological changes on not just humans, but other species as well, which may ultimately have an effect on human health.", [["humans", "ORGANISM", 79, 85], ["human", "ORGANISM", 153, 158], ["humans", "SPECIES", 79, 85], ["human", "SPECIES", 153, 158], ["humans", "SPECIES", 79, 85], ["human", "SPECIES", 153, 158]]], ["There are numerous examples of political ecological studies that look at poor health as an outcome of poor environmental policy related to deforestation, the creation of dams and irrigation systems, shifts from food crops to cash crops like tobacco, misuse of chemical fertilizers and pesticides, the explosion of consumer culture that generates vast quantities of waste, increasing fossil fuel consumption that alters climate and weather patterns, natural or man-made disasters that are exacerbated by environmental modification and degradation, and the loss of local and global biodiversity as wilderness areas are lost or degraded.Political Ecology: Natural versus Cultural LandscapesThe political ecology framework also expands the definition of environment to include social processes and their impact on local ecologies, whereas at the same time recognizing that these are inherently linked assemblages of natural, cultural, political, and ideological environments that interact as a complex system.", [["deforestation", "DISEASE", 139, 152], ["dams", "ORGANISM_SUBDIVISION", 170, 174], ["tobacco", "ORGANISM", 241, 248], ["tobacco", "SPECIES", 241, 248], ["man", "SPECIES", 460, 463], ["tobacco", "SPECIES", 241, 248], ["political ecological studies", "TEST", 31, 59], ["irrigation systems", "TREATMENT", 179, 197], ["chemical fertilizers", "TREATMENT", 260, 280], ["consumer culture", "TEST", 314, 330], ["disasters", "PROBLEM", 469, 478], ["the loss of local and global biodiversity", "PROBLEM", 551, 592], ["fossil fuel", "OBSERVATION", 383, 394], ["local", "OBSERVATION_MODIFIER", 563, 568], ["global", "OBSERVATION_MODIFIER", 573, 579], ["biodiversity", "OBSERVATION_MODIFIER", 580, 592]]], ["Recent scholarship on the social construction of nature addresses this arbitrary distinction between nature and culture and considers the way human behavioral patterns are embedded within environmental contexts.", [["human", "ORGANISM", 142, 147], ["human", "SPECIES", 142, 147], ["human", "SPECIES", 142, 147], ["culture", "TEST", 112, 119], ["scholarship", "OBSERVATION", 7, 18]]], ["This critical stance serves as a useful corrective against simplistic depictions of nature as bounded and an empty space within which social processes play out.Biocultural AnthropologyBiocultural anthropology explores the nexus between culture and human biology and examines human genotypic and behavioral plasticity in context.", [["human", "ORGANISM", 248, 253], ["human", "ORGANISM", 275, 280], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 275, 280], ["human", "SPECIES", 248, 253], ["human", "SPECIES", 275, 280], ["culture", "TEST", 236, 243], ["empty space", "OBSERVATION", 109, 120]]], ["Among other things, a biocultural approach to medical anthropology investigates short-and long-term health outcomes that result from changing and differential access to resources (e.g., stunted growth and development due to malnutrition and poor survivorship resulting from limited access to primary health care), differential exposure to environmental stressors (e.g., from exposure to pollution to exposure to the stresses of poverty, overcrowding, fear of hunger, violence, and oppression), and the cultural practices and social institutions that mediate the effect of these stressors.", [["malnutrition", "DISEASE", 224, 236], ["poverty", "DISEASE", 428, 435], ["violence", "DISEASE", 467, 475], ["stunted growth", "PROBLEM", 186, 200], ["malnutrition", "PROBLEM", 224, 236], ["poor survivorship", "PROBLEM", 241, 258], ["environmental stressors", "PROBLEM", 339, 362], ["hunger", "PROBLEM", 459, 465], ["social institutions", "TREATMENT", 525, 544]]], ["A biocultural approach focuses on what is cultural about biosocial relations.Biocultural AnthropologyLocal biology and the process of embodiment are important considerations for the biocultural approach, and build on three premises: culture and biology exist in an ongoing feedback relationship, the body is a biocultural project in the making that is inextricably linked to place and time, and physical changes in the body are more than the result of gradual adaptations to the environment.", [["body", "ANATOMY", 300, 304], ["body", "ANATOMY", 419, 423], ["body", "ORGANISM_SUBDIVISION", 300, 304], ["body", "ORGANISM_SUBDIVISION", 419, 423], ["A biocultural approach", "TREATMENT", 0, 22], ["the biocultural approach", "TREATMENT", 178, 202], ["culture", "TEST", 233, 240], ["physical changes in the body", "PROBLEM", 395, 423], ["embodiment", "OBSERVATION", 134, 144]]], ["Local biology is an outcome of active bodily engagement in which experiential states are at once the product of cultural and biological processes.", [["active bodily engagement", "TREATMENT", 31, 55]]], ["Cultural interpretation and related bodily practices have a recursive relationship to the ongoing experience of bodily states and biological change.", [["Cultural interpretation", "TEST", 0, 23], ["bodily states", "PROBLEM", 112, 125]]], ["Local biology is studied as an expression of human plasticitythe ability of genotypic biology to change its phenotype in response to the environmentand short-and long-term consequences are discussed in terms of adaptability and adaptation.Biocultural AnthropologyBiocultural oriented medical anthropologists, like their ecosocial epidemiologist colleagues , view humans as embodying the cumulative effect of living in different material, social, and cultural environments throughout their life.", [["human", "ORGANISM", 45, 50], ["humans", "ORGANISM", 363, 369], ["human", "SPECIES", 45, 50], ["humans", "SPECIES", 363, 369], ["human", "SPECIES", 45, 50], ["humans", "SPECIES", 363, 369]]], ["Embodiment refers to the lived experience of one's body, as well as one's experience of life mediated through the body, as this is influenced by its physical, psychological, social, political, economic, cultural, and technologically mediated environments.", [["body", "ANATOMY", 51, 55], ["body", "ANATOMY", 114, 118], ["body", "ORGANISM_SUBDIVISION", 51, 55], ["body", "ORGANISM_SUBDIVISION", 114, 118]]], ["Common outcomes they assess include the incidence and prevalence of chronic illness, and precursors of disease like blood pressure, life expectancy, and birth weight.", [["blood", "ANATOMY", 116, 121], ["chronic illness", "DISEASE", 68, 83], ["blood", "ORGANISM_SUBSTANCE", 116, 121], ["chronic illness", "PROBLEM", 68, 83], ["disease", "PROBLEM", 103, 110], ["blood pressure", "TEST", 116, 130], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["illness", "OBSERVATION", 76, 83], ["pressure", "OBSERVATION_MODIFIER", 122, 130]]], ["Opinions range on the relative contributions of biological, sociocultural, genetic, and environmental factors to states of health, but all biocultural oriented medical anthropologists agree that the 'action is in the interaction'meaning that individual factors are less important than the intersection of them all.Environments of Risk and Risk SubjectivityMedical anthropologists study the ways in which environments are perceived to be dangerous, whether due to spirits, microbes, endemic and epidemic diseases, physical hazards, natural disasters, or violence.", [["violence", "DISEASE", 553, 561], ["Medical anthropologists study", "TEST", 356, 385], ["endemic and epidemic diseases", "PROBLEM", 482, 511]]], ["They look upstream to political and economic factors that foster environments of risk (see the section 'Political Ecology: Natural versus Cultural Landscapes'), and attention is paid not only to the negative impacts of environmental intrusion, modification, and degradation of local ecosystems, but to the integrity of local cosmologies in cultural contexts where maintaining cosmological relations is central to a sense of wellbeing.", [["local ecosystems", "TREATMENT", 277, 293], ["environmental intrusion", "OBSERVATION", 219, 242]]], ["Medical anthropology is attentive to the ways in which perceptions of risk alter behavior, shape government policy, enable governance, frame health care interventions, and influence consumer behavior as well as marketing.", [["health care interventions", "TREATMENT", 141, 166]]], ["Research focuses on issues that include surveillance and regulation of populations at risk, social and technological strategies to reduce risks, perceptions and experiences of risk exposure (risk subjectivity) that lead to the adoption of risk-related practices, and social responses to perceptions of being at risk.Environments of Risk and Risk SubjectivityMedical anthropologists also study risk as a prominent theme found in popular health culture, including ideas about how to mitigate risks to personal health when living in an environment of risk as a means of harm reduction.", [["surveillance", "TEST", 40, 52], ["harm reduction", "TREATMENT", 567, 581]]], ["Prominent social philosophers Ulrich Beck and Anthony Giddens have noted that people live in a global risk society, exposed to increasing risks as well as information about risk, produced by different stakeholders.", [["people", "ORGANISM", 78, 84], ["people", "SPECIES", 78, 84], ["social philosophers", "OBSERVATION", 10, 29]]], ["These stakeholders range from medical and public health professionals working with diagnostic tests to identify risk to marketers cashing in on collective anxieties.", [["diagnostic tests", "TEST", 83, 99]]], ["The preoccupation with risk in popular literature is symptomatic of one of the paradoxes of modernity.", [["symptomatic", "PROBLEM", 53, 64], ["symptomatic", "OBSERVATION_MODIFIER", 53, 64]]], ["These emergent risks are then addressed with more technology in a never-ending feedback loop.Environments of Risk and Risk SubjectivityPeople also live in a time of increasing distrust in information about risk, given competing accounts of risk factors and increasing reports of information bias and downright fraud.", [["People", "ORGANISM", 135, 141], ["People", "SPECIES", 135, 141], ["risk factors", "PROBLEM", 240, 252]]], ["They are also becoming more attentive to the ways in which information about risk can actually place populations at greater risk depending on how segments of the population respond to this informationbe it hypervigilance, disinterest, or fatalism.Environments of Risk and Risk SubjectivityFinally, medical anthropologists have pushed for greater recognition of environments of risk as a counterbalance to public health's preoccupation with risk factors, groups at risk, and the study of risky behavior.", [["hypervigilance", "DISEASE", 206, 220], ["disinterest", "DISEASE", 222, 233], ["hypervigilance", "PROBLEM", 206, 220], ["the study", "TEST", 474, 483]]], ["These foci of investigation unintentionally lead to victim blaming when the local environment context is not taken into account.", [["foci", "OBSERVATION", 6, 10]]], ["Particular environments predispose types of risky behavior and contribute to the maldistribution of ill health and groups at greater risk.Space and Place, Memory, and ExperienceThe concept of place as physical space predisposed to particular types of human interaction contributes to the anthropological investigation of environments of risk.", [["human", "ORGANISM", 251, 256], ["human", "SPECIES", 251, 256], ["human", "SPECIES", 251, 256]]], ["The distinction between space and place originated within the field of human geography.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["space", "OBSERVATION_MODIFIER", 24, 29]]], ["Human cultural landscapes are seen as places embedded with meaning, histories, and memories that set the stage for particular types of interactions, be they associated with risky behavior or behavior conducive to the collective good.", [["Human", "ORGANISM", 0, 5], ["Human", "SPECIES", 0, 5], ["Human cultural landscapes", "PROBLEM", 0, 25]]], ["Perceptions of place are also tied to social norms, and public health advocates compete with industries such as Big Tobacco over who gets to define normative behavior in places where people gather, live, or work.", [["people", "ORGANISM", 183, 189], ["people", "SPECIES", 183, 189]]], ["These place-based meanings have a half-life and fade or persist depending on how their remembrance is framed or reproduced.Structural Violence and Social CapitalAnalyses of structural violence draw attention to health and economic inequality as outcomes of social structures, institutions, and policies that systematically block members of a population from meeting basic needs, resulting in ill health and premature death.", [["premature death", "DISEASE", 407, 422], ["premature death", "PROBLEM", 407, 422], ["Capital", "OBSERVATION", 154, 161]]], ["Structural violence devalues and marginalizes people, although policies that promote it are often dressed up as serving national and global interests.", [["people", "ORGANISM", 46, 52], ["people", "SPECIES", 46, 52]]], ["Other examples include policies in the United States that restrict access to health programs or benefits, or lead to the closing of unprofitable clinics in impoverished neighborhoods.Structural Violence and Social CapitalStructural violence creates environments of health and health care risk.", [["CapitalStructural violence", "DISEASE", 214, 240]]], ["Drawing on biocultural and critical public health reasoning (ecosocial epidemiology, etc.), medical anthropologists study both the short-and long-term impacts of structural violence, as cumulative effects of unhealthy environments may take years to manifest in higher rates of chronic disease among marginalized populations.", [["structural violence", "DISEASE", 162, 181], ["chronic disease", "DISEASE", 277, 292], ["medical anthropologists study", "TEST", 92, 121], ["chronic disease", "PROBLEM", 277, 292], ["chronic", "OBSERVATION_MODIFIER", 277, 284], ["disease", "OBSERVATION", 285, 292]]], ["The consequences of chronic disease are presently under-appreciated in contexts where acute illness is so visible, but in reality, the two are often interrelated.", [["chronic disease", "DISEASE", 20, 35], ["chronic disease", "PROBLEM", 20, 35], ["acute illness", "PROBLEM", 86, 99], ["chronic", "OBSERVATION_MODIFIER", 20, 27], ["disease", "OBSERVATION", 28, 35], ["acute", "OBSERVATION_MODIFIER", 86, 91], ["illness", "OBSERVATION", 92, 99]]], ["For example, fighting malnutrition is at once a child survival priority to prevent stunting and wasting during a child's peak period of development, and a way of reducing chronic disease later in life for children who do survive and are more likely to suffer from diseases like diabetes or heart disease.Structural Violence and Social CapitalMedical anthropologists also study the effect of structural violence on the integrity of social relations and how this affects social support and mutual assistance within communities and between extended kin during times of illness and disaster.", [["heart", "ANATOMY", 290, 295], ["malnutrition", "DISEASE", 22, 34], ["stunting", "DISEASE", 83, 91], ["wasting", "DISEASE", 96, 103], ["diabetes", "DISEASE", 278, 286], ["heart disease", "DISEASE", 290, 303], ["illness", "DISEASE", 566, 573], ["children", "ORGANISM", 205, 213], ["heart", "ORGAN", 290, 295], ["children", "SPECIES", 205, 213], ["fighting malnutrition", "PROBLEM", 13, 34], ["a child survival priority", "TREATMENT", 46, 71], ["stunting and wasting", "PROBLEM", 83, 103], ["reducing chronic disease", "PROBLEM", 162, 186], ["diseases", "PROBLEM", 264, 272], ["diabetes", "PROBLEM", 278, 286], ["heart disease", "PROBLEM", 290, 303], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["disease", "OBSERVATION", 179, 186], ["diseases", "OBSERVATION", 264, 272], ["diabetes", "OBSERVATION", 278, 286], ["heart", "ANATOMY", 290, 295], ["disease", "OBSERVATION", 296, 303]]], ["One of the most dangerous effects of structural violence is degradation of social networks and loss of social capital, which results in loss of family or community security and safety nets.", [["structural violence", "DISEASE", 37, 56], ["loss of social capital", "DISEASE", 95, 117], ["most dangerous", "OBSERVATION_MODIFIER", 11, 25]]], ["Medical anthropologists study individual and environmental effects of these states of anomie, and the social institutions to which people turn as sources of resilience and social revitalization.SyndemicsA disease syndemic framework is used to study concurrent and synergistic health problems linked to common antecedent and contributing factors in environments of risk.", [["people", "ORGANISM", 131, 137], ["people", "SPECIES", 131, 137], ["Medical anthropologists study", "TEST", 0, 29], ["social revitalization", "TREATMENT", 172, 193], ["SyndemicsA disease syndemic framework", "PROBLEM", 194, 231], ["synergistic health problems", "PROBLEM", 264, 291]]], ["Attention is drawn to both causal factors and reciprocal relationships that lead to correlations between patterns of disease incidence and social or economic variables, although recently, more emphasis has been placed on environmental variables as well (see below).", [["disease incidence", "PROBLEM", 117, 134], ["disease", "OBSERVATION", 117, 124]]], ["An analysis focused on syndemics invites to look upstream and consider the importance of how these variables translate into elevated disease concentrations, and to consider not only the current impact of interactions between social factors and health problems, but future problems that result from such interactions.", [["An analysis", "TEST", 0, 11], ["elevated disease concentrations", "PROBLEM", 124, 155]]], ["Some examples of syndemics that are of interest to medical anthropologists include the interrelated problems of drug abuse, violence, tuberculosis (TB) and human immunodeficiency virus (HIV)/acquired immune deficiency syndrome (AIDS) in North American inner cities; or the increasing proportion of overweight residents of the United States, and the linked diseases such as diabetes, hypertension, and heart disease.SyndemicsThese examples focus on the built/urban environment and the conditions that result from the interaction between disease assemblages and social factors that shape their impact and distribution.", [["heart", "ANATOMY", 401, 406], ["drug abuse", "DISEASE", 112, 122], ["violence", "DISEASE", 124, 132], ["tuberculosis", "DISEASE", 134, 146], ["TB", "DISEASE", 148, 150], ["human immunodeficiency virus (HIV)/acquired immune deficiency syndrome", "DISEASE", 156, 226], ["AIDS", "DISEASE", 228, 232], ["diabetes", "DISEASE", 373, 381], ["hypertension", "DISEASE", 383, 395], ["heart disease", "DISEASE", 401, 414], ["human immunodeficiency virus", "ORGANISM", 156, 184], ["heart", "ORGAN", 401, 406], ["human immunodeficiency virus", "SPECIES", 156, 184], ["human immunodeficiency virus", "SPECIES", 156, 184], ["HIV", "SPECIES", 186, 189], ["tuberculosis (TB)", "PROBLEM", 134, 151], ["human immunodeficiency virus", "PROBLEM", 156, 184], ["HIV", "PROBLEM", 186, 189], ["acquired immune deficiency syndrome", "PROBLEM", 191, 226], ["the linked diseases", "PROBLEM", 345, 364], ["diabetes", "PROBLEM", 373, 381], ["hypertension", "PROBLEM", 383, 395], ["heart disease", "PROBLEM", 401, 414], ["the interaction between disease assemblages", "PROBLEM", 512, 555], ["tuberculosis", "OBSERVATION", 134, 146], ["immune deficiency", "OBSERVATION", 200, 217], ["increasing", "OBSERVATION_MODIFIER", 273, 283], ["diabetes", "OBSERVATION", 373, 381], ["hypertension", "OBSERVATION", 383, 395], ["heart", "ANATOMY", 401, 406], ["disease", "OBSERVATION", 407, 414]]], ["More recently, attention has been focused on humananimal interactions, especially as zoonotic diseases such as SARS or influenza (both avian and swine) encourage a consideration of the transmission of microbes/viruses back and forth between humans and animals, and the environmental factors such as deforestation, environmental degradation, or habitat fragmentation that may increase the potential for zoonotic jumps.", [["zoonotic diseases", "DISEASE", 85, 102], ["SARS", "DISEASE", 111, 115], ["influenza", "DISEASE", 119, 128], ["humans", "ORGANISM", 241, 247], ["swine", "SPECIES", 145, 150], ["humans", "SPECIES", 241, 247], ["swine", "SPECIES", 145, 150], ["humans", "SPECIES", 241, 247], ["zoonotic diseases", "PROBLEM", 85, 102], ["SARS", "PROBLEM", 111, 115], ["influenza", "PROBLEM", 119, 128], ["microbes/viruses", "TREATMENT", 201, 217], ["environmental degradation", "PROBLEM", 314, 339], ["habitat fragmentation", "PROBLEM", 344, 365], ["zoonotic jumps", "PROBLEM", 402, 416]]], ["A syndemic framework applied to zoonoses and human-animal interactions points in a more complex direction, encouraging a consideration of not only the consequences of habitat encroachment or environmental degradation in specific cases or regions, but the large-scale practices such as industrial farming, monoculture agriculture, or deforestation as part of a larger global problem, since individual practices or events cannot be isolated from the larger impacts of the human footprint on both local and global environments.", [["zoonoses", "DISEASE", 32, 40], ["human", "ORGANISM", 45, 50], ["human", "ORGANISM", 470, 475], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 470, 475], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 470, 475], ["A syndemic framework", "TREATMENT", 0, 20], ["habitat encroachment", "PROBLEM", 167, 187], ["environmental degradation", "PROBLEM", 191, 216], ["deforestation", "PROBLEM", 333, 346], ["a larger global problem", "PROBLEM", 358, 381], ["larger", "OBSERVATION_MODIFIER", 360, 366], ["global", "OBSERVATION_MODIFIER", 367, 373], ["problem", "OBSERVATION", 374, 381], ["larger", "OBSERVATION_MODIFIER", 448, 454], ["human footprint", "OBSERVATION", 470, 485]]], ["The 'one-health' approach to human-animal interactions, and global environmental health more broadly, emphasizes the synergistic relationships that the syndemic framework suggests, integrating them at multiple scales, from the global to the local, and in multiple nested contexts, including socioeconomic, political, and environmental.Network Society and BiosocialityToday, the most distant points of the earth are connected by flows of information enabled by communications technology and levels of connectivity that were previously unimaginable.", [["human", "ORGANISM", 29, 34], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34]]], ["This has radically altered the notion of personal, social, and political networks, as well as that of 'the local,' which can no longer be viewed in isolation.", [["radically", "OBSERVATION_MODIFIER", 9, 18], ["altered", "OBSERVATION", 19, 26]]], ["The local is now part of an interconnected global network that exchanges information, commodities, images, and ideas, and is facilitated by technologies such as the Internet, cell phones, text messaging, and emerging social media sites such as Twitter or Facebook.", [["cell", "ANATOMY", 175, 179], ["cell", "CELL", 175, 179], ["interconnected", "OBSERVATION_MODIFIER", 28, 42], ["global", "OBSERVATION", 43, 49]]], ["The extent and speed of this exchange means that the plight of a community or the goals of a local environmental group can be communicated almost as fast (or faster!) across the globe as it can to the next town, and new social groupings of individuals coalesce around shared environmental experiences and mutual advocacy interests.", [["a local environmental group", "TREATMENT", 91, 118], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["globe", "ANATOMY", 178, 183]]], ["Paul Rabinow coined the term biosociality to refer to groups that come to share a common biologically understood identity due to illness, health-related condition, or perceived risk.", [["illness", "DISEASE", 129, 136], ["illness", "PROBLEM", 129, 136]]], ["In some instances, shared biological affiliation has led members of a community of affliction to make demands on institutions, governments, and scientists as a form of biopolitics.", [["biopolitics", "TREATMENT", 168, 179]]], ["Medical anthropologists are interested in how such groups (ranging from NGOs to patient advocate and environmental health groups) are formed and mobilized as new actors on the global health stage, how their activism is responded to by those in power, and the novel sorts of social organization that result from these novel groupings centered on biosociality.Mediated Environments and Epidemic FearIn the global network society, the range and extent of media environments has expanded tremendously, as local media is picked up nationally and internationally, and global health surveillance searches local news stories on the Internet for information about emerging diseases and to filter out rumors from credible leads.", [["patient", "ORGANISM", 80, 87], ["patient", "SPECIES", 80, 87], ["emerging diseases", "PROBLEM", 655, 672]]], ["Media environments also include advertising copy and marketing campaigns, which are often difficult to distinguish from legitimate science in the health-medical field, so that much of the public's information about health and illness is gleaned from information and advertising generated by the pharmaceutical industry, an industry that also influences publications in scientific journals cited in support of their products.", [["illness", "DISEASE", 226, 233]]], ["Analysis of media environments does not assume comprehensive availability of information, but focuses on the myriad forces that affect what information is made available or chosen for dissemination, the global network of media conduits that convey this information, the multiple social contexts that receive this information via official (e.g., politics, news media) and unofficial (e.g., rumor) networks, and the impact these flows of information have on risk perception, epidemic fear, and behavior change.Mediated Environments and Epidemic FearThe spread of information about the impending threat of disease can even outpace the spread of the actual disease (e.g., SARS, avian flu), leading the public to either overreact or lose trust in public health warnings, or it can lag behind and fail to report information about diseases that should or would raise concerns in the general population (e.g., TB, HIV/AIDS).", [["SARS", "DISEASE", 668, 672], ["avian flu", "DISEASE", 674, 683], ["TB", "DISEASE", 902, 904], ["HIV/AIDS", "DISEASE", 906, 914], ["avian flu", "SPECIES", 674, 683], ["HIV", "SPECIES", 906, 909], ["media conduits", "TREATMENT", 221, 235], ["epidemic fear", "PROBLEM", 473, 486], ["disease", "PROBLEM", 603, 610], ["the actual disease", "PROBLEM", 642, 660], ["SARS", "PROBLEM", 668, 672], ["diseases", "PROBLEM", 824, 832], ["TB", "PROBLEM", 902, 904], ["disease", "OBSERVATION", 603, 610]]], ["They are equally interested in an 'epidemiology of ideas' that considers what information and representations are contagious and are amenable to spread, as in the study of the contagious pathogens themselves.", [["contagious", "PROBLEM", 114, 124], ["the study", "TEST", 159, 168]]], ["Examples such as SARS, avian flu, and most recently the H1N1 swine flu pandemic raise questions about not only the environmental and political ecological contexts that help or hinder the spread of potentially pandemic diseases, but also the speed at which information about these risks can flow and the effect of this information when it reaches populations before actual exposure.", [["SARS", "DISEASE", 17, 21], ["avian flu", "DISEASE", 23, 32], ["flu pandemic", "DISEASE", 67, 79], ["H1N1 swine", "ORGANISM", 56, 66], ["H1N1 swine flu pandemic", "SPECIES", 56, 79], ["H1N1 swine flu", "SPECIES", 56, 70], ["SARS", "PROBLEM", 17, 21], ["potentially pandemic diseases", "PROBLEM", 197, 226]]], ["They also raise questions related to state control over this information in efforts to control representations of the disease risk itself, and shape international perceptions of effectiveness of treatment and prevention plans, which are tied up within the biopolitical agendas of modernity and national sovereignty.From Risk Perception to Popular EpidemiologyUlrich Beck famously declared that 'smog is democratic,' in a discussion of the universal risks that modern people face as part of the changing nature of industrial and technocratic society.", [["people", "ORGANISM", 467, 473], ["people", "SPECIES", 467, 473], ["the disease risk itself", "PROBLEM", 114, 137], ["treatment", "TREATMENT", 195, 204], ["prevention plans", "TREATMENT", 209, 225]]], ["His intent, of course, was to emphasize the global nature of the risk society in which people live, and that threats to humans are a global, rather than regional or local, phenomena.", [["people", "ORGANISM", 87, 93], ["humans", "ORGANISM", 120, 126], ["people", "SPECIES", 87, 93], ["humans", "SPECIES", 120, 126], ["humans", "SPECIES", 120, 126], ["local", "OBSERVATION_MODIFIER", 165, 170]]], ["He noted that marginalized groups, neighborhoods, or regions often lack the social or political capital to block polluters of what are described in the following text as the commons.", [["political capital", "OBSERVATION", 86, 103]]], ["The end result is a clustering rather than even distribution of pollution and environmental degradation.From Risk Perception to Popular EpidemiologySocial movements arise to fight against both global and local sources of pollution, environmental destruction, and degradation.", [["environmental degradation", "PROBLEM", 78, 103], ["environmental destruction", "PROBLEM", 232, 257], ["pollution", "OBSERVATION", 64, 73], ["environmental degradation", "OBSERVATION", 78, 103], ["pollution", "OBSERVATION", 221, 230], ["destruction", "OBSERVATION", 246, 257]]], ["Popular epidemiology describes an example of an emergent social movement within the United States wherein members of local communities who are dissatisfied with governmental policies and oversight are undertaking their own analyses of local problems related to poor health outcomes.", [["local problems", "PROBLEM", 235, 249]]], ["The management of resources like clean air, water, a stable local food supply, and so on, and practices such as sustainable agriculture and water conservation demonstrate ways that groups come together to preserve/conserve resources.", [["water conservation", "TREATMENT", 140, 158], ["stable", "OBSERVATION_MODIFIER", 53, 59]]], ["Examples of mismanagement, overuse of limited resources, and the cumulative effects of seemingly small negative impacts illustrate the tragedy of these commons, as resources are squandered, degraded, or polluted.", [["mismanagement", "PROBLEM", 12, 25], ["small", "OBSERVATION_MODIFIER", 97, 102], ["negative", "OBSERVATION", 103, 111]]], ["At a local scale, people develop a relationship with land and the surrounding environment, and the knowledge, ideas, and informational resources embedded within the local cultural and physical landscapes are lost when these landscapes are destroyed or altered by habitat loss, environmental degradation, or pollution.", [["people", "ORGANISM", 18, 24], ["people", "SPECIES", 18, 24], ["habitat loss", "PROBLEM", 263, 275], ["environmental degradation", "PROBLEM", 277, 302], ["habitat loss", "OBSERVATION", 263, 275]]], ["Globally, issues such as loss of biodiversity; cumulative impacts of pollution; the overuse of pesticides, antibiotics, and fertilizers; and widespread environmental modification and degradation all point to potential global impacts.", [["loss of biodiversity", "PROBLEM", 25, 45], ["pesticides", "TREATMENT", 95, 105], ["antibiotics", "TREATMENT", 107, 118], ["fertilizers", "TREATMENT", 124, 135], ["widespread environmental modification", "PROBLEM", 141, 178], ["widespread", "OBSERVATION_MODIFIER", 141, 151], ["environmental modification", "OBSERVATION", 152, 178]]], ["Global versus local governance of the commons is a contentious political issue especially as it pertains to issues of national sovereignty and the locus of responsibility, for example, in governing the availability and use of valuable antibiotics like the drug rifampicin (an important TB drug) or antiretroviral drugs for HIV.", [["rifampicin", "CHEMICAL", 261, 271], ["rifampicin", "CHEMICAL", 261, 271], ["rifampicin", "SIMPLE_CHEMICAL", 261, 271], ["HIV", "ORGANISM", 323, 326], ["HIV", "SPECIES", 323, 326], ["HIV", "SPECIES", 323, 326], ["valuable antibiotics", "TREATMENT", 226, 246], ["the drug rifampicin", "TREATMENT", 252, 271], ["an important TB drug", "TREATMENT", 273, 293], ["antiretroviral drugs", "TREATMENT", 298, 318], ["HIV", "PROBLEM", 323, 326], ["local", "OBSERVATION_MODIFIER", 14, 19], ["governance", "OBSERVATION", 20, 30]]], ["If they are misused or sold in diluted doses, resistant pathogens will emerge that affect all nations.", [["resistant pathogens", "PROBLEM", 46, 65]]], ["Medical anthropologists interested in health diplomacy investigate when and under what circumstances a sovereign state allows global bodies to dictate policy within its border or engage in global surveillance.Future Directions for Medical AnthropologyThe following section highlights a few of the research directions presently being pursued by medical anthropologists engaging environmental health as a broad field of inquiry.", [["global surveillance", "TEST", 189, 208]]], ["The following section begins with a note on the development of innovative methods.MethodsMedical anthropologists are experimenting with a number of novel methodologies made possible by the availability of new technologies.", [["innovative methods", "TREATMENT", 63, 81]]], ["When used in conjunction with ethnographic research methods, such mapping permits a better understanding of local perceptions of the distribution of health problems.", [["ethnographic research methods", "TREATMENT", 30, 59]]], ["Local populations are shown maps depicting higher and lower prevalence rates of a focal problem or syndemic, and then asked to participate in problem solving about what factors contribute to the patterns visually shown.", [["maps", "TEST", 28, 32], ["a focal problem", "PROBLEM", 80, 95], ["higher", "OBSERVATION_MODIFIER", 43, 49], ["lower prevalence", "OBSERVATION_MODIFIER", 54, 70], ["focal", "OBSERVATION_MODIFIER", 82, 87]]], ["The method then layers maps with existing information on who inhabits different places and what is known about the space and the people who inhabit these places.MethodsMapping makes transparent what information health officials are collecting and seeing as risk factors, and allows local populations to interrogate these data and the way it is collected.", [["people", "ORGANISM", 129, 135], ["people", "SPECIES", 129, 135], ["MethodsMapping", "TREATMENT", 161, 175], ["these data", "TEST", 315, 325]]], ["This is an empowering methodology that does more than simply validate or cross-check epidemiological patterns and distributions of environmental problems.", [["environmental problems", "PROBLEM", 131, 153], ["environmental problems", "OBSERVATION", 131, 153]]], ["It facilitates community discussion of these patterns, their meaning, and possible solutions.MethodsPhoto voice is another promising methodology that can be used alone or in conjunction with participatory mapping.", [["participatory mapping", "TEST", 191, 212]]], ["It consists of giving community members the technology to create visual representations of their own locale, patterns of social interaction, and physical activity in different spaces at different times.", [["social interaction", "OBSERVATION", 121, 139]]], ["Other things that may be captured by photo voice include seasonal challenges that impact on health and health care seeking, such as water availability and transportation.", [["seasonal challenges", "TREATMENT", 57, 76]]], ["Like maps, these visual representations of local places foster community dialogue and a grounding of discussion in the lifeworld of participants.RepresentationsIn addition to studying the physical environment and its occupants, medical anthropologists have been focusing on the representations of environments by stakeholders who have differing agendas when representing spaces and the people who inhabit them.", [["people", "ORGANISM", 386, 392], ["participants", "SPECIES", 132, 144], ["people", "SPECIES", 386, 392]]], ["For example, much research on emerging and reemerging infectious disease centers on the epidemiology of these diseases, and environmental and behavioral factors that are thought to catalyze their emergence or facilitate their spread.", [["infectious disease", "DISEASE", 54, 72], ["these diseases", "PROBLEM", 104, 118], ["diseases", "OBSERVATION", 110, 118]]], ["Medical anthropologists are contributing to this field of study by assisting public health teams in their efforts to identify routes of disease transmission as well as routes of information flow about diseases that affect community responses to them.", [["disease transmission", "PROBLEM", 136, 156], ["diseases", "PROBLEM", 201, 209]]], ["This includes the monitoring of rumors associated with epidemic fear, whether expressions of current collective anxieties are tied to social memory of past epidemic disease or politically motivated and strategically disseminated.The Consumer EnvironmentThere is a great need for medical anthropologists to study ways in which patterns of consumption affect human biology, ecology, and the epidemiology of emerging and reemerging diseases.", [["human", "ORGANISM", 357, 362], ["human", "SPECIES", 357, 362], ["human", "SPECIES", 357, 362], ["rumors", "PROBLEM", 32, 38], ["epidemic fear", "PROBLEM", 55, 68], ["current collective anxieties", "PROBLEM", 93, 121], ["past epidemic disease", "PROBLEM", 151, 172]]], ["Patterns of consumption create environments of risk through pollution (air, water, garbage disposal), increases in traffic fatalities (road congestion, alcohol consumption, cell phone use while driving), new breeding sites for disease vectors (tires, plastic containers), and breeding grounds for violence (availability of firearms, illegal drugs, etc.).", [["cell", "ANATOMY", 173, 177], ["alcohol", "CHEMICAL", 152, 159], ["violence", "DISEASE", 297, 305], ["alcohol", "CHEMICAL", 152, 159], ["cell", "CELL", 173, 177], ["road congestion", "PROBLEM", 135, 150], ["disease vectors", "PROBLEM", 227, 242], ["traffic fatalities", "OBSERVATION", 115, 133]]], ["For example, lack of safe walkable communities contributes to car-centric transportation and decreases in physical activity.", [["car-centric transportation", "TREATMENT", 62, 88], ["decreases", "OBSERVATION_MODIFIER", 93, 102]]], ["The decreased presence of fresh food vendors due to high rents or lack of space for markets leads to greater consumption of fast foods.", [["high rents", "PROBLEM", 52, 62], ["decreased", "OBSERVATION_MODIFIER", 4, 13], ["fresh food", "OBSERVATION", 26, 36]]], ["The proliferation of advertising of fast food, liquor, and cigarettes in spaces inhabited by the poor predisposes them to lifestyle illnesses.The Consumer EnvironmentLiving in environments of risk and engaging in unhealthy consumption habits also drives a second type of consumption behavior associated with harm reduction.", [["harm reduction", "TREATMENT", 308, 322], ["proliferation", "OBSERVATION_MODIFIER", 4, 17]]], ["Harm reduction behavior is diverse, ranging from the consumption of dietary supplements to detoxify the body, to air filters to clean the air, bottled water, and ways of coping with stress that include everything from yoga classes to the taking of drugs like Prozac.", [["body", "ANATOMY", 104, 108], ["Harm reduction behavior", "DISEASE", 0, 23], ["Prozac", "CHEMICAL", 259, 265], ["body", "ORGANISM_SUBDIVISION", 104, 108], ["Prozac", "SIMPLE_CHEMICAL", 259, 265], ["Harm reduction behavior", "PROBLEM", 0, 23], ["dietary supplements", "TREATMENT", 68, 87], ["air filters", "TREATMENT", 113, 124], ["drugs", "TREATMENT", 248, 253], ["Prozac", "TREATMENT", 259, 265], ["diverse", "OBSERVATION_MODIFIER", 27, 34], ["body", "ANATOMY", 104, 108], ["air filters", "OBSERVATION", 113, 124], ["air", "ANATOMY", 138, 141]]], ["To what extent does this change the age of puberty, increase the incidence of obesity, or predispose populations to chronic diseases like diabetes?Global Citizenship, the Politics of Responsibility, and Health DiplomacyThe ways in which global health problems and the specter of a disease pandemic are framed raise sensitive political issues regarding the politics of responsibility and national sovereignty.", [["obesity", "DISEASE", 78, 85], ["chronic diseases", "DISEASE", 116, 132], ["diabetes", "DISEASE", 138, 146], ["obesity", "PROBLEM", 78, 85], ["chronic diseases", "PROBLEM", 116, 132], ["diabetes", "PROBLEM", 138, 146], ["global health problems", "PROBLEM", 237, 259], ["a disease pandemic", "PROBLEM", 279, 297], ["obesity", "OBSERVATION", 78, 85], ["chronic", "OBSERVATION_MODIFIER", 116, 123], ["diseases", "OBSERVATION", 124, 132], ["diabetes", "OBSERVATION", 138, 146], ["Citizenship", "OBSERVATION", 154, 165]]], ["Many environmental problems are global in nature, but some countries exacerbate them more than others through activities that promote global warming, pesticide overuse, deforestation, or loss of biodiversity.", [["deforestation", "DISEASE", 169, 182], ["loss of biodiversity", "DISEASE", 187, 207], ["Many environmental problems", "PROBLEM", 0, 27], ["pesticide overuse", "PROBLEM", 150, 167], ["deforestation", "PROBLEM", 169, 182], ["loss of biodiversity", "PROBLEM", 187, 207], ["environmental", "OBSERVATION_MODIFIER", 5, 18], ["problems", "OBSERVATION", 19, 27], ["global", "OBSERVATION_MODIFIER", 32, 38]]], ["These arguments are being advanced by various stakeholders, which range from governments to NGOs, and local to transnational business interests.", [["advanced", "OBSERVATION_MODIFIER", 26, 34]]], ["What is the relative success or failure of these arguments?", [["failure", "OBSERVATION", 32, 39]]], ["Medical anthropologists are studying global efforts aimed at the surveillance and control of emerging diseases and antimicrobial resistance, and the control and regulation of industries peddling ill health, such as Big Tobacco.Global Citizenship, the Politics of Responsibility, and Health DiplomacyResponse to emerging diseases has been described as the 'new ping pong' of international relations.", [["the surveillance", "TEST", 61, 77], ["emerging diseases", "PROBLEM", 93, 110], ["antimicrobial resistance", "TREATMENT", 115, 139], ["antimicrobial resistance", "OBSERVATION", 115, 139], ["Citizenship", "OBSERVATION", 234, 245], ["diseases", "OBSERVATION", 320, 328]]], ["Countries that rarely agree are now willing to cooperate when it comes to the surveillance and control of diseases like avian flu and SARS.", [["avian flu", "DISEASE", 120, 129], ["SARS", "DISEASE", 134, 138], ["avian", "ORGANISM", 120, 125], ["avian", "SPECIES", 120, 125], ["diseases", "PROBLEM", 106, 114], ["SARS", "PROBLEM", 134, 138]]], ["The acceptance of global regulations that eclipse national sovereignty has been described as one of the most radical and far-reaching changes in international law on public health since the beginning of international health cooperation in the mid-nineteenth century.", [["global", "OBSERVATION_MODIFIER", 18, 24], ["radical", "OBSERVATION", 109, 116]]], ["How will global funds for surveillance and control be distributed locally, and how will oversight of disease control programs be managed?", [["surveillance", "TEST", 26, 38], ["disease control programs", "TREATMENT", 101, 125]]], ["Medical anthropologists have begun to critically assess the local impact of transnational techniques of governance associated with agenda setting policies and programs, audit, and evaluation.", [["evaluation", "TEST", 180, 190]]], ["They have called for ethnographies of the technologies of governance as a much-needed part of anthropology of emerging health policy in a global health environment.Social Movements, NGOs, and Global Environmental HealthThe emergence of social movements and NGOs in response to both acute environmental health crises and chronic environmental health problems is of considerable interest to medical anthropologists.", [["both acute environmental health crises", "PROBLEM", 277, 315], ["chronic environmental health problems", "PROBLEM", 320, 357], ["acute", "OBSERVATION_MODIFIER", 282, 287], ["chronic", "OBSERVATION_MODIFIER", 320, 327]]], ["NGOs at once place pressure on governments to do something and take pressure off national governments by executing small-scale local responses to problems that the state is either unwilling or incapable of addressing via national policy.", [["small", "OBSERVATION_MODIFIER", 115, 120]]], ["They are further interested in how non-state actors (i.e., foundations, NGOs, advocacy, and professional groups) at once advance a global health agenda and present a problem for the coordination and oversight of health activities in a rapidly changing health care environment.The Study of Protective Factors and ResilienceIn the field of epidemiology far more attention is given to the study of risk factors than protective factors and resilience.", [["The Study", "TEST", 276, 285], ["Protective Factors", "TREATMENT", 289, 307], ["the study", "TEST", 382, 391]]], ["Medical anthropologists have long been interested in social institutions and forms of behavior that reduce the chances and impact of illness and other forms of misfortune, and enable recuperation.", [["illness", "DISEASE", 133, 140], ["misfortune", "TREATMENT", 160, 170]]], ["It will be important to study the resources communities draw on following periodic and relatively rare crises, as well as recurrent or endemic events that chronically persist.", [["periodic and relatively rare crises", "PROBLEM", 74, 109], ["recurrent or endemic events", "PROBLEM", 122, 149], ["endemic", "OBSERVATION_MODIFIER", 135, 142]]], ["It is hoped that the study of positive deviance will provide insights into the resilience of households and social networks, and suggest ways that these social formations may be buffered and strengthened.The Study of Protective Factors and ResilienceSee also: Medical Geology.", [["social networks", "MULTI-TISSUE_STRUCTURE", 108, 123], ["the study", "TEST", 17, 26], ["positive deviance", "PROBLEM", 30, 47]]]], "a8ed47060c05fc6741eaabef7f667a914a1dacc0": [["INTRODUCTIONNewcastle disease (ND) is one of the most economically important poultry diseases in the world.", [["INTRODUCTIONNewcastle disease", "DISEASE", 0, 29], ["ND", "DISEASE", 31, 33], ["poultry diseases", "DISEASE", 77, 93], ["INTRODUCTIONNewcastle disease", "PROBLEM", 0, 29], ["poultry", "OBSERVATION_MODIFIER", 77, 84], ["diseases", "OBSERVATION", 85, 93]]], ["Control of Newcastle disease virus (NDV) is accomlished by vaccination or eradication efforts.", [["Newcastle disease", "DISEASE", 11, 28], ["Newcastle disease virus", "ORGANISM", 11, 34], ["NDV", "ORGANISM", 36, 39], ["Newcastle disease virus", "SPECIES", 11, 34], ["NDV", "SPECIES", 36, 39], ["Newcastle disease virus", "PROBLEM", 11, 34], ["eradication efforts", "TREATMENT", 74, 93], ["Newcastle disease", "OBSERVATION", 11, 28]]], ["Evaluation of the effectiveness of control programs is often determined on the basis of the results of serological procedures.", [["Evaluation", "TEST", 0, 10], ["control programs", "TREATMENT", 35, 51], ["serological procedures", "TEST", 103, 125]]], ["The method most widely employed by the poultry and allied industries has been the hemagglutination-inhibition (HI) test.", [["the hemagglutination", "TEST", 78, 98]]], ["The virus neutralization (VN) test has also been used successfully but has not been widely accepted because it is expensive and requires greater laboratory tech-1 Published as Miscellaneous Paper Number 1135 of the Delaware Agricultural Experiment Station.", [["The virus neutralization (VN) test", "TEST", 0, 34], ["virus", "OBSERVATION", 4, 9]]], ["Applications of the enzymelinked immunosorbant assay (ELISA) to NDV have been more recently reported (Miers et al., 1983; Snyder et al., 1983; Marquardt et al., 1985) .INTRODUCTIONThe agar gel precipitin (AGP) test has been used to detect antibody to poultry viruses (Witter, 1962; Chubb and Churchill, 1968; Beard, 1970; Hirai and Shimakura, 1972; Olsen and Weiss, 1972; McFerran et al, 1975) .", [["NDV", "ORGANISM", 64, 67], ["AGP", "GENE_OR_GENE_PRODUCT", 205, 208], ["AGP", "PROTEIN", 205, 208], ["NDV", "SPECIES", 64, 67], ["poultry viruses (Witter, 1962; Chubb and Churchill, 1968; Beard, 1970; Hirai and Shimakura, 1972; Olsen and Weiss, 1972; McFerran et al, 1975)", "SPECIES", 251, 393], ["the enzymelinked immunosorbant assay", "TEST", 16, 52], ["The agar gel precipitin (AGP) test", "TEST", 180, 214]]], ["Advantages of the AGP test include low cost, simplicity, and results are generally obtained within 24 to 72 hr.INTRODUCTIONNonionic detergent treatment of enveloped animal viruses has been used to facilitate the extraction and isolation of viral envelope proteins (Scheid et al., 1972; Scheid and Choppin, 1973; Garwes et al., 1976; Wege et al., 1979) .", [["AGP", "GENE_OR_GENE_PRODUCT", 18, 21], ["AGP", "PROTEIN", 18, 21], ["viral envelope proteins", "PROTEIN", 240, 263], ["the AGP test", "TEST", 14, 26], ["INTRODUCTIONNonionic detergent treatment", "TREATMENT", 111, 151], ["enveloped animal viruses", "PROBLEM", 155, 179], ["the extraction", "TREATMENT", 208, 222]]], ["Nonionic detergents such as Nonidet P40 and Triton X-100 gently dissociate the lipid-containing viral envelope and thereby solubilize surface proteins.", [["surface", "ANATOMY", 134, 141], ["Nonidet P40", "CHEMICAL", 28, 39], ["Triton X-100", "CHEMICAL", 44, 56], ["Nonidet P40", "CHEMICAL", 28, 39], ["Triton X-100", "CHEMICAL", 44, 56], ["Nonidet P40", "SIMPLE_CHEMICAL", 28, 39], ["Triton X-100", "SIMPLE_CHEMICAL", 44, 56], ["lipid", "SIMPLE_CHEMICAL", 79, 84], ["surface proteins", "PROTEIN", 134, 150], ["Nonionic detergents", "TREATMENT", 0, 19], ["Nonidet P40", "TREATMENT", 28, 39], ["Triton X", "TREATMENT", 44, 52], ["the lipid", "TREATMENT", 75, 84], ["viral envelope", "TREATMENT", 96, 110], ["thereby solubilize surface proteins", "TREATMENT", 115, 150]]], ["Viral proteins extracted using nonionic detergents retain their native conformation, 845 biological activities, and antigenic properties (Makino etal, 1973; Morein etal, 1978; Lupton and Reed, 1980; Turner et al, 1981; Maes and Shutz, 1983) .", [["Viral", "ORGANISM", 0, 5], ["Viral proteins", "PROTEIN", 0, 14], ["Viral proteins", "PROBLEM", 0, 14], ["nonionic detergents", "TREATMENT", 31, 50]]], ["Virus concentration followed by nonionic detergent treatment has been reported to be an effective method for producing AGP test antigens (Lupton and Reed, 1980; Turner et al., 1981) .", [["Virus", "ORGANISM", 0, 5], ["AGP", "GENE_OR_GENE_PRODUCT", 119, 122], ["AGP", "PROTEIN", 119, 122], ["Virus concentration", "TREATMENT", 0, 19], ["nonionic detergent treatment", "TREATMENT", 32, 60]]], ["The objectives of this study were to prepare and characterize nonionic detergent-treated NDV AGP test antigens and to evaluate the test using detergent-treated antigen as a tool for detecting serum antibody in chickens following infection and vaccination.MATERIALS AND METHODSChicken Embryos, Eggs, and Chickens.", [["serum", "ANATOMY", 192, 197], ["infection", "DISEASE", 229, 238], ["NDV", "ORGANISM", 89, 92], ["AGP", "GENE_OR_GENE_PRODUCT", 93, 96], ["serum", "ORGANISM_SUBSTANCE", 192, 197], ["chickens", "ORGANISM", 210, 218], ["Chickens", "ORGANISM", 303, 311], ["NDV AGP test antigens", "PROTEIN", 89, 110], ["detergent-treated antigen", "PROTEIN", 142, 167], ["serum antibody", "PROTEIN", 192, 206], ["chickens", "SPECIES", 210, 218], ["Chickens", "SPECIES", 303, 311], ["NDV", "SPECIES", 89, 92], ["chickens", "SPECIES", 210, 218], ["this study", "TEST", 18, 28], ["nonionic detergent", "TREATMENT", 62, 80], ["NDV AGP test antigens", "TEST", 89, 110], ["the test", "TEST", 127, 135], ["detergent", "TREATMENT", 142, 151], ["a tool", "TEST", 171, 177], ["serum antibody in chickens", "PROBLEM", 192, 218], ["infection", "PROBLEM", 229, 238], ["vaccination", "TREATMENT", 243, 254], ["METHODSChicken Embryos", "TREATMENT", 269, 291], ["Eggs", "TREATMENT", 293, 297], ["infection", "OBSERVATION", 229, 238]]], ["Fertile specific-pathogen-free (SPF) Single Comb White Leghorn (SCWL) chicken eggs were purchased from SPAFAS, Inc., Norwich, CT.", [["chicken", "ORGANISM", 70, 77], ["chicken", "SPECIES", 70, 77], ["chicken", "SPECIES", 70, 77], ["Fertile specific-pathogen", "PROBLEM", 0, 25], ["Single Comb White Leghorn (SCWL) chicken eggs", "TREATMENT", 37, 82], ["CT", "TEST", 126, 128]]], ["Ten-day-old embryos inoculated via the allantoic cavity were used for virus titration, NDV AGP test antigen production, and preparation of chicken embryo fibroblast (CEF) cell cultures.", [["embryos", "ANATOMY", 12, 19], ["allantoic cavity", "ANATOMY", 39, 55], ["embryo fibroblast (CEF) cell cultures", "ANATOMY", 147, 184], ["embryos", "ORGANISM", 12, 19], ["allantoic cavity", "MULTI-TISSUE_STRUCTURE", 39, 55], ["NDV", "ORGANISM", 87, 90], ["AGP", "GENE_OR_GENE_PRODUCT", 91, 94], ["chicken", "ORGANISM", 139, 146], ["embryo fibroblast (CEF) cell cultures", "CELL", 147, 184], ["NDV AGP", "PROTEIN", 87, 94], ["chicken embryo fibroblast (CEF) cell cultures", "CELL_LINE", 139, 184], ["chicken", "SPECIES", 139, 146], ["NDV", "SPECIES", 87, 90], ["chicken", "SPECIES", 139, 146], ["old embryos", "PROBLEM", 8, 19], ["the allantoic cavity", "TREATMENT", 35, 55], ["virus titration", "TREATMENT", 70, 85], ["NDV AGP test antigen production", "TEST", 87, 118], ["chicken embryo fibroblast (CEF", "TREATMENT", 139, 169], ["cell cultures", "TEST", 171, 184], ["allantoic cavity", "ANATOMY", 39, 55]]], ["In addition, fertile eggs were obtained from an oil emulsion inactivated NDV-vaccinated commercial broiler breeder flock.The SPF SCWL chickens were purchased from SPAFAS.", [["eggs", "ANATOMY", 21, 25], ["oil", "ANATOMY", 48, 51], ["eggs", "ORGANISM", 21, 25], ["oil", "ORGANISM_SUBSTANCE", 48, 51], ["NDV", "ORGANISM", 73, 76], ["chickens", "ORGANISM", 134, 142], ["breeder", "SPECIES", 107, 114], ["chickens", "SPECIES", 134, 142], ["NDV", "SPECIES", 73, 76], ["chickens", "SPECIES", 134, 142], ["fertile eggs", "PROBLEM", 13, 25], ["an oil emulsion", "TREATMENT", 45, 60], ["NDV", "PROBLEM", 73, 76], ["The SPF SCWL chickens", "TREATMENT", 121, 142], ["breeder flock", "OBSERVATION", 107, 120]]], ["One-day-old commercial broiler-type chickens from an inactivated NDV-vaccinated breeder flock were obtained from a local hatchery.MATERIALS AND METHODSViruses.", [["chickens", "ORGANISM", 36, 44], ["NDV", "ORGANISM", 65, 68], ["breeder", "ORGANISM", 80, 87], ["chickens", "SPECIES", 36, 44], ["NDV-vaccinated breeder", "SPECIES", 65, 87], ["chickens", "SPECIES", 36, 44], ["NDV", "SPECIES", 65, 68], ["breeder", "SPECIES", 80, 87], ["type chickens", "PROBLEM", 31, 44], ["an inactivated NDV", "TREATMENT", 50, 68], ["vaccinated breeder flock", "TREATMENT", 69, 93]]], ["Lentogenic (LaSota strain), mesogenic (Roakin strain), and neurotropic velogenic (Texas GB strain) NDV were obtained from the NDV Repository, Univ. of Wisconsin, Madison, WI.", [["LaSota strain", "ORGANISM", 12, 25], ["Roakin strain", "ORGANISM", 39, 52], ["Texas GB strain", "ORGANISM", 82, 97], ["NDV", "ORGANISM", 99, 102], ["NDV", "ORGANISM", 126, 129], ["NDV", "SPECIES", 99, 102], ["NDV", "SPECIES", 99, 102], ["NDV", "SPECIES", 126, 129], ["Lentogenic (LaSota strain)", "PROBLEM", 0, 26], ["mesogenic (Roakin strain)", "PROBLEM", 28, 53], ["neurotropic velogenic (Texas GB strain) NDV", "PROBLEM", 59, 102]]], ["Live NDV vaccines containing the Bj or LaSota strains were provided by a commercial manufacturer.MATERIALS AND METHODSAgar Gel Precipitin Antigen Production.", [["NDV", "ORGANISM", 5, 8], ["Bj", "GENE_OR_GENE_PRODUCT", 33, 35], ["NDV", "SPECIES", 5, 8], ["NDV", "SPECIES", 5, 8], ["Live NDV vaccines", "TREATMENT", 0, 17], ["LaSota strains", "TREATMENT", 39, 53], ["METHODSAgar Gel Precipitin Antigen Production", "PROBLEM", 111, 156]]], ["Ten-day-old SPF SCWL or commercial broiler chicken embryos from an inactivated NDV vaccinated breeder flock were inoculated with 10 7 50% embryo infectious doses (EID 50 ) of NDV per egg of strains LaSota, Roakin, or Texas GB.", [["SCWL", "ANATOMY", 16, 20], ["embryos", "ANATOMY", 51, 58], ["embryo", "ANATOMY", 138, 144], ["egg", "ANATOMY", 183, 186], ["SPF", "ORGANISM", 12, 15], ["SCWL", "ORGANISM", 16, 20], ["chicken", "ORGANISM", 43, 50], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 51, 58], ["NDV", "ORGANISM", 79, 82], ["breeder", "ORGANISM", 94, 101], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 138, 144], ["NDV", "ORGANISM", 175, 178], ["chicken", "SPECIES", 43, 50], ["NDV vaccinated breeder", "SPECIES", 79, 101], ["SPF", "SPECIES", 12, 15], ["chicken", "SPECIES", 43, 50], ["NDV", "SPECIES", 79, 82], ["breeder", "SPECIES", 94, 101], ["NDV", "SPECIES", 175, 178], ["old SPF SCWL", "PROBLEM", 8, 20], ["commercial broiler chicken embryos", "PROBLEM", 24, 58], ["an inactivated NDV vaccinated breeder flock", "TREATMENT", 64, 107], ["NDV", "PROBLEM", 175, 178]]], ["After incubation at 37 C for 48 hr, the allantoic fluids (AF) were harvested and pooled according to virus strain.MATERIALS AND METHODSVirus used in AGP antigen production was concentrated using three methods.", [["allantoic fluids", "ANATOMY", 40, 56], ["allantoic fluids", "ORGANISM_SUBSTANCE", 40, 56], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 149, 160], ["AGP", "PROTEIN", 149, 152], ["the allantoic fluids (AF)", "TREATMENT", 36, 61], ["virus strain", "PROBLEM", 101, 113], ["METHODSVirus", "TREATMENT", 128, 140], ["AGP antigen production", "TREATMENT", 149, 171]]], ["The NDV in AF served as the source of antigen for all methods.", [["NDV", "ORGANISM", 4, 7], ["NDV", "SPECIES", 4, 7], ["The NDV in AF", "PROBLEM", 0, 13], ["all methods", "TREATMENT", 50, 61], ["NDV", "OBSERVATION", 4, 7]]], ["Ultracentrifuge-concentrated NDV AGP antigens were produced from strains LaSota, Roakin and Texas GB.", [["NDV", "ORGANISM", 29, 32], ["AGP", "GENE_OR_GENE_PRODUCT", 33, 36], ["Ultracentrifuge-concentrated NDV AGP antigens", "PROTEIN", 0, 45], ["NDV", "SPECIES", 29, 32], ["Ultracentrifuge", "TREATMENT", 0, 15], ["Texas GB", "ANATOMY", 92, 100]]], ["Allantoic fluids containing 10 8 to 10 lo EID 50 of NDV per ml were centrifuged at 3,700 x g for 15 min at 4 C to remove contaminating red blood cells.", [["red blood cells", "ANATOMY", 135, 150], ["NDV", "ORGANISM", 52, 55], ["red blood cells", "CELL", 135, 150], ["red blood cells", "CELL_TYPE", 135, 150], ["NDV", "SPECIES", 52, 55], ["Allantoic fluids", "TREATMENT", 0, 16], ["contaminating red blood cells", "PROBLEM", 121, 150]]], ["The supernatant fluid was centrifuged at 45,000 x g for 2 hr at 4 C to pellet the virus.", [["supernatant fluid", "ANATOMY", 4, 21], ["The supernatant fluid", "TREATMENT", 0, 21], ["fluid", "OBSERVATION", 16, 21], ["virus", "OBSERVATION", 82, 87]]], ["The virus pellet was resuspended in phosphate-buffered saline (PBS) at pH7 containing 1% of the nonionic detergent, Nonidet P40 (Sigma Chemical Co., St. Louis, MO) at l/100th the original AF volume.", [["phosphate", "CHEMICAL", 36, 45], ["Nonidet P40", "CHEMICAL", 116, 127], ["phosphate", "CHEMICAL", 36, 45], ["Nonidet P40", "CHEMICAL", 116, 127], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 36, 61], ["Nonidet P40", "SIMPLE_CHEMICAL", 116, 127], ["St. Louis", "ORGANISM", 149, 158], ["The virus pellet", "TREATMENT", 0, 16], ["phosphate-buffered saline (PBS", "TREATMENT", 36, 66], ["the nonionic detergent", "TREATMENT", 92, 114], ["virus pellet", "OBSERVATION", 4, 16], ["AF volume", "OBSERVATION", 188, 197]]], ["The suspension was then sonicated at 20 kHz for 1 min with a Branson microtip (Heat Systems-Ultrasonics, Plainview, New York).", [["The suspension", "TREATMENT", 0, 14]]], ["The suspension was gently mixed at room temperature (about 22 C) for 20 min.MATERIALS AND METHODSAcid precipitate concentration of LaSota strain NDV was achieved by acidifying AF containing NDV with 1 N HC1 to achieve a final pH of 4.", [["LaSota", "CHEMICAL", 131, 137], ["LaSota", "SIMPLE_CHEMICAL", 131, 137], ["NDV", "ORGANISM", 145, 148], ["NDV", "ORGANISM", 190, 193], ["NDV", "SPECIES", 145, 148], ["NDV", "SPECIES", 190, 193], ["The suspension", "TREATMENT", 0, 14], ["METHODSAcid precipitate concentration", "TREATMENT", 90, 127], ["LaSota strain NDV", "TREATMENT", 131, 148], ["1 N HC1", "TREATMENT", 199, 206], ["a final pH", "TEST", 218, 228], ["suspension", "OBSERVATION_MODIFIER", 4, 14]]], ["About .3 ml of 1 N HC1 was added per milliliter of fluids.", [["HC1", "CHEMICAL", 19, 22], ["HC1", "SIMPLE_CHEMICAL", 19, 22], ["1 N HC1", "TREATMENT", 15, 22], ["fluids", "TREATMENT", 51, 57]]], ["The AF was then mixed for 1 hr at 4 C. The resulting suspension was centrifuged at 2,000 x g for 10 min at 4 C. The precipitate was resuspended in 1 % Nonidet P40 (pH 9) at l/100th the original AF volume.", [["AF", "DISEASE", 4, 6], ["Nonidet P40", "SIMPLE_CHEMICAL", 151, 162], ["The AF", "PROBLEM", 0, 6], ["The resulting suspension", "TREATMENT", 39, 63], ["pH", "TEST", 164, 166], ["AF volume", "OBSERVATION", 194, 203]]], ["The AGP antigen preparation was sonicated and mixed as described.MATERIALS AND METHODSAn NDV AGP antigen was also produced by polyethylene glycol (PEG) precipitation.", [["polyethylene glycol", "CHEMICAL", 126, 145], ["PEG", "CHEMICAL", 147, 150], ["polyethylene glycol", "CHEMICAL", 126, 145], ["PEG", "CHEMICAL", 147, 150], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 4, 15], ["NDV", "ORGANISM", 89, 92], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 93, 104], ["polyethylene glycol", "SIMPLE_CHEMICAL", 126, 145], ["PEG", "SIMPLE_CHEMICAL", 147, 150], ["AGP", "PROTEIN", 4, 7], ["NDV AGP antigen", "PROTEIN", 89, 104], ["NDV", "SPECIES", 89, 92], ["The AGP antigen preparation", "TREATMENT", 0, 27], ["METHODSAn NDV AGP antigen", "TREATMENT", 79, 104], ["polyethylene glycol (PEG) precipitation", "TREATMENT", 126, 165], ["polyethylene glycol", "OBSERVATION", 126, 145]]], ["Final concentrations of 2% NaCl and 6% PEG 6,000 were added to a pooled 48 hr PI LaSota strain NDV AF harvest.", [["NaCl", "CHEMICAL", 27, 31], ["PEG", "CHEMICAL", 39, 42], ["LaSota", "CHEMICAL", 81, 87], ["NaCl", "CHEMICAL", 27, 31], ["PEG", "CHEMICAL", 39, 42], ["NDV", "ORGANISM", 95, 98], ["NDV", "SPECIES", 95, 98], ["2% NaCl", "TREATMENT", 24, 31], ["6% PEG", "TREATMENT", 36, 42], ["a pooled 48 hr PI LaSota strain NDV AF harvest", "TREATMENT", 63, 109], ["AF harvest", "OBSERVATION", 99, 109]]], ["The preparation was mixed overnight at 4 C and then centrifuged at 2,000 x g for 10 min at 4 C. The precipitate was suspended in 1% Nonidet P40 (pH7) at 1/100th the original AF volume.", [["Nonidet P40", "SIMPLE_CHEMICAL", 132, 143], ["AF volume", "OBSERVATION", 174, 183]]], ["All NDV AGP antigens were stored at -20 C until used in the AGP test unless stated otherwise.MATERIALS AND METHODSAgar Gel Precipitin Test Procedure.", [["NDV", "ORGANISM", 4, 7], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 8, 20], ["AGP", "GENE_OR_GENE_PRODUCT", 60, 63], ["NDV AGP antigens", "PROTEIN", 4, 20], ["AGP", "PROTEIN", 60, 63], ["NDV", "SPECIES", 4, 7], ["All NDV AGP antigens", "TEST", 0, 20], ["the AGP test", "TEST", 56, 68], ["METHODSAgar Gel Precipitin Test Procedure", "TREATMENT", 107, 148]]], ["The AGP tests were run on 3 x 1 in. frosted microscope slides containing 3 ml of .7% purified agar and 8% NaCl dissolved in distilled water.", [["NaCl", "CHEMICAL", 106, 110], ["NaCl", "CHEMICAL", 106, 110], ["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["AGP", "PROTEIN", 4, 7], ["The AGP tests", "TEST", 0, 13], ["8% NaCl dissolved", "TREATMENT", 103, 120]]], ["Wells were cut in the gels using a seven-holed template (LKB-Produkter-AB, Stockholm, Sweden).", [["a seven-holed template", "TREATMENT", 33, 55]]], ["The distance between the center and the six outer wells, as well as the adjacent outer wells, was 8 mm.", [["distance", "OBSERVATION_MODIFIER", 4, 12], ["center", "OBSERVATION_MODIFIER", 25, 31], ["six", "OBSERVATION_MODIFIER", 40, 43], ["outer", "OBSERVATION_MODIFIER", 44, 49], ["wells", "OBSERVATION", 50, 55], ["outer", "ANATOMY_MODIFIER", 81, 86], ["wells", "ANATOMY_MODIFIER", 87, 92], ["8 mm", "OBSERVATION_MODIFIER", 98, 102]]], ["The diameter of all wells was 2.5 mm.", [["diameter", "OBSERVATION_MODIFIER", 4, 12], ["all", "OBSERVATION_MODIFIER", 16, 19], ["wells", "OBSERVATION_MODIFIER", 20, 25], ["2.5 mm", "OBSERVATION_MODIFIER", 30, 36]]], ["Volumes of 25 |xl of AGP antigen and NDV serum were used to inoculate the wells.", [["serum", "ANATOMY", 41, 46], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 21, 32], ["NDV", "ORGANISM", 37, 40], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["AGP antigen", "PROTEIN", 21, 32], ["NDV", "SPECIES", 37, 40], ["NDV", "SPECIES", 37, 40], ["Volumes", "TEST", 0, 7], ["AGP antigen", "TEST", 21, 32], ["NDV serum", "TEST", 37, 46]]], ["Gels were placed in a humidified container, incubated at room temperature (approximately 22 C), and examined at 24, 48, and 72 hr for lines of antigen-antibody precipitation using an indirect light source.MATERIALS AND METHODSAgar Gel Precipitin Antigen Titration and Characterization.", [["Gels", "SIMPLE_CHEMICAL", 0, 4], ["antigen", "GENE_OR_GENE_PRODUCT", 143, 150], ["a humidified container", "TREATMENT", 20, 42], ["antigen-antibody precipitation", "TREATMENT", 143, 173], ["METHODSAgar Gel Precipitin Antigen Titration", "TREATMENT", 219, 263], ["Characterization", "TEST", 268, 284]]], ["The NDV AGP antigens were titrated in the AGP test as a means of quantifying the amount of antigen in a preparation.", [["NDV", "ORGANISM", 4, 7], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 8, 20], ["AGP", "GENE_OR_GENE_PRODUCT", 42, 45], ["NDV AGP antigens", "PROTEIN", 4, 20], ["AGP", "PROTEIN", 42, 45], ["NDV", "SPECIES", 4, 7], ["NDV", "SPECIES", 4, 7], ["The NDV AGP antigens", "TEST", 0, 20], ["the AGP test", "TEST", 38, 50]]], ["Two-fold serial dilutions (1:2 to 1:64) of the antigen were prepared in PBS (pH7).", [["Two-fold serial dilutions", "TREATMENT", 0, 25], ["the antigen", "TEST", 43, 54]]], ["Each of the outer AGP test slide wells was inoculated with undiluted or diluted antigen.", [["AGP", "GENE_OR_GENE_PRODUCT", 18, 21], ["the outer AGP test slide wells", "TEST", 8, 38]]], ["The center well was inoculated with NDV serum (HI titer = 64).", [["serum", "ANATOMY", 40, 45], ["NDV", "ORGANISM", 36, 39], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["NDV", "SPECIES", 36, 39], ["NDV serum", "TEST", 36, 45], ["HI titer", "TEST", 47, 55]]], ["Each AGP antigen titration was performed in duplicate.", [["AGP antigen", "GENE_OR_GENE_PRODUCT", 5, 16], ["AGP antigen", "PROTEIN", 5, 16], ["Each AGP antigen titration", "TEST", 0, 26]]], ["The AGP titer was expressed as the reciprocal of the highest dilution of antigen that produced line(s) of precipitation with NDV serum.MATERIALS AND METHODSInfectivity virus titrations were performed on ultracentrifuge-concentrated and acid precipitate-concentrated NDV before and after Nonidet P40 treatment in SPF chicken embryos.", [["serum", "ANATOMY", 129, 134], ["embryos", "ANATOMY", 324, 331], ["Nonidet P40", "CHEMICAL", 287, 298], ["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["NDV", "ORGANISM", 125, 128], ["serum", "ORGANISM_SUBSTANCE", 129, 134], ["NDV", "ORGANISM", 266, 269], ["Nonidet P40", "SIMPLE_CHEMICAL", 287, 298], ["chicken", "ORGANISM", 316, 323], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 324, 331], ["AGP", "PROTEIN", 4, 7], ["chicken", "SPECIES", 316, 323], ["NDV", "SPECIES", 125, 128], ["NDV", "SPECIES", 266, 269], ["SPF", "SPECIES", 312, 315], ["chicken", "SPECIES", 316, 323], ["The AGP titer", "TEST", 0, 13], ["precipitation", "PROBLEM", 106, 119], ["NDV serum", "TEST", 125, 134], ["METHODSInfectivity virus titrations", "TREATMENT", 149, 184], ["ultracentrifuge-concentrated and acid precipitate", "TREATMENT", 203, 252], ["Nonidet P40 treatment", "TREATMENT", 287, 308], ["SPF chicken embryos", "TREATMENT", 312, 331]]], ["Tests were performed on AF from embryos living after the seventh day of incubation.", [["embryos", "ANATOMY", 32, 39], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 32, 39], ["Tests", "TEST", 0, 5], ["AF", "PROBLEM", 24, 26]]], ["An embryo having AF that was HA positive was considered NDV-infected.", [["embryo", "ANATOMY", 3, 9], ["NDV-infected", "DISEASE", 56, 68], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 3, 9], ["NDV", "ORGANISM", 56, 59], ["NDV", "SPECIES", 56, 59], ["An embryo", "PROBLEM", 0, 9], ["AF", "PROBLEM", 17, 19], ["HA positive", "PROBLEM", 29, 40], ["NDV", "PROBLEM", 56, 59], ["infected", "PROBLEM", 60, 68], ["embryo", "OBSERVATION", 3, 9], ["infected", "OBSERVATION", 60, 68]]], ["Virus titers were expressed as EID 50 per milliliter of antigen.MATERIALS AND METHODSHemagglutination Titration of Agar Gel Precipitin Antigen.", [["Virus", "ORGANISM", 0, 5], ["Virus titers", "TEST", 0, 12], ["Agar Gel Precipitin Antigen", "TEST", 115, 142]]], ["The hemagglutination (HA) titers of NDV antigen preparations were determined using a standard microtiter procedure (Subcommittee on Avian Diseases, 1971).", [["NDV", "ORGANISM", 36, 39], ["NDV", "SPECIES", 36, 39], ["The hemagglutination (HA)", "TREATMENT", 0, 25], ["NDV antigen preparations", "TREATMENT", 36, 60], ["a standard microtiter procedure", "TREATMENT", 83, 114], ["hemagglutination", "OBSERVATION_MODIFIER", 4, 20]]], ["Twofold serial dilutions of antigen were prepared in PBS (pH7).", [["Twofold serial dilutions of antigen", "TEST", 0, 35]]], ["The HA titers were expressed as the reciprocal of the highest antigen dilution exhibiting HA.", [["HA", "GENE_OR_GENE_PRODUCT", 4, 6], ["The HA titers", "PROBLEM", 0, 13], ["HA", "PROBLEM", 90, 92]]], ["The AGP antigen stability was assessed.", [["AGP antigen", "GENE_OR_GENE_PRODUCT", 4, 15], ["AGP", "PROTEIN", 4, 7], ["The AGP antigen stability", "TEST", 0, 25], ["stability", "OBSERVATION_MODIFIER", 16, 25]]], ["The effects of freezing and thawing and long term storage at -20 C and 4 C were determined for AGP antigens produced from LaSota strain NDV.MATERIALS AND METHODSUltracentrifuge and acid precipitate-concentrated antigens were placed in separate tubes and stored at -20 C and 4 C. At two month intervals, a tube of each antigen was removed from storage and titrated in the AGP test.", [["4 C", "SIMPLE_CHEMICAL", 71, 74], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 95, 107], ["LaSota strain NDV", "ORGANISM", 122, 139], ["tube", "TISSUE", 305, 309], ["AGP", "GENE_OR_GENE_PRODUCT", 371, 374], ["AGP antigens", "PROTEIN", 95, 107], ["AGP", "PROTEIN", 371, 374], ["NDV", "SPECIES", 136, 139], ["freezing and thawing", "TREATMENT", 15, 35], ["long term storage", "TREATMENT", 40, 57], ["AGP antigens", "PROBLEM", 95, 107], ["LaSota strain NDV", "TREATMENT", 122, 139], ["METHODSUltracentrifuge", "TREATMENT", 154, 176], ["acid precipitate", "TREATMENT", 181, 197], ["concentrated antigens", "TREATMENT", 198, 219], ["a tube of each antigen", "TREATMENT", 303, 325], ["the AGP test", "TEST", 367, 379], ["tubes", "OBSERVATION", 244, 249], ["tube", "OBSERVATION", 305, 309]]], ["Ultracentrifuge and acid precipitate-concentrated antigens were placed in separate tubes and subjected to 20 consecutive freezing and thawing cycles.", [["Ultracentrifuge", "SIMPLE_CHEMICAL", 0, 15], ["Ultracentrifuge", "TREATMENT", 0, 15], ["acid precipitate", "TREATMENT", 20, 36], ["concentrated antigens", "TREATMENT", 37, 58], ["tubes", "OBSERVATION", 83, 88]]], ["The antigens were titrated in the AGP test after 0, 3, 5, 10, 15, and 20 freezing and thawing cycles.MATERIALS AND METHODSOther Serology.", [["AGP", "GENE_OR_GENE_PRODUCT", 34, 37], ["antigens", "PROTEIN", 4, 12], ["AGP", "PROTEIN", 34, 37], ["the AGP test", "TEST", 30, 42], ["METHODSOther Serology", "TEST", 115, 136]]], ["The micro-beta HI procedure (constant virus-diluted serum) was performed using 10 HA units of LaSota strain NDV per microtiter plate well (Subcommittee on Avian Diseases, 1971).", [["serum", "ANATOMY", 52, 57], ["LaSota", "CHEMICAL", 94, 100], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["NDV", "ORGANISM", 108, 111], ["NDV", "SPECIES", 108, 111], ["The micro-beta HI procedure", "TREATMENT", 0, 27], ["constant virus-diluted serum)", "TREATMENT", 29, 58], ["LaSota strain NDV", "TREATMENT", 94, 111]]], ["Titers were expressed as the reciprocal of the highest dilution of serum that inhibited HA.MATERIALS AND METHODSThe micro-beta VN test was conducted using 100 50% tissue culture infectious doses (TCID 50 ) of Texas GB strain NDV per microtiter plate well.", [["serum", "ANATOMY", 67, 72], ["tissue", "ANATOMY", 163, 169], ["serum", "ORGANISM_SUBSTANCE", 67, 72], ["tissue", "TISSUE", 163, 169], ["NDV", "ORGANISM", 225, 228], ["Texas GB strain NDV", "SPECIES", 209, 228], ["HA", "PROBLEM", 88, 90], ["METHODSThe micro-beta VN test", "TEST", 105, 134], ["Texas GB strain NDV", "TREATMENT", 209, 228]]], ["Serum-virus mixtures were incubated at 37 C for 30 min prior to adding primary CEF (10 4 ' 7 cells per well) suspended in Medium 199 containing 5% bovine serum.", [["CEF", "ANATOMY", 79, 82], ["cells", "ANATOMY", 93, 98], ["serum", "ANATOMY", 154, 159], ["CEF", "CELL", 79, 82], ["cells", "CELL", 93, 98], ["bovine", "ORGANISM", 147, 153], ["serum", "ORGANISM_SUBSTANCE", 154, 159], ["bovine", "SPECIES", 147, 153], ["bovine", "SPECIES", 147, 153], ["Serum-virus mixtures", "PROBLEM", 0, 20], ["primary CEF", "TREATMENT", 71, 82], ["5% bovine serum", "TREATMENT", 144, 159]]], ["The procedure for preparing CEF is described in Rosenberger et al. (1975) .", [["CEF", "ANATOMY", 28, 31], ["CEF", "CELL", 28, 31], ["The procedure", "TREATMENT", 0, 13], ["preparing CEF", "TREATMENT", 18, 31]]], ["Cell cultures were fixed and stained after 72 hr with 5% crystal violet in 10% buffered formalin solution.", [["Cell cultures", "ANATOMY", 0, 13], ["crystal violet", "CHEMICAL", 57, 71], ["formalin", "CHEMICAL", 88, 96], ["Cell cultures", "CELL", 0, 13], ["Cell cultures", "TEST", 0, 13], ["5% crystal violet", "TREATMENT", 54, 71], ["10% buffered formalin solution", "TREATMENT", 75, 105]]], ["The endpoints of VN tests were determined by gross observation.", [["VN", "PROTEIN", 17, 19], ["VN tests", "TEST", 17, 25], ["gross observation", "TEST", 45, 62]]], ["Serum VN titers were expressed as the reciprocal of the highest serum dilution that prevented cytopathic effects.MATERIALS AND METHODSIndirect ELISA tests were performed using a commercially available kit (Whittaker M. A. Bioproducts, Walkersville, MD).", [["Serum", "ANATOMY", 0, 5], ["serum", "ANATOMY", 64, 69], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["VN", "GENE_OR_GENE_PRODUCT", 6, 8], ["serum", "ORGANISM_SUBSTANCE", 64, 69], ["VN", "PROTEIN", 6, 8], ["Serum VN titers", "TEST", 0, 15], ["the highest serum dilution", "PROBLEM", 52, 78], ["cytopathic effects", "PROBLEM", 94, 112], ["METHODSIndirect ELISA tests", "TEST", 127, 154], ["cytopathic effects", "OBSERVATION", 94, 112]]], ["Antibody titers were determined using the single serum dilution method.", [["serum", "ANATOMY", 49, 54], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["Antibody titers", "TEST", 0, 15], ["the single serum dilution method", "TREATMENT", 38, 70]]], ["Results were expressed as a mean serum index (SI) and percentage of chickens with a positive SI value.", [["serum", "ANATOMY", 33, 38], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["chickens", "ORGANISM", 68, 76], ["chickens", "SPECIES", 68, 76], ["chickens", "SPECIES", 68, 76], ["a mean serum index", "TEST", 26, 44], ["chickens", "PROBLEM", 68, 76], ["a positive SI value", "PROBLEM", 82, 101], ["positive SI", "OBSERVATION_MODIFIER", 84, 95]]], ["Serum samples with an SI of 1.00 were considered positive.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["Serum samples", "TEST", 0, 13], ["an SI", "TEST", 19, 24]]], ["The SI equals the absorbance at 550 nm of the test serum divided by the absorbance of the low positive control serum sample.MATERIALS AND METHODSAgar Gel Precipitin Response of Susceptible Chickens Vaccinated with Live Newcastle Disease Virus.", [["serum", "ANATOMY", 51, 56], ["serum sample", "ANATOMY", 111, 123], ["Newcastle Disease Virus", "DISEASE", 219, 242], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["serum", "ORGANISM_SUBSTANCE", 111, 116], ["Chickens", "ORGANISM", 189, 197], ["Newcastle Disease Virus", "ORGANISM", 219, 242], ["Chickens", "SPECIES", 189, 197], ["Live Newcastle Disease Virus", "SPECIES", 214, 242], ["the test serum", "TEST", 42, 56], ["the absorbance", "TEST", 68, 82], ["the low positive control serum sample", "PROBLEM", 86, 123], ["METHODSAgar Gel Precipitin", "TREATMENT", 138, 164], ["Susceptible Chickens Vaccinated", "TREATMENT", 177, 208], ["Live Newcastle Disease Virus", "PROBLEM", 214, 242]]], ["Thirty, 35-day-old NDV-susceptible broiler chickens were assigned to three treatment groups consisting of 10 birds per group.", [["NDV", "ORGANISM", 19, 22], ["chickens", "ORGANISM", 43, 51], ["birds", "ORGANISM", 109, 114], ["NDV", "SPECIES", 19, 22], ["chickens", "SPECIES", 43, 51], ["NDV", "SPECIES", 19, 22], ["chickens", "SPECIES", 43, 51], ["NDV", "PROBLEM", 19, 22], ["susceptible broiler chickens", "TREATMENT", 23, 51]]], ["Two groups, the LaSota and B[ vaccinates, received commercial NDV vaccine intraocularly and were placed in separate colony houses.", [["NDV", "ORGANISM", 62, 65], ["NDV", "SPECIES", 62, 65], ["the LaSota and B[ vaccinates", "TREATMENT", 12, 40], ["commercial NDV vaccine", "TREATMENT", 51, 73]]], ["Ten unvaccinated negative control chickens were placed alone in a different colony house.", [["colony", "ANATOMY", 76, 82], ["chickens", "ORGANISM", 34, 42], ["chickens", "SPECIES", 34, 42], ["chickens", "SPECIES", 34, 42]]], ["At 14, 28, and 42 days postvaccination (PV), chickens were bled and sera tested for NDV HI, VN, and AGP antibody.", [["sera", "ANATOMY", 68, 72], ["chickens", "ORGANISM", 45, 53], ["sera", "ORGANISM_SUBSTANCE", 68, 72], ["NDV", "ORGANISM", 84, 87], ["VN", "GENE_OR_GENE_PRODUCT", 92, 94], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 100, 112], ["VN", "PROTEIN", 92, 94], ["AGP antibody", "PROTEIN", 100, 112], ["chickens", "SPECIES", 45, 53], ["NDV", "SPECIES", 84, 87], ["PV", "SPECIES", 40, 42], ["chickens", "SPECIES", 45, 53], ["NDV", "SPECIES", 84, 87], ["chickens", "PROBLEM", 45, 53], ["sera", "TEST", 68, 72], ["NDV", "PROBLEM", 84, 87], ["VN", "TEST", 92, 94], ["AGP antibody", "TEST", 100, 112]]], ["At 42 days PV, the chickens were challenged intraocularly with 10 4 to 10 5 50% embryo lethal dose (ELD 50 ) per bird of Texas GB and observed for 10 days for NDV-induced mortality and central nervous system signs of the disease.MATERIALS AND METHODSAgar Gel Precipitin Response of Day-Old Maternally Immune Chickens Vaccinated with Live Newcastle Disease Virus.", [["embryo", "ANATOMY", 80, 86], ["central nervous system", "ANATOMY", 185, 207], ["Newcastle Disease Virus", "DISEASE", 338, 361], ["chickens", "ORGANISM", 19, 27], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 80, 86], ["NDV", "ORGANISM", 159, 162], ["central nervous system", "ANATOMICAL_SYSTEM", 185, 207], ["Chickens", "ORGANISM", 308, 316], ["Newcastle Disease Virus", "ORGANISM", 338, 361], ["chickens", "SPECIES", 19, 27], ["Chickens", "SPECIES", 308, 316], ["PV", "SPECIES", 11, 13], ["chickens", "SPECIES", 19, 27], ["NDV", "SPECIES", 159, 162], ["Live Newcastle Disease Virus", "SPECIES", 333, 361], ["NDV", "PROBLEM", 159, 162], ["central nervous system signs", "PROBLEM", 185, 213], ["the disease", "PROBLEM", 217, 228], ["METHODSAgar Gel Precipitin", "TREATMENT", 243, 269], ["Live Newcastle Disease Virus", "PROBLEM", 333, 361], ["central nervous", "OBSERVATION", 185, 200], ["disease", "OBSERVATION", 221, 228]]], ["One hundred, one-day-old commercial broiler chickens were vaccinated in the hatchery with B, strain NDV vaccine by the coarse spray method.", [["chickens", "ORGANISM", 44, 52], ["NDV", "ORGANISM", 100, 103], ["chickens", "SPECIES", 44, 52], ["chickens", "SPECIES", 44, 52], ["NDV", "SPECIES", 100, 103], ["commercial broiler chickens", "TREATMENT", 25, 52], ["B, strain NDV vaccine", "TREATMENT", 90, 111], ["the coarse spray method", "TREATMENT", 115, 138]]], ["Fifty chicks were not vaccinated and held as controls.", [["chicks", "ORGANISM", 6, 12], ["chicks", "SPECIES", 6, 12]]], ["The chickens were from an inactivated NDV-vaccinated breeder flock with a NDV HI geometric mean titer of 80.", [["chickens", "ORGANISM", 4, 12], ["NDV", "ORGANISM", 38, 41], ["breeder", "ORGANISM", 53, 60], ["NDV", "ORGANISM", 74, 77], ["chickens", "SPECIES", 4, 12], ["NDV-vaccinated breeder", "SPECIES", 38, 60], ["chickens", "SPECIES", 4, 12], ["NDV", "SPECIES", 38, 41], ["NDV", "SPECIES", 74, 77], ["an inactivated NDV", "PROBLEM", 23, 41], ["a NDV HI geometric mean titer", "TEST", 72, 101]]], ["The vaccinated chicks were divided equally between two treatment groups and placed in separate colony houses.", [["chicks", "ORGANISM", 15, 21], ["chicks", "SPECIES", 15, 21], ["The vaccinated chicks", "TREATMENT", 0, 21], ["colony houses", "OBSERVATION", 95, 108]]], ["At 14 days of age, one of the vaccinated groups was revaccinated with the B, strain by the intraocular route.", [["intraocular", "ANATOMY", 91, 102]]], ["Serum samples were collected at 14, 28, 42, and 56 days of age and tested for HI and AGP antibody.", [["Serum samples", "ANATOMY", 0, 13], ["Serum samples", "ORGANISM_SUBSTANCE", 0, 13], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 85, 97], ["AGP antibody", "PROTEIN", 85, 97], ["Serum samples", "TEST", 0, 13], ["HI", "PROBLEM", 78, 80], ["AGP antibody", "TEST", 85, 97]]], ["At 42 days, all birds were chal-lenged as described earlier with Texas GR NDV and observed for 10 days.MATERIALS AND METHODSAgar Gel Precipitin Response to Inactivated Newcastle Disease Virus.", [["Newcastle Disease Virus", "DISEASE", 168, 191], ["birds", "ORGANISM", 16, 21], ["GR NDV", "ORGANISM", 71, 77], ["Newcastle Disease Virus", "ORGANISM", 168, 191], ["GR", "PROTEIN", 71, 73], ["NDV", "SPECIES", 74, 77], ["Newcastle Disease Virus", "SPECIES", 168, 191], ["METHODSAgar Gel Precipitin", "TREATMENT", 117, 143], ["Inactivated Newcastle Disease Virus", "PROBLEM", 156, 191]]], ["A commercial broiler breeder chicken flock was vaccinated via the drinking water with B, strain NDV at 2 weeks and with LaSota strain at 6 and 14 weeks of age.", [["chicken", "ORGANISM", 29, 36], ["NDV", "ORGANISM", 96, 99], ["breeder", "SPECIES", 21, 28], ["chicken", "SPECIES", 29, 36], ["chicken", "SPECIES", 29, 36], ["NDV", "SPECIES", 96, 99], ["A commercial broiler breeder chicken flock", "TREATMENT", 0, 42], ["LaSota strain", "TREATMENT", 120, 133], ["broiler", "OBSERVATION_MODIFIER", 13, 20], ["breeder chicken flock", "OBSERVATION", 21, 42]]], ["At 24 weeks, the chickens were injected subcutaneously (.5 ml per bird) with an inactivated NDV oil emulsion vaccine.", [["subcutaneously", "ANATOMY", 40, 54], ["oil", "ANATOMY", 96, 99], ["chickens", "ORGANISM", 17, 25], ["NDV", "ORGANISM", 92, 95], ["chickens", "SPECIES", 17, 25], ["chickens", "SPECIES", 17, 25], ["NDV", "SPECIES", 92, 95], ["the chickens", "TREATMENT", 13, 25], ["an inactivated NDV oil emulsion vaccine", "TREATMENT", 77, 116]]], ["Fifteen chickens were bled at 20, 23, 27, 30, 33, 39, 47, 58 , and 68 weeks of age.", [["chickens", "ORGANISM", 8, 16], ["chickens", "SPECIES", 8, 16], ["chickens", "SPECIES", 8, 16]]], ["Serum was tested for HI, VN.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["Serum", "TEST", 0, 5], ["HI", "PROBLEM", 21, 23]]], ["ELISA and AGP antibody.Relationship of Agar Gel Precipitin and Hamagglutination-Inhibition Antibody Responses Over 400 serum samples obtained from chickens of various ages and NDV vaccination histories were evaluated for NDV HI and AGP antibody.", [["serum samples", "ANATOMY", 119, 132], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 10, 22], ["Hamagglutination", "SIMPLE_CHEMICAL", 63, 79], ["serum samples", "ORGANISM_SUBSTANCE", 119, 132], ["chickens", "ORGANISM", 147, 155], ["NDV", "ORGANISM", 176, 179], ["NDV", "ORGANISM", 221, 224], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 232, 244], ["AGP antibody", "PROTEIN", 10, 22], ["NDV HI", "PROTEIN", 221, 227], ["AGP antibody", "PROTEIN", 232, 244], ["chickens", "SPECIES", 147, 155], ["NDV", "SPECIES", 221, 224], ["chickens", "SPECIES", 147, 155], ["NDV", "SPECIES", 176, 179], ["NDV", "SPECIES", 221, 224], ["ELISA", "TEST", 0, 5], ["AGP antibody", "TEST", 10, 22], ["Agar Gel Precipitin", "TREATMENT", 39, 58], ["Hamagglutination", "TEST", 63, 79], ["Inhibition Antibody", "TEST", 80, 99], ["serum samples", "TEST", 119, 132], ["NDV vaccination histories", "TEST", 176, 201], ["NDV", "PROBLEM", 221, 224], ["AGP antibody", "TEST", 232, 244], ["AGP antibody", "OBSERVATION", 10, 22]]], ["AGP test reactions using six different 100-fold concentrated NDV antigen preparations.", [["AGP", "GENE_OR_GENE_PRODUCT", 0, 3], ["NDV", "ORGANISM", 61, 64], ["AGP", "PROTEIN", 0, 3], ["NDV", "SPECIES", 61, 64], ["AGP test reactions", "TEST", 0, 18], ["NDV antigen preparations", "TREATMENT", 61, 85]]], ["Ultracentrifuge and acid precipitate-concentrated antigens treated with 1% Nonidet P40 (Wells A, C, D, E, and F) were found to be excellent AGP antigens.", [["Wells A, C, D, E, and F", "CHEMICAL", 88, 111], ["Ultracentrifuge", "SIMPLE_CHEMICAL", 0, 15], ["Nonidet P40", "SIMPLE_CHEMICAL", 75, 86], ["Wells A", "SIMPLE_CHEMICAL", 88, 95], ["C", "SIMPLE_CHEMICAL", 97, 98], ["D, E", "SIMPLE_CHEMICAL", 100, 104], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 140, 152], ["AGP antigens", "PROTEIN", 140, 152], ["Ultracentrifuge", "TREATMENT", 0, 15], ["acid precipitate", "TREATMENT", 20, 36], ["1% Nonidet P40", "TREATMENT", 72, 86], ["Wells A, C, D, E, and F)", "TEST", 88, 112]]], ["Two to as many as four lines of precipitation were observed on agar gels.", [["precipitation", "TREATMENT", 32, 45], ["agar gels", "TREATMENT", 63, 72]]], ["However, concentrated NDV not treated with detergent (Well B) did not react in the AGP test.", [["NDV", "ORGANISM", 22, 25], ["AGP", "GENE_OR_GENE_PRODUCT", 83, 86], ["AGP", "PROTEIN", 83, 86], ["NDV", "SPECIES", 22, 25], ["the AGP test", "TEST", 79, 91], ["NDV", "OBSERVATION", 22, 25]]], ["The AGP antigens produced from NDV strains LaSota, Roakin, and Texas GB formed at least two lines of identity in the AGP test.Agar Gel Precipitin Antigen Production, Titration, and Characterization.Ultracentrifuge and acid (HC1) precipitateconcentrated AGP antigens had AGP titers of 16 to 32 The PEG-concentrated NDV AGP antigen had a low AGP titer of 8 and was not further evaluated as an AGP antigen.", [["PEG", "CHEMICAL", 297, 300], ["PEG", "CHEMICAL", 297, 300], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 4, 16], ["NDV", "ORGANISM", 31, 34], ["AGP", "GENE_OR_GENE_PRODUCT", 117, 120], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 253, 265], ["AGP", "GENE_OR_GENE_PRODUCT", 270, 273], ["PEG", "SIMPLE_CHEMICAL", 297, 300], ["NDV", "ORGANISM", 314, 317], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 318, 329], ["AGP", "GENE_OR_GENE_PRODUCT", 340, 343], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 391, 402], ["AGP antigens", "PROTEIN", 4, 16], ["AGP", "PROTEIN", 117, 120], ["Ultracentrifuge and acid (HC1) precipitateconcentrated AGP antigens", "PROTEIN", 198, 265], ["AGP", "PROTEIN", 270, 273], ["PEG-concentrated NDV AGP antigen", "PROTEIN", 297, 329], ["AGP", "PROTEIN", 340, 343], ["AGP antigen", "PROTEIN", 391, 402], ["NDV", "SPECIES", 31, 34], ["NDV", "SPECIES", 31, 34], ["NDV", "SPECIES", 314, 317], ["The AGP antigens", "TEST", 0, 16], ["NDV strains LaSota", "TREATMENT", 31, 49], ["the AGP test", "TEST", 113, 125], ["Characterization", "TEST", 181, 197], ["Ultracentrifuge", "TREATMENT", 198, 213], ["acid (HC1", "TREATMENT", 218, 227], ["AGP antigens", "TEST", 253, 265], ["AGP titers", "TEST", 270, 280], ["The PEG-concentrated NDV AGP antigen", "TEST", 293, 329], ["a low AGP titer", "TEST", 334, 349], ["an AGP antigen", "TEST", 388, 402], ["low AGP", "OBSERVATION_MODIFIER", 336, 343]]], ["Figure 2 depicts the decrease in intensity of precipitin lines associated with an AGP antigen titration.", [["AGP antigen", "GENE_OR_GENE_PRODUCT", 82, 93], ["precipitin lines", "CELL_LINE", 46, 62], ["AGP antigen", "PROTEIN", 82, 93], ["precipitin lines", "TREATMENT", 46, 62], ["an AGP antigen titration", "TREATMENT", 79, 103], ["decrease", "OBSERVATION_MODIFIER", 21, 29], ["intensity", "OBSERVATION_MODIFIER", 33, 42], ["precipitin lines", "OBSERVATION", 46, 62]]], ["Table 1 summarizes the effects of nonionic detergent (Nonidet P40) treatment of 100-fold concentrated NDV on reactivity in the AGP test, virus infectivity, and HA titer.", [["Nonidet P40", "CHEMICAL", 54, 65], ["Nonidet P40", "SIMPLE_CHEMICAL", 54, 65], ["NDV", "ORGANISM", 102, 105], ["AGP", "GENE_OR_GENE_PRODUCT", 127, 130], ["AGP", "PROTEIN", 127, 130], ["NDV", "SPECIES", 102, 105], ["nonionic detergent (Nonidet P40", "TREATMENT", 34, 65], ["treatment", "TREATMENT", 67, 76], ["the AGP test", "TEST", 123, 135], ["virus infectivity", "PROBLEM", 137, 154], ["HA titer", "PROBLEM", 160, 168], ["virus infectivity", "OBSERVATION", 137, 154]]], ["Detergent-treated ultracentrifuge and acid (HC1) precipitate-concentrated NDV gave AGP titers of 16 whereas PBS alone-treated concentrated NDV did not react.", [["HC1", "CHEMICAL", 44, 47], ["HC1", "SIMPLE_CHEMICAL", 44, 47], ["NDV", "ORGANISM", 74, 77], ["AGP", "GENE_OR_GENE_PRODUCT", 83, 86], ["PBS", "SIMPLE_CHEMICAL", 108, 111], ["NDV", "ORGANISM", 139, 142], ["AGP", "PROTEIN", 83, 86], ["NDV", "SPECIES", 74, 77], ["NDV", "SPECIES", 139, 142], ["ultracentrifuge and acid (HC1)", "TREATMENT", 18, 48], ["AGP titers", "TEST", 83, 93]]], ["Infectivity and HA titers of detergenttreated NDV were substantially lower than PBS alone-treated controls.Agar Gel Precipitin Antigen Production, Titration, and Characterization.The AGP antigen produced in embryos from NDV immune hens compared favorably with NDV AGP antigen prepared in embryos from susceptible hens.", [["embryos", "ANATOMY", 207, 214], ["embryos", "ANATOMY", 288, 295], ["NDV", "ORGANISM", 46, 49], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 183, 194], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 207, 214], ["NDV", "ORGANISM", 220, 223], ["immune hens", "ORGANISM", 224, 235], ["NDV", "ORGANISM", 260, 263], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 264, 275], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 288, 295], ["AGP antigen", "PROTEIN", 183, 194], ["NDV AGP antigen", "PROTEIN", 260, 275], ["NDV", "SPECIES", 220, 223], ["hens", "SPECIES", 313, 317], ["NDV", "SPECIES", 46, 49], ["NDV", "SPECIES", 220, 223], ["NDV", "SPECIES", 260, 263], ["Infectivity", "PROBLEM", 0, 11], ["HA titers", "PROBLEM", 16, 25], ["detergenttreated NDV", "TREATMENT", 29, 49], ["Characterization", "TEST", 162, 178], ["The AGP antigen", "TEST", 179, 194], ["embryos", "PROBLEM", 207, 214], ["NDV immune hens", "TREATMENT", 220, 235], ["NDV AGP antigen", "PROBLEM", 260, 275]]], ["The AGP titers of antigens prepared using embryos from both sources were 16.", [["embryos", "ANATOMY", 42, 49], ["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 42, 49], ["AGP", "PROTEIN", 4, 7], ["antigens", "PROTEIN", 18, 26], ["The AGP titers", "TEST", 0, 14], ["embryos", "TREATMENT", 42, 49]]], ["The geometric mean NDV serum HI antibody titer of the NDV immune hens was 103.Agar Gel Precipitin Antigen Production, Titration, and Characterization.The AGP antigens produced by the ultracentrifugation or acid precipitation methods were stable for at least six months when stored at -20 C or 4 C.Twenty consecutive freezing and thawing cycles did not reduce the AGP titer of ultracentrifuge and acid precipitate-concentrated NDV AGP antigens.Agar Gel Precipitin Antigen Production, Titration, and Characterization.Agar Gel Precipitin Response of Susceptible Chickens Vaccinated with Live Newcastle Disease Virus.", [["serum", "ANATOMY", 23, 28], ["Newcastle Disease Virus", "DISEASE", 589, 612], ["NDV", "ORGANISM", 19, 22], ["serum", "ORGANISM_SUBSTANCE", 23, 28], ["NDV", "ORGANISM", 54, 57], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 154, 166], ["AGP", "GENE_OR_GENE_PRODUCT", 363, 366], ["NDV", "ORGANISM", 426, 429], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 430, 442], ["Chickens", "ORGANISM", 559, 567], ["Newcastle Disease Virus", "ORGANISM", 589, 612], ["AGP antigens", "PROTEIN", 154, 166], ["AGP", "PROTEIN", 363, 366], ["ultracentrifuge and acid precipitate-concentrated NDV AGP antigens", "PROTEIN", 376, 442], ["NDV", "SPECIES", 54, 57], ["hens", "SPECIES", 65, 69], ["Chickens", "SPECIES", 559, 567], ["NDV", "SPECIES", 19, 22], ["NDV", "SPECIES", 54, 57], ["NDV", "SPECIES", 426, 429], ["Chickens", "SPECIES", 559, 567], ["Live Newcastle Disease Virus", "SPECIES", 584, 612], ["The geometric mean NDV serum HI antibody titer", "TEST", 0, 46], ["the NDV immune hens", "TEST", 50, 69], ["Characterization", "TEST", 133, 149], ["The AGP antigens", "TEST", 150, 166], ["the ultracentrifugation", "TREATMENT", 179, 202], ["acid precipitation methods", "TREATMENT", 206, 232], ["the AGP titer", "TEST", 359, 372], ["ultracentrifuge", "TREATMENT", 376, 391], ["acid precipitate", "PROBLEM", 396, 412], ["concentrated NDV AGP antigens", "PROBLEM", 413, 442], ["Characterization", "TEST", 498, 514], ["Agar Gel Precipitin", "TREATMENT", 515, 534], ["Susceptible Chickens Vaccinated", "TREATMENT", 547, 578], ["Live Newcastle Disease Virus", "PROBLEM", 584, 612]]], ["Chickens vaccinated with LaSota or B, produced HI, VN, and AGP antibody ( Table 2) .", [["Chickens", "ORGANISM", 0, 8], ["B", "CELL", 35, 36], ["VN", "GENE_OR_GENE_PRODUCT", 51, 53], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 59, 71], ["LaSota", "PROTEIN", 25, 31], ["HI", "PROTEIN", 47, 49], ["VN", "PROTEIN", 51, 53], ["AGP antibody", "PROTEIN", 59, 71], ["Chickens", "SPECIES", 0, 8], ["Chickens", "SPECIES", 0, 8], ["LaSota", "TREATMENT", 25, 31], ["AGP antibody", "TEST", 59, 71]]], ["LaSota strain-vaccinated chickens had higher antibody responses than B, strain-vaccinated chickens.", [["LaSota", "CHEMICAL", 0, 6], ["LaSota strain", "ORGANISM", 0, 13], ["chickens", "ORGANISM", 25, 33], ["B", "CELL", 69, 70], ["chickens", "ORGANISM", 90, 98], ["chickens", "SPECIES", 25, 33], ["chickens", "SPECIES", 90, 98], ["chickens", "SPECIES", 25, 33], ["chickens", "SPECIES", 90, 98], ["LaSota strain", "TREATMENT", 0, 13], ["vaccinated chickens", "TREATMENT", 14, 33], ["higher antibody responses", "PROBLEM", 38, 63]]], ["The AGP and VN antibody responses increased through Day 42 PV.", [["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["VN antibody", "GENE_OR_GENE_PRODUCT", 12, 23], ["AGP", "PROTEIN", 4, 7], ["VN antibody", "PROTEIN", 12, 23], ["The AGP", "TEST", 0, 7], ["VN antibody responses", "TEST", 12, 33], ["AGP", "ANATOMY_MODIFIER", 4, 7]]], ["The HI antibody titers were low and remained constant or decreased slightly over the same period.", [["HI antibody", "GENE_OR_GENE_PRODUCT", 4, 15], ["HI antibody", "PROTEIN", 4, 15], ["The HI antibody titers", "TEST", 0, 22], ["low", "OBSERVATION_MODIFIER", 28, 31], ["constant", "OBSERVATION_MODIFIER", 45, 53], ["decreased", "OBSERVATION_MODIFIER", 57, 66], ["slightly", "OBSERVATION_MODIFIER", 67, 75]]], ["High levels of immunity (90 to 100% protection) were evident in vaccinated chickens at challenge.Agar Gel Precipitin Response of Day-Old Maternally Immune Chickens Vaccinated withLive Newcastle Disease Virus.", [["Newcastle Disease Virus", "DISEASE", 184, 207], ["chickens", "ORGANISM", 75, 83], ["Newcastle Disease Virus", "ORGANISM", 184, 207], ["chickens", "SPECIES", 75, 83], ["Chickens", "SPECIES", 155, 163], ["chickens", "SPECIES", 75, 83], ["Newcastle Disease Virus", "SPECIES", 184, 207], ["Newcastle Disease Virus", "PROBLEM", 184, 207]]], ["Very low or undetectable prechallenge antibody levels preceded a substantial rise in HI and AGP antibody production in one and two-time vaccinates following velogenic virus challenge (Table 3) .", [["AGP antibody", "GENE_OR_GENE_PRODUCT", 92, 104], ["velogenic virus", "ORGANISM", 157, 172], ["prechallenge antibody", "PROTEIN", 25, 46], ["AGP antibody", "PROTEIN", 92, 104], ["Very low or undetectable prechallenge antibody levels", "PROBLEM", 0, 53], ["a substantial rise", "PROBLEM", 63, 81], ["HI", "PROBLEM", 85, 87], ["AGP antibody production", "PROBLEM", 92, 115], ["velogenic virus challenge", "TREATMENT", 157, 182], ["low", "OBSERVATION_MODIFIER", 5, 8], ["substantial", "OBSERVATION_MODIFIER", 65, 76], ["rise", "OBSERVATION_MODIFIER", 77, 81]]], ["Challenge of immunity studies with velogenic NDV indicated one-day-old coarse spray-vaccinated chickens were poorly protected (26% protection).", [["velogenic NDV", "ORGANISM", 35, 48], ["chickens", "ORGANISM", 95, 103], ["chickens", "SPECIES", 95, 103], ["NDV", "SPECIES", 45, 48], ["chickens", "SPECIES", 95, 103], ["immunity studies", "TEST", 13, 29], ["velogenic NDV", "TREATMENT", 35, 48], ["old coarse spray", "TREATMENT", 67, 83], ["vaccinated chickens", "TREATMENT", 84, 103]]], ["Birds revaccinated at 14 days of age by the intraocular route were only moderately better protected (65% protection).Agar Gel Precipitin Response of Day-Old Maternally Immune Chickens Vaccinated withAgar Gel Precipitin Response of Commercial Broiler-Breeder Chickens Vaccinated with Inactivated Newcastle Disease Virus.", [["intraocular", "ANATOMY", 44, 55], ["Newcastle Disease Virus", "DISEASE", 295, 318], ["Chickens", "ORGANISM", 175, 183], ["Chickens", "ORGANISM", 258, 266], ["Newcastle Disease Virus", "ORGANISM", 295, 318], ["Chickens", "SPECIES", 175, 183], ["Chickens", "SPECIES", 258, 266], ["Newcastle Disease Virus", "SPECIES", 295, 318], ["Maternally Immune Chickens Vaccinated withAgar Gel Precipitin", "TREATMENT", 157, 218], ["Commercial Broiler", "TREATMENT", 231, 249], ["Breeder Chickens Vaccinated", "TREATMENT", 250, 277], ["Inactivated Newcastle Disease Virus", "PROBLEM", 283, 318], ["moderately", "OBSERVATION_MODIFIER", 72, 82]]], ["Serum antibody responses prior to inactivated NDV vaccination were low (Table 4 ).", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["NDV", "ORGANISM", 46, 49], ["Serum antibody", "PROTEIN", 0, 14], ["NDV", "SPECIES", 46, 49], ["Serum antibody responses", "TEST", 0, 24], ["NDV vaccination", "TEST", 46, 61]]], ["However, antibody production increased by 3 weeks postvaccination (27 weeks old) with inactivated NDV.", [["NDV", "ORGANISM", 98, 101], ["NDV", "SPECIES", 98, 101], ["antibody production", "PROBLEM", 9, 28], ["inactivated NDV", "PROBLEM", 86, 101], ["NDV", "OBSERVATION", 98, 101]]], ["Serum VN, ELISA, and AGP antibody responses reflected a more rapid change in serological status than HI titers.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["VN", "GENE_OR_GENE_PRODUCT", 6, 8], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 21, 33], ["VN", "PROTEIN", 6, 8], ["AGP antibody", "PROTEIN", 21, 33], ["Serum VN", "TEST", 0, 8], ["ELISA", "TEST", 10, 15], ["AGP antibody responses", "TEST", 21, 43], ["a more rapid change in serological status", "PROBLEM", 54, 95], ["HI titers", "TEST", 101, 110], ["rapid", "OBSERVATION_MODIFIER", 61, 66], ["change", "OBSERVATION_MODIFIER", 67, 73]]], ["Peak VN, ELISA, and AGP responses occurred at 30 weeks and then gradually declined by 39 weeks of age.", [["VN", "GENE_OR_GENE_PRODUCT", 5, 7], ["AGP", "GENE_OR_GENE_PRODUCT", 20, 23], ["VN", "PROTEIN", 5, 7], ["AGP", "PROTEIN", 20, 23], ["Peak VN", "TEST", 0, 7], ["ELISA", "TEST", 9, 14]]], ["Maximum vaccinal HI titers were not evident until 33 weeks.", [["Maximum vaccinal HI titers", "TEST", 0, 26]]], ["A rise in VN, ELISA, and AGP antibody production likely resulting from a natural NDV infection occurred between 39 and 47 weeks of age.", [["NDV infection", "DISEASE", 81, 94], ["VN", "GENE_OR_GENE_PRODUCT", 10, 12], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 25, 37], ["NDV", "ORGANISM", 81, 84], ["VN", "PROTEIN", 10, 12], ["AGP antibody", "PROTEIN", 25, 37], ["NDV", "SPECIES", 81, 84], ["A rise in VN", "PROBLEM", 0, 12], ["ELISA", "TEST", 14, 19], ["AGP antibody production", "PROBLEM", 25, 48], ["a natural NDV infection", "PROBLEM", 71, 94], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["VN", "ANATOMY", 10, 12], ["natural", "OBSERVATION_MODIFIER", 73, 80], ["NDV", "OBSERVATION_MODIFIER", 81, 84], ["infection", "OBSERVATION", 85, 94]]], ["As was the case follow- ing inactivated NDV vaccination, HI titers after the natural NDV infection increased after VN, ELISA, and AGP responses.Agar Gel Precipitin Response of Day-Old Maternally Immune Chickens Vaccinated withRelationship of Agar Gel Precipitin and Hemagglutination Inhibition Antibody Response.", [["infection", "DISEASE", 89, 98], ["NDV", "ORGANISM", 40, 43], ["NDV", "ORGANISM", 85, 88], ["AGP", "GENE_OR_GENE_PRODUCT", 130, 133], ["VN", "PROTEIN", 115, 117], ["AGP", "PROTEIN", 130, 133], ["Chickens", "SPECIES", 202, 210], ["NDV", "SPECIES", 40, 43], ["NDV", "SPECIES", 85, 88], ["NDV vaccination", "TREATMENT", 40, 55], ["HI titers", "TREATMENT", 57, 66], ["the natural NDV infection", "PROBLEM", 73, 98], ["VN", "TEST", 115, 117], ["ELISA", "TEST", 119, 124], ["Maternally Immune Chickens Vaccinated", "TREATMENT", 184, 221], ["Agar Gel Precipitin", "TREATMENT", 242, 261], ["NDV", "OBSERVATION_MODIFIER", 85, 88], ["infection", "OBSERVATION", 89, 98]]], ["None of the chickens with HI titers of 4 and only 25% of the birds with HI titers of 8 were positive for AGP antibody.", [["chickens", "ORGANISM", 12, 20], ["birds", "ORGANISM", 61, 66], ["AGP antibody", "GENE_OR_GENE_PRODUCT", 105, 117], ["AGP antibody", "PROTEIN", 105, 117], ["chickens", "SPECIES", 12, 20], ["chickens", "SPECIES", 12, 20], ["HI titers", "TEST", 26, 35], ["HI titers", "TEST", 72, 81], ["AGP antibody", "TEST", 105, 117]]], ["However, the percentage of AGP-positive chickens with HI titers of 16, 32, and 64 increased to 62, 80, and 91%, respectively (Figure 3 ).DISCUSSIONIn this study, 100-fold concentrated NDV . treated with a nonionic detergent (Nonidet P40) was found to be a suitable AGP test antigen.", [["Nonidet P40", "CHEMICAL", 225, 236], ["AGP", "GENE_OR_GENE_PRODUCT", 27, 30], ["chickens", "ORGANISM", 40, 48], ["NDV", "ORGANISM", 184, 187], ["Nonidet P40", "SIMPLE_CHEMICAL", 225, 236], ["AGP", "GENE_OR_GENE_PRODUCT", 265, 268], ["AGP", "PROTEIN", 27, 30], ["AGP test antigen", "PROTEIN", 265, 281], ["chickens", "SPECIES", 40, 48], ["chickens", "SPECIES", 40, 48], ["NDV", "SPECIES", 184, 187], ["AGP", "TEST", 27, 30], ["HI titers", "TEST", 54, 63], ["this study", "TEST", 150, 160], ["a nonionic detergent (Nonidet P40", "TREATMENT", 203, 236], ["a suitable AGP test antigen", "TEST", 254, 281], ["percentage", "OBSERVATION_MODIFIER", 13, 23], ["AGP", "OBSERVATION_MODIFIER", 27, 30], ["positive", "OBSERVATION_MODIFIER", 31, 39], ["chickens", "OBSERVATION_MODIFIER", 40, 48], ["NDV", "OBSERVATION", 184, 187]]], ["Nonionic detergents have been used to produce AGP antigens from other enveloped animal viruses such as the herpes viruses of swine pseudorabies and infectious bovine rhinotracheitis (Lupton and Reed, 1980; Turner et al., 1981) .DISCUSSIONNonionic detergents have been used to dissociate enveloped virions and solubilized viral proteins without destroying native conformation, biological activity, and antigenicity (Makino et al., 1973; Morein et al., 1978; Lupton and Reed, 1980; Turner et al., 1981; Maes and Schutz, 1983) .", [["virions", "ANATOMY", 297, 304], ["herpes viruses", "DISEASE", 107, 121], ["swine pseudorabies", "DISEASE", 125, 143], ["infectious bovine rhinotracheitis", "DISEASE", 148, 181], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 46, 58], ["herpes viruses", "ORGANISM", 107, 121], ["swine pseudorabies", "ORGANISM", 125, 143], ["bovine", "ORGANISM", 159, 165], ["rhinotracheitis", "ORGANISM", 166, 181], ["AGP antigens", "PROTEIN", 46, 58], ["solubilized viral proteins", "PROTEIN", 309, 335], ["swine", "SPECIES", 125, 130], ["pseudorabies", "SPECIES", 131, 143], ["bovine", "SPECIES", 159, 165], ["rhinotracheitis", "SPECIES", 166, 181], ["swine pseudorabies", "SPECIES", 125, 143], ["bovine rhinotracheitis", "SPECIES", 159, 181], ["Nonionic detergents", "TREATMENT", 0, 19], ["AGP antigens", "PROBLEM", 46, 58], ["the herpes viruses of swine pseudorabies", "PROBLEM", 103, 143], ["infectious bovine rhinotracheitis", "PROBLEM", 148, 181], ["solubilized viral proteins", "TREATMENT", 309, 335], ["viruses", "OBSERVATION", 87, 94], ["infectious", "OBSERVATION_MODIFIER", 148, 158]]], ["Although some intact virions have been shown to migrate in agar gels (Barron, 1971) , soluble viral proteins generally are better AGP antigens because most virions are too large to diffuse through agar (Fenner et al., 1974) .", [["virions", "ANATOMY", 21, 28], ["virions", "ANATOMY", 156, 163], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 130, 142], ["soluble viral proteins", "PROTEIN", 86, 108], ["AGP antigens", "PROTEIN", 130, 142], ["some intact virions", "PROBLEM", 9, 28], ["soluble viral proteins", "TREATMENT", 86, 108], ["intact virions", "OBSERVATION", 14, 28], ["diffuse", "OBSERVATION_MODIFIER", 181, 188]]], ["In contrast to results presented here, Barron et al. (1967) produced an AGP antigen from nondissociated NDV.", [["AGP antigen", "GENE_OR_GENE_PRODUCT", 72, 83], ["NDV", "ORGANISM", 104, 107], ["AGP antigen", "PROTEIN", 72, 83], ["NDV", "SPECIES", 104, 107], ["an AGP antigen", "TEST", 69, 83], ["nondissociated NDV", "PROBLEM", 89, 107], ["NDV", "OBSERVATION", 104, 107]]], ["However, the virus was concentrated 200-fold as opposed to the 100-fold concentration factor used in this study.", [["100-fold concentration factor", "PROTEIN", 63, 92], ["the virus", "PROBLEM", 9, 18], ["this study", "TEST", 101, 111], ["virus", "OBSERVATION", 13, 18]]], ["Irrespective of the magnitude of virus concentration, results of both studies showed NDV antigens formed at least two lines of precipitation with NDV immune sera.DISCUSSIONThe AGP antigens derived from LaSota, Roakin, and Texas GB strains formed at least two lines of identity in the AGP test.", [["sera", "ANATOMY", 157, 161], ["NDV", "ORGANISM", 85, 88], ["NDV", "ORGANISM", 146, 149], ["sera", "ORGANISM_SUBSTANCE", 157, 161], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 176, 188], ["LaSota", "GENE_OR_GENE_PRODUCT", 202, 208], ["Texas GB strains", "ORGANISM", 222, 238], ["AGP", "GENE_OR_GENE_PRODUCT", 284, 287], ["NDV antigens", "PROTEIN", 85, 97], ["AGP antigens", "PROTEIN", 176, 188], ["AGP", "PROTEIN", 284, 287], ["NDV", "SPECIES", 146, 149], ["NDV", "SPECIES", 85, 88], ["NDV", "SPECIES", 146, 149], ["virus concentration", "TREATMENT", 33, 52], ["both studies", "TEST", 65, 77], ["NDV antigens", "PROBLEM", 85, 97], ["NDV immune sera", "TREATMENT", 146, 161], ["Texas GB strains", "PROBLEM", 222, 238], ["the AGP test", "TEST", 280, 292], ["virus", "OBSERVATION", 33, 38]]], ["Barron et al. (1967) reported the same finding using AGP antigens made from the VIC and B, strains of NDV.", [["AGP antigens", "GENE_OR_GENE_PRODUCT", 53, 65], ["VIC", "GENE_OR_GENE_PRODUCT", 80, 83], ["B", "GENE_OR_GENE_PRODUCT", 88, 89], ["NDV", "ORGANISM", 102, 105], ["AGP antigens", "PROTEIN", 53, 65], ["NDV", "SPECIES", 102, 105], ["NDV", "SPECIES", 102, 105], ["AGP antigens", "TREATMENT", 53, 65], ["NDV", "PROBLEM", 102, 105], ["NDV", "OBSERVATION", 102, 105]]], ["Pennington (1978) , in comparing the antigenic characteristics of 5 NDV strains dissociated by ether and Tween 80 treatment, found 2 to 6 lines of precipitation were produced in the AGP test.", [["Tween 80", "CHEMICAL", 105, 113], ["ether", "CHEMICAL", 95, 100], ["Tween 80", "CHEMICAL", 105, 113], ["NDV", "ORGANISM", 68, 71], ["ether", "SIMPLE_CHEMICAL", 95, 100], ["Tween 80", "SIMPLE_CHEMICAL", 105, 113], ["AGP", "GENE_OR_GENE_PRODUCT", 182, 185], ["AGP", "PROTEIN", 182, 185], ["NDV", "SPECIES", 68, 71], ["5 NDV strains", "PROBLEM", 66, 79], ["Tween 80 treatment", "TREATMENT", 105, 123], ["the AGP test", "TEST", 178, 190]]], ["Some lines of partial identity were evident.", [["Some lines of partial identity", "PROBLEM", 0, 30], ["partial identity", "OBSERVATION", 14, 30]]], ["However, at least one line of complete identity was common between all NDV strains tested.", [["NDV", "ORGANISM", 71, 74], ["NDV", "SPECIES", 71, 74], ["all NDV strains", "TREATMENT", 67, 82], ["NDV strains", "OBSERVATION", 71, 82]]], ["These results suggest that endemic NDV strains found in different countries may be suitable for AGP antigen production.", [["NDV", "ORGANISM", 35, 38], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 96, 107], ["AGP antigen", "PROTEIN", 96, 107], ["NDV", "SPECIES", 35, 38], ["endemic NDV strains", "PROBLEM", 27, 46], ["AGP antigen production", "PROBLEM", 96, 118], ["endemic", "OBSERVATION_MODIFIER", 27, 34], ["NDV", "OBSERVATION", 35, 38]]], ["Acid (HC1) precipitation was found to be a simple, practical, and inexpensive alternative to ultracentrifugation for concentrating NDV.", [["Acid", "CHEMICAL", 0, 4], ["HC1", "CHEMICAL", 6, 9], ["Acid", "SIMPLE_CHEMICAL", 0, 4], ["HC1", "SIMPLE_CHEMICAL", 6, 9], ["NDV", "ORGANISM", 131, 134], ["NDV", "SPECIES", 131, 134], ["Acid (HC1) precipitation", "PROBLEM", 0, 24], ["ultracentrifugation", "TREATMENT", 93, 112], ["concentrating NDV", "PROBLEM", 117, 134]]], ["The AGP titer of acid precipitate-concentrated anti-gen was the same as ultracentrifuge-concentrated antigen.", [["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["anti-gen", "SIMPLE_CHEMICAL", 47, 55], ["AGP", "PROTEIN", 4, 7], ["ultracentrifuge-concentrated antigen", "PROTEIN", 72, 108], ["The AGP titer", "TEST", 0, 13], ["acid precipitate", "PROBLEM", 17, 33]]], ["The PEG-concentrated antigen produced lines of precipitation but had a low AGP titer in comparison to acid precipitate and ultracentrifuge-concentrated antigens.", [["PEG", "CHEMICAL", 4, 7], ["PEG", "CHEMICAL", 4, 7], ["PEG", "SIMPLE_CHEMICAL", 4, 7], ["AGP", "GENE_OR_GENE_PRODUCT", 75, 78], ["PEG-concentrated antigen", "PROTEIN", 4, 28], ["AGP", "PROTEIN", 75, 78], ["ultracentrifuge-concentrated antigens", "PROTEIN", 123, 160], ["The PEG", "TREATMENT", 0, 7], ["a low AGP titer", "PROBLEM", 69, 84], ["acid precipitate", "TREATMENT", 102, 118], ["ultracentrifuge-concentrated antigens", "TREATMENT", 123, 160], ["PEG", "OBSERVATION", 4, 7]]], ["This is likely related to difficulties in handling and accurately resuspending the PEG-virus precipitate mixture in nonionic detergent following concentration.", [["PEG", "CHEMICAL", 83, 86], ["PEG", "CHEMICAL", 83, 86], ["difficulties in handling", "PROBLEM", 26, 50], ["the PEG-virus precipitate mixture", "TREATMENT", 79, 112], ["nonionic detergent", "TREATMENT", 116, 134], ["likely related to", "UNCERTAINTY", 8, 25]]], ["The use of antigens with low AGP titers would decrease the sensitivity of the AGP test.DISCUSSIONFurther cost savings may be realized by using chicken embryos from commercial breeder flocks for AGP antigen production.", [["embryos", "ANATOMY", 151, 158], ["AGP", "GENE_OR_GENE_PRODUCT", 29, 32], ["AGP", "GENE_OR_GENE_PRODUCT", 78, 81], ["chicken", "ORGANISM", 143, 150], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 151, 158], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 194, 205], ["antigens", "PROTEIN", 11, 19], ["AGP", "PROTEIN", 29, 32], ["AGP", "PROTEIN", 78, 81], ["AGP antigen", "PROTEIN", 194, 205], ["chicken", "SPECIES", 143, 150], ["chicken", "SPECIES", 143, 150], ["low AGP titers", "PROBLEM", 25, 39], ["the AGP test", "TEST", 74, 86], ["chicken embryos", "PROBLEM", 143, 158], ["commercial breeder flocks", "TREATMENT", 164, 189], ["AGP antigen production", "PROBLEM", 194, 216]]], ["The AGP titers of antigens prepared from eggs from NDV immune hens compared favorably with AGP antigens produced from embryos from NDV susceptible breeders.DISCUSSIONDisruption of NDV by Nonidet P40 treatment reduced virus infectivity and HA titers by 87.5% or more compared to nondetergent-treated virus preparations.", [["eggs", "ANATOMY", 41, 45], ["embryos", "ANATOMY", 118, 125], ["Nonidet P40", "CHEMICAL", 187, 198], ["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 41, 45], ["NDV", "ORGANISM", 51, 54], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 91, 103], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 118, 125], ["NDV", "ORGANISM", 131, 134], ["NDV", "ORGANISM", 180, 183], ["Nonidet P40", "SIMPLE_CHEMICAL", 187, 198], ["AGP", "PROTEIN", 4, 7], ["antigens", "PROTEIN", 18, 26], ["AGP antigens", "PROTEIN", 91, 103], ["NDV", "SPECIES", 51, 54], ["NDV", "SPECIES", 51, 54], ["NDV", "SPECIES", 131, 134], ["NDV", "SPECIES", 180, 183], ["The AGP titers", "TEST", 0, 14], ["NDV immune hens", "TREATMENT", 51, 66], ["AGP antigens", "PROBLEM", 91, 103], ["embryos", "PROBLEM", 118, 125], ["NDV susceptible breeders", "PROBLEM", 131, 155], ["NDV", "TREATMENT", 180, 183], ["Nonidet P40 treatment", "TREATMENT", 187, 208], ["reduced virus infectivity", "PROBLEM", 209, 234], ["HA titers", "TEST", 239, 248], ["virus preparations", "TREATMENT", 299, 317]]], ["Since viral proteins required for infection and HA are associated with the envelope, solubilization of these proteins decreased virus infectivity and HA titers.", [["infection", "DISEASE", 34, 43], ["HA", "GENE_OR_GENE_PRODUCT", 48, 50], ["viral proteins", "PROTEIN", 6, 20], ["viral proteins", "PROBLEM", 6, 20], ["infection", "PROBLEM", 34, 43], ["HA", "PROBLEM", 48, 50], ["the envelope", "PROBLEM", 71, 83], ["solubilization", "TREATMENT", 85, 99], ["these proteins decreased virus infectivity", "PROBLEM", 103, 145], ["HA titers", "PROBLEM", 150, 159], ["infection", "OBSERVATION", 34, 43]]], ["It is important to recognize that residual live NDV is present in the AGP antigen.", [["NDV", "ORGANISM", 48, 51], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 70, 81], ["AGP antigen", "PROTEIN", 70, 81], ["NDV", "SPECIES", 48, 51], ["residual live NDV", "PROBLEM", 34, 51], ["NDV", "OBSERVATION", 48, 51]]], ["Since all three NDV pathotypes produced good AGP antigens, laboratory personnel could select a lentogenic NDV isolate for AGP antigen production and eliminate the inherent biosecurity risks of working with a highly virulent strain.DISCUSSIONThe AGP antigens were found to be very stable as there were little or no reduction in AGP titers of antigens that had undergone 20 consecutive freezing and thawing cycles or storage at 4 C and -20 C for 6 months.", [["NDV", "ORGANISM", 16, 19], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 45, 57], ["NDV", "ORGANISM", 106, 109], ["AGP antigen", "GENE_OR_GENE_PRODUCT", 122, 133], ["AGP antigens", "GENE_OR_GENE_PRODUCT", 245, 257], ["AGP", "GENE_OR_GENE_PRODUCT", 327, 330], ["AGP antigens", "PROTEIN", 45, 57], ["AGP antigen", "PROTEIN", 122, 133], ["AGP antigens", "PROTEIN", 245, 257], ["AGP", "PROTEIN", 327, 330], ["antigens", "PROTEIN", 341, 349], ["NDV", "SPECIES", 16, 19], ["NDV", "SPECIES", 106, 109], ["a lentogenic NDV isolate", "TREATMENT", 93, 117], ["AGP antigen production", "PROBLEM", 122, 144], ["a highly virulent strain", "PROBLEM", 206, 230], ["The AGP antigens", "TEST", 241, 257], ["reduction in AGP titers of antigens", "PROBLEM", 314, 349], ["virulent strain", "OBSERVATION", 215, 230], ["very", "OBSERVATION_MODIFIER", 275, 279], ["stable", "OBSERVATION", 280, 286], ["no", "UNCERTAINTY", 311, 313], ["reduction", "OBSERVATION_MODIFIER", 314, 323]]], ["The NDV AGP test was found to be a simple, inexpensive, and practical procedure for detecting serum antibody.", [["serum", "ANATOMY", 94, 99], ["NDV", "ORGANISM", 4, 7], ["AGP", "GENE_OR_GENE_PRODUCT", 8, 11], ["serum", "ORGANISM_SUBSTANCE", 94, 99], ["AGP", "PROTEIN", 8, 11], ["serum antibody", "PROTEIN", 94, 108], ["NDV", "SPECIES", 4, 7], ["The NDV AGP test", "TEST", 0, 16], ["practical procedure", "TREATMENT", 60, 79], ["serum antibody", "TEST", 94, 108]]], ["The test was used to assess NDV vaccination and infection of chickens.", [["infection", "DISEASE", 48, 57], ["NDV", "ORGANISM", 28, 31], ["chickens", "ORGANISM", 61, 69], ["chickens", "SPECIES", 61, 69], ["NDV", "SPECIES", 28, 31], ["chickens", "SPECIES", 61, 69], ["The test", "TEST", 0, 8], ["NDV vaccination", "TREATMENT", 28, 43], ["infection of chickens", "PROBLEM", 48, 69]]], ["The AGP procedure can be used to identify flocks with low levels of NDV serum antibody or demonstrate an increase in the number of AGP positive chickens by testing paired serum samples collected before and after natural NDV infection or vaccination.", [["serum", "ANATOMY", 72, 77], ["serum samples", "ANATOMY", 171, 184], ["infection", "DISEASE", 224, 233], ["AGP", "GENE_OR_GENE_PRODUCT", 4, 7], ["NDV", "ORGANISM", 68, 71], ["serum", "ORGANISM_SUBSTANCE", 72, 77], ["AGP", "GENE_OR_GENE_PRODUCT", 131, 134], ["chickens", "ORGANISM", 144, 152], ["serum samples", "ORGANISM_SUBSTANCE", 171, 184], ["NDV", "ORGANISM", 220, 223], ["AGP", "PROTEIN", 4, 7], ["NDV serum antibody", "PROTEIN", 68, 86], ["AGP", "PROTEIN", 131, 134], ["chickens", "SPECIES", 144, 152], ["NDV", "SPECIES", 68, 71], ["chickens", "SPECIES", 144, 152], ["NDV", "SPECIES", 220, 223], ["The AGP procedure", "TREATMENT", 0, 17], ["NDV serum antibody", "TEST", 68, 86], ["an increase", "PROBLEM", 102, 113], ["AGP positive chickens", "PROBLEM", 131, 152], ["testing paired serum samples", "TEST", 156, 184], ["natural NDV infection", "PROBLEM", 212, 233], ["vaccination", "PROBLEM", 237, 248], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["NDV", "OBSERVATION_MODIFIER", 220, 223], ["infection", "OBSERVATION", 224, 233]]], ["Suspicious or questionable AGP test results could then be re-evaluated quantitatively using the HI, VN, or ELISA procedure.", [["AGP", "GENE_OR_GENE_PRODUCT", 27, 30], ["AGP", "PROTEIN", 27, 30], ["AGP test", "TEST", 27, 35], ["ELISA procedure", "TREATMENT", 107, 122]]], ["Applications of the AGP test to other species of domestic poultry and wild birds may also be possible.", [["AGP", "GENE_OR_GENE_PRODUCT", 20, 23], ["AGP", "PROTEIN", 20, 23], ["the AGP test", "TEST", 16, 28], ["domestic poultry", "TREATMENT", 49, 65], ["may also be possible", "UNCERTAINTY", 81, 101]]], ["The NDV AGP test may be valuable in areas of the world where limited facilities or technical capabilities prevent using other serological procedures.", [["NDV", "ORGANISM", 4, 7], ["AGP", "GENE_OR_GENE_PRODUCT", 8, 11], ["AGP", "PROTEIN", 8, 11], ["NDV", "SPECIES", 4, 7], ["The NDV AGP test", "TEST", 0, 16], ["other serological procedures", "TREATMENT", 120, 148]]]]}